NCT03181750	1:4:age,5:7:lower_bound,8:16:upper_bound	Age 18-90 years
NCT03181750	1:7:cancer	Cancer diagnosis
NCT03181750	109:115:cancer	Meeting medium to high risk for death at 1 year using the CARING criteria (although excluding patients with cancer diagnosis)
NCT03181750	1:9:pregnancy	Pregnant
NCT03181750	18:24:ethnicity	Self-identify as Latino
NCT03181126	4:12:upper_bound,16:19:age	<= 18 years of age
NCT03181126	3:48:treatment,56:62:upper_bound	A strong or moderate CYP3A inhibitor or inducer within 7 days
NCT03181126	13:25:treatment,26:44:treatment,50:67:treatment,106:112:upper_bound	An excluded antiplatelet/anticoagulant drug or a herbal supplement that affects platelet function within 7 days, or 5 half-lives, whichever is longer
NCT03181126	1:8:treatment,16:22:upper_bound	Aspirin within 7 days, or 5 half-lives, whichever is longer
NCT03181126	1:42:clinical_variable,53:54:upper_bound	Eastern Cooperative Oncology Group (ECOG) less than 3
NCT03181126	1:12:treatment,30:41:treatment	Hydroxyurea that is ongoing (hydroxyurea is permitted up to the first dose)
NCT03181126	1:11:treatment,19:26:upper_bound,41:44:clinical_variable,46:49:clinical_variable,54:63:clinical_variable	Inotuzumab within 30 days and must have ALT, AST and bilirubin < ULN
NCT03181126	1:10:clinical_variable,36:38:lower_bound	Karnofsky greater than or equal to 50
NCT03181126	1:7:clinical_variable,33:35:lower_bound	Lansky greater than or equal to 50
NCT03181126	34:68:cancer,95:122:cancer	Must have relapsed or refractory acute lymphoblastic leukemia (ALL) or relapsed or refractory lymphoblastic lymphoma (LL)
NCT03181126	17:53:chronic_disease,93:102:treatment	Participant has central nervous system (CNS) disease with cranial involvement that requires radiation
NCT03181126	17:27:treatment	Participants on venetoclax at screening may enroll and remain on venetoclax
NCT03181126	19:41:chronic_disease	Participants with malabsorption syndrome or any other condition that precludes enteral administration
NCT03181126	1:34:cancer,47:51:treatment,90:129:treatment	Philadelphia Chromosome (Ph)+ ALL subjects on TKIs at Screening may enroll and remain on Tyrosine Kinase Inhibitor (TKI) therapy to control disease
NCT03181126	60:61:lower_bound,73:85:treatment	Refractory is defined as persistent disease after at least 2 courses of chemotherapy
NCT03181126	1:16:treatment,51:57:upper_bound	Steroid therapy for anti-neoplastic intent within 5 days
NCT03181126	14:22:lower_bound,26:29:age	greater than 16 years of age
NCT03181126	15:33:clinical_variable	have adequate performance status
NCT03181126	23:31:upper_bound,35:38:age	less than or equal to 16 years of age
NCT03181126	1:6:clinical_variable,32:37:lower_bound	weigh greater than or equal to 20 kg
NCT03178734	25:54:treatment,55:83:treatment	All patients undergoing pelvic reconstructive surgery/anti-incontinence procedures who are planned to be discharged home with a catheter
NCT03178734	1:9:chronic_disease,12:38:chronic_disease	Dementia / altered cognitive function
NCT03178734	1:31:chronic_disease,39:52:treatment	Intra-operative bladder injury during index surgery
NCT03175978	21:30:chronic_disease	Active uncontrolled infection or severe systemic infection (enrollment is possible after control of infection)
NCT03175978	32:39:upper_bound	Adequate organ function within 14 days of study registration
NCT03175978	16:24:chronic_disease,30:46:chronic_disease,66:74:chronic_disease	Any history of epilepsy or a seizure disorder or any known prior seizures
NCT03175978	34:46:pregnancy,72:141:pregnancy	Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening
NCT03175978	35:53:treatment,74:81:upper_bound	Confirmed histologic diagnosis on bone marrow biopsy and aspirate within 28 days of trial entry prior to starting cycle 1
NCT03175978	14:17:cancer,18:22:cancer,62:78:treatment,71:78:treatment	Diagnosis of MDS/CMML that is refractory to or intolerant to standard therapy and is no longer likely to respond to such therapy (at least one line of therapy)
NCT03175978	1:24:clinical_variable,28:29:lower_bound,36:37:upper_bound	ECOG performance status of 0, 1 or 2
NCT03175978	1:30:chronic_disease,38:45:upper_bound	Grade 3 peripheral neuropathy within 14 days before enrollment
NCT03175978	1:25:treatment	Intrathecal methotrexate is allowed prior to and during treatment per investigator discretion
NCT03175978	101:104:allergy_name,108:120:allergy_name	Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to IGF or methotrexate
NCT03175978	1:25:gender,59:95:contraception_consent	Male and female patients with reproductive potential must use an approved contraceptive method if appropriate
NCT03175978	1:25:pregnancy,34:41:gender	Negative serum pregnancy test in females
NCT03175978	15:44:chronic_disease	Patients with active extramedullary disease
NCT03175978	1:10:clinical_variable,13:24:lower_bound	Platelets > 10 x 10^9/L
NCT03175978	1:10:pregnancy,80:85:gender	Pregnancy testing is not required for post-menopausal or surgically sterilized women
NCT03175978	1:9:pregnancy	Pregnant or breastfeeding
NCT03175978	1:28:treatment,30:43:treatment,48:66:treatment,68:85:treatment,93:100:treatment	Prior systemic chemotherapy, immunotherapy, or biological therapy, radiation therapy and/or surgery are allowed
NCT03175978	27:42:clinical_variable	Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant
NCT03175978	21:39:chronic_disease,47:76:chronic_disease,80:101:chronic_disease,106:127:chronic_disease	Serious concomitant systemic disorders (e.g., active uncontrolled infection or uncontrolled diabetes) or psychiatric disorders that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study
NCT03175978	1:31:chronic_disease,14:22:chronic_disease,45:59:clinical_variable,61:64:lower_bound	Uncontrolled diabetes mellitus defined as a Hemoglobin A1C≥ 10% in patients with a prior history of diabetes, prior to study enrollment
NCT03175978	1:13:treatment,17:26:pregnancy	methotrexate is Pregnancy Category X - has been reported to cause fetal death and/or congenital abnormalities
NCT03175978	1:35:treatment,38:51:lower_bound	prior use of systemic methotrexate > 1 month prior to study entry is allowed
NCT03170856	23:38:chronic_disease,42:61:chronic_disease	Any current, serious, chronic medical or psychiatric disease that, in the Principal Investigator's judgment, may interfere with study participation or data integrity
NCT03170856	205:228:chronic_disease	Concussion will be diagnosed by board-certified sports medicine physicians, and defined as a direct or indirect blow to the head, face, neck, or elsewhere that manifests with the presence of symptoms and neurological impairment
NCT03170856	15:25:chronic_disease,37:49:upper_bound	Experienced a concussion within the last 2 weeks
NCT03170856	12:32:treatment	History of neurological surgery
NCT03170856	1:17:chronic_disease	Seizure disorder
NCT03170453	1:41:language_fluency	Ability to read and speak fluent English
NCT03170453	1:4:age,5:7:lower_bound,8:16:upper_bound	Age 16-45 years
NCT03170453	10:57:chronic_disease	Comorbid attention deficit hyperactivity disorder (ADHD) that is untreated
NCT03170453	1:30:chronic_disease	Comorbid personality disorder
NCT03170453	14:20:chronic_disease,22:41:chronic_disease,46:78:chronic_disease	Diagnosis of autism, Asperger's syndrome, or pervasive developmental disorder not otherwise specified (NOS) verified by the autism diagnostic observation schedule (ADOS) or autism diagnostic interview-revised (ADI-R)
NCT03170453	1:24:clinical_variable,33:50:upper_bound	English language skills below a sixth grade level
NCT03170453	1:3:clinical_variable,6:8:upper_bound	IQ < 80
NCT03170453	1:27:clinical_variable,41:43:lower_bound	Intelligence quotient (IQ) greater than 80
NCT03170453	1:23:chronic_disease	Organic brain syndrome
NCT03170453	36:56:chronic_disease	Presence of significant social and cognitive disability, based on the Cognitive Style and Social Cognition Eligibility Interview (Hogarty et al., 2004)
NCT03170453	1:31:chronic_disease	disruptive or violent behavior
NCT03168347	1:4:age,5:7:lower_bound,8:10:upper_bound	Age 18-80
NCT03168347	40:59:treatment	Currently or previously managed with a biologic medication
NCT03168347	16:25:chronic_disease	Diagnosed with psoriasis (ICD-9: 696.1)
NCT03168347	26:28:upper_bound	Individuals younger than 18
NCT03162731	1:26:clinical_variable,27:34:lower_bound	Absolute neutrophil count 1500/ul or more
NCT03162731	18:34:chronic_disease,38:71:treatment,83:91:lower_bound,95:105:treatment,113:120:upper_bound	Any diagnosis of immunodeficiency or current immunosuppressive therapy including >10mg/day of prednisone within 14 days of enrollment is not permitted
NCT03162731	11:23:treatment,27:44:treatment	Any prior chemotherapy or radiation therapy for the current diagnosis
NCT03162731	5:23:treatment	Any prior radiotherapy to the neck
NCT03162731	5:18:treatment,24:33:treatment,35:45:treatment,47:67:treatment	Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
NCT03162731	1:10:clinical_variable,33:64:upper_bound,87:103:chronic_disease,124:133:clinical_variable,136:143:upper_bound	Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)
NCT03162731	1:61:clinical_variable,62:63:lower_bound,64:65:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status 0-1
NCT03162731	1:11:clinical_variable,12:18:lower_bound	Hemoglobin 9 g/dl or more
NCT03162731	1:28:treatment,34:62:clinical_variable,66:70:upper_bound,132:157:chronic_disease	Inhaled or topical steroids, and adrenal replacement steroids </=10mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
NCT03162731	1:4:gender,60:65:gender,97:125:contraception_consent,159:170:upper_bound	Men of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year
NCT03162731	1:24:cancer,34:53:cancer,68:70:lower_bound,71:74:upper_bound	Oropharyngeal primaries that are HPV-mediated (p16+) must be stage II-III
NCT03162731	18:26:lower_bound,30:33:age	Patients must be 18 years of age and older
NCT03162731	30:48:chronic_disease,59:77:treatment,89:102:upper_bound	Patients that have an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease
NCT03162731	90:97:upper_bound	Patients who have participated in a study with an investigational agent or device within 2 weeks of initiation of treatment
NCT03162731	23:82:chronic_disease,86:131:chronic_disease	Patients with a known human immunodeficiency virus infection (HIV 1/2 antibodies) or acquired immunodeficiency syndrome (HIV/AIDS)
NCT03162731	27:52:chronic_disease,64:90:chronic_disease	Patients with evidence of interstitial lung disease or active, non-infectious pneumonitis
NCT03162731	28:50:chronic_disease,84:100:chronic_disease,111:127:treatment,139:150:chronic_disease,154:181:chronic_disease	Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial
NCT03162731	1:10:clinical_variable,11:21:lower_bound	Platelets 100,000/ul or more
NCT03162731	1:6:cancer,36:43:cancer,48:61:treatment	Tumor sample must be available for HPV p16 and PD-L1 testing
NCT03162731	1:18:clinical_variable,19:26:lower_bound	White blood cells 2000/ul or more
NCT03162731	1:6:gender,38:80:contraception_consent,90:99:pregnancy,104:112:lower_bound	Women of reproductive potential must use highly effective contraception methods to avoid pregnancy for 23 weeks after the last dose of study drugs
NCT03162731	1:6:gender,47:80:pregnancy,107:114:lower_bound,138:172:clinical_variable,181:189:upper_bound	Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours of the start of study drugs
NCT03162731	8:19:chronic_disease	active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive)
NCT03162731	1:10:chronic_disease,20:43:chronic_disease,44:66:clinical_variable	hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
NCT03162731	1:4:gender,13:24:chronic_disease	men who are azoospermic do not require contraception
NCT03162731	1:4:gender,67:90:contraception_consent,95:103:upper_bound	men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs
NCT03162731	49:59:chronic_disease,65:70:gender,76:78:lower_bound	menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
NCT03162731	40:50:cancer,79:94:treatment,135:142:upper_bound	patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 3 years post-diagnosis
NCT03162731	1:24:cancer	squamous cell carcinoma of the skin
NCT03162731	15:23:chronic_disease,25:49:chronic_disease,73:79:chronic_disease,80:85:chronic_disease	subjects with vitiligo, type I diabetes mellitus, or resolved childhood asthma/atopy would be an exception to this rule
NCT03162731	1:27:cancer,31:54:cancer,86:102:treatment	superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy
NCT03162731	24:41:treatment,45:50:lower_bound,57:67:treatment,84:108:treatment	syndrome that requires systemic steroids (> 10 mg daily prednisone equivalents) or immunosuppressive agents
NCT03162731	1:6:gender,51:57:gender,137:149:treatment,153:175:treatment	women of reproductive potential is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal
NCT03162731	1:6:gender,17:20:age,24:26:upper_bound,50:96:clinical_variable,107:116:lower_bound	women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level more than 40 mIU/mL
NCT03161028	9:16:lower_bound,37:47:clinical_variable,51:83:clinical_variable,85:87:upper_bound	Current Grade 1 or greater abnormal creatinine or glomerular filtration rate (GFR) <55
NCT03161028	9:34:chronic_disease,46:48:chronic_disease,56:62:cancer,64:77:chronic_disease,89:112:chronic_disease,114:144:chronic_disease	Current major disease or disorder other than MS (e.g., cancer, renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may interfere with study procedures
NCT03161028	1:40:clinical_variable,1:50:lower_bound,47:50:upper_bound,76:85:lower_bound	Expanded Disability Status Scale (EDSS) 3.0 - 6.5: ambulatory for at least 20 meters without rest and use of bilateral aids (canes, crutches, walker) or better
NCT03161028	1:3:treatment,7:20:treatment,28:41:upper_bound	IV or oral steroids in the 60 days prior to enrolment
NCT03161028	1:27:chronic_disease,19:27:chronic_disease,58:83:treatment	Insulin-dependent diabetes or diabetes not controlled on oral diabetes medications
NCT03161028	1:9:pregnancy	Pregnant
NCT03161028	53:66:treatment	Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to enrolment
NCT03161028	1:39:language_fluency	Unable to follow directions in English as standardized scales are not all validated in other languages
NCT03161028	19:22:treatment	Unable to undergo MRI
NCT03161028	18:31:upper_bound	Use of LA in the prior 2 years exceeding the equivalent of 1200mg daily for 3 months
NCT03159754	12:22:allergy_name	Allergy to penicillin plus any one of the following
NCT03159754	21:34:allergy_name,42:55:allergy_name	Hypersensitivity to ciprofloxacin and/or metronidazole
NCT03159754	1:18:chronic_disease	Immunocompromized state
NCT03159754	16:26:treatment	Patient taking tizanidine
NCT03159754	17:29:treatment	Patients taking theophylline
NCT03159754	1:9:pregnancy	Pregnant
NCT03159754	1:9:pregnancy,10:15:gender	Pregnant women
NCT03159754	10:22:chronic_disease	Previous appendicitis
NCT03159754	1:29:clinical_variable,31:33:lower_bound	White blood cell count (WBC) >15
NCT03157492	14:25:lower_bound,45:47:treatment	Greater than three years post-activation of CI
NCT03157492	11:19:upper_bound,23:26:age	Less than 18 years of age
NCT03157492	7:27:treatment,33:49:treatment	Prior Aural Rehabilitation with cochlear implant
NCT03157492	1:41:clinical_variable,50:53:lower_bound,58:61:upper_bound	Sentence recognition scores (CasperSent) between 10% and 85%
NCT03139318	1:2:lower_bound,3:11:upper_bound,15:18:age	5-21 years of age
NCT03139318	1:8:gender,16:40:pregnancy	Females with a positive urine pregnancy test
NCT03139318	25:45:treatment,50:65:treatment,74:83:treatment,87:124:cancer	Subject is eligible for routine chemotherapy and routine surgery for the treatment of non-metastatic extremity osteosarcoma
NCT03137082	103:140:clinical_variable,145:153:lower_bound	EKG evidence at baseline screening of any clinically significant conduction abnormalities including a Bazlett's QTc (corrected QT interval) of >470 msec
NCT03137082	26:54:chronic_disease	Having any other current Axis I psychiatric disorders or medical conditions requiring treatment or medication
NCT03137082	9:60:language_fluency	Must be able to read English and complete study evaluations
NCT03137082	11:84:clinical_variable,101:134:chronic_disease	Must meet Diagnostic and Statistical Manual of Mental Disorders-V (DSM- V) criteria for moderate to severe Alcohol Use Disorder (AUD)
NCT03137082	1:9:pregnancy	pregnant
NCT03134274	41:60:technology_access	Do not own or are not familiar with the use of a smartphone
NCT03134274	1:17:language_fluency	English Speaking
NCT03134274	6:14:chronic_disease	Have dementia
NCT03134274	6:21:chronic_disease	Have impaired vision that prevents them from reading instructions
NCT03134274	6:55:technology_access	Have no access to a wifi / or cellular data connection at their home
NCT03134274	1:46:technology_access	Own and are familiar with use of a smartphone
NCT03134274	1:16:chronic_disease	mental disorder
NCT03131635	20:36:chronic_disease,46:55:chronic_disease	A well-established genetic syndrome, such as Fragile X
NCT03131635	10:13:lower_bound	At least one room of the house must be available to be dedicated to treatment during session times
NCT03131635	26:29:lower_bound,30:46:language_fluency	Availability of at least one English-speaking parent who can consistently participate in parent training and research measures
NCT03131635	9:44:language_fluency	Child's primary language other than English
NCT03131635	25:33:lower_bound,37:48:treatment	Children with more than 20 hours of in-home ABA
NCT03131635	1:98:clinical_variable,100:101:lower_bound	Clinical Global Impression(CGI) Severity Social Interaction and Communication Integrated Subscale ≥4
NCT03131635	41:61:chronic_disease,69:85:chronic_disease	Current or lifetime diagnosis of severe psychiatric disorder (e.g., bipolar disorder, etc.)
NCT03131635	14:38:chronic_disease	Diagnosis of Autism Spectrum Disorder based on Autism Diagnostic Interview Revised (ADI-R), Autism Diagnostic Observation Schedule (ADOS-2), DSM-5, and expert clinical opinion
NCT03131635	1:6:gender	Males
NCT03131635	21:27:chronic_disease	Meet the cutoff for Autism on the ADOS-2
NCT03131635	1:17:treatment,25:50:treatment,53:67:treatment,69:95:treatment,99:125:treatment,139:152:lower_bound	Stable treatment (e.g., applied behavior analysis), speech therapy, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation
NCT03131635	9:12:lower_bound,17:34:upper_bound	between 2.0 and 5 years 11 months
NCT03131635	1:8:gender	females
NCT03128008	3:18:clinical_variable,21:28:upper_bound,30:62:clinical_variable,65:74:upper_bound	A total bilirubin ≤ 1.5 ULN, aspartate aminotransferase (AST) ≤ 2.0 x ULN
NCT03128008	1:26:clinical_variable,32:37:lower_bound,42:56:clinical_variable,59:66:lower_bound	Absolute neutrophil count of ≥ 1,500 and platelet count ≥ 100,000
NCT03128008	1:42:clinical_variable,48:57:lower_bound,61:98:lower_bound	Cockcroft calculated creatinine clearance of ≥ 45 ml/min or 1.5 x the upper limit of normal (ULN)
NCT03128008	39:73:cancer	Histologic/cytologic documentation of non-small cell lung cancer (NSCLC)
NCT03128008	30:50:allergy_name	Medical contraindications to thoracic irradiation
NCT03128008	1:19:pregnancy,28:33:gender	Negative pregnancy test in women of child-bearing potential
NCT03128008	1:17:chronic_disease,57:64:treatment,74:85:treatment,89:103:treatment	Pleural effusion: when pleural fluid is visible on both CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative
NCT03128008	14:41:clinical_variable,44:45:lower_bound	Pre-existing sensory neuropathy of grade ≥ 2
NCT03128008	1:27:treatment	Prior thoracic irradiation
NCT03128008	14:45:cancer	Unresectable stage II, IIIA, or IIIB disease
NCT03128008	1:31:clinical_variable,32:33:lower_bound,34:35:upper_bound	Zubrod/ECOG performance status 0-1
NCT03122535	50:55:treatment	Any patient that is not a suitable candidate for LASIK will not be included
NCT03122535	49:64:treatment	Subjects who are deemed suitable candidates for bilateral LASIK will be considered eligible for participation in this study
NCT03121352	10:31:treatment	A second post-treatment biopsy will be offered but will not be mandated
NCT03121352	1:11:clinical_variable,14:55:upper_bound	ALT (SGPT) ≤ 2.5 X institutional upper limit of normal
NCT03121352	1:11:clinical_variable,14:55:upper_bound	AST (SGOT) ≤ 2.5 X institutional upper limit of normal
NCT03121352	1:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	ECOG Performance Status 0-1
NCT03121352	1:11:clinical_variable,14:23:lower_bound	Hemoglobin ≥ 10.0 g/dl
NCT03121352	45:116:allergy_name,118:129:allergy_name,131:144:allergy_name,149:161:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, carboplatin, pembrolizumab, or other agents used in this study
NCT03121352	10:26:chronic_disease,49:65:treatment	Patients active infection requiring intravenous systemic therapy
NCT03121352	35:56:treatment	Patients who have participated in MK-3475 Merck studies
NCT03121352	30:42:treatment,50:63:upper_bound,85:98:treatment	Patients who have received a live vaccine within 30 days prior to the first dose of pembrolizumab
NCT03121352	28:40:treatment,42:73:treatment,77:86:treatment,98:105:upper_bound,123:134:treatment	Patients who have received chemotherapy, small molecule targeted therapy or radiation within the 2 weeks of first dose of study drugs
NCT03121352	28:59:treatment,67:74:upper_bound	Patients who have received monoclonal anti-cancer antibody within 4 weeks of first dose of study drugs
NCT03121352	34:44:cancer,77:93:treatment,106:118:upper_bound	Patients with a known additional malignancy that is progressing or requires active treatment (within the last 5 years)
NCT03121352	15:39:cancer	Patients with carcinomatous meningitis
NCT03121352	15:41:chronic_disease	Patients with chronic autoimmune disease
NCT03121352	36:65:treatment,69:87:chronic_disease,99:112:chronic_disease,114:131:chronic_disease	Patients with conditions requiring immunosuppressive medications or chronic infections (including HIV infection, hepatitis B and C)
NCT03121352	50:59:chronic_disease	Patients with evidence of active, non-infectious pneumonia
NCT03121352	15:28:treatment,34:74:treatment,82:91:treatment,93:103:treatment	Patients with prior therapy with antibodies that modulate T-cell function (e.g., anti-PD-1, anti-PD-L1)
NCT03121352	1:15:clinical_variable,18:28:lower_bound	Platelet count ≥ 100,000/μL
NCT03121352	1:17:clinical_variable,20:51:upper_bound	Serum creatinine ≤ 1.5 normal institutional limits
NCT03121352	42:49:upper_bound,50:59:treatment	Subjects must have received no more than 2 prior therapies for this disease
NCT03121352	47:63:cancer	Subjects with radiographically stable treated brain metastases
NCT03121352	28:48:chronic_disease,90:106:chronic_disease,120:144:chronic_disease,146:170:chronic_disease,172:190:chronic_disease,195:232:chronic_disease	Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT03121352	1:16:clinical_variable	Total bilirubin within normal institutional limits
NCT03121352	1:21:cancer	basal cell carcinoma of the skin
NCT03121352	23:38:treatment,52:59:lower_bound	must not have been on steroid therapy for at least 4 weeks
NCT03121352	46:56:cancer	willing to undergo a preliminary biopsy of a metastatic focus for research purposes
NCT03119363	24:41:chronic_disease,80:86:chronic_disease,105:115:treatment,177:179:clinical_variable,180:187:upper_bound	Confounding underlying medical illnesses which may cause fatigue (e.g., severe Anemia not controlled by medication, per self-report corroborated by medical chart review (e.g., Hb<10gm/dl)
NCT03119363	1:13:chronic_disease,80:89:chronic_disease,91:99:chronic_disease,131:151:chronic_disease,153:162:chronic_disease,164:187:chronic_disease,191:204:chronic_disease	Eye Diseases which limit the ability of light to be processed (e.g., untreated cataracts, glaucoma that causes visual impairment, macular degeneration, blindness, pupil dilation problems or retina damage)
NCT03119363	1:10:pregnancy	Pregnancy
NCT03119363	1:74:treatment	Previous use of light therapy to alleviate fatigue or depressive symptoms
NCT03119363	1:17:cancer,58:70:upper_bound	Secondary cancer diagnosis (prior or current) within the past 5 years
NCT03119363	8:32:chronic_disease,86:100:upper_bound	Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months)
NCT03119363	8:23:chronic_disease,30:40:chronic_disease	Severe sleep disorders (e.g. Narcolepsy)
NCT03119363	7:10:age,11:13:upper_bound	Under age 18
NCT03119363	24:27:age,28:30:upper_bound,53:55:lower_bound,71:75:treatment	Who are currently over age 18 and were at least age 16 at the time of ASCT
NCT03119363	19:23:treatment,41:67:cancer,76:78:cancer,80:85:cancer	With a history of ASCT as treatment for hematological malignancies such as MM, DLBCL, and related diseases and who are between three months and five years post-transplant
NCT03119363	36:38:upper_bound,46:65:clinical_variable	With a score equal to or less than 35 on the FACIT-Fatigue scale (see below)
NCT03117556	16:46:cancer	Diagnosed with stage III/IV pancreatic cancer
NCT03117556	18:40:treatment,62:68:cancer	Participating in another clinical trial for the treatment of cancer at the time of screening
NCT03115463	1:20:clinical_variable	Non-viable newborns
NCT03115463	22:53:chronic_disease	Prenatally diagnosed congenital diaphragmatic hernia
NCT03115463	22:55:chronic_disease	Prenatally diagnosed cyanotic congenital heart disease
NCT03115463	1:4:age,5:7:lower_bound,8:16:upper_bound	age 23-30 weeks
NCT03114124	41:48:lower_bound,54:63:treatment	Patients must be available for at least 1 month post procedure
NCT03114124	43:51:lower_bound	Patients must be greater than or equal to 18 years old
NCT03112824	1:21:technology_access	Access to a computer and are able to enter information into the computer
NCT03112824	1:4:age,5:7:lower_bound,11:19:upper_bound	Age 18 to 70 years
NCT03112824	1:4:bmi,8:16:lower_bound,22:35:chronic_disease,39:47:lower_bound	BMI of 27 kg/m2 with comorbidities or 30 kg/m2 and above
NCT03112824	22:38:treatment	Currently undergoing cancer treatment
NCT03112824	1:11:treatment	Fluoxetine
NCT03112824	1:15:treatment	MAO inhibitors
NCT03112824	1:21:chronic_disease	Oral Corticosteroids
NCT03112824	1:35:clinical_variable,41:43:lower_bound	Perceived Stress Scale (PSS) score of ≥ 20 at screening
NCT03112824	1:9:pregnancy,10:15:gender	Pregnant women
NCT03112824	1:7:treatment	SSRI's
NCT03112824	20:32:upper_bound	Started within the last 14 days or plan to start taking
NCT03112824	16:28:treatment	Taking chronic anti-anxiety
NCT03112824	1:26:treatment	Tricyclic antidepressants
NCT03112824	1:25:treatment	anti-insomnia medication on a regular basis
NCT03112824	1:13:treatment,26:37:treatment	anti-obesity (other than phentermine)
NCT03112824	79:86:upper_bound	unwilling to stop taking these classes of medications for the duration of the 12 week trial
NCT03112603	1:32:clinical_variable,35:44:lower_bound	Absolute neutrophil count (ANC) > 1000/mm^3
NCT03112603	5:27:treatment,55:60:clinical_variable,72:83:lower_bound,84:102:treatment,124:130:upper_bound	Any corticosteroid therapy for indications other than cGvHD at doses > 1 mg/kg/day methylprednisolone or equivalent within 7 days of Cycle 1 Day 1
NCT03112603	10:13:lower_bound	At least one organ (not lung) with a score of 2, 3 or more organs involved with a score of 1 in each organ, or lung score of 1
NCT03112603	59:68:treatment,74:84:treatment,90:103:lower_bound,107:130:lower_bound,144:151:lower_bound	Disease persistence without improvement despite continued treatment with prednisone at > 0.5 mg/kg/day or 1 mg/kg/every other day for at least 4 weeks
NCT03112603	8:21:treatment,33:46:upper_bound	Failed prior alloSCT within the past 6 months from Cycle 1 Day 1
NCT03112603	16:62:treatment	Have undergone allogeneic stem cell transplantation (alloSCT) from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood
NCT03112603	52:64:chronic_disease	Participants with clinically diagnosed moderate to severe cGvHD according to NIH Consensus Criteria prior to randomization
NCT03112603	28:46:cancer	Participants with relapsed primary malignancy
NCT03112603	26:31:upper_bound,55:69:treatment,110:125:treatment	Patients receiving up to 30 mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids
NCT03112603	38:43:chronic_disease,47:52:chronic_disease,74:95:treatment,113:122:treatment	Patients that transition from active aGvHD to cGvHD without tapering off corticosteroids ± CNI and any systemic treatment
NCT03112603	1:13:chronic_disease	Severe cGvHD
NCT03112603	1:8:treatment,20:25:chronic_disease,58:89:treatment,107:127:treatment,131:141:cancer	Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence
NCT03112603	21:56:treatment,78:83:chronic_disease,104:119:upper_bound	currently receiving systemic or topical corticosteroids for the treatment of cGvHD for a duration of < 12 months prior to Cycle 1 Day 1 (if applicable)
NCT03112603	205:239:treatment,250:268:treatment,270:297:treatment,299:340:treatment,342:352:treatment,354:363:treatment,365:376:treatment,378:386:treatment,388:397:treatment	must accept to be treated with only one of the following BAT options on Cycle 1 Day 1 (additions and changes are allowed during the course of the study, but only with BAT from the following BAT options): extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, ibrutinib
NCT03112603	68:91:treatment,105:118:lower_bound	participant achieved complete or partial response and has been off JAK inhibitor treatment for at least 8 weeks prior to Cycle 1 Day 1
NCT03112603	1:15:clinical_variable,18:30:lower_bound	platelet count > 25,000/ mm^3
NCT03112603	19:20:lower_bound,29:47:treatment,52:57:chronic_disease,73:88:treatment,91:94:treatment	who have received 2 or more systemic treatment for cGvHD in addition to corticosteroids ± CNI for cGvHD
NCT03112603	31:34:treatment,52:72:treatment,99:109:cancer	who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse
NCT03112603	29:43:treatment,48:53:chronic_disease	who were treated with prior JAK inhibitors for aGvHD
NCT03111017	1:26:chronic_disease,47:59:chronic_disease,64:72:chronic_disease,77:114:chronic_disease,118:131:chronic_disease	Chronic medical condition (e.g. self reported hypertension, or diabetes, or chronic obstructive pulmonary disease or heart disease)
NCT03111017	14:39:chronic_disease,43:67:chronic_disease	Greater than moderate valvular disease or congenital heart disease
NCT03111017	1:35:clinical_variable,37:40:lower_bound	Left ventricular ejection fraction ≥50%
NCT03111017	16:19:age	matched to the age and sex of HFpEF patients
NCT03109262	1:9:pregnancy	pregnant
NCT03109262	18:40:treatment,44:58:cancer	referred for 90Y SIRT radioembolization of liver tumor(s)
NCT03108950	8:23:chronic_disease	Active pressure ulcers
NCT03108950	32:41:chronic_disease	Current use of medications for psychosis
NCT03108950	16:22:chronic_disease	Diagnosed with stroke
NCT03108950	8:21:clinical_variable,27:36:upper_bound,40:46:upper_bound	Recent weight change (+/- 25 pounds in 1 year)
NCT03108950	1:14:chronic_disease	Renal failure
NCT03108950	1:25:chronic_disease	Severe pulmonary disease
NCT03091790	1:17:chronic_disease	Active infection
NCT03091790	28:49:treatment	Patient scheduled for open ventral hernia repair at LBJ General Hospital
NCT03091790	38:50:upper_bound	Patient unlikely to survive with the next 2 years based upon surgeon judgment
NCT03088592	1:4:age,5:7:lower_bound,10:18:upper_bound,22:25:age	Age 18 - 85 years of age
NCT03088592	26:42:lower_bound	Alcohol use of more than 4 drinks per day
NCT03088592	47:57:chronic_disease,59:62:clinical_variable,63:65:lower_bound	Currently uncontrolled clinically significant depression (BDI>20)
NCT03088592	49:60:treatment	Medically cleared for undergoing anesthesia and DBS surgery
NCT03088592	1:10:pregnancy	Pregnancy
NCT03087799	1:4:age,5:7:lower_bound,8:10:upper_bound	Age 20-50
NCT03087799	1:17:clinical_variable,21:23:lower_bound	ISI cutoff score of 10 or higher
NCT03087799	1:28:chronic_disease,43:57:chronic_disease	Major psychiatric diagnosis with comorbid sleep problems
NCT03087799	30:33:chronic_disease	Meet diagnostic criteria for IBS
NCT03087799	1:10:pregnancy	Pregnancy (self-reported)
NCT03087799	23:26:chronic_disease,40:47:lower_bound	Stable medication for IBS for at least 1 month
NCT03087799	42:49:lower_bound	Stable medication for sleep for at least 1 month
NCT03087799	7:28:chronic_disease	other neurological disorder
NCT03085043	35:51:treatment,57:92:treatment,100:106:treatment,108:117:treatment,119:130:treatment,132:144:treatment,149:172:treatment	Currently receiving or history of systemic therapy with testosterone suppressing medication (i.e., lupron, degarelix, abiraterone, enzalutamide) or local radiation therapy
NCT03085043	1:14:clinical_variable,17:18:lower_bound	Gleason score = 8/ > 8
NCT03085043	28:38:cancer,44:57:clinical_variable,73:74:upper_bound	Patient is at low risk for metastasis with Gleason score at diagnosis < 8
NCT03085043	1:19:cancer,46:56:cancer	Prostate carcinoma patients at high risk for metastasis
NCT03085043	1:32:clinical_variable,43:51:lower_bound	prostate-specific antigen (PSA) more than 20 ng/ml
NCT03076333	1:24:chronic_disease,47:73:treatment	Active vaginal bleeding requiring packing and emergent radiation therapy
NCT03076333	1:4:age,7:15:lower_bound,19:22:age	Age ≥ 18 years of age (no upper age limit)
NCT03076333	1:22:bmi,25:27:lower_bound	Body Mass Index (BMI) > 35
NCT03076333	20:30:cancer,38:50:upper_bound	History of a prior malignancy within past 5 years
NCT03076333	61:67:lower_bound	Inability to tolerate MRI (e.g., inability to lie flat for >1 hour)
NCT03076333	31:48:treatment,52:75:treatment	Medical conditions precluding radiation therapy or curative intent surgery
NCT03076333	41:58:treatment,63:86:treatment	Must be in acceptable health to undergo radiation therapy and curative intent surgery as assessed by UNC surgeons and radiation oncologist
NCT03076333	20:49:treatment,54:77:treatment	Must receive their neoadjuvant radiation therapy and curative intent surgery at UNC Hospitals
NCT03076333	19:36:chronic_disease	Poorly controlled diabetes mellitus
NCT03076333	1:10:pregnancy	Pregnancy
NCT03076333	40:57:treatment	Previous radiation exposure precluding radiation therapy
NCT03076333	1:6:gender,45:78:pregnancy,101:113:upper_bound	Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to each PET/MRI
NCT03076333	1:22:chronic_disease	intracranial aneurysm clip
NCT03076333	11:17:gender	lactating female
NCT03075085	1:5:age,6:7:lower_bound,8:15:upper_bound	aged 3-5 years old in our partnering Head Start agency
NCT03067051	39:49:clinical_variable,52:62:upper_bound	Adequate renal function as defined by creatinine ≤ 1.5 mg /dl
NCT03067051	1:61:clinical_variable,65:66:lower_bound,70:71:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
NCT03067051	1:18:clinical_variable,21:29:lower_bound	Expected survival ≥ 8 months
NCT03067051	1:14:clinical_variable,17:18:lower_bound	Gleason score ≥ 8 at initial diagnosis
NCT03067051	1:6:gender	Males
NCT03067051	1:18:chronic_disease,22:41:chronic_disease	Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give informed consent or to complete follow-up visits
NCT03067051	10:17:treatment,25:47:treatment	On-going therapy with a photosensitizing agent
NCT03067051	1:10:chronic_disease	Porphyria or other diseases exacerbated by light
NCT03067051	49:66:clinical_variable,69:77:lower_bound,79:93:clinical_variable,96:107:lower_bound	Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3
NCT03067051	60:77:treatment,92:107:cancer	gone through external or internal, high dose rate (brachy) radiation therapy for localized prostate cancer with histopathologically verified local recurrence
NCT03067051	12:20:clinical_variable,21:28:lower_bound,56:57:lower_bound,105:113:lower_bound,134:154:treatment,156:173:chronic_disease,188:197:treatment	history of CTCAE v4 grade 3 or greater or persistent (>1 separate episode or symptoms lasting more than 3 months after initiation of medical intervention) grade 2 proctitis attributed to radiation
NCT03067051	19:41:cancer,46:64:cancer	locally advanced (AJCC 7th edition T3/T4) or metastatic disease
NCT03067051	18:25:treatment,29:50:treatment	not eligible for surgery or curative radiotherapy
NCT03067051	7:32:chronic_disease	other severe concurrent disease
NCT03067051	7:16:clinical_variable,19:28:upper_bound	total bilirubin ≤ 1.5 mg/dl
NCT03067051	14:31:treatment,32:45:treatment	treated with seed implantation brachytherapy
NCT03062462	1:26:clinical_variable,29:37:upper_bound	Creatinine clearance rate < 30ml/min
NCT03062462	14:52:chronic_disease	Diagnosed as respiratory or circulatory instability
NCT03062462	1:5:clinical_variable,19:22:lower_bound,59:79:clinical_variable,104:120:treatment,138:141:lower_bound	PAgR is more than 46% and the percentage of inhibition of ADP-induced platelet aggregation measured by thrombelastogram is not more than 30%
NCT03062462	1:15:clinical_variable,17:23:upper_bound	Platelet count <100g/L
NCT03062462	5:89:clinical_variable,116:119:upper_bound	The platelet aggregation rate (PAgR) measured with light transmission aggregometry (LTA) is decreased no more than 10% from baseline level
NCT03062462	1:14:chronic_disease	cardiac shock
NCT03062462	1:43:chronic_disease	severe congestive heart failure NYHA II-IV
NCT03058029	1:48:clinical_variable,49:54:clinical_variable,56:60:lower_bound,63:74:lower_bound	Abnormal serum thyroid-stimulating hormone(TSH) HbA1c >8.5% (>69 mmol/mol)
NCT03058029	48:55:gender	Absence of medically approved contraception in females of childbearing potential[exempli gratia (e.g.), hysterectomy, oral contraceptive medications,intrauterine device combined with a barrier method, two (2) combined barrier methods such as diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal ligation and vasectomy are acceptable contraceptive methods when combined with another single method from above]
NCT03058029	19:37:treatment,39:57:treatment,59:69:treatment,73:83:treatment	Administration of Prototype 2 (GSP2), Prototype 3 (GSP3), Gelesis100,or Gelesis200 in a previous study
NCT03058029	1:7:chronic_disease,9:24:treatment,29:50:chronic_disease,58:76:upper_bound	Angina, coronary bypass, or myocardial infarction within six(6)months prior to Screening Visit
NCT03058029	1:25:treatment,33:52:upper_bound,33:46:lower_bound,96:105:treatment,110:126:treatment,171:186:chronic_disease	Antidiabetic medications within one (1) month prior to Screening Visit [except stable doses of metformin and DPP-4 inhibitors for at least one (1) month in subjects with Type 2 Diabetes]
NCT03058029	71:90:upper_bound	Any other medication known to cause weight loss or weight gain within one (1) month prior to Screening Visit
NCT03058029	1:18:treatment,32:48:upper_bound	Blood transfusion within three (3) months prior to Screening Visit
NCT03058029	1:22:clinical_variable,24:26:lower_bound,32:59:upper_bound	Body Mass Index (BMI) ≥27 and ≤40 kilogram (kg)/meter (M)2
NCT03058029	32:44:chronic_disease,52:71:upper_bound	Change in medications treating dyslipidemia within one (1) month prior to Screening Visit
NCT03058029	11:22:treatment,32:44:chronic_disease,52:71:upper_bound	Change in medications treating hypertension within one (1) month prior to Screening Visit
NCT03058029	1:9:chronic_disease	Diabetic subjects
NCT03058029	1:22:clinical_variable,24:57:upper_bound	Fasting serum insulin <24 microunit (µU)/milliliter (mL)at both Screening Visits in normoglycemic subjects Ability to follow verbal and written instructions Consent obtained via signed ICF
NCT03058029	12:41:treatment	History of abdominal radiation treatment
NCT03058029	12:18:cancer,30:48:upper_bound	History of cancer within the past five(5) years
NCT03058029	12:28:chronic_disease,85:91:clinical_variable,93:99:lower_bound,115:128:clinical_variable,130:132:lower_bound	History of eating disorders including binge eating (except for mild binge eating)or emesis ≥2/week from any cause Weight change >3% within three(3) months prior to and during the Screening period
NCT03058029	12:26:treatment,40:55:treatment	History of gastric bypass or any other gastric surgery
NCT03058029	12:37:chronic_disease	History of gastric or duodenal ulcer
NCT03058029	12:28:chronic_disease,29:73:chronic_disease	History of hepatitis B or C History of human immunodeficiency virus(HIV)
NCT03058029	12:34:chronic_disease,94:105:chronic_disease	History of intestinal obstruction or high risk of intestinal obstruction,including suspected small bowel adhesions
NCT03058029	12:32:chronic_disease,40:55:chronic_disease	History of intestinal stricture (e.g., Crohn's disease)
NCT03058029	12:24:chronic_disease,36:50:upper_bound	History of pancreatitis within the past 12 months
NCT03058029	12:33:chronic_disease,56:68:treatment	History of small bowel resection (except if related to appendectomy)
NCT03058029	7:22:chronic_disease	Known Type 1 Diabetes
NCT03058029	1:5:gender	Male
NCT03058029	5:13:chronic_disease	Non-diabetic subjects
NCT03058029	1:14:clinical_variable,29:32:clinical_variable,34:66:lower_bound,72:81:upper_bound,84:113:lower_bound,119:129:upper_bound,161:166:clinical_variable,168:172:upper_bound,175:186:upper_bound	Normoglycemic subjects with FPG ≥90 milligram (mg)/deciliter (dL) and <100 mg/dL [≥5.0millimole (mmol)/liter (L) and <5.6 mmol/L] at both Screening Visits with HbA1c <5.7% (<39 mmol/mol)
NCT03058029	120:155:treatment,195:213:upper_bound	Positive test for drugs of abuse in the urine Any relevant biochemical abnormality interfering with the assessments of Gelesis200 Anti-obesity medications (including herbal preparations) within one(1) month prior to Screening Visit
NCT03058029	27:30:clinical_variable,31:40:lower_bound,46:54:upper_bound,57:87:lower_bound,93:102:upper_bound,134:139:clinical_variable,141:145:upper_bound,147:165:upper_bound	Prediabetic subjects with FPG≥100 mg/dL and <126mg/dL [≥5.6 millimole (mmol)/liter (L) and <7.0mmol/L] at both Screening Visits with HbA1c ≤6.4%[≤46 mmol/mole (mol)]
NCT03058029	1:10:pregnancy	Pregnancy
NCT03058029	1:48:clinical_variable,49:57:lower_bound,60:70:lower_bound	Serum low-density lipoprotein (LDL) cholesterol≥160mg/dL (≥4.15mmol/L)
NCT03058029	1:20:clinical_variable,22:31:lower_bound,34:44:lower_bound	Serum triglycerides ≥350 mg/dL (≥3.96mmol/L)
NCT03058029	26:45:upper_bound	Smoking cessation within six(6) months prior to Screening Visit or considering smoking cessation during the study
NCT03058029	1:37:clinical_variable,39:72:lower_bound,79:115:clinical_variable,117:123:lower_bound	Supine systolic blood pressure (SBP) >160 millimeters of mercury (mmHg)and/or supine diastolic blood pressure(DBP) >95mmHg
NCT03058029	1:25:treatment,33:52:upper_bound	Systemic corticosteroids within one (1) month prior to Screening Visit
NCT03058029	41:60:upper_bound,103:122:treatment,136:149:lower_bound	Thyroid hormones or preparations within one (1) month prior to Screening Visit [except stable dose of replacement therapy for at least two(2) months]
NCT03058029	25:28:clinical_variable,30:39:upper_bound,42:53:upper_bound,217:222:clinical_variable,224:228:lower_bound,231:242:lower_bound	Untreated subjects with FPG ≤200 mg/dL (≤11.2 mmol/L)at both Screening Visits and either FPG ≥126 mg/dL (≥7.0 mmol/L) at both Screening Visits or FPG <126 mg/dL (<7.0 mmol/L) at one (1) or both Screening Visits with HbA1c ≥6.5% (≥48 mmol/mol)
NCT03058029	30:52:cancer,71:86:cancer	adequately-treated localized basal cell skin cancer or in situuterine cervical cancer
NCT03058029	1:7:gender	female
NCT03058029	75:83:lower_bound,86:95:lower_bound,101:106:clinical_variable,118:122:lower_bound,125:136:lower_bound,143:147:upper_bound,149:160:upper_bound	if only one (1)value is within this range, the other value should not be ≥126mg/dL (≥7.0mmol/L) and HbA1c should be ≥5.7% (≥39 mmol/mol) and ≤6.4%(≤46 mmol/mol)
NCT03058029	1:34:pregnancy,46:53:gender	positive serum or urine pregnancy test(s) in females of childbearing potential
NCT03053908	40:70:clinical_variable,79:83:clinical_variable,84:86:lower_bound	All subjects enrolled will have both a Clinical Dementia Rating (CDR)=0 and a MMSE≥27
NCT03053908	41:49:lower_bound	All subjects will have had a minimum of 12 years of education
NCT03053908	26:29:lower_bound	Among minority subjects >80% of the elderly individuals coming to the NYU-ADC meet this criterion
NCT03053908	1:27:clinical_variable,41:42:lower_bound	Geriatric Depression Scale (short form)>5
NCT03053908	59:62:age,64:72:upper_bound,74:82:chronic_disease	History of a first-degree family member with early onset (age <60 years) dementia
NCT03053908	12:23:cancer	History of brain tumor
NCT03053908	1:29:chronic_disease	Irregular sleep-wake rhythms (based on the actigraphy recordings)
NCT03053908	17:46:chronic_disease,69:75:chronic_disease	MRI evidence of brain damage or brain disease including significant trauma
NCT03053908	1:5:gender	Male
NCT03053908	1:20:chronic_disease	Parkinson's disease
NCT03053908	48:85:chronic_disease	Presence of any known or suspected obstructive disease of the gastrointestinal tract
NCT03053908	10:32:chronic_disease	Subjects hypomotility disorders of the gastrointestinal tract including but not limited to Ileus
NCT03053908	17:30:clinical_variable,32:33:lower_bound	Subjects with a Fazekas scale >2
NCT03053908	1:8:chronic_disease	bipolar
NCT03053908	1:46:chronic_disease	diverticulitis and inflammatory bowel disease
NCT03053908	1:7:gender	female
NCT03053908	1:14:chronic_disease	hydrocephalus
NCT03053908	22:38:chronic_disease	life-long history of major depression
NCT03053908	1:19:chronic_disease,29:58:chronic_disease	mental retardation or other serious neurological disorder
NCT03053908	7:25:chronic_disease	other movement disorders
NCT03053908	1:10:chronic_disease	pulmonary
NCT03053908	1:14:chronic_disease	schizophrenia
NCT03053908	1:9:chronic_disease	seizures
NCT03053908	36:38:lower_bound,39:47:upper_bound,51:54:age	subjects with normal cognition and 55-75 years of age
NCT03053271	1:4:bmi,13:15:lower_bound,20:28:upper_bound	BMI between 18 and 60 kg/m2, inclusive
NCT03053271	10:13:clinical_variable,14:17:lower_bound,21:53:upper_bound	Baseline UFC 1.3 to 10 × upper limit of normal (ULN)
NCT03053271	16:34:treatment,38:56:chronic_disease	Candidates for surgical treatment of Cushing's syndrome, unless surgery is not anticipated to occur during the study
NCT03053271	1:26:chronic_disease	Pseudo-Cushing's syndrome
NCT03053271	1:13:treatment,38:46:upper_bound	Radiotherapy of the pituitary within 6 months
NCT03053271	9:38:chronic_disease	current iatrogenic Cushing's syndrome
NCT03053271	1:26:chronic_disease	cyclic Cushing's syndrome
NCT03051282	3:27:pregnancy	A positive urine pregnancy test in the MCRU prior to the study
NCT03051282	1:7:ethnicity	Asians will not be included in the study as the CES1 SNP G143E is absent in this population
NCT03051282	28:33:upper_bound	No subjects weighing under 50 kg will be selected
NCT03051282	27:37:chronic_disease	Subject with a history of angioedema
NCT03051282	28:37:allergy_name	Subjects hypersensitive to enalapril
NCT03051282	13:17:age,21:23:lower_bound,24:32:upper_bound	between the ages of 18-55 years
NCT03051282	45:52:treatment,55:67:lower_bound	habitual consumption of large quantities of ethanol (>3 drinks/day)
NCT03046771	47:53:upper_bound	EMTs who expect to leave the job in less than 1 year
NCT03046771	10:13:age,17:25:lower_bound	over the age of 18 years
NCT03043963	1:18:pregnancy	current pregnancy
NCT03043963	16:25:treatment,29:38:treatment	current use of hypnotics or clonidine
NCT03043963	1:9:chronic_disease,54:59:clinical_variable,60:64:lower_bound	diabetic patients who are insulin dependent (or have HbA1c>9.0%)
NCT03043963	5:17:chronic_disease,45:47:clinical_variable,49:55:lower_bound,61:68:upper_bound	pre-hypertension or stage one hypertension (BP ≥120/80 and <160/100)
NCT03043963	1:28:chronic_disease	renal/electrolyte disorders and any other condition that the study screening physician considers would significantly impede participation in the study
NCT03043963	36:51:chronic_disease	significant active or uncontrolled sleep disorders
NCT03043807	32:63:clinical_variable,64:72:upper_bound,74:88:clinical_variable,90:101:upper_bound,103:113:clinical_variable,115:121:upper_bound	Abnormal bone marrow function [absolute neutrophil count (ANC)<1500/mm3, platelet count <100,000/mm3, hemoglobin <9 g/dL]
NCT03043807	26:35:clinical_variable,42:45:clinical_variable,47:50:clinical_variable,53:80:lower_bound	Abnormal liver function (bilirubin >ULN; AST, ALT > 2.5 x upper limit of normal)
NCT03043807	1:23:chronic_disease,35:48:chronic_disease,50:86:chronic_disease,91:112:chronic_disease,120:139:upper_bound	Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within previous six months
NCT03043807	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT03043807	1:14:treatment,21:33:treatment,35:45:treatment	Antiandrogens (e.g. bicalutamide, nilutamide)
NCT03043807	37:51:cancer	Documented histologically confirmed adenocarcinoma of the prostate
NCT03043807	1:61:clinical_variable,63:64:upper_bound	Eastern cooperative oncology group (ECOG) performance status ≤2
NCT03043807	59:70:chronic_disease	Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study
NCT03043807	1:17:treatment,24:34:treatment,36:45:treatment,47:58:treatment,60:69:treatment	Hormonal therapy (e.g. leuprolide, goserelin, triptorelin, degarelix)
NCT03043807	18:28:cancer,36:48:upper_bound,71:121:cancer,129:141:cancer	Prior history of malignancy in the past 3 years with the exception of basal cell and squamous cell carcinoma of the skin. Other malignancies that are considered to have a low potential to progress may be enrolled at discretion of PI
NCT03043807	1:33:treatment,43:58:cancer,65:82:treatment,84:97:treatment	Prior local non-surgical therapy to treat prostate cancer (e.g. radiation therapy, brachytherapy)
NCT03043807	18:34:treatment,39:54:cancer	Prior or ongoing systemic therapy for prostate cancer
NCT03043807	1:16:treatment,42:49:upper_bound	hormone therapy was recently initiated (<90 days duration))
NCT03037502	1:4:age,6:8:lower_bound,9:11:upper_bound	Age: 35-64 at enrollment
NCT03037502	1:4:bmi,6:8:lower_bound,9:11:upper_bound	BMI: 30-50
NCT03037502	1:59:language_fluency	Fluent in English (Nashville and Miami) or Spanish (Miami)
NCT03037502	1:35:treatment	Prior or planned bariatric surgery
NCT03037502	18:34:ethnicity,36:41:ethnicity,45:51:ethnicity,53:61:ethnicity	Race/ ethnicity: African American/ Black or Latino/ Hispanic
NCT03037502	1:7:clinical_variable,18:28:upper_bound	Weight less than 400 pounds
NCT03035799	7:21:chronic_disease	Known Celiac disease
NCT03035799	10:33:language_fluency	Patients unable to speak English
NCT03035799	32:62:chronic_disease,84:91:chronic_disease,95:105:chronic_disease	Patients with mild to moderate Irritable Bowel Syndrome (IBS) and mild to moderate anxiety or depression
NCT03035799	1:9:pregnancy	Pregnant
NCT03035799	14:29:chronic_disease,49:97:clinical_variable	Uncontrolled thyroid disease as indicated by an abnormal thyroid stimulating hormone (TSH) level
NCT03035799	9:14:gender	nursing women
NCT03034395	1:7:treatment,15:36:cancer	Biopsy proven T2 malignant melanoma
NCT03034395	1:48:clinical_variable,52:53:lower_bound,54:55:upper_bound	Eastern Cooperative Oncology Group (ECOG) score of 0-2
NCT03034395	1:9:cancer	Melanoma located on face or digits
NCT03034395	20:38:treatment	Unable to tolerate general anesthesia
NCT03032328	14:26:pregnancy	Patients who are pregnant
NCT03032328	32:41:chronic_disease,43:53:chronic_disease,58:78:chronic_disease,119:144:chronic_disease	Patients will be excluded if a metabolic, mechanical, or mucosal inflammatory cause has been defined to explain their gastrointestinal symptoms
NCT03032328	113:122:chronic_disease	Patients will be recruited from the pediatric GI clinic if they meet Rome III criteria for childhood functional dyspepsia with nausea as the predominant symptom
NCT03032328	15:23:chronic_disease,110:131:chronic_disease	Patients with diabetes will be excluded due to the possibility that the autonomic dysfunction results from a peripheral neuropathy
NCT03032328	16:42:chronic_disease,44:58:chronic_disease,60:87:chronic_disease,89:102:chronic_disease,107:124:chronic_disease	a diagnosis of inflammatory bowel disease, celiac disease, liver or pancreatic disease, hiatal hernia, or bowel obstruction
NCT03032328	1:4:age,14:16:lower_bound,17:25:upper_bound	age range of 10-18 years
NCT03029884	1:18:chronic_disease,20:23:clinical_variable,26:28:lower_bound,39:84:chronic_disease,86:117:chronic_disease,119:132:chronic_disease,134:150:chronic_disease,152:187:chronic_disease	Active depression (BDI > 20) or other untreated or uncontrolled psychiatric illness (active general anxiety disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder (OCD)
NCT03029884	1:4:age,7:15:lower_bound	Age ≥ 21 years
NCT03029884	57:68:allergy_name,82:90:allergy_name,92:104:allergy_name,106:114:allergy_name,116:130:allergy_name,132:147:allergy_name	Allergies or known hypersensitivity to materials in the Activa PC+S system (i.e. titanium, polyurethane, silicone, polyetherimide, stainless steel)
NCT03029884	1:8:chronic_disease	Aphasia severe enough to limit the consent process or communication between the investigators and the patient
NCT03029884	57:75:chronic_disease,132:151:treatment	Clinical diagnosis of post-stroke pain (thalamic pain), spinal cord injury or phantom limb pain with allodynia or dysesthesia with pinprick anesthesia or hypoesthesia on the affected hemibody or limb (anesthesia dolorosa)
NCT03029884	1:13:chronic_disease	Coagulopathy
NCT03029884	46:61:treatment,63:80:treatment,84:99:treatment	Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or medication pump
NCT03029884	14:41:language_fluency	Inability to speak and / or read English
NCT03029884	19:27:treatment,31:64:treatment,69:76:treatment	Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery
NCT03029884	18:26:upper_bound,115:136:chronic_disease	MRI (done within one year of the first visit) with significant abnormalities other than those associated with the neurological disorder causing chronic pain
NCT03029884	1:4:treatment,17:25:upper_bound,62:69:treatment	MRI done within one year not showing any contraindication to surgery such as mass, lesion, hemorrhage or other abnormality near target
NCT03029884	1:4:treatment,17:25:upper_bound,58:65:treatment,74:78:chronic_disease,80:86:chronic_disease,88:98:chronic_disease	MRI done within one year not showing contraindication to surgery such as mass, lesion, hemorrhage or other abnormality near target
NCT03029884	7:28:chronic_disease,87:95:chronic_disease,97:124:chronic_disease,143:150:chronic_disease	Major neurological disorder other than the one that led to the chronic pain including epilepsy, neurodegenerative condition or any history of seizure
NCT03029884	179:182:treatment	Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS
NCT03029884	23:34:treatment,224:239:treatment,242:265:treatment	Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation / antiaggregation therapy discontinuation
NCT03029884	14:29:pregnancy	Patients who become pregnant after enrollment may be excluded from the study
NCT03029884	1:18:chronic_disease	Phantom limb pain
NCT03029884	1:17:chronic_disease	Post-Stroke Pain
NCT03029884	1:10:pregnancy	Pregnancy or breast feeding
NCT03029884	10:39:treatment,66:88:chronic_disease	Previous ablative intracranial surgery for the management of the thalamic pain syndrome
NCT03029884	13:33:chronic_disease,47:51:clinical_variable,54:56:upper_bound	Significant cognitive impairment or Dementia (MoCA < 25)
NCT03029884	1:28:chronic_disease	Stroke of ischemic etiology only
NCT03029884	1:16:clinical_variable,21:30:upper_bound	Suicide attempt </= 12 months or imminent suicide risk
NCT03029884	1:6:gender,23:26:age,38:88:contraception_consent	Women of childbearing age must be on regular use of an accepted contraceptive method(s)
NCT03029884	1:22:chronic_disease,29:58:chronic_disease,60:91:chronic_disease,108:135:chronic_disease	personality disorders (e.g. multiple personality disorder, borderline personality disorder, etc.) or other neuropsychiatric conditions that evaluating psychiatrist would recommend exclusion of patient after neuropsychiatric evaluation
NCT03023449	1:22:chronic_disease	Acute ischemic stroke in the territory of the anterior, middle, or posterior cerebral artery, on either side of the brain
NCT03023449	1:21:chronic_disease	Cognitive impairment
NCT03023449	16:36:chronic_disease	History of any neurological disease
NCT03023449	12:37:chronic_disease,46:52:chronic_disease,56:93:chronic_disease	History of chronic pulmonary disease such as asthma or chronic obstructive pulmonary disease
NCT03023449	18:24:chronic_disease,28:53:chronic_disease	History of prior stroke or transient ischemic attack
NCT03023449	1:10:pregnancy	Pregnancy
NCT03023449	1:10:pregnancy	Pregnancy (urine or blood tests will not be performed)
NCT03023449	31:39:upper_bound,43:49:chronic_disease	Study can be initiated within 72 hours of stroke symptom onset
NCT03021538	1:16:chronic_disease,17:31:chronic_disease,42:51:chronic_disease,115:127:treatment	Cystic fibrosis/bronchiectasis/resistant infection patients where surgeon will need to remove both lungs prior to implantation
NCT03021538	49:70:chronic_disease,79:108:chronic_disease	Patient with specific anatomy that require full cardiac decompression such as severe pulmonary hypertension or large heart that are shifted severely into the left chest
NCT03021538	37:41:treatment	Patients bridged to transplant with ECMO
NCT03021538	60:63:treatment,76:80:treatment	Patients who the surgeon feels would be better served with CPB rather than ECMO- These patients will be entered into a registry and followed
NCT03021538	24:39:treatment,65:85:treatment	all patients requiring cardiopulmonary support while undergoing lung transplantation
NCT03017118	1:9:lower_bound,13:16:age	40 years of age or older
NCT03017118	1:39:chronic_disease	Basal joint arthritis of Eaton stage 3
NCT03017118	1:18:chronic_disease	Diabetes Mellitus
NCT03017118	1:29:language_fluency	English fluency and literacy
NCT03017118	13:21:treatment,22:30:treatment,31:37:treatment,38:45:treatment	Patients on Coumadin/Steroids/NSAIDs/Tylenol
NCT03017118	1:30:chronic_disease	Post-traumatic osteoarthritis
NCT03017118	1:9:pregnancy,23:28:gender	Pregnant or lactating women
NCT03017118	1:45:treatment	Radiographic evidence of Eaton stage 1 and 2 only
NCT03017118	1:21:chronic_disease,31:52:chronic_disease	Rheumatoid Arthritis or other inflammatory disorder diagnoses
NCT03007030	13:26:treatment	Any line of prior therapy
NCT03007030	1:32:clinical_variable,44:56:lower_bound	Calculated creatinine clearance must be >= 30 mL/minute
NCT03007030	1:61:clinical_variable,62:63:lower_bound,64:65:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status 0-2
NCT03007030	19:41:cancer	Have unresectable malignant mesothelioma (any histology)
NCT03007030	1:17:clinical_variable,20:28:lower_bound	Hemoglobin (Hgb) > 8.5 g/dL
NCT03007030	27:57:allergy_name	Known hypersensitivity to brentuximab vedotin components
NCT03007030	1:13:gender	Male subject
NCT03007030	1:10:clinical_variable,13:25:lower_bound	Platelets > 100,000/mm^3
NCT03007030	1:14:cancer	Positive CD30+ immunohistochemical expression
NCT03007030	1:18:treatment,32:35:lower_bound	Radiation therapy to more than 25% of the bone marrow
NCT03007030	1:39:chronic_disease	Serious medical or psychiatric illness likely to interfere with participation in this clinical study
NCT03007030	7:16:clinical_variable,20:53:upper_bound	Total bilirubin =< 1.5 x upper limit of normal (ULN)
NCT03007030	99:107:upper_bound,131:150:treatment	completely abstain from heterosexual intercourse during the entire study treatment period through 6 months after the last dose of brentuximab vedotin
NCT03007030	34:46:pregnancy,72:138:pregnancy	confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening
NCT03007030	12:23:cancer	cured of a skin cancer
NCT03007030	61:121:contraception_consent,123:154:contraception_consent	even if surgically sterilized (i.e., status postvasectomy), agrees to use an acceptable barrier method for contraception (condom with a spermicidal agent)
NCT03007030	83:96:upper_bound	examinations for assessment of measurable disease must have been completed within 28 days prior to registration
NCT03007030	10:32:cancer,40:47:upper_bound	no prior hematologic malignancy within 3 years
NCT03007030	1:8:lower_bound,9:12:upper_bound,13:24:cancer	stage I-III solid tumor
NCT03007030	1:23:treatment,49:52:lower_bound	whole pelvic radiation is considered to be over 25%
NCT03007030	1:53:contraception_consent,63:85:contraception_consent,87:107:contraception_consent,109:134:contraception_consent,136:158:contraception_consent,163:173:contraception_consent,218:226:lower_bound,250:269:treatment	willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and at least 6 months after the last dose of brentuximab vedotin
NCT03006770	8:18:cancer	Active malignancy
NCT03006770	1:20:clinical_variable,22:29:upper_bound,33:35:clinical_variable,37:44:upper_bound	Ankle pressure (AP) ≤70 mmHg or TP ≤50 mmHg in the index leg
NCT03006770	1:21:chronic_disease,25:55:chronic_disease,57:60:lower_bound	Aorto-iliac stenosis or common femoral artery stenosis ≥70%
NCT03006770	1:27:chronic_disease,29:50:clinical_variable	CLI with major tissue loss (Rutherford Category 6) in either leg
NCT03006770	1:4:chronic_disease	CLI, with minor tissue loss up to the ankle level (Rutherford Category 5)
NCT03006770	1:20:treatment,75:88:lower_bound	Concomitant therapy with a statin and an anti-platelet agent for at least 2 weeks prior to randomization
NCT03006770	23:48:chronic_disease	Current or history of proliferative retinopathy
NCT03006770	1:18:chronic_disease,24:29:clinical_variable,31:34:lower_bound	Diabetes mellitus with HbA1c >10%
NCT03006770	1:18:chronic_disease	Hepatitis C virus
NCT03006770	118:129:allergy_name,130:141:allergy_name	History of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with IV steroids/epinephrine
NCT03006770	1:17:chronic_disease,55:62:lower_bound	Ischemic lesions in the index leg stable for at least 2 weeks
NCT03006770	1:16:clinical_variable,30:38:upper_bound	Life expectancy of less than 6 months
NCT03006770	1:24:chronic_disease,31:48:chronic_disease	Non-atherosclerotic PAD (e.g. Buerger's disease)
NCT03006770	31:53:treatment,61:78:treatment,86:93:upper_bound	Planned or potential need for major/minor amputation or any revascularization within 1 month of study entry upon investigator's judgment
NCT03006770	1:32:chronic_disease,77:85:chronic_disease	Severe congestive heart failure symptoms (New York Heart Association [NYHA] Stage IV)
NCT03006770	26:52:treatment,56:72:treatment,83:96:upper_bound	Subject having undergone surgical revascularization or major amputation less than 1 month prior to screening
NCT03006770	15:51:clinical_variable,53:56:lower_bound	Subjects with international normalized ratio (INR) >2.5
NCT03006770	14:33:chronic_disease	Uncontrolled severe hypertension
NCT03006770	7:16:treatment,50:62:chronic_disease,64:78:chronic_disease,80:88:chronic_disease	Under treatment for cardiovascular risk factors: hypertension, hyperlipidemia, diabetes, in accordance with applicable guidelines
NCT03006770	8:33:treatment,35:46:treatment,48:71:treatment,73:93:treatment,95:109:treatment,149:187:treatment	Use of hyperbaric oxygen therapy, prostanoids, spinal cord stimulation, lumbar sympathectomy, wound dressing containing cells or growth factors, or topical platelet derived growth factor
NCT03006770	1:6:gender,45:69:pregnancy	Women of childbearing potential must have a negative serum pregnancy test at screening
NCT03006770	1:53:chronic_disease	acquired immunodeficiency syndrome (AIDS) infections
NCT03006770	9:12:age,9:13:age,14:16:lower_bound,17:25:upper_bound	between ages 45-99 years of age
NCT03006770	1:31:treatment	endovascular revascularization
NCT03006770	44:51:lower_bound	has not yet completed a period of at least 30 days since ending another investigational device or drug trial(s)
NCT03006770	12:22:cancer,30:43:upper_bound	history of malignancy within 5 years prior to study entry
NCT03006770	1:5:gender	male
NCT03006770	1:17:treatment,28:41:upper_bound	minor amputation less than 2 weeks prior to screening
NCT03004287	22:42:cancer	Diagnosis of primary plasma cell leukemia
NCT03004287	1:34:clinical_variable,36:63:clinical_variable,68:93:clinical_variable,96:99:lower_bound	Forced Expiratory Volume 1 (FEV1), Forced Vital Capacity (FVC) and diffusion capacity (DLCO) > 50% of predicted
NCT03004287	1:28:clinical_variable,31:38:lower_bound	Lactate Dehydrogenase (LDH) ≥ 360 U/L
NCT03004287	1:44:clinical_variable,47:50:lower_bound	Multiple-gated Acquisition Scan (MUGA) scan ≥ 45%
NCT03004287	27:35:lower_bound,39:42:age,62:70:upper_bound	Patients must be at least 18 years of age and not older than 75 years of age at the time of registration
NCT03004287	66:70:lower_bound,81:100:treatment,107:134:treatment,136:175:treatment,177:198:treatment,203:222:treatment	Patients must be either untreated or have not received more than four cycles of systemic MM therapy (e.g. Revlimid Dexamethasone (RD), Bortezomib Revlimid Dexamethasone (VRD). Prior bisphosphonates and localized radiation are allowed
NCT03004287	22:36:clinical_variable,39:48:lower_bound	Patients must have a platelet count ≥ 50,000/μL
NCT03004287	29:55:clinical_variable,58:61:lower_bound	Patients must have adequate pulmonary function studies > 50% of predicted on mechanical aspects
NCT03004287	36:64:cancer	Patients must have newly diagnosed active Multiple Myeloma (MM) requiring treatment
NCT03004287	30:40:cancer,72:82:cancer,86:111:cancer,105:111:cancer,116:136:cancer,193:202:treatment,207:221:upper_bound	Patients must not have prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has not received treatment for one year prior to enrollment
NCT03004287	19:31:chronic_disease,33:50:chronic_disease,75:84:chronic_disease	Poorly controlled hypertension, diabetes mellitus, active or uncontrolled hepatitis
NCT03004287	1:9:pregnancy	Pregnant
NCT03004287	10:40:clinical_variable,43:73:upper_bound	baseline Alanine Aminotransferase (ALT) < 3x Upper Limit of Normal (ULN)
NCT03004287	9:14:gender	nursing women may not participate
NCT03004287	26:45:chronic_disease,102:111:treatment	other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
NCT03004287	48:73:cancer	unless lower levels are explained by extensive bone marrow plasmacytosis
NCT03002571	1:8:gender,17:25:pregnancy	Females who are pregnant
NCT03002571	45:54:chronic_disease,56:63:chronic_disease,65:77:chronic_disease,82:92:chronic_disease,105:124:chronic_disease	History of confounding skin conditions, eg, psoriasis, rosacea, erythroderma, or ichthyosis (other than ichthyosis vulgaris)
NCT03002571	1:5:gender	Male
NCT03002571	22:36:gender,79:109:treatment,114:116:chronic_disease,135:145:treatment	Nonimmunocompromized male or female who failed to respond adequately to other topical prescription treatment for AD or for whom those treatments are not advisable
NCT03002571	20:23:age	subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent
NCT03002571	13:28:pregnancy	who wish to become pregnant during the study period
NCT02992899	33:43:chronic_disease,33:53:chronic_disease,63:77:chronic_disease,79:95:chronic_disease,97:104:chronic_disease,106:111:chronic_disease,133:149:chronic_disease	A history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness
NCT02992899	32:45:chronic_disease,47:71:chronic_disease,76:84:chronic_disease,98:102:chronic_disease	Current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia, based on the SCID
NCT02992899	26:63:chronic_disease	Do not meet criteria for post traumatic stress disorder (PTSD)
NCT02992899	12:33:clinical_variable,47:57:lower_bound	History of loss of consciousness greater than one minute
NCT02992899	1:22:chronic_disease,26:49:chronic_disease	Neurological disorder or organic mental disorder
NCT02992899	1:19:pregnancy	Positive pregnancy test
NCT02992899	1:23:chronic_disease	Traumatic brain injury
NCT02992899	13:28:chronic_disease	other major mental disorder as determined by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5 SCID) interview for PTSD
NCT02992483	26:34:cancer,70:79:cancer	Histologically confirmed lymphoma (WHO classification), or confirmed MM (IMWG), that is relapsed and/or refractory
NCT02992483	12:32:chronic_disease	History of chronic pancreatitis
NCT02992483	18:39:chronic_disease	Known history of chronic liver disease
NCT02992483	1:37:treatment	Prior treatment with Mcl-1 inhibitor
NCT02990377	1:19:pregnancy	Currently pregnant
NCT02990377	26:32:treatment	DSM-V moderate or severe opiate (heroin or OA)
NCT02990377	1:13:upper_bound,26:47:treatment	Past 3-month non-medical opioid analgesic (OA) use
NCT02990377	32:52:treatment	Presenting for pain related to acute cancer therapy
NCT02990377	1:34:language_fluency	Unable to read/understand English
NCT02989597	1:11:clinical_variable,12:13:lower_bound,14:17:upper_bound	ASA grades I-III
NCT02989597	1:24:chronic_disease	Obstructive sleep apnea
NCT02989597	1:14:clinical_variable	Prolonged QTc on pre-operative EKG
NCT02989597	1:18:chronic_disease,29:48:treatment	Pulmonary disease requiring home oxygen therapy
NCT02989597	1:14:chronic_disease,25:33:treatment	Renal failure requiring dialysis
NCT02989597	1:21:chronic_disease	Severe heart disease
NCT02989597	22:47:treatment	Treatment with other NMDA receptor antagonists
NCT02989597	12:33:treatment	Undergoing lumbar fusion surgery
NCT02989597	1:4:age,13:15:lower_bound,16:18:upper_bound	age between 18-80
NCT02989597	1:16:bmi,19:27:lower_bound	body mass index > 50 kg/m2
NCT02988895	2:14:upper_bound	<1000 microns as determined by angiography
NCT02988895	13:28:treatment	A change in anti-VEGF agent in the previous two administrations
NCT02988895	1:38:chronic_disease,42:66:chronic_disease	Active ocular or periocular infection or intraocular inflammation
NCT02988895	28:43:treatment	Anticipate a change to the anti-VEGF agent during the conduct of the study
NCT02988895	1:5:clinical_variable	BCVA 20/63
NCT02988895	14:24:chronic_disease	Diagnosis of active CNV
NCT02988895	19:23:clinical_variable,27:51:lower_bound,76:79:chronic_disease,81:113:chronic_disease,126:144:chronic_disease	Fellow eye with a BCVA of 20/63 Snellen Equivalent or worse, with advanced AMD (neovascular or non-exudative AMD with foveal geographic atrophy)
NCT02988895	1:19:chronic_disease,38:41:chronic_disease	Neovascularization other than due to AMD
NCT02988895	30:46:treatment	Patient unsuitable for IV or local anesthesia
NCT02988895	40:70:treatment,75:79:chronic_disease	Poor or non-responsive to FDA approved intravitreal anti-VEGF therapy for nAMD
NCT02988895	1:39:clinical_variable,41:44:lower_bound	Sub-foveal lesion hemorrhage obscuring >50% of lesion
NCT02988895	14:31:chronic_disease,38:61:chronic_disease	Uncontrolled systemic diseases (e.g. controlled hypertension is acceptable)
NCT02988895	1:13:clinical_variable,18:24:lower_bound	axial length of >26.5mm
NCT02988895	14:33:chronic_disease	demonstrated myopic degeneration
NCT02988895	45:67:treatment,69:91:treatment,96:126:treatment	increase the risk of structural damage from retrobulbar anesthesia, sub-Tenon's anesthesia, or retrobulbar device positioning
NCT02988895	197:213:chronic_disease	other co-morbidities that in the investigator's opinion could require medical or surgical intervention to prevent or treat visual loss or media opacity that might result from that condition (i.e. severe cataracts)
NCT02985554	1:4:age,6:14:lower_bound	Age ≥18 years
NCT02985554	1:5:clinical_variable,9:12:lower_bound,15:18:age,31:37:clinical_variable,56:72:clinical_variable,82:86:gender	CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
NCT02985554	1:7:gender	Female
NCT02985554	52:71:allergy_name	History of severe hypersensitivity reaction to any monoclonal antibody
NCT02985554	1:8:treatment,12:28:treatment,33:58:clinical_variable,60:71:upper_bound	Inhaled or topical steroids and adrenal replacement doses <10 mg daily prednisone equivalents
NCT02985554	43:47:chronic_disease,72:79:lower_bound,80:95:chronic_disease,108:113:chronic_disease	Patients who have disease relapse, active GVHD or history of more than Stage 1 skin acute GVHD, history of cGVHD
NCT02985554	23:35:treatment,39:51:treatment,96:107:treatment	Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier
NCT02985554	45:65:chronic_disease,67:90:chronic_disease,92:106:chronic_disease,111:135:cancer,245:254:treatment	Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study
NCT02985554	15:40:chronic_disease,22:40:chronic_disease,141:169:treatment,180:204:treatment	Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids
NCT02985554	15:31:chronic_disease,56:63:lower_bound	Patients with active infection, un-resolving more than grade 2 transplant-related toxicities
NCT02985554	15:39:cancer,47:66:treatment,111:115:chronic_disease,140:147:lower_bound,148:163:chronic_disease	Patients with hematologic malignancies status post allogeneic SCT without evidence of disease relapse, active GVHD or history of more than Stage I skin acute GVHD
NCT02985554	25:32:cancer,36:57:cancer,61:81:treatment	Patients with high risk myeloid or lymphoid malignancies at stem cell transplant following ASBMT criteria (http://www.asbmt.org/displaycommon.cfm?an=1&subarticlenbr=35, under disease classification), including but not limited to conditions listed
NCT02985554	15:35:chronic_disease,46:59:chronic_disease,61:79:chronic_disease,84:93:chronic_disease,110:128:treatment,156:164:treatment,174:202:treatment,204:227:treatment,316:334:treatment	Patients with rheumatoid arthritis and other arthropathies, Sjögren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment
NCT02985554	15:23:chronic_disease,25:47:chronic_disease,58:69:chronic_disease,126:141:treatment	Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids
NCT02985554	1:50:cancer,51:98:cancer,99:124:cancer,148:176:cancer,194:195:lower_bound,257:299:cancer,303:320:cancer,358:368:treatment,379:407:cancer,468:485:treatment	Refractory acute myelogenous or lymphoid leukemia Relapsed acute myelogenous or lymphoid leukemia Myelodysplastic syndromes with 5% or more blasts Chronic myelogenous leukemia in chronic phase 3 or more, blast phase presently, or second accelerated phase, Recurrent or refractory malignant lymphoma or Hodgkin's disease with less than a partial response at transplant High risk chronic lymphocytic leukemia defined as no response or stable disease to the most recent treatment regimen
NCT02985554	1:17:clinical_variable,19:27:upper_bound	Serum creatinine ≤1.5× ULN OR
NCT02985554	14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02985554	17:26:treatment,49:72:contraception_consent	WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational product
NCT02985554	46:55:pregnancy,114:123:treatment	WOCBP should use an adequate method to avoid pregnancy for 23 weeks) after the last dose of investigational drug Nivolumab
NCT02985554	1:6:gender	Women must not be breastfeeding
NCT02985554	1:6:gender,59:65:gender,145:157:treatment,161:183:treatment	Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal
NCT02985554	1:6:gender,45:78:pregnancy,105:112:lower_bound,136:139:clinical_variable,148:162:upper_bound,179:188:treatment	Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab
NCT02985554	1:6:gender,3:6:gender	Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception
NCT02985554	1:26:clinical_variable,28:37:lower_bound	absolute neutrophil count ≥1,000/mcL
NCT02985554	1:28:clinical_variable,30:39:lower_bound	creatinine clearance (CrCl) ≥40 mL/min
NCT02985554	1:11:clinical_variable,13:21:lower_bound	leukocytes ≥2000/mcL
NCT02985554	15:31:chronic_disease	patients with Gilbert Syndrome
NCT02985554	28:61:chronic_disease,63:81:chronic_disease,83:120:chronic_disease,122:145:chronic_disease,147:164:chronic_disease,166:193:chronic_disease,202:205:chronic_disease,207:233:chronic_disease,235:246:chronic_disease,248:280:chronic_disease,282:289:chronic_disease,291:309:chronic_disease,311:320:chronic_disease,353:385:chronic_disease,387:411:chronic_disease,416:437:chronic_disease	patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as SLE, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome
NCT02985554	62:65:clinical_variable,67:74:lower_bound	recovery to the baseline count(in the absence of transfusion)Hgb >9.0g/dL
NCT02985554	1:16:clinical_variable,18:64:upper_bound	total bilirubin ≤1.5× institutional upper limit of normal (ULN)
NCT02983240	3:27:chronic_disease	A fetal cardiac arrhythmia
NCT02983240	21:30:treatment	A permanent cardiac pacemaker
NCT02983240	27:44:clinical_variable,47:51:lower_bound	Active preterm labor with cervical dilation > 6 cm
NCT02983240	12:14:lower_bound,17:25:upper_bound,29:32:age	Be between 18 - 50 years of age
NCT02983240	12:14:lower_bound,18:26:upper_bound,27:35:pregnancy	Be between 23 to 34 weeks pregnant with a singleton gestation
NCT02983240	22:31:allergy_name,104:126:chronic_disease,132:160:chronic_disease,162:190:chronic_disease,192:205:chronic_disease	Contraindication for tocolysis e.g. premature rupture of the amniotic membranes allowing for ascending intrauterine infection with group B streptococcus or GBS (beta hemolytic streptococcus, S. agalactiae) or other micro-organisms
NCT02983240	1:14:chronic_disease	Fetal anomaly incompatible with life
NCT02983240	7:23:chronic_disease	Frank chorioamnionitis
NCT02983240	1:12:chronic_disease	Hepatitis C
NCT02983240	10:34:clinical_variable,37:51:upper_bound	IV or po narcotic pain medication < 12 hours prior to admission
NCT02983240	1:33:clinical_variable,36:38:upper_bound	Pregnancy Depression Scale score < 16
NCT02983240	1:26:chronic_disease	Severe abruption placenta
NCT02983240	1:32:chronic_disease,34:37:clinical_variable,40:42:upper_bound	Severe fetal growth restriction (EFW < 5%)
NCT02983240	1:20:chronic_disease	Severe preeclampsia
NCT02983240	1:17:clinical_variable,20:25:lower_bound	Vaginal bleeding > 10 cc
NCT02983240	13:37:treatment,43:52:treatment,54:62:treatment,64:71:treatment	long acting oral maintenance opiates i.e. methadone, Suboxone, Subutex
NCT02983240	1:20:treatment	regional anesthesia
NCT02981069	1:6:clinical_variable,8:12:lower_bound,18:23:upper_bound	HbA1c >7.0% and <10.0%
NCT02981069	30:64:chronic_disease,66:83:clinical_variable,85:88:lower_bound,89:96:gender,91:96:gender,101:104:lower_bound,115:146:clinical_variable,149:155:lower_bound	Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine >1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg will be excluded
NCT02981069	21:32:clinical_variable,52:57:lower_bound,68:90:upper_bound	Only subjects whose body weight has been stable (± 3 lbs) over the preceding three months
NCT02967315	16:24:lower_bound	Are older than 18 years
NCT02967315	1:7:cancer	Cancer patients
NCT02967315	1:6:allergy_name	Latex allergic patients
NCT02967315	33:56:chronic_disease	Patients that present with free pulmonary insufficiency
NCT02967315	122:154:chronic_disease,215:238:chronic_disease,256:278:chronic_disease	Patients who have lesions predisposing to chronic volume overload (i.e. patients with significant residual postoperative ventricular septal defects (VSD), or large aorto-pulmonary collaterals or more than moderate tricuspid insufficiency) since all these hemodynamic conditions can influence the late function of the right ventricle and potentially affect the response of the right side of the heart in changes in volume status
NCT02967315	40:63:treatment,97:113:treatment,145:170:chronic_disease,193:211:treatment	Patients who have significant residual right-sided obstruction (i.e. patients who have residual RVOT obstruction or significant residual branch pulmonary artery stenosis), as it is shown that residual pulmonary stenosis may protect from RV dilation and from deterioration of the RV function
NCT02967315	15:23:chronic_disease	Patients with diabetes
NCT02967315	15:28:chronic_disease,33:52:chronic_disease	Patients with renal failure and renal insufficiency
NCT02967315	15:42:chronic_disease	Patients with uncompensated heart failure
NCT02967315	1:9:pregnancy,10:17:gender	Pregnant females
NCT02967315	1:4:chronic_disease,42:60:treatment	TOF patients who have had repair using a transannular patch
NCT02967315	15:85:chronic_disease	patients with anomalous coronary crossing the right ventricular outflow tract (RVOT)
NCT02967315	1:18:chronic_disease,23:26:chronic_disease	pulmonary atresia and VSD
NCT02956486	10:26:clinical_variable	Absolute lymphocyte count below the lower limit of normal (LLN)
NCT02956486	13:33:chronic_disease,85:111:treatment,115:139:treatment	Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy
NCT02956486	43:63:chronic_disease,114:116:chronic_disease	Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
NCT02956486	1:21:clinical_variable,25:28:lower_bound	CDR Memory Box score of 0.5 or greater
NCT02956486	1:17:clinical_variable	CDR global score of 0.5
NCT02956486	1:8:gender,41:87:contraception_consent,131:138:upper_bound	Females of child-bearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation
NCT02956486	1:8:gender,34:42:pregnancy	Females who are breastfeeding or pregnant at Screening or Baseline
NCT02956486	36:54:chronic_disease,66:68:chronic_disease,72:81:treatment	Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
NCT02956486	19:55:treatment,63:71:upper_bound	Have received any live vaccine/live attenuated vaccine in the 3 months before randomization
NCT02956486	12:48:chronic_disease,56:65:upper_bound	History of transient ischemic attacks or stroke within 12 months of Screening
NCT02956486	1:20:cancer,28:35:upper_bound	Malignant neoplasms within 5 years of Screening
NCT02956486	36:73:chronic_disease,79:102:chronic_disease	Participants who have a history of moderate to severe hepatic impairment (eg, Child-Pugh Class B or C)
NCT02956486	32:40:chronic_disease,48:55:upper_bound	Participants with a history of seizures within 5 years of Screening
NCT02956486	42:56:chronic_disease,58:74:chronic_disease,76:85:chronic_disease	Psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, delusions, etc.)
NCT02956486	1:36:chronic_disease	Severe visual or hearing impairment
NCT02956486	1:18:chronic_disease,26:43:chronic_disease,51:59:upper_bound	Suicidal ideation or any suicidal behavior within 6 months before Screening
NCT02950649	3:11:upper_bound,15:18:age	< 18 years of age
NCT02950649	12:21:chronic_disease	history of Raynaud's
NCT02950649	7:39:chronic_disease	known severe peripheral artery disease
NCT02950649	11:12:upper_bound	less than 5 metabolic equivalents (METs)
NCT02950649	44:59:clinical_variable,70:74:upper_bound	poor perfusion to fingers (as defined as a perfusion index less than 0.5%- www.Masimo.com)
NCT02950649	1:10:pregnancy	pregnancy
NCT02950337	3:9:gender,44:49:gender,104:118:treatment	A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice)
NCT02950337	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT02950337	1:4:age,6:8:lower_bound	Age ≥75
NCT02950337	1:7:treatment	Biopsy was performed or attempted but with complications requiring abortion of procedure
NCT02950337	1:9:chronic_disease,11:18:chronic_disease,23:50:chronic_disease	Cerebral, cardiac, or peripheral vascular disease
NCT02950337	1:22:chronic_disease	Chronic heart disease
NCT02950337	1:18:chronic_disease	Diabetes mellitus with end organ damage
NCT02950337	1:5:clinical_variable,7:10:upper_bound	FEV1 <50%
NCT02950337	52:73:lower_bound	Has not been naturally postmenopausal for at least 12 consecutive months
NCT02950337	21:33:treatment,37:59:treatment	Has not undergone a hysterectomy or bilateral oophorectomy
NCT02950337	33:47:treatment,51:71:treatment	High risk of complications from transbronchial or transthoracic biopsy
NCT02950337	175:188:upper_bound	History/Physical examination by an experienced thoracic cancer clinician (thoracic surgeon, interventional pulmonologist, medical oncologist, or radiation oncologist) within 4 weeks prior to registration
NCT02950337	19:24:cancer,146:156:cancer	Multidisciplinary tumor board determines patient's history, clinical findings, and radiographic findings are consistent with high probability of malignancy
NCT02950337	41:54:cancer,58:76:cancer	No clinical or radiographic evidence of nodal disease or distant metastases
NCT02950337	13:26:treatment,35:61:treatment,63:72:treatment,77:95:treatment	No previous local therapy such as external beam radiotherapy, lobectomy, or sublobar resection
NCT02950337	18:25:treatment	Patient declines surgery
NCT02950337	18:36:pregnancy	Patients who are currently pregnant
NCT02950337	34:44:cancer,75:88:upper_bound	Patients with a known history of malignancy with a disease-free interval <3 years prior to enrollment
NCT02950337	36:47:cancer	Patients with any prior history of lung cancer
NCT02950337	22:61:chronic_disease	Patients with severe obstructive or restrictive lung disease
NCT02950337	18:29:cancer	Prior history of lung cancer
NCT02950337	1:20:treatment,22:29:treatment,33:45:treatment,85:90:cancer	Prior local therapy (surgery or radiotherapy) for the current, clinically-diagnosed NSCLC
NCT02950337	1:23:chronic_disease	Pulmonary hypertension
NCT02950337	47:72:clinical_variable,78:81:lower_bound	Validated clinical prediction model estimates probability of malignancy is ≥ 85%
NCT02950337	1:40:treatment,43:75:treatment,83:91:upper_bound	Whole body Positron Emission Tomography / Computerized Tomography (PET/CT) within 12 weeks of registration
NCT02950337	1:6:gender,47:56:pregnancy	Women of child-bearing potential must undergo pregnancy testing prior to enrollment on study
NCT02950337	10:19:chronic_disease,27:38:chronic_disease	baseline hypoxemia and/or hypercapnia
NCT02950337	1:19:chronic_disease	cardiac arrhythmia
NCT02950337	1:19:clinical_variable,21:24:upper_bound	diffusion capacity <50%
NCT02950337	12:28:cancer	history of brain metastases
NCT02950337	30:46:cancer	must not have any history of brain metastases
NCT02950337	34:58:chronic_disease	nursing due to the potential for congenital abnormalities and potential harm to nursing infants
NCT02950337	12:28:chronic_disease	ongoing or active infection
NCT02950337	1:37:treatment,65:80:cancer	positron emission tomography imaging clinically consistent with lung malignancy
NCT02950337	1:30:treatment,31:34:upper_bound	post-operative predicted FEV1<30% predicted
NCT02950337	1:38:chronic_disease	psychiatric illness/social situations that could limit compliance with study requirements
NCT02950337	1:46:chronic_disease	severely symptomatic congestive heart failure
NCT02944825	1:4:age,8:16:lower_bound,20:23:age	Age: >=18 years of age
NCT02944825	22:56:treatment	Patients who perform clean intermittent catheterization
NCT02944825	60:73:upper_bound	Patients with indwelling ureteral stents placed within the 2 weeks prior to the procedure visit for removal
NCT02944825	66:69:gender,78:83:gender,115:128:chronic_disease	We anticipated enrolling a study population of approximately 60% men and 40% women based on a higher incidence of kidney stones among men in NHANES data
NCT02944825	1:35:treatment	percutaneous nephrolithotomy [PNL]
NCT02944825	1:37:treatment	retrograde intrarenal surgery [RIRS]
NCT02944825	1:28:treatment	shockwave lithotripsy [SWL]
NCT02944825	1:19:treatment	ureteroscopy [URS]
NCT02944825	1:6:gender	women
NCT02940288	1:26:treatment	Anticoagulant medications
NCT02940288	1:18:chronic_disease	Bleeding disorder
NCT02940288	12:19:chronic_disease,25:37:treatment	History of syncope with venipuncture
NCT02940288	1:26:chronic_disease	Local auricular infection
NCT02940288	19:30:treatment	Patients naïve to acupuncture
NCT02940288	46:53:treatment,67:77:lower_bound,85:97:treatment,123:135:treatment	Patients will be withdrawn from the study if surgery time exceeds 90 minutes or the laparoscopic procedure turned into an open surgery
NCT02940288	1:26:treatment	Prosthetic cardiac valves
NCT02932956	1:36:clinical_variable,66:90:cancer	Barcelona Clinic Liver Cancer Stage A, B or C (for patients with hepatocellular carcinoma only)
NCT02932956	1:26:clinical_variable,29:30:upper_bound,50:74:cancer	Child-Pugh-Turcotte score < 7 (for patients with hepatocellular carcinoma only)
NCT02932956	1:26:clinical_variable,28:29:upper_bound,49:73:cancer	Child-Pugh-Turcotte score <7 (for patients with hepatocellular carcinoma only)
NCT02932956	1:21:clinical_variable,68:77:lower_bound	Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml/min
NCT02932956	47:73:treatment,77:82:cancer,139:140:lower_bound,143:146:lower_bound,147:167:clinical_variable,230:231:lower_bound,235:236:upper_bound	GPC3 expression will be evaluated by standard immunohistochemistry (IHC). A tumor is considered GPC3 positive, when the staining is Grade 2 (>25% positive tumor cells) or above with an intensity score of 2 or above on a scale of 0 to 4
NCT02932956	1:4:clinical_variable,6:14:lower_bound	Hgb ≥7.0 g/dl (can be transfused)
NCT02932956	1:4:clinical_variable,6:9:upper_bound,29:53:cancer	INR ≤1.7 (for patients with hepatocellular carcinoma only)
NCT02932956	1:7:clinical_variable,11:26:clinical_variable,29:32:lower_bound	Lansky or Karnofsky score ≥ 60%
NCT02932956	1:7:clinical_variable,11:26:clinical_variable,28:31:lower_bound	Lansky or Karnofsky score ≥60%
NCT02932956	1:16:clinical_variable,22:30:lower_bound	Life expectancy of ≥ 12 weeks
NCT02932956	1:10:pregnancy	Pregnancy
NCT02932956	49:61:treatment,66:88:treatment	Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study
NCT02932956	105:113:upper_bound,124:139:treatment	Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion
NCT02932956	1:23:chronic_disease	Uncontrolled infection
NCT02932956	1:26:clinical_variable,29:43:lower_bound	absolute neutrophil count > 500/microliter
NCT02932956	1:15:clinical_variable,18:35:lower_bound	platelet count > 25,000/microliter (can be transfused)
NCT02932956	1:15:clinical_variable,17:20:lower_bound	pulse oximetry >90% on room air
NCT02932956	1:10:clinical_variable,12:23:upper_bound	serum AST< 5 times ULN
NCT02932956	7:16:clinical_variable,19:30:upper_bound,35:38:age	total bilirubin < 3 times ULN for age
NCT02926378	1:18:chronic_disease	Cerebral aneurysm clips - if magnetic, can move
NCT02926378	1:17:treatment	Cochlear implant - malfunction
NCT02926378	1:22:treatment	Deep brain stimulator
NCT02926378	10:30:chronic_disease	Evidence cognitive impairment that would negatively impact capacity to understand and participate in this study
NCT02926378	9:26:clinical_variable,35:37:lower_bound,38:46:upper_bound	Have an educational level between 14-18 years
NCT02926378	28:39:allergy_name,43:46:allergy_name	Have contraindications for acupuncture or MRI
NCT02926378	38:47:upper_bound	Have had a change in medication over two weeks before the start of study procedures or through the study protocol
NCT02926378	1:25:treatment	IV anticoagulant therapy
NCT02926378	1:25:treatment	Magnetic dental implants - loss of magnetic hold to keep the implant in place
NCT02926378	28:39:treatment	Main contraindications for acupcunture in this study
NCT02926378	38:73:clinical_variable,83:97:lower_bound,149:150:lower_bound,151:159:upper_bound,165:171:chronic_disease	Participants must have experienced a left Cerebrovascular Accident (CVA) at least one year prior to study participation and the injury timeframe is 1-10 years post stroke
NCT02926378	1:10:pregnancy	Pregnancy
NCT02926378	1:19:treatment	Swan-Ganz catheter
NCT02926378	10:19:treatment,21:34:treatment,55:68:treatment	having a pacemaker, defibrillator or wires other than sternal wires
NCT02926378	26:41:chronic_disease,47:59:chronic_disease,60:76:cancer,82:97:chronic_disease	uncontrolled coagulation blood disorders like haemophilia, malignant tumors, and fear of needles
NCT02919436	12:19:allergy_name	Allergy to lactose
NCT02919436	12:35:chronic_disease	History of orthostatic hypotension or current orthostatic hypotension
NCT02919436	12:25:chronic_disease,27:43:chronic_disease,47:64:cancer	History of spinal trauma, spinal infection or spinal cord tumor
NCT02919436	1:13:gender	Male patient
NCT02919436	1:14:chronic_disease	Renal failure
NCT02919436	40:51:allergy_name	Serious or life-threatening allergy to sulfa drugs
NCT02919436	12:34:treatment,44:50:lower_bound	Undergoing elective spine surgery at least 5 days after enrollment
NCT02919436	1:4:age,5:7:lower_bound,10:18:upper_bound	age 50 - 85 years
NCT02913612	1:2:lower_bound,3:10:upper_bound,21:24:age	0-84 days postnatal age at time of first study dose or when enrolled into the non-intervention cohort
NCT02913612	1:11:clinical_variable,13:33:upper_bound	Heart rate <100 beats per minute at screening visit
NCT02913612	29:51:chronic_disease	Hemodynamically significant cardiovascular disease, as determined by the investigator
NCT02913612	12:42:chronic_disease	History of Reactive Airways Disease (RAD)
NCT02913612	40:53:treatment,57:70:treatment	History of previous treatment with any pharmacologic or laser therapy for IH
NCT02913612	1:3:chronic_disease,18:34:treatment,47:73:clinical_variable,75:76:lower_bound	IH that requires systemic therapy (defined by dynamic complication scale >3)
NCT02913612	28:38:chronic_disease,53:60:treatment	Infants with more than one hemangioma that requires therapy
NCT02913612	42:79:chronic_disease	Known prenatal or postnatal diagnosis of 2nd/3rd degree atrioventricular block
NCT02911831	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT02911831	32:43:treatment,45:57:treatment,59:83:treatment,85:95:treatment,97:117:treatment,119:129:treatment,131:146:treatment	Can be previously treated with Depo-Lupron, Depo-Provera, Oral Contraceptive pills, Mirena IUD, endometrial ablation, myomectomy, oral progestins
NCT02911831	102:117:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to tranexamic acid
NCT02911831	57:63:cancer	Patients currently undergoing treatment for any type of cancer
NCT02911831	25:37:treatment,102:118:chronic_disease,120:131:chronic_disease,133:149:chronic_disease,151:162:chronic_disease,164:175:chronic_disease,177:189:chronic_disease,191:212:chronic_disease,216:229:chronic_disease	Patients presenting for hysterectomy for any benign indication including but not limited to abnormal uterine bleeding, menorrhagia, uterine fibroids, adenomyosis, pelvic pain, dysmenorrhea, pelvic organ prolapse or endometriosis
NCT02911831	21:33:treatment,38:61:chronic_disease,65:83:chronic_disease	Patients undergoing hysterectomy for endometrial hyperplasia or cervical dysplasia
NCT02911831	21:48:chronic_disease,65:80:chronic_disease,92:114:chronic_disease,118:136:chronic_disease	Patients with known bleeding/clotting disorders or a history of thromboembolism (including deep venous thrombosis or pulmonary embolism)
NCT02911831	34:69:cancer	Patients with known or suspected endometrial/ovarian/cervical cancer
NCT02911831	21:34:chronic_disease,42:44:clinical_variable,47:48:lower_bound,60:73:upper_bound	Patients with known renal failure and/or Cr > 5 within the last 6 months
NCT02911831	1:25:clinical_variable,27:33:lower_bound	Pre-operative hemoglobin >8 g/dl
NCT02911831	72:88:chronic_disease,102:126:chronic_disease,128:151:chronic_disease,153:177:chronic_disease,179:197:chronic_disease,202:221:chronic_disease	Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, subarachnoid hemorrhage, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02911831	17:35:treatment,41:48:treatment,58:70:treatment	Willing to have IV tranexamic acid or a placebo prior to hysterectomy
NCT02910726	11:19:upper_bound,46:57:cancer,68:78:treatment	Patients <30 years old with an extracoelomic solid tumor requiring SLN biopsy
NCT02910726	30:37:treatment	Patients who are cleared for surgery
NCT02910726	25:38:treatment,97:115:treatment	Patients with extensive prior surgery at the primary site or nodal basin expected to affect the lymphatic drainage
NCT02910726	1:6:gender,45:63:pregnancy	Women of childbearing potential must have a negative pregnancy test (urine or blood) pre-operatively as per the standard hospital policy
NCT02910726	1:6:gender,11:23:pregnancy	Women who are pregnant or breast-feeding
NCT02907918	47:115:allergy_name,117:126:allergy_name,128:139:allergy_name,151:170:allergy_name,182:201:allergy_name,206:236:allergy_name	A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase inhibitor, any other monoclonal antibody, or other agents used in the study
NCT02907918	1:20:clinical_variable,23:33:upper_bound	AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
NCT02907918	1:26:clinical_variable,29:38:lower_bound	Absolute neutrophil count ≥ 1,500/mcl
NCT02907918	10:18:lower_bound,22:25:age	At least 18 years of age
NCT02907918	1:38:clinical_variable,41:47:upper_bound	Baseline corrected QT interval (QTcF) < 480 ms
NCT02907918	1:61:clinical_variable,64:65:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
NCT02907918	27:38:clinical_variable	Indeterminate or negative HER2 status
NCT02907918	1:27:cancer	Inflammatory breast cancer
NCT02907918	7:33:chronic_disease	Known hepatitis B or C infection
NCT02907918	1:42:clinical_variable,45:48:lower_bound,52:80:treatment,84:118:treatment	Left ventricular ejection fraction (LVEF) ≥ 50% by transthoracic echocardiogram or multigated acquisition scan (MUGA)
NCT02907918	1:11:clinical_variable,14:23:lower_bound	Leukocytes ≥ 3,000/mcL
NCT02907918	91:103:cancer	Patients with histologically confirmed palpable lymph nodes may be enrolled regardless of breast tumor size
NCT02907918	1:10:clinical_variable,13:24:lower_bound	Platelets ≥ 100,000/mcl
NCT02907918	1:9:pregnancy	Pregnant
NCT02907918	1:11:clinical_variable,21:25:lower_bound	Tumor size at least 2 cm in one dimension by clinical or radiographic exam (World Health Organization (WHO) criteria)
NCT02907918	66:93:chronic_disease,95:131:chronic_disease,133:157:chronic_disease,162:180:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
NCT02907918	1:6:gender,80:87:upper_bound,107:142:contraception_consent	Women of childbearing potential must agree to undergo pregnancy testing within 14 days of study entry and agree to use adequate contraception (barrier method of birth control, abstinence, not hormonal) prior to study entry and for the duration of study participation as well as chemical LHRH Agonist with goserelin
NCT02907918	1:6:gender,45:63:pregnancy,76:83:upper_bound	Women of childbearing potential must have a negative pregnancy test within 14 days of study entry
NCT02905656	1:9:lower_bound	18 years or older
NCT02905656	1:27:language_fluency	Able to understand English
NCT02905656	1:22:technology_access	Access to a telephone
NCT02905656	1:19:pregnancy	Currently pregnant
NCT02905656	17:24:treatment,28:38:treatment	Currently using chantix or wellbutrin
NCT02905656	19:43:chronic_disease	Diagnosed with an unstable heart condition
NCT02905656	9:23:upper_bound,36:37:lower_bound	For the past 12 months, has smoked 5 or more cigarettes a day
NCT02905656	21:28:treatment,32:42:treatment	Not currently using chantix or wellbutrin
NCT02905656	44:56:upper_bound	Planning to quit smoking cigarettes in the next 30 days
NCT02905656	25:28:treatment	Willing and able to use NRT in the form of gum
NCT02905656	1:28:pregnancy,36:50:upper_bound	planning to become pregnant in the next 12 months
NCT02905578	3:19:clinical_variable,33:70:upper_bound,101:121:clinical_variable,134:152:lower_bound	A creatinine level of less than 1 1/2 times the upper limit of normal for the local lab test, or, a creatinine clearance of at least 60 mL/(min*1.73m2)
NCT02905578	1:30:contraception_consent	Commit to using birth control during the study (all participants)
NCT02905578	1:52:chronic_disease	Glucose-6-phosphate dehydrogenase (G6PD) deficiency
NCT02905578	1:4:chronic_disease,37:44:treatment,88:108:treatment,123:140:treatment	HIV positive individuals undergoing therapy due to known drug:drug interaction between antiretroviral drugs and high-dose ascorbate therapy
NCT02905578	97:131:treatment	If all of the above are met, the potential participant will receive a 15 gram challenge dose of ascorbate via intravenous infusion. This is the final screening procedure
NCT02905578	1:36:chronic_disease	Metastatic or node positive disease
NCT02905578	7:14:treatment,26:35:treatment,48:60:upper_bound	Other therapy (including radiation) within the past 4 weeks
NCT02905578	75:89:cancer	Pathologic diagnosis (cell samples, biopsy, brushing, surgical sample) of adenocarcinoma of the pancreas
NCT02905578	29:36:treatment	Patients actively receiving insulin
NCT02905578	7:19:treatment,33:51:cancer	Prior chemotherapy to treat the metastatic disease
NCT02905578	19:34:treatment	Side effects from prior therapies that are still deemed moderate to severe by a physician
NCT02905578	30:45:treatment,78:94:treatment,102:119:treatment,121:138:treatment	The patient must have failed initial therapy or be ineligible for definitive curative therapy (e.g., surgical excision, radiation therapy)
NCT02905578	15:35:chronic_disease	Uncontrolled, intercurrent illness
NCT02905578	1:10:treatment	methadone
NCT02905188	1:4:age,6:14:lower_bound	Age >18 years
NCT02905188	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT02905188	11:47:treatment	Available autologous transduced T cell product
NCT02905188	1:26:clinical_variable,29:30:upper_bound	Child-Pugh-Turcotte score < 8
NCT02905188	1:26:clinical_variable,28:29:upper_bound	Child-Pugh-Turcotte score <7
NCT02905188	1:14:chronic_disease,18:27:lower_bound,28:30:upper_bound	Heart failure of Class III-IV and / or C-D per NYHA Criteria
NCT02905188	1:23:chronic_disease	Hepatic encephalopathy
NCT02905188	1:4:clinical_variable,6:14:lower_bound	Hgb ≥7.0 g/dl
NCT02905188	1:4:clinical_variable,6:9:upper_bound	INR ≤1.7
NCT02905188	1:16:clinical_variable,18:21:lower_bound	Karnofsky score >60%
NCT02905188	1:16:clinical_variable,22:30:lower_bound	Life expectancy of ≥ 12 weeks
NCT02905188	1:10:pregnancy	Pregnancy
NCT02905188	1:15:clinical_variable,17:20:lower_bound	Pulse oximetry >90% on room air
NCT02905188	34:100:contraception_consent,105:113:upper_bound,124:139:treatment	Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion
NCT02905188	1:27:clinical_variable,54:60:lower_bound,61:71:treatment	Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day)
NCT02905188	1:26:clinical_variable,29:43:lower_bound	absolute neutrophil count > 500/microliter
NCT02905188	1:21:clinical_variable,58:67:lower_bound	creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 ml/min
NCT02905188	1:15:clinical_variable,18:35:lower_bound	platelet count > 20,000/microliter
NCT02905188	1:10:clinical_variable,12:23:upper_bound	serum AST< 5 times ULN
NCT02905188	1:16:clinical_variable,19:30:upper_bound,35:38:age	total bilirubin < 3 times ULN for age
NCT02891759	1:3:lower_bound,7:15:upper_bound	22 to 70 years old
NCT02891759	1:8:gender	Females
NCT02891759	1:42:treatment,59:85:treatment	Skin-sparing or nipple-sparing mastectomy with or without sentinel lymph node biopsy
NCT02891447	1:26:clinical_variable,30:38:lower_bound	Absolute neutrophil count >= 1,500/uL
NCT02891447	15:49:treatment,54:85:treatment	Completion of preoperative systemic chemotherapy and preoperative laparoscopic HIPEC
NCT02891447	9:27:cancer,55:77:cancer,79:84:cancer,86:108:cancer,110:114:cancer	Distant metastatic disease not limited to peritoneum: Solid organ metastases (liver, central nervous system, lung)
NCT02891447	9:41:cancer	Distant metastatic disease of peritoneum
NCT02891447	1:61:clinical_variable,65:66:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 2
NCT02891447	20:29:chronic_disease,33:49:chronic_disease,70:86:treatment	Infections such as pneumonia or wound infections that would preclude protocol therapy
NCT02891447	1:11:clinical_variable,15:23:lower_bound	Leukocytes >= 3,000/uL
NCT02891447	1:10:clinical_variable,14:23:lower_bound	Platelets >= 60,000/Ul
NCT02891447	1:29:cancer	Positive peritoneal cytology
NCT02891447	43:73:allergy_name	Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
NCT02885649	10:26:clinical_variable,31:64:lower_bound	Adequate hepatic function (>= 1.5 x upper limit of normal [ULN]
NCT02885649	83:104:chronic_disease,106:129:treatment,131:146:chronic_disease,148:167:chronic_disease,188:212:chronic_disease,217:241:chronic_disease,249:273:upper_bound	Any unstable, serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within twelve (12) months prior to screening
NCT02885649	16:38:treatment	Current use of exogenous testosterone
NCT02885649	1:61:clinical_variable,65:66:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 2
NCT02885649	37:62:chronic_disease,70:88:upper_bound	History of loss of consciousness or transient ischemic attack within twelve (12) months of enrollment
NCT02885649	12:19:chronic_disease,81:96:chronic_disease,112:124:chronic_disease	History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma)
NCT02885649	23:71:chronic_disease	History of unprovoked deep vein thrombosis/pulmonary embolism (DVT/PE) in past twelve (12) months
NCT02885649	1:4:gender,10:47:contraception_consent,68:76:lower_bound,131:137:gender,155:158:age	Men must use adequate methods of contraception during and at least 3 months after treatment if engaging in sexual activity with a female of child bearing age
NCT02885649	1:15:cancer	Metastatic RCC
NCT02885649	16:34:cancer	No evidence of metastatic disease on baseline imaging (chest x-ray [CXR] or chest CT, abdominal CT or MRI)
NCT02885649	1:9:pregnancy,10:15:gender,50:53:age,62:111:contraception_consent,119:128:treatment,119:146:treatment,155:169:upper_bound	Pregnant women or women who are of child bearing age who are not willing to use two (2) forms of contraception during treatment with enzalutamide and for six (6) months after treatment
NCT02885649	14:34:treatment,45:57:treatment	Prior use of androgen deprivation including enzalutamide
NCT02885649	1:33:chronic_disease	Retroperitoneal/hilar adenopathy concerning for locally advanced disease
NCT02885649	1:6:cancer,12:34:clinical_variable,48:62:lower_bound	Tumor with androgen receptor (AR) expressed >= 4580 copies/ug ribonucleic acid (RNA)
NCT02885649	16:33:chronic_disease	patient's with Gilbert's disease are not excluded
NCT02872857	37:45:upper_bound	Ability to obtain medication within 36 hours of presentation
NCT02872857	49:57:chronic_disease	Clinically manifested by no attempt at securing aneurysm
NCT02872857	27:35:upper_bound	Expected mortality within 72 hours as determined by PI
NCT02872857	1:26:chronic_disease,64:93:treatment	Fisher grade 3 hemorrhage (thick subarachnoid clot) on initial computed tomography (CT) scan
NCT02872857	12:20:chronic_disease	History of dementia
NCT02872857	19:37:chronic_disease,39:55:clinical_variable,59:61:lower_bound,62:64:upper_bound	History of severe hepatic impairment (Child-Pugh score of 10-15)
NCT02872857	1:14:clinical_variable,15:22:lower_bound,23:24:upper_bound	Hunt and Hess grade 1-5 at time of randomization
NCT02872857	30:63:clinical_variable,65:66:lower_bound	Pre-existing disability with modified Rankin Scale (mRS) score ≥2
NCT02872857	15:32:chronic_disease	Presence of a cerebral aneurysm on computed tomographic angiography (CTA) or Angiogram for which clipping or coiling is possible
NCT02872857	1:14:chronic_disease,29:49:clinical_variable,60:77:upper_bound	Renal disease as defined by creatinine clearance less than 9 milliliters/min
NCT02869880	1:21:language_fluency	Non-English speaking
NCT02866279	59:64:gender	Admission to Labor and Delivery with a plan for delivery (women in both latent and active labor will be eligible)
NCT02866279	32:53:allergy_name	Allergy or Contraindication to contraceptive implant
NCT02866279	1:9:chronic_disease	Diabetes (gestational or pre-gestational)
NCT02866279	28:36:upper_bound	Expected delivery prior to 34 weeks
NCT02866279	14:52:contraception_consent	Intention to use a contraceptive implant postpartum
NCT02866279	6:15:pregnancy,28:36:lower_bound	Live pregnancy of at least 24 weeks gestation
NCT02866279	1:8:chronic_disease,24:27:bmi,29:31:lower_bound	Obesity (pre-pregnancy BMI >35)
NCT02866279	1:28:chronic_disease	Polycystic Ovarian Syndrome
NCT02864862	62:66:upper_bound,117:127:treatment,136:149:treatment,155:167:treatment	Location of buccal alveolar crest has to be generally within 4 mm from the free gingival margin, verified after the extraction, before randomization; and fenestration
NCT02864862	46:66:treatment	The reasons for extraction will include poor endodontic prognosis
NCT02864862	41:44:allergy_name,46:56:allergy_name,58:67:allergy_name,69:78:allergy_name,80:91:allergy_name,96:106:allergy_name	allergy to antibiotics contained in the ADM (Gentimicin, Cefoxitin, Lincomcin, polymixin B and Vancomycin) will not be included in the immediate implant combined with ADM group
NCT02864862	5:13:pregnancy	are pregnant
NCT02864862	27:45:lower_bound	currently smoke exceeding 10 cigarettes/ day
NCT02864862	10:33:clinical_variable,89:93:upper_bound	level of radiographic bone level has the distance from CEJ to interproximal crest up to 4 mm
NCT02864862	31:47:treatment,117:141:treatment	patients who are in need of a tooth extraction at the maxillary premolar, canine and incisor region, and subsequent single implant placement
NCT02864862	8:29:chronic_disease,31:43:chronic_disease,57:76:treatment	severe parafunctional habits, malocclusion or intent of orthodontic therapy in the future
NCT02864862	89:96:treatment	the eligible tooth has esthetically acceptable buccal gingival margin position prior to surgery
NCT02864862	190:194:upper_bound	unrestorable teeth (extensive caries, traumatic fractures, fractures of endodontically treated teeth, root perforation, root resorption with or without radiographic periapical lesion up to 3 mm in diameter)
NCT02864862	7:22:upper_bound,78:81:upper_bound	up to 3mm in diameter at the apical part of the root and affecting less than 30% of the buccal socket wall
NCT02862158	17:19:lower_bound	Adult patients (18 and over)
NCT02862158	1:9:pregnancy,10:15:gender	pregnant women
NCT02862158	5:37:language_fluency	who speak English, Spanish or Creole
NCT02859142	10:12:lower_bound,14:17:gender,23:24:lower_bound,26:31:gender	Consume >14 (men) or >7 (women) standard alcohol drinks per week
NCT02859142	9:26:chronic_disease,28:41:upper_bound	Current suicidal ideation (past 6 months)
NCT02859142	33:50:allergy_name	History of adverse reactions to varenicline (VAR)
NCT02859142	12:20:chronic_disease	History of seizures
NCT02859142	7:8:age,9:11:upper_bound	Smoke 3-30 cigarettes/day
NCT02859142	10:13:lower_bound	at least 8th grade education
NCT02859142	1:10:chronic_disease	cirrhosis
NCT02859142	1:33:pregnancy,37:54:upper_bound	current plans to become pregnant in next three months
NCT02859142	11:19:pregnancy	currently pregnant
NCT02859142	1:10:chronic_disease	hepatitis
NCT02859142	18:34:chronic_disease	history of major suicide attempts
NCT02859142	1:21:chronic_disease	psychiatric disorder
NCT02859142	8:28:chronic_disease	recent major cardiovascular event
NCT02859142	1:17:chronic_disease	seizure disorder
NCT02859142	1:42:contraception_consent	unable to agree to adequate birth control during study participation
NCT02856594	1:4:age,7:9:lower_bound	Age ≥ 60
NCT02856594	1:6:chronic_disease,8:16:chronic_disease,24:50:language_fluency	Blind, deafness or the inability to speak English
NCT02856594	30:52:chronic_disease,54:72:chronic_disease	Follow-up difficulties (i.e. active substance abuse, psychotic disorder, homelessness)
NCT02856594	10:25:treatment,33:39:upper_bound	Previous cardiac surgery within 1 year of surgical procedure
NCT02856594	1:6:chronic_disease,11:24:chronic_disease,35:43:treatment,47:63:clinical_variable,66:67:lower_bound	Renal and liver failure requiring dialysis or Child-Pugh score > 5
NCT02856594	17:43:treatment,89:94:clinical_variable,101:109:lower_bound	Scheduled for a cardiac surgical procedure with planned post-operative admission to the CSICU for ≥ 24 hours
NCT02856594	24:42:treatment	Scheduled for a second surgical procedure during hospital stay
NCT02833207	1:4:age,7:9:lower_bound,14:22:upper_bound,26:29:age	Age: ≥18 - ≤ 40 years of age
NCT02833207	1:4:bmi,6:14:upper_bound,35:43:lower_bound	BMI <25 kg/m2 (Lean control) and ≥30 kg/m2 (Obese subjects)
NCT02833207	1:24:clinical_variable,26:29:upper_bound,34:43:clinical_variable,45:67:upper_bound,73:76:upper_bound,92:99:upper_bound	Blood pressure systolic ≤125 and diastolic ≤85 mmHg (Lean control) and <140 and diastolic <90 mmHg (Obese subjects)
NCT02833207	1:8:gender,24:33:pregnancy,71:98:chronic_disease	Females: Self-reported pregnancy and/or breastfeeding, diagnosed with polycystic ovarian syndrome, or without regular menses
NCT02833207	30:46:clinical_variable,48:53:lower_bound,54:55:upper_bound,66:81:clinical_variable	Must be studied in the early follicular phase (day 1-5) of their menstrual cycle or the low hormone phase of oral contraceptive use
NCT02833207	1:19:pregnancy	Negative pregnancy test
NCT02833207	45:64:lower_bound	Participation in vigorous aerobic exercise >90 minutes per week
NCT02833207	13:24:lower_bound,31:51:treatment	Regularly (≥5 days/week) take acetylsalicylic acid
NCT02833207	47:70:chronic_disease	Self-reported current diagnosis of exhibiting obstructive sleep apnea
NCT02833207	26:45:chronic_disease	Self-reported history of hematologic disease
NCT02833207	26:41:chronic_disease	Self-reported history of hepatic disease
NCT02833207	26:53:chronic_disease	Self-reported history of peripheral vascular disease
NCT02833207	26:39:chronic_disease	Self-reported history of renal disease
NCT02833207	16:25:treatment	Sensitivity to lidocaine
NCT02833207	65:83:chronic_disease	Specific to obese subjects only (to exclude obese subjects with metabolic syndrome)
NCT02833207	8:34:treatment,36:54:treatment,56:63:treatment,65:84:treatment,95:116:treatment,118:137:treatment	Taking cardiovascular medications (anti-hypertensives, statins, platelet inhibitors, etc.) or metabolic medications (insulin-sensitizing)
NCT02833207	1:47:treatment	non-steroidal anti-inflammatory drugs (NSAIDs)
NCT02826967	1:10:pregnancy	Pregnancy
NCT02824276	1:5:chronic_disease,28:36:lower_bound	CLBP lasting for more than 6 months as the primary complaint
NCT02824276	15:34:treatment	candidate for oral opioid therapy as assessed at the BWH Pain Management Center
NCT02824276	24:52:chronic_disease	current (i.e., active) substance use disorder (SUD)
NCT02824276	9:30:chronic_disease	current peripheral neuropathy
NCT02824276	9:18:pregnancy	current pregnancy
NCT02824276	13:21:chronic_disease,23:31:chronic_disease,33:42:chronic_disease,53:73:chronic_disease	evidence of delirium, dementia, psychosis, or other cognitive impairment preventing completion of study procedures
NCT02824276	28:34:treatment,71:79:lower_bound	past history of persistent opioid use (i.e., opioid use for more than 6 months) given that this could affect the biological systems of interest in the present study
NCT02824276	1:21:clinical_variable,24:28:lower_bound,34:55:clinical_variable	typical pain ratings ≥ 4/10 on a visual analogue scale
NCT02824263	1:25:chronic_disease	Congestive heart failure
NCT02824263	1:9:chronic_disease,31:38:treatment	Diabetes requiring the use of insulin
NCT02824263	1:11:clinical_variable,14:21:upper_bound	Hemoglobin < 10 g/dL on point of care screening
NCT02824263	24:60:chronic_disease	History of moderate to severe Obstructive sleep apnea (OSA)
NCT02824263	7:16:pregnancy,38:43:gender,61:64:age	Known pregnancy, by urine testing in women of child-bearing age
NCT02824263	14:26:chronic_disease,32:55:clinical_variable,57:60:lower_bound,64:88:clinical_variable,91:94:lower_bound	Uncontrolled hypertension with systolic blood pressure >170 or diastolic blood pressure > 110
NCT02822768	1:17:language_fluency	English-speaking subjects only
NCT02822768	1:21:language_fluency	Non-English speaking subjects
NCT02822768	76:97:treatment	Patients being admitted to the hospital or going to the operating room for incision and drainage
NCT02822768	20:28:upper_bound,32:35:age	Patients less than 18 years of age
NCT02822768	1:9:pregnancy	Pregnant patients
NCT02819635	1:26:chronic_disease,35:53:clinical_variable,57:58:lower_bound,62:63:upper_bound	Active ulcerative colitis with an Adapted Mayo score of 5 to 9 points
NCT02819635	30:36:treatment,78:80:chronic_disease	Appropriate documentation of biopsy results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available
NCT02819635	22:39:chronic_disease,47:62:chronic_disease	Current diagnosis of fulminant colitis and/or toxic megacolon
NCT02819635	14:32:chronic_disease,37:44:lower_bound	Diagnosis of ulcerative colitis for 90 days or greater prior to Baseline, confirmed by colonoscopy during the Screening Period
NCT02819635	1:7:gender	Female participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit prior to study drug dosing
NCT02819635	4:10:gender	If female, participant must meet the criteria for Contraception Recommendations
NCT02819635	16:28:treatment,32:48:treatment,56:63:upper_bound	Participant on azathioprine or 6-mercaptopurine within 10 days of baseline
NCT02819635	39:59:chronic_disease	Participant with current diagnosis of Crohn's disease (CD)
NCT02819635	49:69:chronic_disease,92:101:treatment	Participant with disease limited to the rectum (ulcerative proctitis) during the Screening endoscopy
NCT02819635	10:22:treatment,24:34:treatment,36:57:treatment,62:73:treatment,81:94:upper_bound	Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline
NCT02819635	10:37:treatment,45:58:upper_bound	Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period
NCT02819635	1:19:treatment	biologic therapies in the opinion of the investigator
NCT02819635	1:16:treatment	corticosteroids
NCT02819635	14:40:chronic_disease	diagnosis of indeterminate colitis (IC)
NCT02819635	1:19:treatment	immunosuppressants
NCT02819635	24:38:clinical_variable	meet the definition of Tanner Stage 5 at Screening Visit
NCT02819635	1:22:treatment	oral aminosalicylates
NCT02819635	1:6:clinical_variable,10:22:lower_bound	weigh >= 40 kilograms
NCT02808702	8:16:chronic_disease,20:38:chronic_disease	Active suicidal or homicidal ideation
NCT02808702	9:12:treatment	Current CBT and/or formal mindfulness/meditation training
NCT02808702	17:40:chronic_disease,44:62:chronic_disease	Current or past manic/hypomanic episode or psychotic symptoms
NCT02808702	16:40:treatment,49:64:treatment	Current use of psychotropic medications, except antidepressants taken at a stable dose for 2 weeks, to maximize generalizability of sample
NCT02808702	1:18:language_fluency	Fluent in English, and willing to provide informed consent
NCT02808702	62:83:chronic_disease,104:116:upper_bound,124:129:clinical_variable	For healthy controls only: no current or lifetime history of psychiatric disorders, and score of below 1 SD of mean on the SCS-R
NCT02808702	220:253:clinical_variable	For patients: treatment-seeking individuals presenting with at least moderate levels of social anxiety/body dysmorphic symptoms, and a score of at least 1 SD above the mean on the public self-consciousness scale of the Self-Consciousness Scale- Revised
NCT02808702	25:46:chronic_disease,51:74:chronic_disease	History of head injury, neurological disorder, or neurosurgical procedure
NCT02808702	22:24:lower_bound,37:40:treatment	History of more than 10 sessions of CBT and formal mindfulness/meditation training
NCT02808702	1:4:gender	Men
NCT02808702	1:6:gender	women
NCT02800629	14:26:chronic_disease	Diagnosis of fibromyalgia
NCT02800629	27:47:chronic_disease,80:100:chronic_disease,102:121:chronic_disease,123:127:chronic_disease,129:139:chronic_disease	Presence of an underlying inflammatory disease in the affected knee, including Rheumatoid Arthritis, Psoriatic Arthritis, Gout, Pseudogout, or other inflammatory disease
NCT02800629	98:107:chronic_disease,109:131:clinical_variable,142:145:upper_bound,147:157:clinical_variable,168:170:upper_bound,175:184:clinical_variable,195:198:upper_bound,209:232:chronic_disease,234:260:clinical_variable,271:273:upper_bound,278:300:chronic_disease	While this supplement is considered very safe and low risk, patients with underlying significant cytopenia (white blood cell count less than 4.0, hemoglobin less than 10, or platelets less than 100), or with impaired renal function (glomerular filtration rate less than 60) or elevated liver enzymes will be excluded as well
NCT02793583	11:18:treatment	Any major surgery
NCT02793583	14:36:cancer,47:76:cancer,78:88:cancer,90:110:cancer,115:137:cancer	Diagnosis of Non-Hodgkin's Lymphoma including Diffuse Large B-cell Lymphoma, Follicular, Mantle Cell Lymphoma and Marginal Zone Lymphoma
NCT02793583	13:30:chronic_disease,32:49:chronic_disease	Evidence of hepatitis B virus, hepatitis C virus
NCT02793583	1:50:treatment	Prior Allogeneic hematologic stem cell transplant
NCT02793583	1:14:treatment,22:42:treatment	Prior therapy with a PI3K delta inhibitor
NCT02793583	1:13:treatment	chemotherapy
NCT02786706	55:73:chronic_disease	Admitted to an ICU in the University of Michigan with Acute Brain Injury
NCT02786706	1:30:chronic_disease,42:58:chronic_disease	Pre-existing ocular pathology other than refractive error
NCT02784535	1:9:lower_bound	40 years old or older
NCT02784535	20:38:chronic_disease	History of serious neurologic disease
NCT02784535	21:32:allergy_name	Hypersensitivity to atomoxetine
NCT02784535	1:24:chronic_disease,26:42:clinical_variable,62:71:lower_bound	Impaired renal function (serum creatinine equal or more than 1.6 mg/dl)
NCT02784535	1:22:chronic_disease,30:44:upper_bound	Myocardial infarction within 6 months prior to enrollment
NCT02784535	1:22:chronic_disease	Narrow-angle glaucoma
NCT02784535	26:39:upper_bound	Previous history (within 14 days prior to enrollment)
NCT02784535	60:82:treatment,84:105:treatment,107:128:treatment,130:154:treatment,156:177:treatment	Use of other norepinephrine transporter inhibitors such as Wellbutrin (Bupropion), Cymbalta (Duloxetine), Effexor (venlafaxine), Pristiq (desvenlafaxine), Savella (milnacipran)
NCT02784535	1:20:chronic_disease	cerebral hemorrhage
NCT02784535	16:44:treatment	current use of monoamine oxidase inhibitors
NCT02784535	1:10:chronic_disease	urticaria
NCT02780401	1:2:lower_bound,3:4:upper_bound,6:10:cancer,25:51:treatment	0-1+ HER2 expression by immunohistochemistry (IHC)
NCT02780401	1:23:chronic_disease	Dilated cardiomyopathy
NCT02780401	1:42:treatment	Fluorescence in situ hybridization (FISH) negative
NCT02780401	1:44:clinical_variable,47:51:upper_bound	Glycosylated hemoglobin measurement (HbA1c) < 5.7%
NCT02780401	1:17:clinical_variable,21:28:lower_bound	Hemoglobin (Hgb) >= 10 g/dl
NCT02780401	102:108:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to WOKVAC
NCT02780401	59:68:treatment,76:90:upper_bound	History of autoimmunity that has not been controlled with treatment in the last 12 months
NCT02780401	18:62:chronic_disease	Known history of human immunodeficiency virus (HIV) infection
NCT02780401	1:42:clinical_variable,62:89:clinical_variable,177:198:treatment	Left ventricular ejection fraction (LVEF) results must be >= lower limit of normal (LLN) for institution performing based on results from the multi-gated acquisition (MUGA) or echocardiogram (ECHO) done at baseline
NCT02780401	1:17:clinical_variable,21:29:lower_bound	Lymphocyte count >= 800/mm^3
NCT02780401	52:65:chronic_disease,69:85:treatment	New York Heart Association functional class III-IV heart failure on active treatment
NCT02780401	27:34:lower_bound,35:62:treatment,64:76:treatment,78:97:treatment,111:127:treatment	Patients must be at least 28 days post cytotoxic chemotherapy, radiotherapy, monoclonal antibody and/or other biologic therapy, prior to enrollment
NCT02780401	27:34:lower_bound	Patients must be at least 28 days post systemic steroids prior to enrollment
NCT02780401	20:86:clinical_variable,93:94:upper_bound	Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score of =< 2
NCT02780401	35:51:chronic_disease,59:78:treatment	Patients must have recovered from major infections and/or surgical procedures
NCT02780401	46:55:pregnancy,61:155:contraception_consent	Patients who are having sex that can lead to pregnancy must agree to use adequate contraception (hormonal, barrier method of birth control, or abstinence) for the duration of study participation
NCT02780401	75:89:allergy_name,91:169:allergy_name	Patients with any contraindication or known hypersensitivity to receiving sargramostatin (recombinant human granulocyte macrophage colony stimulating factor [rhuGM-CSF]) or other yeast based products
NCT02780401	15:29:cancer,31:44:cancer,46:73:cancer	Patients with non-metastatic, node positive, HER2 negative breast cancer, confirmed by pathology report, who are in remission and defined as having no evidence of disease (NED)
NCT02780401	1:15:clinical_variable,19:30:lower_bound	Platelet count >= 75,000/mm^3
NCT02780401	1:9:pregnancy,10:15:gender	Pregnant women
NCT02780401	1:39:chronic_disease	Symptomatic restrictive cardiomyopathy
NCT02780401	1:16:chronic_disease,24:38:upper_bound	Unstable angina within 4 months prior to enrollment
NCT02780401	28:79:treatment,83:101:treatment,114:121:upper_bound,122:138:treatment	Willing to not undergo any elective surgical procedure with general anesthesia or conscious sedation through the 1 month post-vaccination visit
NCT02780401	1:21:clinical_variable,24:33:lower_bound	creatinine clearance > 60 ml/min
NCT02780401	13:28:treatment,30:39:treatment,48:65:treatment	patients on bisphosphonates, denosumab, and/or endocrine therapy and may continue throughout duration of study
NCT02776475	18:26:pregnancy,30:49:pregnancy	Patients who are pregnant or may become pregnant
NCT02776475	15:37:chronic_disease	Patients with cognitive disabilities or those lacking the mental capacity to understand and answer questionnaires
NCT02776475	15:50:chronic_disease	Patients with degenerative neurological disorders or spinal cord injuries
NCT02776475	25:33:upper_bound	Patients with less than 6 months of expected battery life on their device established at office testing
NCT02776475	57:70:upper_bound	Patients with poor control of their symptoms within the last one year
NCT02776475	1:6:gender	Women
NCT02776475	1:5:age,6:8:lower_bound,9:11:upper_bound,137:145:lower_bound	aged 18-85 with who have previously had the InterStim device implanted and have experienced good control of their symptoms for at least one year
NCT02772237	12:22:chronic_disease,34:48:upper_bound	A previous concussion within the last 12 months
NCT02772237	14:22:lower_bound	Greater than 24 hours have elapsed since the concussion occurred
NCT02772237	11:19:upper_bound	Less than 18 years old
NCT02772237	84:94:treatment	The student-athlete has already participated in the study during which he/she took Riboflavin
NCT02772237	10:13:age,17:25:lower_bound	over the age of 18 years old
NCT02772237	26:51:chronic_disease	who are diagnosed with a sports related concussion
NCT02770326	1:4:clinical_variable,6:14:upper_bound	ANC <1000/mm3
NCT02770326	8:15:chronic_disease	Active fistula
NCT02770326	63:71:chronic_disease,87:90:lower_bound,110:128:treatment,132:142:cancer	Clinical and microbiologic relapse of C. difficile associated diarrhea after at least one course of adequate antibiotic therapy or refractory disease that does not respond to treatment
NCT02770326	22:32:allergy_name	Contraindications to anesthesia for procedure
NCT02770326	1:22:chronic_disease	Gastrointestinal (GI) contraindications
NCT02770326	1:14:chronic_disease	Gastroparesis
NCT02770326	1:4:clinical_variable,6:12:upper_bound	HGB <8 g/dL
NCT02770326	1:4:chronic_disease,20:29:clinical_variable,31:34:upper_bound	HIV infection with CD4 count <240
NCT02770326	1:23:cancer	Hematologic malignancy
NCT02770326	12:53:treatment	History of hematopoietic stem cell transplant (HSCT)
NCT02770326	1:6:chronic_disease	Ileus
NCT02770326	1:27:chronic_disease	Inflammatory bowel disease
NCT02770326	1:16:clinical_variable,21:29:lower_bound	Life expectancy of >3 months
NCT02770326	1:4:clinical_variable,6:18:upper_bound	PLT <50,000 K/mcL
NCT02770326	15:37:cancer,56:68:treatment,80:95:upper_bound	Patients with solid organ malignancy who have received chemotherapy within the past six months
NCT02770326	9:38:chronic_disease	Serious cardiopulmonary comorbidities
NCT02770326	1:24:chronic_disease	Small bowel obstruction
NCT02770326	2:10:lower_bound	≥18 years old
NCT02762825	3:15:upper_bound,19:22:gender	< 24 mL/kg/min in men
NCT02762825	2:14:upper_bound,18:23:gender	<21 mL/kg/min in women
NCT02762825	39:52:chronic_disease,80:87:lower_bound	Any patient recently hospitalized for heart failure will have to wait at least 2 weeks before starting CR
NCT02762825	1:20:chronic_disease	Atrial fibrillation
NCT02762825	1:11:clinical_variable,12:14:lower_bound,18:21:upper_bound	NYHA class II or III symptoms
NCT02762825	32:38:chronic_disease	Patients with exercise induced angina during CR
NCT02762825	1:9:pregnancy	Pregnant
NCT02762825	34:51:treatment,84:101:clinical_variable,104:108:lower_bound	Referred by physician to CR with echocardiographic evidence of HFpEF defined as an ejection fraction ≥ 50 %
NCT02762825	1:56:chronic_disease	moderate to severe (grade II-III) diastolic dysfunction
NCT02762825	1:28:pregnancy	planning to become pregnant
NCT02762825	27:48:chronic_disease	those with mild (grade I) diastolic dysfunction
NCT02762825	3:11:lower_bound,15:18:age	≥ 50 years of age
NCT02762006	2:13:lower_bound,22:37:treatment	>160/90 mmHg despite medical therapy
NCT02762006	1:11:clinical_variable,12:22:clinical_variable,25:30:upper_bound,31:66:clinical_variable	AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal
NCT02762006	1:32:clinical_variable,35:46:lower_bound,50:62:lower_bound	Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (≥ 1500 per mm3)
NCT02762006	28:46:chronic_disease,58:70:upper_bound	Active or prior documented autoimmune disease within the past 2 years
NCT02762006	25:53:treatment,61:68:upper_bound,94:104:treatment,144:167:treatment,152:166:treatment,171:195:treatment,244:253:upper_bound,257:267:treatment	Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
NCT02762006	1:61:clinical_variable,65:66:lower_bound,70:71:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
NCT02762006	1:38:clinical_variable,81:84:upper_bound,87:90:age,102:108:clinical_variable,116:118:upper_bound,121:137:clinical_variable,150:154:upper_bound,159:174:gender	Estimated creatinine clearance (Clcr) in mL/min by the Cockcroft-Gault (C-G): {[140 − age ( years)]× weight (kg)}/{72 × serum creatinine (mg / dL)} ×0.85 for female patients
NCT02762006	13:44:cancer	Evidence of metastatic renal cell carcinoma on imaging and/or biopsy
NCT02762006	1:16:gender	Female subjects must either be of non-reproductive potential
NCT02762006	1:16:gender,21:33:pregnancy	Female subjects who are pregnant
NCT02762006	1:27:clinical_variable,30:45:lower_bound,93:113:clinical_variable,115:123:lower_bound	Glomerular filtration rate > 40ml/min/1.73m2 as estimated by the Cockcroft-Gault formula or creatinine clearance >50ml/min as determined by 24-hour urine collection
NCT02762006	1:11:clinical_variable,14:22:lower_bound	Hemoglobin ≥ 8.0 g/dL
NCT02762006	12:39:treatment	History of allogeneic organ transplant
NCT02762006	32:44:allergy_name,52:61:allergy_name	History of hypersensitivity to tremelimumab or any excipient
NCT02762006	12:41:chronic_disease	History of leptomeningeal carcinomatosis
NCT02762006	12:36:chronic_disease	History of primary immunodeficiency
NCT02762006	66:76:clinical_variable,78:84:lower_bound	In case of clinically significant ECG abnormalities, including a QTcF value >470 ms, 2 additional 12-lead ECGs should be obtained over a brief period (eg, 30 minutes) to confirm the finding
NCT02762006	1:48:clinical_variable,50:56:lower_bound,76:99:treatment	Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from an electrocardiogram (ECG) using Fridericia's Correction (QTcF)
NCT02762006	13:22:treatment,28:41:treatment,50:60:cancer,71:79:cancer,81:99:treatment,101:117:chronic_disease	No previous treatment with immunotherapy for any malignancy including cytokine, anti-tumor vaccine, T-cell activator, co-stimulator or immune checkpoint inhibitor
NCT02762006	84:96:upper_bound	Participation in another clinical study with an investigational product during the last 30 days
NCT02762006	1:15:clinical_variable,18:29:lower_bound,32:47:lower_bound	Platelet count ≥ 100 x 109/L (≥100,000 per mm3)
NCT02762006	1:9:pregnancy	Pregnant
NCT02762006	26:46:cancer,52:70:clinical_variable,92:110:cancer	Radiographic evidence of renal cell carcinoma (any histologic subtype) without evidence of distant metastatic disease
NCT02762006	12:39:treatment,47:54:upper_bound,47:60:upper_bound,107:117:treatment,121:133:treatment	Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
NCT02762006	1:16:clinical_variable,19:66:upper_bound	Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
NCT02762006	21:24:chronic_disease,26:44:chronic_disease,49:67:chronic_disease,123:145:treatment,224:234:treatment,242:254:treatment	Subjects with known HIV, active hepatitis B, or active hepatitis C (detectable RNA). HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with durvalumab and/or tremelimumab
NCT02762006	8:26:chronic_disease,84:103:chronic_disease,105:116:chronic_disease,137:171:chronic_disease	active bleeding diathesis including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C (detectable RNA) or human immunodeficiency virus (HIV)
NCT02762006	8:28:chronic_disease,32:41:chronic_disease	active peptic ulcer disease or gastritis
NCT02762006	15:20:gender	breastfeeding women
NCT02762006	1:19:chronic_disease	cardiac arrhythmia
NCT02762006	1:31:chronic_disease	controlled atrial fibrillation
NCT02762006	1:16:gender	female patients of reproductive potential who are not employing an effective method of birth control
NCT02762006	12:34:treatment	history of bilateral oophorectomy
NCT02762006	12:36:treatment	history of bilateral tubal ligation
NCT02762006	1:5:gender	male
NCT02762006	13:37:pregnancy	must have a negative serum pregnancy test upon study entry
NCT02762006	30:38:lower_bound,62:68:lower_bound	post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause
NCT02762006	1:20:chronic_disease,21:38:chronic_disease	psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
NCT02762006	1:25:chronic_disease,37:45:treatment	unstable angina pectoris (requiring nitrates
NCT02750319	18:20:chronic_disease	History of prior AF
NCT02750319	7:16:pregnancy	Known pregnancy
NCT02750319	1:5:gender,7:10:age,12:14:lower_bound	Male- age ≥75 (No BNP limit)
NCT02750319	13:25:chronic_disease	Patients in sinus rhythm
NCT02750319	24:50:treatment	Patients scheduled for extrapleural pneumonectomy
NCT02750319	45:65:chronic_disease	Patients with stable respiratory status (no respiratory distress)
NCT02750319	11:19:lower_bound,38:63:treatment	Patients ≥18 years old scheduled for elective thoracic surgery
NCT02750319	11:19:chronic_disease	having an acute MI
NCT02750319	8:25:chronic_disease	not in cardiogenic shock
NCT02746458	162:169:upper_bound,173:192:treatment	Additional fracture, dislocations or soft tissue injuries to the study limb that would compromise the ability to weight bear as tolerated and initiate PT within 28 days of definitive fixation
NCT02746458	8:12:age,13:15:lower_bound,16:18:upper_bound	Adults ages 18-55 inclusive
NCT02746458	174:181:upper_bound	Any fractures, dislocations or soft tissue injuries to the contralateral limb or pelvis that would compromise the ability to weight bear as tolerated and initiate PT within 28 days of definitive fixation
NCT02746458	22:30:chronic_disease	Current diagnosis of acidosis
NCT02746458	22:28:cancer	Current diagnosis of cancer
NCT02746458	9:14:cancer	Current tumor (malignant or benign) distal to study injury and future tourniquet placement
NCT02746458	14:33:chronic_disease	Diagnosis of severe hypertension (blood pressure of 180/110)
NCT02746458	14:32:chronic_disease	Diagnosis of sickle cell anemia
NCT02746458	18:33:treatment	Extremities with dialysis access
NCT02746458	12:82:chronic_disease	History of Peripheral Artery Disease and/or Peripheral Vascular Disease (PAD/PVD)
NCT02746458	12:24:cancer	History of lymphotomies
NCT02746458	1:21:chronic_disease	Impaired circulation
NCT02746458	145:152:upper_bound,156:175:treatment	Injuries to other body systems (or other medical conditions) that would preclude the ability to weight bear as tolerated and initiate PT within 28 days of definitive fixation
NCT02746458	17:20:bmi,23:25:lower_bound	Morbidly obese (BMI > 40)
NCT02746458	6:31:chronic_disease	Open diaphyseal femur fracture
NCT02746458	12:20:pregnancy	Patient is pregnant
NCT02746458	18:21:treatment,58:73:treatment	Patient received BFR between date of injury and start of Physical Therap
NCT02746458	1:12:treatment	Skin grafts in which all bleeding points must be readily distinguished
NCT02746458	1:42:language_fluency	Unable to speak either English or Spanish
NCT02746458	84:100:treatment	Use of blood flow restriction (BFR) at any time between treatment and the start of physical therapy for the study
NCT02746458	15:36:chronic_disease	have document psychiatric disorders
NCT02746458	1:30:chronic_disease	severe traumatic brain injury
NCT02746458	1:11:treatment	skin graft
NCT02746458	1:24:treatment	vascular reconstruction
NCT02744391	28:35:chronic_disease,39:59:chronic_disease	Acute, severe, or unstable medical or neurological illness
NCT02744391	1:4:age,6:14:lower_bound	Age >59 years
NCT02744391	1:67:clinical_variable,70:71:lower_bound	Center for Epidemiological Studies Depression (CES-D) Rating Scale > 9
NCT02744391	31:43:upper_bound,45:133:treatment	Current or recent (within the past 4 weeks) treatment with antidepressants, antipsychotics, dopaminergic agents, or mood stabilizers
NCT02744391	21:46:chronic_disease,48:57:chronic_disease,62:72:chronic_disease	DSM 5 non-psychotic Major Depressive Disorder, Dysthymia, or Depression Not Otherwise Specified
NCT02744391	40:43:lower_bound,53:56:age	Decreased processing speed (defined as 0.5 SD below age-adjusted norms on the Digit Symbol Test)
NCT02744391	23:42:chronic_disease,44:61:chronic_disease,66:68:chronic_disease	Diagnosis of probable Alzheimer's Disease, Vascular Dementia, or PD
NCT02744391	55:75:chronic_disease,88:102:upper_bound	Diagnosis of substance abuse or dependence (excluding Tobacco Use Disorder) within the past 12 months
NCT02744391	15:32:chronic_disease,34:52:chronic_disease,54:59:chronic_disease,64:80:chronic_disease	History of or current psychosis, psychotic disorder, mania, or bipolar disorder
NCT02744391	1:12:chronic_disease,14:17:clinical_variable,23:35:chronic_disease,42:45:lower_bound,49:52:clinical_variable,65:71:chronic_disease,80:87:chronic_disease,91:108:chronic_disease,110:129:chronic_disease,167:189:chronic_disease	Hypotension (SBP<90), hypertension (SBP >150 or DBP > 90), past stroke causing sensory or movement deficits, cardiac arrhythmias, or any other severe or uncontrolled cardiovascular disease
NCT02744391	1:31:clinical_variable,34:36:upper_bound	Mini Mental Status Exam (MMSE) < 25
NCT02744391	56:59:chronic_disease,61:70:chronic_disease,75:89:chronic_disease,97:122:treatment,126:139:treatment	Prefer not to be treated with a standard treatment for MDD, Dysthymia, or Depression NOS (e.g., antidepressant medication or psychotherapy)
NCT02744391	38:55:chronic_disease,57:75:chronic_disease,77:103:chronic_disease,118:140:chronic_disease,185:208:chronic_disease	Presence of a clinically significant brain abnormality, significant anemia, insulin dependent diabetes, a history of cardiovascular disease, or uncontrolled/untreated risk factors for coronary artery disease
NCT02744391	34:71:clinical_variable,74:79:upper_bound	decreased gait speed (defined as average walking speed over 15' course < 1 m/s)
NCT02741180	47:57:treatment,61:89:treatment	Contraindications for MRI examinations (e.g., pacemakers or ferromagnetic vascular clips)
NCT02741180	1:9:chronic_disease,11:23:chronic_disease,38:52:chronic_disease	Diabetes, hypertension, smoking, and hyperlipidemia, etc
NCT02741180	1:24:chronic_disease	Hemodynamic instability
NCT02741180	18:40:chronic_disease	History of prior cardiovascular disease or significant risk factors
NCT02741180	15:31:chronic_disease	No history of heart arrhythmia
NCT02741180	25:41:chronic_disease,73:76:clinical_variable	Patients diagnosed with heart arrhythmia scheduled for routine clinical MRI examinations)
NCT02740595	1:16:chronic_disease	Cardiac disease
NCT02740595	1:18:chronic_disease	Diabetes mellitus
NCT02740595	1:20:chronic_disease	Respiratory disease
NCT02739620	1:11:chronic_disease,13:21:chronic_disease,25:46:chronic_disease	autoimmune, vascular or neuromuscular disease that could alter skeletal muscle
NCT02739620	30:66:allergy_name,81:112:allergy_name,116:125:allergy_name,127:153:allergy_name,157:169:allergy_name	contraindications for use of neuromuscular electrical stimulation, including an implanted cardiac defibrillator or pacemaker, lower extremity blood clot or coagulopathy
NCT02739620	1:19:cancer,40:46:cancer,58:82:cancer,104:116:treatment	metastatic disease, a prior history of cancer, excluding non-melanoma skin cancer, or prior receipt of chemotherapy
NCT02739620	1:10:pregnancy	pregnancy
NCT02739620	1:30:treatment	prior knee or hip replacement
NCT02739620	11:22:treatment,26:47:treatment,64:73:treatment	receiving neoadjuvant or adjuvant chemotherapy with or without radiation
NCT02739620	1:33:cancer	stage I, II or III breast cancer
NCT02737202	1:3:lower_bound,7:15:upper_bound,19:22:age	18 to 65 years of age
NCT02737202	10:21:chronic_disease,23:28:chronic_disease,30:37:chronic_disease,39:59:chronic_disease,63:81:chronic_disease,86:89:bmi,94:96:lower_bound	Advanced hematologic, renal, hepatic, non-LAM lung disease or metabolic diseases; or BMI of >35
NCT02737202	39:42:chronic_disease,86:116:treatment	All patients must have a diagnosis of LAM as defined by compatible cystic changes on chest computed tomography (CT)
NCT02737202	22:53:cancer,55:75:cancer,77:107:chronic_disease,123:152:chronic_disease	Clinical findings of tuberous scleroma complex (TSC), renal angiomyolipoma, cystic abdominal lymphangiomas, or history of chylous effusion in the chest or abdome
NCT02737202	9:18:chronic_disease	Current infection
NCT02737202	1:29:pregnancy	Current or planned pregnancy
NCT02737202	1:7:gender	Female patients
NCT02737202	1:14:treatment,26:39:upper_bound	Major surgery within the past 2 months
NCT02737202	38:43:gender	Not using adequate contraception (in woman of childbearing potential)
NCT02737202	1:32:treatment,58:61:chronic_disease	Open or needle abdominal biopsy findings consistent with LAM
NCT02737202	10:30:treatment	Previous lung transplantation
NCT02737202	46:58:upper_bound	Significant clinical change in health in the past 30 days
NCT02737202	46:89:clinical_variable,95:104:lower_bound,127:130:lower_bound,131:163:clinical_variable,182:190:lower_bound,209:224:upper_bound	Subjects must have had a recent reduction in forced expiratory volume at 1-second (FEV1) of > 50ml/year, as shown by at least two pulmonary function testing (PFT) measured at least 6 months apart in the last 24 months prior to enrolling study
NCT02737202	48:55:upper_bound	The use of another investigational drug within 30 days
NCT02736227	30:37:upper_bound	Listed for or recent (within 1 month) recipient of deceased or living donor liver transplantation
NCT02736227	3:11:lower_bound,15:18:age	≥ 18 years of age
NCT02729350	1:9:lower_bound,13:16:age	18 years of age or older
NCT02729350	5:8:chronic_disease	Has SCD diagnosis
NCT02729350	14:15:lower_bound,43:51:upper_bound,53:54:lower_bound,55:63:upper_bound	Reports pain 3 or greater in the previous 24 hours (0-10 scale)
NCT02729350	1:25:language_fluency	Speaks and reads English
NCT02728284	1:23:treatment,32:46:treatment,48:62:treatment,64:74:treatment,76:93:treatment,95:118:treatment,120:135:treatment,137:145:treatment,172:186:treatment	ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
NCT02728284	70:78:chronic_disease,82:106:chronic_disease,150:164:chronic_disease	pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
NCT02709317	4:12:lower_bound	be 18 years or older
NCT02709317	30:39:treatment,60:66:treatment	currently be receiving daily treatment with a prescription opioid for chronic pain
NCT02709317	1:53:technology_access	have a cell phone capable of receiving text messages
NCT02709317	16:34:chronic_disease	have a current psychotic disorder severe enough to require inpatient treatment
NCT02709317	51:64:technology_access	willing to be in a study where they might receive text messages
NCT02699697	12:33:treatment,35:51:treatment,66:81:treatment,127:139:treatment	Changes in systemic chemotherapy, hormonal therapy or the use of bisphosphonates for 4 weeks before and after the delivery of radiotherapy are allowed, but recording and accounting for this in the statistical analysis is required
NCT02699697	1:61:clinical_variable,65:66:lower_bound,69:70:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3
NCT02699697	1:11:cancer,19:24:cancer,26:31:cancer,33:37:cancer,55:64:treatment	Metastases to the skull, hands, feet are not eligible treatment sites
NCT02699697	1:19:pregnancy	Negative pregnancy test at study registration
NCT02699697	1:11:clinical_variable,40:41:lower_bound,44:46:upper_bound,75:88:clinical_variable,101:106:lower_bound,110:118:treatment	Pain score of at least 5 on a scale of 0 - 10 within a week of enrollment OR pain score < 5 with >= 60 mg of morphine (or equivalent) per day
NCT02699697	10:22:treatment,26:44:treatment	Previous radiotherapy or palliative surgery to the painful site
NCT02699697	26:41:cancer,49:56:upper_bound	Radiographic evidence of bone metastases within 8 weeks of study
NCT02699697	16:51:chronic_disease,55:75:cancer	Spinal cord or cauda equine compression/effacement in vertebral metastases with neurological symptoms other than just pain
NCT02699697	21:29:cancer,31:39:cancer	Up to 5 consecutive cervical, thoracic or lumbar vertebral bodies
NCT02699697	27:37:cancer	for patients with painful metastases that are contiguous but do not fit into the definition of a site listed above
NCT02699697	68:69:upper_bound	multiple sites eligible if they can be included in no greater than 3 treatment sites
NCT02699697	91:101:cancer,232:263:treatment	the patient must have pain which appears to be related to the radiographically documented metastasis in the opinion of the treating physician, and the decision has been made by the responsible clinician that a course of palliative external beam radiation therapy is appropriate treatment
NCT02699697	74:83:treatment,131:133:cancer,135:137:cancer,142:144:cancer,226:230:lower_bound	those patients will still be eligible but will be considered to have two treatment sites; for example, a patient with a lesion of T4, T7 and T9 would be eligible but would be considered as two treatment sites since more than five consecutive vertebral bodies would be treated
NCT02698722	1:72:clinical_variable,75:91:upper_bound	Chronic Kidney Disease Epidemiology Collaboration for estimation of GFR < 30 ml/min/1.73m2
NCT02698722	1:17:language_fluency	English-speaking during clinical encounters
NCT02698722	18:26:chronic_disease	Known history of dementia
NCT02698722	9:14:chronic_disease	Legally blind
NCT02698722	12:29:treatment	Listed for kidney transplant
NCT02698722	1:17:chronic_disease	Stage 4 or 5 CKD
NCT02697799	1:9:lower_bound	18 years or older
NCT02697799	1:15:language_fluency	Speaks English
NCT02685761	1:4:bmi,27:29:lower_bound	BMI equal or greater than 40
NCT02685761	1:14:pregnancy	pre-pregnancy
NCT02682147	14:24:allergy_name,26:33:allergy_name,35:39:allergy_name,43:49:allergy_name	Allergies to shell fish, seafood, eggs or iodine
NCT02682147	1:22:bmi,36:38:lower_bound	Body Mass Index (BMI) greater than 32
NCT02682147	14:20:chronic_disease	Diagnosis of asthma
NCT02682147	1:5:clinical_variable,6:9:clinical_variable,10:13:upper_bound	FEV1/FVC<0.7
NCT02682147	1:5:clinical_variable,6:9:lower_bound	FEV1>80% of predicted
NCT02682147	1:4:clinical_variable,18:21:lower_bound	FVC greater than 80% of predicted
NCT02682147	1:56:clinical_variable,59:75:lower_bound	Forced Expiratory Flow at 25-75% of predicted(FEF25-75) > 79% of predicted
NCT02682147	1:14:chronic_disease	Heart disease
NCT02682147	1:9:pregnancy	Pregnant
NCT02682147	38:48:allergy_name	Prior history of hypersensitivity to Sildenafil
NCT02682147	1:7:clinical_variable,24:43:lower_bound	Weight of greater than 220 pounds (100 kg)
NCT02682147	1:18:treatment,24:35:treatment,40:52:chronic_disease,57:82:chronic_disease	antihypertensives, and medications for osteoporosis and gastrointestinal diseases
NCT02682147	13:17:age,21:23:lower_bound,28:30:upper_bound	between the ages of 25 and 65
NCT02682147	15:22:gender	breastfeeding females
NCT02682147	28:40:lower_bound	currently smoking at least 1/2 pack/day (confirmed with cotinine level)
NCT02682147	1:9:chronic_disease	diabetes
NCT02682147	1:15:chronic_disease	kidney disease
NCT02680535	7:30:chronic_disease	Acute urinary tract infection
NCT02680535	1:14:clinical_variable,17:18:upper_bound	Gleason Score ≤ 7
NCT02680535	8:23:treatment	If the standard biopsy cores are positive, they must be from the same location in the prostate as MR lesion was biopsied and proven to be cancerous
NCT02680535	1:29:chronic_disease,41:84:clinical_variable,87:89:lower_bound	Lower urinary tract symptoms defined by International Prostate symptom score (IPSS) > 20
NCT02680535	32:46:upper_bound,50:58:treatment	Prior MRI results dated within 120 days prior to ablation
NCT02680535	1:16:cancer,33:57:treatment	Prostate cancer is diagnosed by MR image guided biopsies
NCT02680535	1:27:chronic_disease	active bacterial infection
NCT02680535	1:37:chronic_disease,94:101:clinical_variable,109:116:clinical_variable,121:137:clinical_variable,198:205:lower_bound,218:221:clinical_variable,223:226:clinical_variable,228:231:clinical_variable,233:242:clinical_variable,247:250:clinical_variable	acute or chronic hepatic dysfunction as evidenced by clinically significant abnormalities in albumin, total protein, or prothrombin time, or evidence of hepatic injury with clinically important (> grade 1) changes in AST, ALT, ALP, bilirubin, or GGT values
NCT02680535	52:76:cancer	documented histological or cytological evidence of tumor(s) of the prostate
NCT02680535	1:15:treatment	extra capsular
NCT02680535	1:15:chronic_disease	mental illness
NCT02680535	1:19:chronic_disease	metastatic disease
NCT02680535	10:33:treatment,53:65:upper_bound	received investigational therapy within a period of 5 half-lives of the investigational therapy in question prior to the day of dosing with the PEGylated AuroShell particles
NCT02680535	1:20:chronic_disease,29:66:clinical_variable,70:72:upper_bound	renal insufficiency with an estimated glomerular filtration (EGF) <= 30
NCT02680535	1:25:cancer	seminal vesicle invasion
NCT02680535	15:30:cancer	treatment for prostate cancer
NCT02680535	14:28:chronic_disease	uncontrolled coagulopathies who are at increased risk of bleeding
NCT02676193	1:3:lower_bound,4:12:upper_bound,16:19:age	21-65 years of age
NCT02676193	1:18:pregnancy,32:47:pregnancy,64:72:upper_bound	Current pregnancy or intent to become pregnant during the next 12 weeks
NCT02676193	27:43:lower_bound,149:162:upper_bound	Daily smokers of at least 5 cigarettes/day who are classified as in the pre-contemplator stage of change (i.e. do not intend to quit smoking in the next 6-months)
NCT02676193	1:53:technology_access	Have a cell phone with a text messaging service plan
NCT02676193	67:83:chronic_disease	Marked organic impairment or unstable medical problems (such as a seizure disorder)
NCT02665962	1:8:lower_bound,12:15:age	18 year of age or older
NCT02665962	1:4:age	Age18
NCT02665962	26:45:cancer,64:79:upper_bound,103:119:treatment,132:154:treatment,158:167:treatment	Diagnosed with any other invasive malignancy currently, in the last five years or expected to undergo active treatment with either cytotoxic chemotherapy or radiation during the 6 week caloric restriction period
NCT02665962	14:36:language_fluency	Inability to communicate in English
NCT02665962	22:40:cancer	Newly diagnosed with Endometrial Cancer
NCT02665962	26:47:treatment,49:61:treatment,63:124:treatment,143:144:lower_bound,145:152:upper_bound	Scheduled for definitive surgical intervention (hysterectomy, bilateral salpingoopherectomy with or without lymphadenectomy) in the following 2-3 weeks as part of the standard of care
NCT02665962	1:16:clinical_variable,29:35:lower_bound	life expectancy of at least 1 year
NCT02665962	22:29:chronic_disease,33:55:chronic_disease,156:173:chronic_disease,182:189:chronic_disease,197:214:chronic_disease,222:232:chronic_disease	uncontrolled serious medical or psychiatric conditions that would affect their ability to participate in an intervention study, (e.g., severe/uncontrolled diabetes mellitus, severe cardiac and/or pulmonary disease and/or depression)
NCT02661386	1:14:treatment,29:36:treatment,40:46:treatment	Anticoagulant usage such as heparin or Plavix
NCT02661386	1:11:chronic_disease	Arrhythmia
NCT02661386	20:41:chronic_disease,56:76:chronic_disease,78:105:treatment,107:132:chronic_disease,134:152:chronic_disease,154:163:chronic_disease	Known or suspected Zenker's diverticulum of esophagus, esophageal stricture, head/neck radiation therapy, hereditary telangiectasis, esophageal varices, cirrhosis
NCT02661386	1:9:pregnancy	Pregnant
NCT02661386	26:43:chronic_disease	Prior known or suspected nasal obstruction
NCT02661386	1:17:clinical_variable,20:27:lower_bound	Serum creatinine > 2 mg/dl
NCT02661386	1:23:clinical_variable,26:35:upper_bound	White Blood Cell count < 5,000/mm3
NCT02661386	53:60:language_fluency,64:71:language_fluency	Willing and able to give informed consent in either English or Spanish
NCT02649790	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT02649790	25:28:chronic_disease,34:35:lower_bound,36:39:upper_bound,40:51:clinical_variable	Documented diagnosis of MDS with 5-19% myeloblasts
NCT02649790	13:37:cancer	Higher Risk Myelodysplastic Syndrome
NCT02649790	13:37:cancer	Higher risk Myelodysplastic Syndrome
NCT02649790	1:5:clinical_variable,33:36:cancer	IPSS low or intermediate-1 risk MDS
NCT02649790	1:14:treatment,22:29:upper_bound,37:41:treatment	Major surgery within 4 weeks before C1D1
NCT02649790	25:29:clinical_variable	Patients believed to be IPSS high risk, without clearly meeting IPSS categories above should be discussed with the medical monitor prior to enrolling
NCT02649790	20:65:treatment,69:126:treatment,138:151:upper_bound,155:159:treatment	Patients receiving granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) within the 3 weeks prior to C1D1
NCT02649790	26:79:cancer,84:121:cancer	Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (i.e. cervix) may enroll irrespective of the time of diagnosis
NCT02649790	21:49:cancer	Patients with known symptomatic brain metastasis
NCT02649790	28:46:chronic_disease,57:79:treatment,81:91:treatment,96:107:treatment,115:129:upper_bound	Uncontrolled active severe systemic infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to C1D1
NCT02649790	2:12:lower_bound	≥20% blasts in bone marrow or peripheral blood
NCT02642640	1:3:lower_bound,4:12:upper_bound,16:19:age	21-55 years of age
NCT02642640	1:10:ethnicity	Caucasian
NCT02642640	12:26:chronic_disease	History of sleep disorder or regular use of sleep-promoting medication
NCT02642640	46:59:upper_bound	Traveling across 2 or more time zones within past 3 months
NCT02642640	44:55:upper_bound	Worked night or rotating shift work within past 1 year
NCT02639065	1:4:age,7:15:lower_bound	Age ≥ 18 years at the time of consent
NCT02639065	99:108:treatment	Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued
NCT02639065	20:38:chronic_disease,49:67:treatment,75:93:upper_bound,187:204:treatment,208:232:treatment	Evidence of active autoimmune disease requiring systemic treatment within preceding 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents
NCT02639065	1:8:gender,3:8:gender,91:162:contraception_consent,201:209:upper_bound,216:225:treatment	Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 12 weeks after treatment discontinuation
NCT02639065	1:8:gender,47:71:pregnancy,84:100:upper_bound,118:134:treatment	Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration for protocol therapy
NCT02639065	1:14:clinical_variable,17:18:upper_bound,19:35:cancer	Gleason score ≤ 7 prostate cancers
NCT02639065	12:52:treatment	History of allogeneic organ or stem cell transplant
NCT02639065	32:42:allergy_name	History of hypersensitivity to durvalumab or any excipient
NCT02639065	12:49:chronic_disease	History of psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
NCT02639065	49:61:chronic_disease	Known history of previous clinical diagnosis of tuberculosis
NCT02639065	9:48:clinical_variable,51:59:lower_bound	Mean QT interval corrected for heart rate (QTc) > 470 msec calculated from 3 ECGs by Bazett's Correction
NCT02639065	29:31:lower_bound,32:35:upper_bound,36:50:clinical_variable	Moderate response (Grade 2, 10-50% residual tumor)
NCT02639065	33:36:lower_bound,46:51:cancer	No definite response (Grade 3, >50% residual tumor)
NCT02639065	4:18:cancer,13:18:cancer	No residual tumor (Grade 0, complete response, 0% tumor)
NCT02639065	20:59:treatment,52:59:treatment,69:94:treatment,102:115:upper_bound	Patients receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy within 28 days prior to registration for protocol therapy
NCT02639065	28:52:chronic_disease	Patients with diagnosis of primary immunodeficiency
NCT02639065	13:38:chronic_disease,53:64:chronic_disease,90:105:treatment	Presence of interstitial lung disease or history of pneumonitis requiring treatment with corticosteroids
NCT02639065	1:14:treatment,22:26:treatment,28:33:treatment,38:54:treatment,58:89:treatment	Prior therapy with a PD-1, PD-L1, or CTLA-4 inhibitor or cancer-specific vaccine therapy
NCT02639065	17:35:treatment,43:56:upper_bound,86:93:treatment	Receipt of live attenuated vaccine within 30 days prior to registration for protocol therapy
NCT02639065	1:24:chronic_disease	Ventricular arrhythmias requiring medication(s)
NCT02639065	20:59:cancer	adequately treated basal cell or squamous cell skin cancer
NCT02639065	4:24:cancer	in situ cervical cancer
NCT02639065	1:39:treatment,24:38:treatment,43:67:treatment,116:125:upper_bound,129:139:treatment	intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
NCT02639065	7:13:cancer,71:78:lower_bound	other cancer for which the subject has been disease-free for at least 3 years
NCT02639065	1:9:chronic_disease,30:36:chronic_disease,37:42:chronic_disease,59:87:treatment,91:115:treatment,117:131:chronic_disease,163:172:chronic_disease,218:230:upper_bound,233:249:chronic_disease,254:272:chronic_disease	vitiligo, resolved childhood asthma/atopy, requirement of intermittent bronchodilators or local steroid injections, hypothyroidism stable on hormone replacement, psoriasis not requiring systemic treatment (within the past 2 years), Graves's disease and Sjogren's syndrome
NCT02632422	1:3:lower_bound,7:15:upper_bound	18 to 70 years old
NCT02632422	1:58:clinical_variable,59:66:lower_bound,67:68:upper_bound	American Spinal Injury Association Impairment Scale (AIS) grade A-D
NCT02632422	7:9:lower_bound	above L5 with at least motor function preserved below the neurologic level
NCT02632422	1:10:chronic_disease,17:24:chronic_disease,27:39:chronic_disease,41:63:chronic_disease,65:82:chronic_disease,84:103:chronic_disease,135:159:chronic_disease,200:216:chronic_disease	infection (e.g. bladder), hypertension, cardiovascular disease, pulmonary disease, severe osteoporosis (history of fractures), active heterotopic ossification in the lower extremities, or history of peripheral nerve injury in the legs
NCT02632422	29:42:chronic_disease	non-progressive etiology of spinal injury
NCT02632422	1:10:pregnancy	pregnancy
NCT02632422	1:24:chronic_disease	pulmonary complications
NCT02632422	17:19:upper_bound,23:39:clinical_variable	score less than 24 on Mini-Mental Exam
NCT02632422	1:29:chronic_disease	severe autonomic dysreflexia
NCT02632422	1:26:chronic_disease,55:63:chronic_disease,65:83:chronic_disease,87:108:chronic_disease	severe concurrent illness or pain, including unhealed decubiti, severe neuropathic or chronic pain syndrome, infection (e.g. bladder)
NCT02632422	1:25:chronic_disease	spinal cord injury (SCI) at or below C3 (phrenic sparing)
NCT02632422	1:16:clinical_variable	timed up-and-go
NCT02629731	14:30:chronic_disease	diagnosis of ankle OA or PTTD [non-control subjects only]
NCT02629731	11:27:technology_access	lack of a telephone number or stable mailing address
NCT02629731	10:16:upper_bound,18:26:treatment,28:40:chronic_disease,55:81:chronic_disease,169:187:chronic_disease	recent (<1 year) surgical, neurological, metabolic or lower limb musculoskeletal problem that might impair the ambulation measures in the study, such as severe knee or hip osteoarthritis
NCT02629731	1:21:chronic_disease,31:51:chronic_disease	rheumatoid arthritis or other inflammatory disease
NCT02624765	1:16:chronic_disease	AF with hydrops
NCT02624765	1:21:treatment	Antiarrhythmic drugs
NCT02624765	5:30:chronic_disease	Any maternal-fetal conditions associated with high odds of premature delivery or death
NCT02624765	1:16:clinical_variable,19:31:lower_bound,37:49:upper_bound	Gestational age > 12 0/7 weeks and <36 0/7 weeks at time of enrollment
NCT02624765	24:48:chronic_disease	History of significant maternal heart condition
NCT02624765	1:37:clinical_variable,42:50:upper_bound,54:61:upper_bound	Maternal ionized serum calcium level of <1 mmol/L / <4 mg/dL)
NCT02624765	10:32:clinical_variable,35:46:lower_bound,49:58:lower_bound	Maternal serum creatinine level > 97.2 µmol/L (>1.1 mg/dl)
NCT02624765	1:31:clinical_variable,33:43:upper_bound,47:56:upper_bound	Maternal serum potassium level <3.3 mmol/L / <3.3 mEq/L (at start of treatment)
NCT02624765	1:12:treatment	Pentamidine
NCT02624765	31:57:chronic_disease	Relevant preexisting maternal obstructive airway disease
NCT02624765	1:4:chronic_disease	SVT with fetal hydrops (irrespective of duration)
NCT02624765	11:20:pregnancy	Singleton Pregnancy
NCT02624765	1:12:clinical_variable,15:21:lower_bound	Systolic BP ≥ 85 bpm
NCT02624765	1:12:clinical_variable,15:22:lower_bound,47:59:upper_bound	Tachycardia ≥ 170 bpm during +100% of time (≤ 30 0/7 weeks of gestation)
NCT02624765	1:12:clinical_variable,15:22:lower_bound	Tachycardia ≥ 280 bpm (irrespective of SVA duration)
NCT02624765	11:22:chronic_disease	Untreated tachycardia at time of enrollment
NCT02624765	1:7:chronic_disease	asthma
NCT02624765	1:15:chronic_disease	cardiomyopathy
NCT02624765	1:34:chronic_disease	life-threatening maternal disease
NCT02624765	1:14:chronic_disease	pre-eclampsia
NCT02624765	8:12:chronic_disease	severe IUGR
NCT02624765	1:38:chronic_disease,52:77:clinical_variable,80:87:upper_bound	severe congenital fetal abnormalities (T 13 or 18; surgery or death expected < 1 month)
NCT02624765	1:20:chronic_disease	sick sinus syndrome
NCT02624765	1:12:chronic_disease	tachycardia
NCT02620449	18:23:allergy_name	Allergies to any foods in the standardized diets
NCT02620449	10:25:clinical_variable,29:32:lower_bound,38:47:upper_bound	abnormal serum phosphate (≥ 4.6 or < 2.5 mg/dl)
NCT02620449	50:74:chronic_disease,110:115:gender	conditions affecting phosphate metabolism (e.g., hyper- or hypothyroidism; irregular menses for menstruating women)
NCT02620449	16:42:treatment	current use of blood pressure medications
NCT02620449	1:5:clinical_variable,6:8:lower_bound,9:18:upper_bound	eGFR 20-50 ml/min
NCT02620449	9:16:chronic_disease,18:21:bmi,24:32:lower_bound	extreme obesity (BMI ≥ 35 kg/m2)
NCT02620449	25:29:clinical_variable,32:34:lower_bound	normal kidney function (eGFR > 60 and normal urinalysis)
NCT02620449	1:14:chronic_disease,16:26:clinical_variable,29:35:upper_bound,40:45:gender,42:45:gender,52:58:upper_bound	severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
NCT02617589	11:37:cancer	Any known tumor outside of the brain
NCT02617589	1:7:treatment,23:26:upper_bound,30:35:cancer	Biopsy with less than 20% of tumor removed
NCT02617589	1:6:gender	Males
NCT02617589	17:29:cancer,33:38:cancer,46:58:cancer,62:65:cancer	Newly-diagnosed brain cancer or tumor called glioblastoma or GBM
NCT02617589	21:24:cancer,37:55:treatment	Prior treatment for GBM (other than surgical resection)
NCT02617589	24:27:cancer	Recurrent or secondary GBM
NCT02617589	1:4:age,7:15:lower_bound	age ≥ 18 years old
NCT02615249	1:9:lower_bound,13:16:age	18 years of age or older
NCT02615249	1:17:chronic_disease,7:17:chronic_disease	Acute dermatitis outbreak or dermatitis on or near the test area on the back
NCT02615249	21:33:chronic_disease,35:50:chronic_disease,52:62:chronic_disease,64:84:chronic_disease,86:103:chronic_disease,105:113:chronic_disease,121:129:chronic_disease	Conditions such as; fibromyalgia, chronic fatigue, depression, cognitive impairment, flu-like symptoms, diarrhea and/or headache without at least one of the symptoms related to metal exposure listed in Section 10.1 under physical examination
NCT02615249	14:29:pregnancy,43:76:gender,113:119:lower_bound,155:167:treatment,169:190:treatment,192:208:treatment,212:236:treatment	Inability to become pregnant includes all male subjects and female subjects who are postmenopausal for at least 1 year, or surgically sterile- have had a hysterectomy, bilateral ovariectomy, uterine ablation or bilateral tubal ligation
NCT02615249	1:19:treatment	Inhaled treatments
NCT02615249	41:61:treatment,63:72:treatment,76:82:treatment,104:117:upper_bound	Participation in a clinical trial of an investigational drug, treatment or device during this study or 3 weeks prior to inclusion in this study
NCT02615249	44:57:upper_bound	Past positive patch test result within the past 10 years (to one of the dilution series metals being tested on this study)
NCT02615249	14:51:contraception_consent	Subject must agree to use acceptable contraception for the duration of the entire study
NCT02615249	1:73:treatment,110:123:upper_bound	Topical treatment with corticosteroids or other immunosuppressive agents on or near the test area during the 14 days prior to inclusion in this study
NCT02615249	1:58:treatment,70:83:upper_bound	Treatment with ultraviolet (UV) light (including tanning) during the 3 weeks prior to inclusion in this study
NCT02615249	1:26:pregnancy	Unable to become pregnant
NCT02615249	1:29:pregnancy	intending to become pregnant during the course of the study
NCT02615249	7:31:treatment,43:56:upper_bound	other immunosuppressive agents during the 14 days prior to inclusion in this study
NCT02615249	1:9:pregnancy	pregnant (as determined by urine pregnancy test)
NCT02615249	21:26:allergy_name	strong suspicion of metal contact allergy based on results of the Qualification Questionnaire
NCT02615249	1:53:contraception_consent,65:74:pregnancy,78:84:gender	willing to use an acceptable method of contraception to prevent pregnancy if female of childbearing potential
NCT02613936	1:4:chronic_disease,12:39:chronic_disease,50:58:upper_bound	TBI with + loss of consciousness (LOC) less than 24 hours
NCT02613936	1:5:age,6:8:lower_bound,9:11:upper_bound	aged 18-55
NCT02613936	5:17:chronic_disease	any skull defect
NCT02613936	12:32:chronic_disease,36:44:chronic_disease	history of neurological disease or seizures
NCT02613936	12:21:chronic_disease	history of psychosis
NCT02613936	17:25:lower_bound,30:37:upper_bound	injured between 3 months and 5 years ago
NCT02613936	11:17:upper_bound,21:49:chronic_disease	less than 1 week of post-traumatic amnesia (PTA)
NCT02613936	1:10:pregnancy	pregnancy
NCT02613585	1:21:language_fluency	non-English speakers
NCT02613585	6:14:lower_bound,18:21:age	over 18 years of age
NCT02613585	1:18:pregnancy	planned pregnancy during the follow-up period (since exposure to an insecticide is involved)
NCT02613585	1:10:pregnancy	pregnancy
NCT02613585	16:28:allergy_name	sensitivity to insecticides
NCT02613585	24:26:lower_bound	spending an average of 10 or more hours of outdoor work per week during peak tick season
NCT02597985	1:24:chronic_disease	Acute coronary syndrome
NCT02597985	1:21:chronic_disease	Advanced Parkinson's
NCT02597985	17:21:treatment	Eligibility for TAVR
NCT02597985	1:7:chronic_disease,13:33:chronic_disease	Stroke with neurological deficit
NCT02597985	11:33:chronic_disease	Sustained ventricular arrhythmia
NCT02589353	1:9:lower_bound	61 years old and above
NCT02589353	13:17:age,21:23:lower_bound,24:26:upper_bound	between the ages of 18-60
NCT02589353	1:18:language_fluency	fluent in English
NCT02589353	18:22:allergy_name	has a history of food allergy
NCT02589353	69:91:chronic_disease	has a history of taste or smell loss or other oral disorders (e.g., burning mouth syndrome)
NCT02589353	13:25:chronic_disease,27:39:chronic_disease,44:53:chronic_disease	has current oral lesions, canker sores, or piercings
NCT02589353	1:9:pregnancy,10:15:gender	pregnant women
NCT02589353	31:49:treatment	taking any prescription pain/ insulin medication
NCT02588612	1:17:chronic_disease,23:57:chronic_disease,53:56:chronic_disease,59:82:chronic_disease,84:107:chronic_disease,111:149:chronic_disease,211:239:chronic_disease,289:317:chronic_disease,369:381:treatment,646:657:chronic_disease	Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or human T-cell lymphotropic virus (HTLV) as minimally defined below: a) Positive serology for HIV. b) Active hepatitis B infection as determined by hepatitis B surface antigen. c) Active hepatitis C infection as determined by hepatitis C RNA; A subject who is HCV antibody positive will be screened for HCV ribonucleic acid (RNA) by any reverse transcriptase (RT) polymerase chain reaction (PCR) or bDNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value. d) Positive serology for HTLV 1 or 2
NCT02588612	22:25:gender,29:34:gender,163:176:gender,312:324:treatment,338:353:lower_bound,368:383:treatment,552:608:contraception_consent,700:725:contraception_consent,737:771:contraception_consent,773:788:gender,792:806:gender,844:856:pregnancy,888:891:lower_bound,938:943:gender,1001:1075:contraception_consent	Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male subjects: Male subjects are eligible to participate if they agree to the following during the intervention period starting at the first dose of chemotherapy for at least 12 months after receiving the T-cell infusion, or 4 months after there is no evidence of persistence/ gene modified cells in the subject's blood, whichever is longer. A) Refrain from donating sperm Plus either: B) Be abstinent from heterosexual or homosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR C) Must agree to use contraception/barrier. Female subjects: A female subject is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP who will agree to use a barrier method (male condom) and use a contraceptive method that is highly effective during the intervention period and for at least 12 months after receiving the T-cell infusion, or 4 months after there is no evidence of persistence/ gene modified cells in the subject's blood, whichever is longer. WOCBP should also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention
NCT02588612	11:28:clinical_variable,24:27:clinical_variable,30:53:lower_bound,62:70:lower_bound,89:114:chronic_disease	Corrected QT interval (QTc) >450 milliseconds (msec) or QTc >480 msec for subjects with Bundle Branch Block (BBB)
NCT02588612	9:40:chronic_disease,64:82:chronic_disease,86:109:chronic_disease,111:127:cancer,148:169:chronic_disease,275:282:chronic_disease,284:298:chronic_disease,300:312:chronic_disease,314:329:chronic_disease,331:360:chronic_disease,385:394:chronic_disease	Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per Investigator assessment). Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice or cirrhosis
NCT02588612	32:44:cancer,67:74:treatment,102:133:cancer,158:175:cancer	Exceptions: adequately treated malignancies not likely to require therapy (e.g., completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma)
NCT02588612	1:7:gender	Female
NCT02588612	102:118:allergy_name,120:131:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, or other agents used in the study
NCT02588612	83:93:chronic_disease,104:127:chronic_disease,138:146:treatment,156:184:treatment	History of chronic or recurrent (within the last year prior to enrollment) severe autoimmune or active immune-mediated disease requiring steroids or other immunosuppressive treatments
NCT02588612	1:15:treatment,27:54:treatment,82:100:treatment	Immune therapy (including monoclonal antibody therapy, checkpoint inhibitors) or biological therapy with no wash-out times required
NCT02588612	1:26:treatment,34:47:upper_bound,51:64:treatment,66:98:treatment,106:120:upper_bound,223:243:treatment,257:271:upper_bound,294:340:treatment	Investigational treatment within 4 weeks prior to leukapheresis; experimental anti-cancer vaccine within 2 months prior to leukapheresis in the absence of response or in the opinion of the Investigator is responding to an experimental vaccine given within 6 months prior to leukapheresis; any prior gene therapy using an integrating vector
NCT02588612	1:5:gender	Male
NCT02588612	14:26:cancer,35:40:cancer,48:61:upper_bound	Other active malignancies besides NSCLC within 3 years prior to Screening
NCT02588612	13:73:clinical_variable,74:75:lower_bound,76:77:upper_bound,109:124:clinical_variable,126:134:lower_bound	Subject has Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 10. Subject has an anticipated life expectancy >3 months
NCT02588612	79:105:cancer,107:117:lower_bound,121:123:upper_bound	Subject has a diagnosis of histologically or cytologically confirmed advanced non-small cell lung cancer (Stage IIIB or IV) or recurrent disease
NCT02588612	20:36:cancer,40:65:cancer	Subject has active brain metastases or leptomeningeal metastases
NCT02588612	20:36:cancer,40:65:cancer,98:114:cancer,134:147:treatment,155:169:treatment,177:186:treatment,253:272:upper_bound	Subject has active brain metastases or leptomeningeal metastases. Subjects with prior history of brain metastasis who have undergone local therapy (i.e., metastatectomy and/or radiation) and show no evidence of local recurrence or progression over the past 3 months prior to Screening are eligible
NCT02588612	13:47:clinical_variable,50:53:lower_bound	Subject has left ventricular ejection fraction >=50%
NCT02588612	14:22:lower_bound,26:29:age	Subject is >=18 years of age on the day of signing informed consent
NCT02588612	20:33:treatment	Subject is fit for leukapheresis and has adequate venous access for the cell collection
NCT02588612	12:20:pregnancy,64:92:treatment,208:230:treatment,238:251:upper_bound,285:299:treatment,311:338:treatment,340:361:treatment,366:384:treatment,392:405:upper_bound,436:451:treatment,465:490:treatment,498:511:upper_bound,545:570:treatment,577:586:treatment,588:597:treatment,613:634:treatment,642:654:upper_bound,688:701:treatment,858:870:treatment,916:930:upper_bound,973:999:treatment	Subject is pregnant or breastfeeding. Furthermore and prior to lymphodepleting chemotherapy, a subject meeting the following criteria is not eligible for participation in the study: 1) Subject has received: Cytotoxic chemotherapy within 3 weeks prior to lymphodepleting chemotherapy; Immune therapy (including monoclonal antibody therapy, checkpoint inhibitors) or biological therapy within 4 weeks prior lymphodepleting chemotherapy; Corticosteroids or any other immunosuppressive therapy within 2 weeks prior to lymphodepleting chemotherapy; Tyrosine kinase inhibitor (e.g. erlotinib, gefitinib) and any other anti-cancer treatment within 1 week prior to lymphodepleting chemotherapy; Major surgery within 4 weeks prior to lymphodepleting chemotherapy; subjects must have recovered from any surgical-related toxicities in the opinion of the Investigator; Radiotherapy that involves the lung or mediastinum within 3 months prior to lymphodepleting chemotherapy; however, electron beam radiotherapy to superficial structures in the chest is permitted
NCT02588612	95:126:clinical_variable,129:153:lower_bound,182:191:clinical_variable,195:205:lower_bound,210:220:clinical_variable,222:251:lower_bound,288:294:upper_bound,309:322:treatment,328:384:clinical_variable,387:424:upper_bound,442:469:treatment,474:507:clinical_variable,597:640:clinical_variable,643:677:lower_bound,682:703:clinical_variable,706:719:upper_bound,751:769:chronic_disease,775:848:clinical_variable,851:864:upper_bound	Subject must have adequate organ function as indicated by the following laboratory values: a) Absolute Neutrophil count (ANC) >=1.0 x10^9 per liter (/L) (without G-CSF support); b) Platelets >= 75 x10^9/L; c) Hemoglobin >80 grams per deciliter (g/dL) (without transfusion support within 7 days from start of leukapheresis); d) Prothrombin Time or International Normalized Ratio (INR) <=1.5 times upper limit of normal (ULN) unless receiving therapeutic anticoagulation. e) Partial Thromboplastin Time (PTT) <=1.5 times upper limit of normal (ULN) unless receiving therapeutic anticoagulation. f) Calculated or measured creatinine clearance >=40 milliliters per minute (mL/min); g) Serum total bilirubin <=1.5 times ULN (unless subject had documented Gilbert's Syndrome); h) Alanine aminotransferase (ALT)/Serum Glutamic Pyruvic Transaminase (SGPT) <=2.5 times ULN
NCT02588612	21:43:treatment,51:64:upper_bound,68:81:treatment	Subject who has had cytotoxic chemotherapy within 2 weeks prior to leukapheresis
NCT02588612	11:16:cancer,57:63:treatment	Subject's tumor (either an archival specimen or a fresh biopsy if archival tissue is unavailable) has been pathologically reviewed by an Adaptimmune- / GSK-designated central laboratory confirming NY-ESO-1 and/or LAGE-1a expression
NCT02588612	51:61:cancer	Subjects must be in complete remission from prior malignancy in order to be eligible to enter the study
NCT02588612	74:77:treatment,175:185:treatment,196:226:treatment	Subjects with known epidermal growth factor receptor (EGFR) mutations or ALK or ROS1 gene rearrangements must have failed (disease progression [PD] or unacceptable toxicity) prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively (PD or unacceptable toxicity)
NCT02588612	32:48:cancer,68:81:treatment,89:120:treatment,187:206:upper_bound	Subjects with prior history of brain metastasis who have undergone local therapy (i.e., metastasectomy and/or radiation) and show no evidence of local recurrence or progression over the past 3 months prior to Screening are eligible
NCT02588612	15:43:treatment,72:79:upper_bound,157:165:chronic_disease,167:175:chronic_disease,201:212:chronic_disease,228:237:treatment	Toxicity from previous anti-cancer therapy that has not recovered to <=Grade 1 prior to enrollment (except for non-clinically significant toxicities, e.g., alopecia, vitiligo). Subjects with existing pneumonitis as a result of radiation are not excluded; however, subjects cannot be oxygen dependent
NCT02588612	1:23:clinical_variable,25:28:lower_bound,32:40:upper_bound	Unintended weight loss >10% in 6 months preceding study entry
NCT02588612	1:16:treatment,30:55:treatment,63:76:upper_bound,80:93:treatment	corticosteroids or any other immunosuppressive therapy within 2 weeks prior to leukapheresis
NCT02587403	1:9:lower_bound,13:16:age	18 years of age or greater
NCT02587403	3:11:upper_bound,15:18:age	< 18 years of age
NCT02587403	60:67:lower_bound	Able and willing to return for scheduled study visits over 2 years post-operatively (following research related surgery)
NCT02587403	1:24:chronic_disease	Enterocutaneous fistula
NCT02587403	8:11:bmi,26:28:upper_bound	Have a BMI < or equal to 40
NCT02587403	8:11:bmi,13:15:lower_bound	Have a BMI >40
NCT02587403	8:14:clinical_variable,32:39:upper_bound	Have a hernia estimated to be <200 cm2
NCT02587403	21:31:cancer,51:63:treatment,64:78:lower_bound,64:72:upper_bound,164:167:cancer,171:174:cancer	Have a known active malignancy present and/or had chemotherapy 12 weeks prior to screening or planned chemotherapy within 12 weeks of enrollment with exception of BCC or SCC
NCT02587403	14:42:chronic_disease,50:67:chronic_disease	Have a known collagen metabolism disorder or any medical condition that could interfere with normal tissue healing process as determined by the Investigator
NCT02587403	8:23:clinical_variable,37:43:lower_bound	Have a life expectancy greater than 1 year in the opinion of the Investigator
NCT02587403	8:23:clinical_variable,34:40:upper_bound	Have a life expectancy less than 1 year
NCT02587403	8:45:clinical_variable,49:56:lower_bound,60:83:clinical_variable	Have a pre-operative estimated hernia defect of 200 cm2 OR multiple hernia defects whose combined area is ≥ an estimated 200 cm2
NCT02587403	13:34:chronic_disease,70:88:chronic_disease	Have active necrotizing fasciitis or any other known active local or systemic infection
NCT02587403	31:40:chronic_disease	Have known moderate to severe cirrhosis which in the opinion of the Investigator would impact the outcome of this trial
NCT02587403	30:42:upper_bound	Known tobacco use within the past 6 weeks or positive serum cotinine test at time of admission
NCT02587403	21:51:treatment,210:228:upper_bound	Participation in an investigational drug or device study that would impact the safety or scientific integrity of this study (in the opinion of the Investigator and with the approval of the Sponsor) within the past 6 weeks prior to enrollment into this trial
NCT02587403	25:28:treatment	Planned use of external VAC dressing intra-operatively
NCT02587403	1:10:pregnancy	Pregnancy
NCT02587403	20:28:treatment,33:38:lower_bound,42:52:treatment,65:77:lower_bound	Received high dose steroids (>/=100mg of prednisone) within the past 6 weeks
NCT02587403	34:91:clinical_variable,96:97:lower_bound,105:106:upper_bound	Subject is determined to have an American Society of Anesthesiologists'(ASA) physical class of 4, 5, or 6
NCT02587403	1:22:chronic_disease,35:46:clinical_variable,49:51:lower_bound,63:75:upper_bound	Uncontrolled diabetes (i.e. known HbA1C value > 7% within the last 6 weeks)
NCT02587403	1:15:chronic_disease,34:50:chronic_disease	Ventral hernia repairs involving active infection
NCT02579161	1:15:clinical_variable,42:48:lower_bound	Foley catheter in place for greater than 1 week duration
NCT02579161	11:19:lower_bound	Patients <18 years old
NCT02579161	11:19:lower_bound	Patients >18 years old
NCT02579161	23:34:treatment	Patients currently on antibiotics immediately prior to the procedure
NCT02579161	21:27:chronic_disease,31:35:chronic_disease	Previous history of sepsis or SIRS from stone manipulations
NCT02579161	1:14:chronic_disease,45:49:treatment,54:63:treatment	Renal Calculi which would optimally require PCNL for treatment
NCT02579161	1:22:clinical_variable,30:43:upper_bound	egative urine culture within 1 month prior to procedure
NCT02578641	1:26:clinical_variable,28:36:lower_bound	Absolute neutrophil count >1200/mm3
NCT02578641	1:22:treatment	Adjuvant chemotherapy
NCT02578641	1:23:treatment,25:34:treatment	Adjuvant immunotherapy/ biologics
NCT02578641	1:4:age,6:14:lower_bound	Age ≥21 years
NCT02578641	1:10:clinical_variable,12:43:upper_bound	Bilirubin <2 x upper limit of normal (ULN)
NCT02578641	1:39:clinical_variable,41:50:lower_bound	Calculated creatinine clearance (CRCL) ≥40 mL/min
NCT02578641	1:34:cancer	Central nervous system metastasis
NCT02578641	1:63:clinical_variable,65:66:upper_bound	Eastern Cooperative Oncology Group Performance Scale (ECOG-PS) ≤2
NCT02578641	1:33:clinical_variable	Glomerular Filtration Rate (GFR) is calculated based on Cockcroft-Gault method
NCT02578641	1:4:chronic_disease	HIV Positive
NCT02578641	1:35:chronic_disease	Human Immunodeficiency Virus (HIV) negative
NCT02578641	1:24:treatment,35:50:upper_bound	Investigational therapy less than one month prior to study entry
NCT02578641	18:29:chronic_disease	Known history of hepatitis C
NCT02578641	1:16:clinical_variable,18:26:lower_bound	Life expectancy >6 months
NCT02578641	11:34:treatment,41:53:treatment,64:72:lower_bound	Localised palliative radiotherapy Prior chemotherapy must be > 6 months before screening
NCT02578641	1:5:gender	Male
NCT02578641	1:11:cancer,33:45:chronic_disease	Metastatic or locally recurrent EBV-positive
NCT02578641	10:21:chronic_disease	Positive hepatitis B surface antigen (HBsAg) results
NCT02578641	14:35:chronic_disease,37:121:clinical_variable,123:124:lower_bound	Pre-existing peripheral neuropathy (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] ≥2)
NCT02578641	1:9:pregnancy	Pregnant
NCT02578641	24:30:cancer	Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study
NCT02578641	1:46:treatment	Prior chemo-radiotherapy with curative intent
NCT02578641	1:19:treatment,24:34:cancer,38:63:chronic_disease	Prior chemotherapy for metastatic or locally recurrent disease
NCT02578641	1:20:treatment	Prior immunotherapy for metastatic or locally recurrent disease
NCT02578641	1:40:treatment	Prior radiotherapy with curative intent
NCT02578641	1:31:contraception_consent,51:75:gender	Refuse of use of contraception during trial (both male and female patients)
NCT02578641	1:27:chronic_disease	Severe concomitant illness
NCT02578641	1:31:chronic_disease	Severe intercurrent infections
NCT02578641	11:14:chronic_disease,102:118:upper_bound	Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screening
NCT02578641	73:76:cancer	Subjects will be enrolled based on confirmed histology diagnosis of the NPC
NCT02578641	8:23:chronic_disease	active angina pectoris
NCT02578641	8:40:chronic_disease	active congestive cardiac failure (CCF)
NCT02578641	1:31:clinical_variable,33:40:upper_bound	alanine aminotransferase (ALT) <3 x ULN
NCT02578641	5:11:cancer,32:45:lower_bound	any cancer curatively treated >3 years prior to study entry
NCT02578641	1:33:clinical_variable	aspartate aminotransferase (AST)
NCT02578641	1:27:cancer	cervical carcinoma in situ
NCT02578641	1:45:chronic_disease	chronic obstructive pulmonary disease (COPD)
NCT02578641	1:7:gender	female
NCT02578641	1:16:clinical_variable,18:25:lower_bound,30:39:clinical_variable,41:52:lower_bound	hemoglobin (Hb) ≥10 g/dL and platelets ≥100,000/mm3
NCT02578641	1:29:chronic_disease	ischemic heart disease (IHD)
NCT02578641	11:18:gender	lactating females
NCT02578641	1:44:cancer	superficial bladder tumors [Ta, Tis and T1]
NCT02578641	9:29:cancer	treated basal cell carcinoma
NCT02578641	14:24:chronic_disease	uncontrolled arrhythmia
NCT02578641	14:26:chronic_disease	uncontrolled hypertension
NCT02578641	18:21:cancer,64:79:treatment,83:90:treatment	undifferentiated NPC* who do not have curative options such as chemo-radiation or surgery
NCT02574650	5:8:clinical_variable,16:29:upper_bound,37:52:treatment,64:72:upper_bound	Any PCI within 30 days prior to the index procedure or planned 3 months post the index procedure
NCT02574650	9:49:chronic_disease	Chronic functional tricuspid regurgitation (FTR) with a minimum of moderate tricuspid regurgitation
NCT02574650	9:21:treatment,28:36:lower_bound	Chronic oral steroid use (≥6 months)
NCT02574650	1:5:clinical_variable,7:10:lower_bound	LVEF ≥35%
NCT02574650	1:16:clinical_variable,30:39:upper_bound	Life expectancy of less than 12-months
NCT02574650	1:3:chronic_disease,13:28:chronic_disease,40:53:upper_bound	MI or known unstable angina within the 30-days prior to the index procedure
NCT02574650	1:13:chronic_disease	NYHA II - IV
NCT02574650	1:9:pregnancy	Pregnant
NCT02574650	10:47:treatment	Previous tricuspid valve repair or replacement
NCT02574650	8:31:chronic_disease	Severe coronary artery disease
NCT02574650	21:33:chronic_disease,35:38:clinical_variable,41:49:lower_bound,57:60:clinical_variable,63:71:lower_bound	Severe uncontrolled hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg)
NCT02574650	1:33:clinical_variable,36:41:lower_bound,46:54:lower_bound,75:80:upper_bound,85:93:upper_bound	Tricuspid valve annular diameter ≥ 40 mm (or 21 mm/m2 (Superscript)) and ≤55 mm (or 29 mm/m2 (Superscript)
NCT02574650	11:17:gender	lactating female
NCT02574650	2:4:lower_bound,10:18:upper_bound	≥18 and ≤85 years old
NCT02570321	1:4:age,10:18:lower_bound	Age over 18 years
NCT02570321	1:14:chronic_disease	Corneal ulcer that is smear positive for either bacteria or filamentous fungus
NCT02570321	46:56:treatment,63:69:chronic_disease	Evidence of concomitant infection on exam or gram stain (i.e. herpes, both bacteria and acanthamoeba on gram stain)
NCT02570321	12:35:treatment,39:65:treatment	History of corneal transplantation or recent intraocular surgery
NCT02570321	14:31:chronic_disease	Impending or frank perforation at recruitment
NCT02570321	1:39:chronic_disease	Non-infectious or autoimmune keratitis
NCT02570321	26:51:treatment	Not treated already with antimicrobial medications at presentation
NCT02570321	42:62:chronic_disease	Participants who are decisionally and/or cognitively impaired
NCT02570321	1:22:clinical_variable,34:40:lower_bound	Pinhole visual acuity worse than 20/200 in the unaffected eye
NCT02570321	1:22:clinical_variable,34:39:lower_bound	Pinhole visual acuity worse than 20/70 in the affected eye
NCT02570256	15:21:chronic_disease,32:41:lower_bound	Chronic stage stroke recovery (8+ months post)
NCT02570256	1:7:chronic_disease	STROKE SURVIVORS
NCT02570256	3:19:clinical_variable,29:31:lower_bound,32:34:upper_bound	a Fugl-Meyer score (between 15-50) to evaluate arm motor impairment level
NCT02570256	1:4:age,6:8:lower_bound	age >18
NCT02570256	1:8:chronic_disease,10:30:chronic_disease	aphasia, cognitive impairment or affective dysfunction that would influence the ability to perform the experiment
NCT02570256	1:18:chronic_disease	bilateral paresis
NCT02570256	34:49:chronic_disease	diffuse/multiple lesion sites or multiple stroke events
NCT02570256	40:46:chronic_disease	healthy individuals with no history of stroke or neural injury
NCT02570256	1:20:chronic_disease,24:40:chronic_disease	hemispatial neglect or visual field cut that would prevent subjects from seeing the targets
NCT02570256	8:36:chronic_disease	severe sensory deficits in the limb
NCT02570256	8:18:chronic_disease,20:37:clinical_variable	severe spasticity (Modified Ashworth of 4) preventing movement
NCT02570256	1:8:chronic_disease,22:38:chronic_disease	strokes caused by an ischemic infarct in the middle cerebral artery
NCT02567422	1:26:clinical_variable,30:39:lower_bound	Absolute neutrophil count >= 1,500/mcL
NCT02567422	1:160:clinical_variable,164:205:upper_bound	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
NCT02567422	1:10:cancer	Carcinoma of the neck of unknown primary site origin (regardless of HPV/p16 status)
NCT02567422	1:16:clinical_variable,17:20:lower_bound,24:26:upper_bound,27:32:cancer,57:75:treatment	Clinical staged III or IV HNSCC that is not amenable to surgical resection
NCT02567422	1:11:clinical_variable,50:70:clinical_variable,74:92:lower_bound,111:128:clinical_variable	Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
NCT02567422	49:67:cancer,71:81:chronic_disease	Definitive clinical or radiographic evidence of distant metastasis or adenopathy below the clavicles
NCT02567422	1:61:clinical_variable,65:66:upper_bound,68:77:clinical_variable,81:84:lower_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
NCT02567422	1:4:chronic_disease,26:81:treatment,85:105:treatment	HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4
NCT02567422	102:116:allergy_name,120:129:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or cisplatin
NCT02567422	1:35:chronic_disease,138:160:treatment,203:222:treatment	Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial
NCT02567422	1:11:clinical_variable,15:24:lower_bound	Leukocytes >= 3,000/mcL
NCT02567422	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 3 months
NCT02567422	1:22:chronic_disease,34:47:upper_bound	Myocardial infarction within the last 6 months
NCT02567422	12:28:chronic_disease,39:62:treatment,78:87:treatment	Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation
NCT02567422	22:34:treatment	Patient who requires live vaccine administration
NCT02567422	62:104:cancer,115:138:cancer	Patients must have histologically or cytologically confirmed head and neck squamous cell cancer (HNSCC) including paranasal sinus cancers
NCT02567422	60:63:lower_bound,224:229:lower_bound,234:238:lower_bound,278:283:lower_bound,288:292:lower_bound,299:335:treatment,337:369:treatment,374:382:treatment	Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
NCT02567422	13:23:treatment,37:55:treatment,90:99:treatment	Patients on tacrolimus or any other immunosuppressants with significant interaction with cisplatin
NCT02567422	28:51:treatment,58:76:treatment	Patients who are receiving adjuvant chemoradiation after surgical resection of the primary site of disease
NCT02567422	38:60:treatment	Patients who are receiving any other investigational agents
NCT02567422	23:35:treatment,39:51:treatment,80:92:treatment,96:107:treatment	Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
NCT02567422	21:37:cancer	Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
NCT02567422	15:39:cancer,41:75:cancer,81:106:cancer	Patients with nasopharyngeal carcinoma, skin squamous cell carcinoma (SCC), and salivary gland carcinomas
NCT02567422	1:10:clinical_variable,14:25:lower_bound	Platelets >= 100,000/mcL
NCT02567422	1:9:pregnancy,10:15:gender,136:147:treatment	Pregnant women are excluded from this study because M6620 (VX-970) as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects
NCT02567422	1:30:treatment,79:96:treatment	Prior receipt of radiotherapy that would result in overlap of the new and old radiation therapy fields
NCT02567422	7:28:treatment,45:51:cancer	Prior systemic chemotherapy for the current cancer
NCT02567422	1:38:chronic_disease	Psychiatric illness/social situations that would limit compliance with study requirements
NCT02567422	13:37:chronic_disease,74:87:upper_bound	Symptomatic congestive heart failure (requiring hospital stay within the last 6 months)
NCT02567422	16:30:treatment	The effects of M6620 (VX-970) on the developing human fetus are unknown
NCT02567422	1:25:chronic_disease,27:45:chronic_disease	Unstable angina pectoris, cardiac arrhythmia
NCT02567422	1:6:gender,67:134:treatment,150:159:treatment,193:211:upper_bound,239:254:treatment	Women of childbearing potential who are sexually active should be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for up to 6 months following the last administration of study treatment
NCT02567422	83:101:treatment	for this reason and because DNA-damage response (DDR) inhibitors as well as other therapeutic agents used in this trial may have teratogenic potential
NCT02567422	1:4:gender,52:87:contraception_consent,157:165:upper_bound	men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of M6620 (VX-970) administration
NCT02567422	1:4:gender,37:104:contraception_consent,120:129:treatment,157:165:upper_bound,186:200:treatment	men who are sexually active must be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for 6 months after completion of M6620 (VX-970) administration
NCT02567422	1:26:cancer	nasopharyngeal carcinomas
NCT02567422	33:36:chronic_disease	patients with poorly controlled HIV
NCT02567422	1:19:treatment,36:42:cancer	prior chemotherapy for a different cancer
NCT02567422	1:6:gender,3:6:gender,47:82:contraception_consent,84:127:contraception_consent	women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control
NCT02565199	4:8:age,9:11:lower_bound,12:20:upper_bound	Be aged 18-80 years old
NCT02565199	4:8:age,9:11:lower_bound,12:20:upper_bound	Be aged 55-80 years old
NCT02565199	9:19:chronic_disease,37:38:lower_bound,46:85:clinical_variable	Current depression (score more than 7 on the Hamilton Depression Rating Scale (HDRS))
NCT02565199	24:27:allergy_name	Has a contradiction to TMS
NCT02565199	52:67:lower_bound,75:149:clinical_variable	Have intact cognitive abilities (score higher than 75th percentile on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS))
NCT02565199	1:29:chronic_disease,49:64:upper_bound,72:146:clinical_variable	Impaired cognitive abilities (score lesser than 75th percentile on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS))
NCT02565199	23:26:lower_bound	Inability to tolerate one or more TMS strengths
NCT02565199	1:14:clinical_variable,41:44:lower_bound	MEP amplitude must increase by at least 20% as the TMS intensity increases
NCT02565199	1:4:clinical_variable,27:30:treatment	MEP cannot be evoked with TMS in the ECU muscle
NCT02565199	1:21:chronic_disease	Neurological disease
NCT02565199	22:61:treatment	No contradictions to Transcranial Magnetic Stimulation (TMS)
NCT02565199	12:22:chronic_disease,40:41:upper_bound,49:88:clinical_variable	No current depression (score less than 7 on the Hamilton Depression Rating Scale (HDRS))
NCT02565199	12:22:chronic_disease,42:43:upper_bound,51:90:clinical_variable	No current depression (score less than a 7 on the Hamilton Depression Rating Scale (HDRS))
NCT02565199	4:24:chronic_disease	No neurological disease
NCT02565199	49:52:treatment	The subjects must be comfortable when receiving TMS of all strengths
NCT02562430	12:14:lower_bound,33:87:clinical_variable	A score of 16 or greater on the Hamilton Depression Rating Scale -32 items (HAM-D- 32)
NCT02562430	5:38:treatment	Any investigational psychotropic drug within the last year
NCT02562430	34:47:treatment,49:59:chronic_disease	Any unstable concomitant form of psychotherapy (depression-focused)
NCT02562430	1:52:clinical_variable,55:56:upper_bound	Clinical Global Impression Improvement (CGI) scores ≤ 3 (i.e. minimally improved or less) from the screen to the baseline visit
NCT02562430	40:49:treatment	Color-blindness for blue or green (see fMRI task)
NCT02562430	20:29:treatment,37:43:upper_bound	Concomitant use of trazodone (up to 200 mg daily)
NCT02562430	41:44:chronic_disease	Continuing to meet criteria for current MDD at baseline
NCT02562430	22:46:treatment	Currently taking any exclusionary medications
NCT02562430	1:11:treatment,16:26:treatment	Gabapentin and pregabalin are allowed
NCT02562430	12:30:chronic_disease,34:58:chronic_disease	History of hepatic impairment or congestive heart failure
NCT02562430	53:61:allergy_name	History of inadequate response/poor tolerability to bupropio
NCT02562430	1:4:gender	Men
NCT02562430	1:29:treatment	Monoamine oxidase inhibitors
NCT02562430	27:41:treatment	Only one failed one prior antidepressant in the current episode
NCT02562430	30:54:treatment,79:92:lower_bound	Patients must have either no antidepressant treatment or stable (for at least 4 weeks prior to screening)
NCT02562430	1:9:pregnancy,10:15:gender	Pregnant women
NCT02562430	53:56:treatment,58:61:treatment,65:69:treatment	Receiving or have received during the index episode VNS, ECT or rTMS
NCT02562430	1:16:chronic_disease	Serious suicide
NCT02562430	48:62:treatment,95:105:treatment,106:115:lower_bound	Subjects who have not responded to two or more antidepressant trials of adequate doses (e.g., fluoxetine 40 mg/day or higher)
NCT02562430	44:53:treatment,72:80:chronic_disease,95:140:chronic_disease,166:179:upper_bound	Subjects with medical contraindications to bupropion (e.g., history of seizures, uncontrolled electrolyte imbalance due to eating disorders, etc.) unless stable for 8 weeks prior to screening and there will be no changes during participation in the study
NCT02562430	25:42:chronic_disease,49:54:chronic_disease,56:59:chronic_disease,63:76:chronic_disease,183:186:chronic_disease	Subjects with secondary anxiety disorders, like panic, GAD or simple phobia will be allowed, in order to make the population studied more representative of the general population of MDD
NCT02562430	1:5:age,6:8:lower_bound,12:20:upper_bound	aged 18 to 60 years old
NCT02562430	1:15:treatment,17:32:treatment,34:44:treatment,46:65:treatment	antipsychotics, anticonvulsants, stimulants, dopaminergic agents
NCT02562430	16:32:chronic_disease	any history of seizure disorder
NCT02562430	1:17:chronic_disease	bipolar disorder
NCT02562430	30:44:chronic_disease,46:59:chronic_disease,61:65:chronic_disease,67:70:chronic_disease,75:78:chronic_disease	current primary diagnoses of panic disorder, social phobia, PTSD, GAD, or OCD
NCT02562430	21:35:treatment,111:120:treatment,124:131:treatment	currently taking an antidepressant as defined by the MGH-ATRQ, in the current episode and are willing to take bupropion or placebo as augmentation, since we are using subjects as their own controls and we are comparing changes within subjects
NCT02562430	12:27:chronic_disease,56:69:lower_bound	history of eating disorder unless if in remission for ≥5 years prior to screening and presenting no current electrolyte abnormalities
NCT02562430	1:15:chronic_disease,19:45:chronic_disease	mood congruent or mood incongruent psychotic features
NCT02562430	1:25:chronic_disease	organic mental disorders
NCT02562430	11:28:treatment,36:38:treatment,40:44:treatment,46:61:treatment,63:70:treatment	potential augmenting agents (e.g., T3, SAMe, St. John's Wort, lithium,)
NCT02562430	1:20:chronic_disease	psychotic disorders
NCT02562430	8:18:chronic_disease,22:53:chronic_disease	severe borderline or antisocial personality disorder
NCT02562430	1:6:gender	women
NCT02562430	1:6:gender,34:87:contraception_consent	women of child bearing potential not using a medically accepted means of contraception
NCT02561988	20:27:lower_bound,43:51:lower_bound	(Grade 3) at least 28 days apart over the 12 weeks before study entry
NCT02561988	45:59:upper_bound	1 of the procedures is performed during the 6 weeks before study start (C1D1)
NCT02561988	3:6:upper_bound,7:18:clinical_variable,57:75:upper_bound,77:87:upper_bound	> 10% weight loss that is medically documented over the preceding 24 weeks (± 12 weeks)
NCT02561988	2:9:lower_bound,50:84:chronic_disease	>5 × ULN if associated with clinically suspected liver infiltration by mastocytosis or another disease for which the patient enrolled into the study
NCT02561988	29:33:lower_bound	A spleen that is palpable ≥ 5 cm below the left costal margin
NCT02561988	1:4:cancer,6:9:cancer	AML, MDS that is very high- or high-risk as defined by the IPSS-R
NCT02561988	1:26:clinical_variable,28:34:upper_bound	Absolute neutrophil count <500/μL
NCT02561988	1:29:cancer	Acute myeloid leukemia (AML)
NCT02561988	1:39:chronic_disease	Aggressive systemic mastocytosis (ASM)
NCT02561988	1:17:cancer	Brain malignancy
NCT02561988	1:11:chronic_disease,13:16:clinical_variable,19:30:upper_bound	Cytopenias: ANC < 1.0 × 10⁹/L
NCT02561988	1:61:clinical_variable,65:66:lower_bound,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
NCT02561988	1:13:chronic_disease	Eosinophilia and known positivity for the FIP1L1-PGDFRA fusion
NCT02561988	45:63:cancer,107:117:treatment	Histologically- or cytologically- confirmed myeloid malignancy that is relapsed or refractory to standard treatments
NCT02561988	14:21:chronic_disease,50:73:treatment	History of a seizure disorder or requirement for anti-seizure medication
NCT02561988	15:36:chronic_disease,48:62:chronic_disease,77:85:chronic_disease,89:110:chronic_disease	Known risk of intracranial bleeding, such as a brain aneurysm or history of subdural or subarachnoid bleeding
NCT02561988	1:4:cancer	MCL
NCT02561988	1:25:cancer	Mast cell leukemia (MCL)
NCT02561988	1:31:cancer,126:151:cancer	Myelodysplastic syndrome (MDS) that is very high- or high-risk as defined by the International prognostic scoring system for myelodysplastic syndromes (IPSS-R)
NCT02561988	1:46:cancer	Philadelphia chromosome positive malignancies
NCT02561988	1:15:clinical_variable,17:26:upper_bound	Platelet count <25,000/μL
NCT02561988	1:56:clinical_variable,58:74:lower_bound	QT interval corrected using Fridericia's formula (QTcF) >480 milliseconds
NCT02561988	1:7:cancer	SM-AHN
NCT02561988	13:20:chronic_disease,24:40:chronic_disease	Symptomatic ascites or pleural effusion requiring medical intervention
NCT02561988	10:22:chronic_disease,42:62:cancer	Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)
NCT02561988	1:16:clinical_variable,18:27:upper_bound,30:37:lower_bound	Total bilirubin >1.5 × ULN; >3 × ULN
NCT02561988	1:22:treatment,23:39:chronic_disease,70:77:lower_bound,81:100:clinical_variable,107:114:lower_bound,118:130:clinical_variable,134:154:clinical_variable,167:185:upper_bound,186:202:treatment	Transfusion-dependent thrombocytopenia, defined as: transfusion of ≥ 6 units of apheresed platelets (or ≥ 6 pools of random donor or buffy coat platelets) during the 12 weeks preceding treatment (C1D1)
NCT02561988	1:31:clinical_variable,33:68:lower_bound	alanine aminotransferase (ALT) >3 x the upper limit of normal (ULN)
NCT02561988	1:25:clinical_variable,27:30:clinical_variable,34:43:lower_bound	alanine aminotransferase (ALT; > 3.0 × ULN)
NCT02561988	1:21:clinical_variable,25:34:lower_bound,100:119:chronic_disease,123:151:chronic_disease,160:166:treatment,206:229:chronic_disease	alkaline phosphatase (> 2.5 × ULN) with 1 of the following present: ascites or clinically relevant portal hypertension or liver mast cell infiltration that is biopsy-proven or no other identified cause of abnormal liver function
NCT02561988	1:27:clinical_variable,29:32:clinical_variable,36:45:clinical_variable	aspartate aminotransferase (AST; > 3.0 × ULN)
NCT02561988	10:11:lower_bound,38:64:cancer	at least 1 C-finding attributable to systemic mastocytosis (SM)
NCT02561988	1:11:clinical_variable,14:21:upper_bound,25:39:clinical_variable,42:52:upper_bound	hemoglobin < 10 g/dL or platelet count < 75 × 10⁹/L
NCT02561988	1:30:clinical_variable,32:41:upper_bound	measured creatinine clearance <40 mL/min
NCT02561988	1:24:cancer	metastases to the brain
NCT02561988	13:24:treatment,46:63:upper_bound,97:107:clinical_variable,110:118:upper_bound	most recent transfusion occurring during the preceding 4 weeks and transfusion administered for hemoglobin ≤ 8.5 g/dL
NCT02561988	78:87:cancer	other relapsed or refractory, potentially avapritinib-responsive hematologic neoplasms (e.g., evidence of aberrant KIT or platelet derived growth factor receptor (PDGFR) signaling)
NCT02561988	12:23:treatment,31:39:chronic_disease,41:50:chronic_disease,55:62:treatment	reason for transfusion is not bleeding, hemolysis, or therapy-related
NCT02561988	1:12:treatment,18:25:lower_bound,64:79:upper_bound,89:98:treatment	transfusion of ≥ 6 units packed red blood cells (PRBCs) in the 12 weeks before start of treatment (C1D1)
NCT02561988	8:17:treatment,25:26:lower_bound,35:59:treatment,63:76:treatment	use of diuretics (Grade 2) or ≥ 2 therapeutic paracenteses or thoracenteses
NCT02561988	3:10:lower_bound,43:50:upper_bound,55:67:treatment,85:99:clinical_variable,102:112:upper_bound	≥ 2 units transfused during the preceding 4 weeks and transfusions administered for platelet count < 20 × 10⁹/L
NCT02561988	3:10:lower_bound,28:44:clinical_variable,48:81:lower_bound	≥ Grade 2 abnormalities in direct bilirubin (> 1.5 × upper limit of normal [ULN])
NCT02561988	3:10:lower_bound,11:26:clinical_variable,30:38:upper_bound	≥ Grade 2 hypoalbuminemia (< 3.0 g/dL)
NCT02559817	14:15:upper_bound,14:22:lower_bound,148:156:treatment,158:169:treatment,174:179:treatment,195:213:upper_bound	For at least 2 months before the Screening Visit, the patient has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) in the toilet per week
NCT02559817	23:49:chronic_disease	History of painful or hard bowel movements (BMs)
NCT02559817	129:131:lower_bound,143:150:upper_bound	Patient or parent/guardian/LAR or caregiver is compliant with eDiary by completing both the morning and evening assessments for 10 out of the 14 days immediately preceding the Randomization Visit
NCT02559817	34:35:lower_bound,102:146:clinical_variable,138:144:clinical_variable,267:275:treatment,355:362:upper_bound	Patient reports having more than 1 loose, mushy stool (eDiary-recorded stool consistency of 6 on the Pediatric Bristol Stool Form Scale [p-BSFS]) or any watery stool (eDiary-recorded stool consistency of 7 on the p-BSFS) with any SBM that occurred in the absence of laxative use on the calendar day of the BM or the calendar day before the BM during the 14 days before the randomization day and up to the randomization
NCT02559817	37:45:lower_bound	at least once per week for at least 2 months before Screening Visit, the patient experienced abdominal discomfort (an uncomfortable sensation not described as pain)
NCT02559817	7:24:treatment,46:49:chronic_disease	meets Rome III criteria for child/adolescent IBS
NCT02559817	22:23:lower_bound,58:61:lower_bound	pain associated with 2 or more of the following at least 25% of the time
NCT02559817	118:132:upper_bound	required manual disimpaction anytime prior to randomization or disimpaction during in-patient hospitalization within one year prior to randomization
NCT02559817	24:31:treatment	unable to tolerate the placebo during rhe Screening Period
NCT02559817	1:7:clinical_variable,17:33:lower_bound	weighs at least 18 kg (39.7 lbs)
NCT02559817	28:37:treatment	willing to discontinue any laxatives used before the Pretreatment Visit in favor of the protocol-permitted rescue medicine
NCT02557321	14:15:upper_bound,86:110:treatment,114:146:treatment	A minimum of 1 measurable Target Lesion that can be accurately measured by calipers, computed tomography (CT) or magnetic resonance imaging (MRI)
NCT02557321	1:4:age,5:13:lower_bound	Age 18 years or older
NCT02557321	10:11:lower_bound,149:153:lower_bound,190:195:treatment	At least 1 Injectable Lesion (i.e., cutaneous, subcutaneous, soft tissue, superficial nodal or palpable nodal lesion with longest diameter at least 5 mm that is suitable for injection with PV-10)
NCT02557321	24:29:chronic_disease,33:56:chronic_disease,58:82:chronic_disease,84:89:chronic_disease,91:107:chronic_disease,109:118:chronic_disease,120:133:chronic_disease,135:144:chronic_disease,149:181:chronic_disease	Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders
NCT02557321	36:53:treatment	Evidence of clinically significant immunosuppression
NCT02557321	1:16:gender,91:105:upper_bound,127:145:treatment,160:173:treatment,183:223:contraception_consent,231:250:contraception_consent,252:272:contraception_consent,274:296:contraception_consent,305:312:contraception_consent,317:327:contraception_consent,329:339:contraception_consent	Female subjects of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) who are not using highly effective contraception (e.g., oral contraceptives, intrauterine devices, double barrier methods such as condoms and diaphragms, abstinence or equivalent measures)
NCT02557321	1:16:gender,21:33:pregnancy	Female subjects who are pregnant
NCT02557321	1:16:gender,41:50:pregnancy,69:76:upper_bound,94:109:treatment	Female subjects who have positive serum pregnancy test taken within 14 days of initiation of study treatment
NCT02557321	56:64:cancer	Histologically or cytologically confirmed diagnosis of melanoma
NCT02557321	47:58:chronic_disease,60:78:chronic_disease,80:90:chronic_disease,101:128:chronic_disease	History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other systemic autoimmune disease
NCT02557321	74:104:chronic_disease	Impaired wound healing or other extremity complications due to severe or uncontrolled diabetes mellitus in subjects whose Injectable Lesions are located in an extremity
NCT02557321	1:14:gender,23:84:contraception_consent	Male subjects who are unwilling to use acceptable method of effective contraception
NCT02557321	1:11:cancer,23:31:cancer,39:46:upper_bound	Malignancy other than melanoma within 2 years of enrollment
NCT02557321	7:27:treatment,31:50:treatment,72:79:upper_bound,83:102:upper_bound,103:126:treatment	Other prior cancer therapy or anti-cancer vaccine within the lesser of 4 weeks or 5 half-lives before initial study treatment
NCT02557321	1:62:clinical_variable,63:64:lower_bound,65:66:upper_bound	Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-1
NCT02557321	1:27:treatment	Prior treatment with PV-10 or any checkpoint inhibitor
NCT02557321	8:35:chronic_disease,50:62:clinical_variable,95:105:upper_bound,130:149:chronic_disease	Severe peripheral vascular disease (i.e., severe claudication [pain occurring after less than 200 meters of walking], rest pain, ischemic ulceration or gangrene) in subjects whose Injectable Lesions are located in an extremity
NCT02557321	27:47:chronic_disease,49:70:chronic_disease	Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise the subject's safety or compliance or interfere with interpretation of study results
NCT02557321	1:71:cancer	Stage IV or Stage III (unresectable, in-transit or satellite) melanoma
NCT02557321	17:21:lower_bound,27:28:lower_bound,47:63:cancer	Subjects with > 1 cm or > 3 in number treated brain metastases
NCT02557321	17:18:upper_bound,19:35:clinical_variable,47:51:upper_bound,87:105:treatment,113:130:treatment	Subjects with ≤ 3 brain metastases and each ≤ 1 cm size that were treated with either surgical resection and/or radiation therapy
NCT02557321	32:90:clinical_variable,91:92:upper_bound	Thyroid function abnormality ≤ Common Toxicity Criteria for Adverse Effects (CTCAE) Grade 2
NCT02557321	14:29:chronic_disease,33:48:chronic_disease	Uncontrolled thyroid disease or cystic fibrosis
NCT02557321	41:57:cancer	Untreated or clinically active melanoma brain metastases
NCT02557321	1:32:clinical_variable,35:46:lower_bound,51:65:clinical_variable,67:78:lower_bound	absolute neutrophil count (ANC) ≥ 1.5 x 109/L and platelet count ≥100 x 109/L
NCT02557321	32:47:treatment,49:54:cancer,58:81:cancer,83:114:cancer,116:159:cancer,161:184:cancer,203:217:cancer	adequately treated (i.e., with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer
NCT02557321	1:29:clinical_variable,31:57:clinical_variable,62:88:clinical_variable,91:130:upper_bound	aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ≤ 5 times the upper limit of normal (ULN)
NCT02557321	10:13:lower_bound,14:30:clinical_variable,24:30:clinical_variable,46:51:lower_bound,77:86:upper_bound,116:133:clinical_variable	at least one cutaneous lesion (each lesion ≥ 10 mm longest diameteror up to 5 lesions in aggregate having a sum of longest diameters ≥ 10 mm)
NCT02557321	10:13:lower_bound,20:26:clinical_variable,42:47:lower_bound,74:76:treatment,80:83:treatment	at least one nodal lesion (each lesion ≥ 15 mm in short axis diameter by CT or MRI)
NCT02557321	10:13:lower_bound,42:48:clinical_variable,64:69:lower_bound,93:95:treatment,99:102:treatment	at least one subcutaneous or soft tissue lesion (each lesion ≥ 10 mm in longest diameter by CT or MRI)
NCT02557321	10:13:lower_bound,45:50:lower_bound,62:70:clinical_variable,74:76:treatment,80:83:treatment	at least one visceral lesion (each lesion ≥ 10 mm in longest diameter by CT or MRI)
NCT02557321	1:44:clinical_variable,47:64:lower_bound	estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
NCT02557321	1:7:gender	female
NCT02557321	1:5:gender	male
NCT02557321	27:37:treatment,42:47:lower_bound	the subject is not taking prednisone at >10 mg or equivalent daily
NCT02557321	37:48:chronic_disease,52:65:treatment,75:88:lower_bound,89:111:treatment,119:136:treatment	there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy
NCT02557321	37:73:chronic_disease,77:90:treatment,100:113:lower_bound,114:134:treatment	there is no evidence of progressive central nervous system (CNS) disease on brain imaging at least 30 days after definitive treatment
NCT02557321	1:16:clinical_variable,19:58:upper_bound	total bilirubin ≤ 3 times the upper limit of normal (ULN)
NCT02557321	66:74:upper_bound,99:120:treatment	who have failed to achieve a complete or partial response within 24 weeks following initiation of checkpoint inhibition
NCT02557321	32:40:lower_bound	who progressed after more than 12 weeks of checkpoint inhibition are eligible for study participation in the Phase 1b Expansion Cohort 1 without washout period for checkpoint inhibition
NCT02555280	8:18:cancer,52:71:cancer,80:103:cancer,238:248:lower_bound	Active malignancy: a patient with a history of any invasive malignancy (except nonmelanoma skin cancer), unless he/she has been treated with curative intent and there has been no clinical signs or symptoms of the malignancy for at least five years
NCT02555280	1:7:chronic_disease,11:28:chronic_disease,31:39:chronic_disease,43:48:chronic_disease	Active or chronic infection - systemic or local
NCT02555280	1:4:age,13:15:lower_bound,19:27:upper_bound	Age between 40 to 80 years
NCT02555280	27:36:treatment	Appropriate candidate for treatment using posterior surgical approach
NCT02555280	1:22:chronic_disease,35:53:chronic_disease,62:78:chronic_disease,104:159:chronic_disease	Cauda equina syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction
NCT02555280	20:43:treatment,112:120:treatment,139:155:treatment	Chronically taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids), not including a medrol dose pack
NCT02555280	1:30:chronic_disease,32:42:clinical_variable,59:62:lower_bound	Degenerative lumbar scoliosis (Cobb angle of greater than 25°)
NCT02555280	1:16:chronic_disease,47:68:treatment	Disc herniation at any lumbar level requiring surgical intervention
NCT02555280	1:18:chronic_disease,36:51:chronic_disease	Facet hypertrophy and subarticular recess stenosis at the affected level(s)
NCT02555280	55:62:upper_bound,63:80:chronic_disease,95:109:chronic_disease	For single level disease, there may be up to a stable Grade I spondylolisthesis or equivalent retrolisthesis at the affected level as determined on flexion/extension files by the investigator
NCT02555280	52:77:chronic_disease,92:106:chronic_disease	For two level disease, there may be up to a stable Grade I spondylolisthesis or equivalent retrolisthesis at ONLY ONE of the two contiguous affected levels as determined on flexion/extension films by the investigator
NCT02555280	1:19:chronic_disease	Foraminal stenosis at the affected level(s)
NCT02555280	24:45:chronic_disease	History of significant peripheral neuropathy
NCT02555280	11:17:chronic_disease	In active spinal litigation
NCT02555280	1:26:chronic_disease,30:43:chronic_disease	Isthmic spondylolisthesis or spondylolysis
NCT02555280	18:26:allergy_name,28:43:allergy_name,48:87:allergy_name	Known allergy to titanium, titanium alloys, or MR (magnetic resonance) contrast agents
NCT02555280	18:33:chronic_disease,35:47:chronic_disease,62:84:chronic_disease	Known history of Paget's disease, osteomalacia, or any other metabolic bone disease
NCT02555280	64:68:chronic_disease,70:73:chronic_disease,82:91:chronic_disease	Known or documented history of communicable disease, including AIDS, HIV, active Hepatitis
NCT02555280	1:22:chronic_disease,24:34:clinical_variable,41:44:upper_bound	Mild lumbar scoliosis (Cobb angle up to 25º)
NCT02555280	10:18:clinical_variable,35:38:lower_bound,219:252:treatment,256:259:treatment	Moderate stenosis is defined as > 25% reduction of the antero-posterior dimension compared to the next adjacent normal level, with nerve root crowding compared to the normal level, as determined by the investigator on computerized tomography (CT) Scan or MRI
NCT02555280	1:15:chronic_disease,29:44:bmi,47:49:lower_bound	Morbid obesity defined as a body mass index > 40
NCT02555280	11:14:lower_bound,15:33:treatment	More than one surgical procedure at any combination of lumbar levels
NCT02555280	11:14:lower_bound,53:75:treatment	More than two contiguous vertebral levels requiring surgical decompression
NCT02555280	1:24:treatment	Neurogenic claudication as defined by leg/buttocks or groin pain that can be relieved by flexion such as sitting in a chair
NCT02555280	1:11:chronic_disease,43:53:chronic_disease,157:196:treatment	Osteopenia: A screening questionnaire for osteopenia, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA (dual-energy x-ray absorptiometry) bone mineral density measurement
NCT02555280	67:69:lower_bound,70:72:upper_bound	Oswestry Low Back Pain Disability Questionnaire score of at least 20/50 (40%)
NCT02555280	19:22:lower_bound,36:54:treatment,93:101:lower_bound	Patient has undergone at least one epidural injection at any prior time point, AND at least 6 months of prior conservative care without adequate and sustained symptom relief
NCT02555280	17:35:cancer	Patients with a primary bony tumor
NCT02555280	28:53:chronic_disease	Patients with up to stable Grade I spondylolisthesis at two contiguous levels
NCT02555280	1:9:pregnancy,27:44:pregnancy,52:68:upper_bound	Pregnant or interested in becoming pregnant in the next three years
NCT02555280	1:13:treatment,15:55:treatment,57:77:treatment,82:128:treatment	Prior fusion, implantation of a total disc replacement, complete laminectomy, or implantation of an interspinous process device at index level
NCT02555280	1:25:treatment	Prior surgical procedure that resulted in translatory instability of the lumbar spine [as defined by White & Panjabi (see 3.4.1 Inclusion Criteria, Item #2)]
NCT02555280	123:132:treatment	Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures
NCT02555280	48:63:chronic_disease,141:143:lower_bound,144:146:upper_bound,160:182:treatment	Radiographic confirmation of at least moderate lumbar stenosis, which narrows the central spinal canal at one or two contiguous levels from L1-L5 that require surgical decompression
NCT02555280	1:13:treatment,153:179:clinical_variable,181:186:lower_bound,190:193:lower_bound,197:220:clinical_variable,222:225:lower_bound,255:258:lower_bound	Radiographic confirmation of no angular or translatory instability of the spine at index or adjacent levels (instability as defined by White & Panjabi: Sagittal plane translation >4.5mm or 15% or sagittal plane rotation >15° at L1-L2, L2-L3, and L3-L4; >20° at L4-L5 based on standing flexion/extension X-rays)
NCT02555280	96:102:chronic_disease,106:111:cancer	Radiographically compromised vertebral bodies at any lumbar level(s) caused by current or past trauma or tumor
NCT02555280	1:21:chronic_disease,31:50:chronic_disease	Rheumatoid arthritis or other autoimmune diseases
NCT02555280	8:25:chronic_disease	Severe facet hypertrophy that requires extensive bone removal which would cause instability
NCT02555280	13:40:chronic_disease	Significant peripheral vascular disease (e.g., with diminished dorsalis pedis or posterior tibial pulses)
NCT02555280	45:76:treatment	Subject is currently involved in a study of another investigational product for similar purpose
NCT02555280	14:22:chronic_disease	Uncontrolled diabetes
NCT02555280	14:21:upper_bound,35:52:chronic_disease,54:63:clinical_variable,94:108:chronic_disease,126:133:treatment,134:149:treatment	Up to stable Grade I degenerative spondylolisthesis (Meyerding classification) or equivalent retrolisthesis as determined by flexion/extension X ray
NCT02555280	1:20:clinical_variable,21:30:chronic_disease,49:54:lower_bound,60:72:upper_bound	Visual Analog Scale back pain score of at least 50 mm on a 100 mm scale
NCT02555280	1:21:chronic_disease	compression fracture
NCT02555280	1:11:chronic_disease	osteopenia
NCT02555280	1:14:chronic_disease	pars fracture
NCT02555280	21:53:chronic_disease	patients with up to Grade I stable spondylolisthesis at the adjacent level
NCT02553941	20:44:cancer,48:63:cancer	Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
NCT02553941	1:19:treatment,30:42:treatment,44:57:treatment,59:71:treatment,73:112:treatment,120:127:upper_bound	Anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy within 14 days or 5 half-lives prior to first dose of study drug
NCT02553941	5:29:chronic_disease,31:48:chronic_disease,53:77:chronic_disease	Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
NCT02553941	1:10:clinical_variable,14:23:upper_bound,57:75:chronic_disease	Bilirubin =< 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
NCT02553941	20:28:treatment,38:59:treatment	Concomitant use of warfarin or other vitamin K antagonists
NCT02553941	12:46:treatment	Concurrent systemic immunosuppressant therapy
NCT02553941	42:64:chronic_disease,87:97:chronic_disease,114:138:chronic_disease,157:183:clinical_variable,227:248:chronic_disease,250:265:chronic_disease,270:293:chronic_disease,301:315:upper_bound	Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to enrollment
NCT02553941	1:31:clinical_variable,35:44:lower_bound	Estimated creatinine clearance >= 30 ml/min (Cockcroft-Gault)
NCT02553941	1:16:gender,106:112:lower_bound,128:140:contraception_consent,156:180:contraception_consent,196:218:contraception_consent,225:240:gender,279:303:pregnancy	Female subjects who are of non-reproductive potential (ie, post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy); or, female subjects of childbearing potential must have a negative serum pregnancy test upon study entry
NCT02553941	38:67:treatment,79:101:treatment	For the dose escalation cohorts, any prior number of MDS therapies, including hypomethylating agents
NCT02553941	18:30:cancer	History of other malignancies
NCT02553941	12:18:chronic_disease,22:45:chronic_disease,53:67:upper_bound	History of stroke or intracranial hemorrhage within 6 months prior to enrollment
NCT02553941	1:54:clinical_variable,58:61:lower_bound	Karnofsky performance status (KPS) performance status of 60% or greater
NCT02553941	7:25:chronic_disease,84:89:clinical_variable,93:94:lower_bound	Known bleeding disorders, active bleeding disorders or clinical signs of bleeding (grade >= 2)
NCT02553941	18:52:chronic_disease,68:91:chronic_disease,95:118:chronic_disease	Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV)
NCT02553941	10:25:cancer,26:48:treatment	Low-risk prostate cancer after curative surgery
NCT02553941	1:14:treatment,22:29:upper_bound,47:57:treatment	Major surgery within 4 weeks of first dose of study drug
NCT02553941	1:5:gender	Male
NCT02553941	1:11:cancer,25:40:treatment,89:103:lower_bound,122:132:treatment	Malignancy treated with curative intent and with no known active disease present for >= 1 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician
NCT02553941	39:63:cancer	Pathologically confirmed diagnosis of myelodysplastic syndrome
NCT02553941	1:29:treatment,37:45:upper_bound,54:92:chronic_disease	Prior bone marrow transplant within 3 months or with acute graft versus host disease (GVHD)
NCT02553941	1:64:treatment	Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor
NCT02553941	1:22:clinical_variable,23:59:clinical_variable,62:71:upper_bound,76:109:clinical_variable,111:127:clinical_variable	Prothrombin time (PT)/international normalized ratio (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN
NCT02553941	8:17:chronic_disease,28:58:treatment	Recent infection requiring intravenous systemic treatment
NCT02553941	10:64:treatment,66:77:treatment,79:112:treatment	Requires treatment with a strong cytochrome P450 (CYP) family 3, subfamily A, polypeptide 4/5 (3A4/5) inhibitor
NCT02553941	1:57:clinical_variable	Revised international prognostic scoring system (IPSS-R) intermediate, high or very high
NCT02553941	1:66:clinical_variable,70:103:upper_bound	Serum aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN)
NCT02553941	31:53:chronic_disease,170:196:chronic_disease,200:218:chronic_disease,243:260:chronic_disease	Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
NCT02553941	28:53:treatment,89:163:clinical_variable,167:168:upper_bound	Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria
NCT02553941	17:21:treatment,23:42:treatment,50:57:upper_bound,75:85:treatment	Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
NCT02553941	1:16:gender	female subjects
NCT02553941	49:60:treatment,86:115:treatment	for the dose expansion cohort, subjects must be azacitidine naïve, but otherwise any prior number of MDS therapies
NCT02553941	1:9:pregnancy	pregnant
NCT02553941	1:12:treatment,49:64:clinical_variable,99:110:lower_bound	transfusion-dependent patients are eligible and platelet counts should be maintained greater than 10,000/mm^3
NCT02553941	5:59:contraception_consent,81:88:treatment,97:110:upper_bound,128:138:treatment	who agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of study drug
NCT02553447	89:108:cancer	Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the investigator?s opinion, may interfere with protocol adherence or a subject?s ability to give informed consent
NCT02553447	1:14:chronic_disease	Hypercalcemia
NCT02553447	188:195:treatment	Patients must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts
NCT02553447	111:120:treatment	Patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment
NCT02553447	31:64:treatment	Simultaneous participation in other therapeutic clinical trials will be allowed
NCT02553447	29:41:treatment,45:72:treatment,101:123:cancer,127:130:cancer	have received two cycles of chemotherapy or localized radiation therapy before going on this study) non-Hodgkin?s lymphoma or CLL
NCT02547584	1:4:age,8:16:lower_bound	Age: ≥ 18 years
NCT02547584	14:21:treatment,25:48:treatment	On long-term steroid or anti-inflammatory drugs
NCT02547584	11:29:treatment,53:69:chronic_disease	Receiving behavioral therapy or medications for the anxiety disorder
NCT02547584	12:29:treatment,34:44:chronic_disease,48:61:chronic_disease	Undergoing catheter ablation for paroxysmal or persistent AF
NCT02547584	1:7:gender	female
NCT02538484	70:79:chronic_disease,84:87:chronic_disease	Active systemic illness (infection including viral illnesses such as Hepatitis and HIV)
NCT02538484	5:19:treatment,23:62:treatment,74:86:upper_bound	Any NSAIDs aspirin or omega-3 free fatty acid supplementation within the last 14 days
NCT02538484	10:18:lower_bound,22:25:age	At least 18 years of age
NCT02538484	1:16:bmi,20:22:lower_bound	Body mass index of 30 or greater
NCT02538484	1:9:chronic_disease	Cachexia
NCT02538484	16:69:treatment,73:112:treatment,124:136:upper_bound,174:192:lower_bound	Chronic use of NSAIDs (nonsteroidal anti-inflammatory drugs) aspirin or omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)
NCT02538484	28:41:cancer	Estrogen receptor positive breast cancer
NCT02538484	111:118:upper_bound	Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days
NCT02526511	19:42:cancer,19:29:cancer,85:105:cancer,146:150:lower_bound,154:156:treatment,160:163:treatment	For patients with metastatic renal tumors to be enrolled, a histologic diagnosis of renal cell carcinoma must exist and any burden of disease >= 1 cm by CT or MRI is acceptable; the metastatic sites may be kidney, intra-abdominal (such as liver), brain, bone, or lymph nodes; lung lesions are NOT eligible because of the motion artifact caused by respiration
NCT02526511	40:46:cancer,67:77:clinical_variable,89:105:lower_bound,109:133:treatment,137:169:clinical_variable,200:203:lower_bound,204:206:upper_bound	For patients with organ confined renal tumors to be enrolled, the renal mass must be >= 1 cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) and can be any clinical stage T1a-T4 (non-metastatic); a histologic diagnosis is not required for enrollment; the primary imaging site would be kidney
NCT02526511	1:19:pregnancy,28:34:gender,52:55:age	Negative pregnancy test if female of child-bearing age
NCT02526511	15:33:cancer,52:69:treatment,77:99:treatment,185:194:treatment	Patients with metastatic disease may have received prior nephrectomy and/or prior systemic therapy (no limit on number); their baseline pMRI would be performed prior to starting a new treatment
NCT02526511	8:26:chronic_disease,28:37:chronic_disease	Severe concurrent disease, infection, or medical co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment
NCT02526511	1:33:chronic_disease,35:78:clinical_variable,81:99:upper_bound,182:217:chronic_disease,238:280:treatment	Severe renal function impairment (estimated glomerular filtration rate [eGFR] < 45 mL/min/1.73 m^2) would make the patient inappropriate for enrollment due to the increased risk of nephrogenic systemic fibrosis (NSF) with higher dose of IV gadolinium-based contrast agents (GBCA) administration
NCT02526511	73:87:chronic_disease,123:132:treatment,134:148:treatment	Subjects who are unable to tolerate or are not eligible for MR imaging (claustrophobia, metal implantable devices such as pacemaker, aneurysm clips, etc)
NCT02526511	38:45:allergy_name	Subjects with established allergy to IV GBCA
NCT02526511	1:6:gender,11:23:pregnancy	Women who are pregnant
NCT02520011	1:13:pregnancy	Are pregnant
NCT02520011	29:38:upper_bound,42:44:treatment,61:78:treatment,90:93:treatment,100:135:treatment,141:154:treatment,155:165:treatment,168:177:treatment	Be in first relapse (within 24 months of CR) or have failed induction therapy* (no CR or CRi after treatment with an intensive regimen (eg, anthracycline/cytarabine ± etoposide, gemtuzumab ozogamicin, or cladribine)
NCT02520011	18:66:contraception_consent,117:157:contraception_consent,273:281:lower_bound,283:288:gender,294:302:lower_bound,304:311:gender,336:346:treatment	Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry, for the duration of study participation, and for at least 3 months (males) and 6 months (females) after the last dose of study drug
NCT02520011	13:18:clinical_variable,34:37:lower_bound	Demonstrate MCL-1 dependence of ≥40% by mitochondrial profiling in bone marrow
NCT02520011	16:54:cancer	Diagnosed with acute promyelocytic leukemia (APL, M3)
NCT02520011	8:49:clinical_variable,51:54:lower_bound,58:79:treatment,83:117:treatment	Have a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
NCT02520011	8:30:clinical_variable,35:45:lower_bound,55:66:treatment	Have a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #5 above)
NCT02520011	8:30:clinical_variable,32:41:upper_bound	Have a serum creatinine level ≤1.8 mg/dL
NCT02520011	8:23:clinical_variable,30:40:upper_bound,62:78:chronic_disease,80:89:chronic_disease,94:102:cancer	Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)
NCT02520011	13:50:cancer	Have active central nervous system (CNS) leukemia
NCT02520011	9:74:clinical_variable,76:77:upper_bound	Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2
NCT02520011	30:39:chronic_disease	Have an active, uncontrolled infection
NCT02520011	9:78:clinical_variable,80:115:upper_bound	Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ≤5 times upper limit of normal (ULN)
NCT02520011	60:63:clinical_variable,118:155:cancer,179:181:lower_bound	Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M3) with a bone marrow of >5% blasts based on histology or flow cytometry
NCT02520011	29:61:chronic_disease,56:60:chronic_disease,109:118:treatment,130:142:upper_bound	Have clinically significant graft versus host disease (GVHD), or GVHD requiring initiation or escalation of treatment within the last 21 days
NCT02520011	31:69:chronic_disease	Have evidence of uncontrolled disseminated intravascular coagulation
NCT02520011	6:21:chronic_disease,29:40:chronic_disease	Have mental deficits and/or psychiatric history that may compromise the ability to give written informed consent or to comply with the study protocol
NCT02520011	19:31:cancer,80:93:upper_bound,102:125:cancer,129:163:cancer	Have other active malignancies or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia
NCT02520011	19:31:treatment,39:52:upper_bound,62:72:treatment	Have received any live vaccine within 14 days prior to first study drug administration
NCT02520011	11:20:lower_bound,36:48:treatment	Received >360 mg/m2 equivalents of daunorubicin
NCT02520011	12:46:treatment,58:75:upper_bound	Received a hematopoietic stem cell transplant within the previous 2 months
NCT02520011	10:30:treatment,23:30:treatment,42:54:upper_bound,78:89:treatment	Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor
NCT02520011	23:47:treatment,61:74:treatment	Received any previous treatment with alvocidib or any other CDK inhibitor
NCT02520011	20:28:lower_bound,32:49:treatment,54:57:cancer,59:81:treatment,93:111:treatment,185:196:treatment	Received more than 2 cycles of induction therapy for AML. Investigational agents as part of front-line therapy for AML may by acceptable following discussion with the Medical Monitor. Hydroxyurea is permitted (see #5 below)
NCT02520011	9:33:treatment,35:52:treatment,57:70:treatment,72:83:treatment,145:153:upper_bound,167:176:treatment	Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm
NCT02520011	13:17:age,22:24:lower_bound,30:38:upper_bound	between the ages of ≥18 and ≤65 years
NCT02519140	1:4:chronic_disease,16:25:treatment	Pts undergoing colectomy
NCT02519140	16:34:treatment	Pts undergoing sleeve gastrectomy
NCT02518594	8:24:clinical_variable,118:135:treatment	Active vaginal bleeding greater than spotting at the time of randomization, because of potential exacerbation due to pessary placement
NCT02518594	18:49:chronic_disease,51:57:chronic_disease,62:68:chronic_disease	Active, unhealed herpetic lesion on labia minora, vagina, or cervix due to the potential for significant patient discomfort or increasing genital tract viral spread. Once lesion(s) heal and the patient is asymptomatic, she may be randomized
NCT02518594	12:24:allergy_name,26:34:allergy_name,57:67:treatment,79:86:allergy_name,90:100:allergy_name,122:129:allergy_name	Allergy to progesterone, silicone, or excipients in the study drug, including peanuts or peanut oil in the study drug or placebo
NCT02518594	5:10:chronic_disease,11:29:chronic_disease,82:91:treatment,151:187:chronic_disease	Any fetal/maternal condition which would require invasive in-utero assessment or treatment, for example significant red cell antigen sensitization or neonatal alloimmune thrombocytopenia
NCT02518594	33:37:lower_bound,52:71:treatment,176:207:treatment,185:195:treatment	Cervical dilation (internal os) 3 cm or greater on digital examination or evidence of prolapsed membranes beyond the external cervical os either at the time of the qualifying cervical ultrasound examination or at a cervical exam immediately before randomization. There is no lower threshold of cervical length measurement threshold on ultrasound
NCT02518594	20:44:treatment,58:63:upper_bound,71:84:upper_bound	Cervical length on transvaginal examination of less than 30 mm within 10 days prior to randomization by a study certified sonographer
NCT02518594	13:58:chronic_disease,61:75:upper_bound,80:95:clinical_variable	Evidence of severe IUGR (intrauterine growth restriction) (<5th percentile for gestational age) in either fetus
NCT02518594	1:14:chronic_disease,70:86:chronic_disease,175:188:chronic_disease,190:202:chronic_disease,212:236:chronic_disease,270:285:lower_bound,289:304:upper_bound	Fetal anomaly in either twin or imminent fetal demise. This includes lethal anomalies, or anomalies that may lead to early delivery or increased risk of neonatal death e.g., gastroschisis, spina bifida, serious karyotypic abnormalities). An ultrasound examination from 14 weeks 0 days to 23 weeks 6 days by project EDC (estimated date of conception) must be performed prior to randomization to evaluate the fetuses for anomalies
NCT02518594	1:16:clinical_variable,42:57:lower_bound,62:77:upper_bound	Gestational age at randomization between 16 weeks 0 days and 23 weeks 6 days based on clinical information and evaluation of the earliest ultrasound
NCT02518594	12:18:chronic_disease	History of herpes
NCT02518594	7:24:chronic_disease,44:57:chronic_disease,94:110:treatment	Known liver dysfunction or disease because liver disease is a contraindication to the active study medication
NCT02518594	13:44:chronic_disease,59:69:chronic_disease,71:82:chronic_disease,87:101:chronic_disease,194:206:treatment	Known major Mullerian anomaly of the uterus (specifically bicornuate, unicornuate, or uterine septum not resected) due to increased risk of preterm delivery which is unlikely to be affected by progesterone
NCT02518594	32:45:cancer,110:120:treatment	Known, suspected or history of breast cancer because breast cancer is a contraindication to the active study medication
NCT02518594	75:84:pregnancy,129:141:chronic_disease,162:165:lower_bound,173:198:treatment,203:211:chronic_disease,240:259:chronic_disease,279:289:clinical_variable,291:300:lower_bound,302:325:cancer,351:386:treatment	Major maternal medical illness associated with increased risk for adverse pregnancy outcome or indicated preterm birth (treated hypertension requiring more than one agent, pre-gestational treatment for diabetes prior to pregnancy, chronic renal insufficiency failure defined by creatinine >1.4 mg/dL, carcinoma of the breast, conditions treated with chronic oral glucocorticoid therapy
NCT02518594	58:67:pregnancy	Monoamniotic gestation, due to increased risk of adverse pregnancy outcome
NCT02518594	11:14:lower_bound,130:145:treatment	More than six contractions per hour reported or documented prior to randomization. It is not necessary to place the patient on a tocodynamometer
NCT02518594	18:46:treatment,63:78:clinical_variable	Participation in another interventional study that influences gestational age at delivery or neonatal morbidity or mortality
NCT02518594	43:52:pregnancy	Participation in this trial in a previous pregnancy
NCT02518594	42:51:pregnancy	Patients who were screened in a previous pregnancy, but not randomized
NCT02518594	1:16:chronic_disease	Placenta previa, because of risk of bleeding and high potential for indicated preterm birth
NCT02518594	9:17:treatment,86:93:treatment	Planned cerclage or cerclage already in place since it would preclude placement of a pessary
NCT02518594	19:41:treatment,62:83:upper_bound,95:112:pregnancy	Planned or actual progesterone treatment of any type or form after 14 weeks 6 days during the current pregnancy
NCT02518594	43:52:pregnancy,112:121:chronic_disease	Rupture of membranes due to likelihood of pregnancy loss and preterm delivery as well as the risk of ascending infection which could be increased with pessary placement
NCT02518594	29:46:chronic_disease,48:51:chronic_disease,178:197:treatment,198:202:treatment,203:207:treatment	Specifically, patients with seizure disorders, HIV, and other medical conditions not specifically associated with an increased risk of indicated preterm birth are not excluded. Prior cervical cone/LOOP/LEEP
NCT02518594	1:31:chronic_disease,66:75:pregnancy	Twin-twin transfusion syndrome, due to increased risk of adverse pregnancy outcome
NCT02517307	1:23:chronic_disease,27:49:chronic_disease	cardiovascular disease or elevated plasma lipids
NCT02517307	24:29:chronic_disease,31:36:chronic_disease,38:41:chronic_disease,45:60:chronic_disease,77:80:age,85:88:bmi,109:138:chronic_disease	confirmed diagnosis of VLCAD, LCHAD, TFP or MCAD deficiency or same gender, age and BMI as a subject with a fatty acid oxidation disorder
NCT02517307	1:19:chronic_disease,28:36:chronic_disease,40:65:chronic_disease	endocrine disorder such as diabetes or untreated thyroid disease
NCT02517307	1:11:clinical_variable,13:19:upper_bound,21:57:clinical_variable,59:62:lower_bound,63:85:clinical_variable,87:93:lower_bound,95:104:clinical_variable,106:114:upper_bound	hemoglobin <10g/dl, international normalized ratio (INR) >1.2 Prothrombin time (PTT) >36 sec, Platelets <150K/mm3
NCT02517307	1:9:pregnancy,23:30:gender	pregnant or lactating females
NCT02517307	18:22:treatment	regularly taking meds that strongly affect bleeding, bruising or platelets
NCT02516813	1:15:treatment,26:31:cancer,46:47:lower_bound,48:68:cancer,69:79:cancer,89:93:lower_bound,152:165:treatment	Ancillary cPoP Part: any tumor with at least 2 (sub)cutaneous tumor/metastases at least 2 cm apart which are RT naïve with an indication for high dose palliative RT
NCT02516813	1:23:chronic_disease,40:50:clinical_variable,52:61:upper_bound,63:79:clinical_variable,81:92:upper_bound,94:103:clinical_variable,105:116:upper_bound	Bone marrow impairment as evidenced by hemoglobin <10.0 g/dL, neutrophil count <1.0 × 109/L, platelets <100 × 109/L
NCT02516813	1:64:clinical_variable,67:68:upper_bound	Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1
NCT02516813	11:19:treatment,24:27:lower_bound,31:42:clinical_variable,84:101:treatment,102:127:treatment,135:149:upper_bound	Extensive prior RT on ≥30% of bone marrow reserve as judged by the investigator or prior bone marrow/stem cell transplantation within 5 years before trial start
NCT02516813	1:16:gender,3:16:gender,66:81:gender,133:142:pregnancy	Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy
NCT02516813	58:71:treatment,75:94:treatment,103:145:treatment,103:111:treatment,138:145:chronic_disease,149:165:chronic_disease	History of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion (as per Investigator's judgement) or a psychiatric condition that might impair the subject's well-being or preclude full participation in the trial
NCT02516813	66:90:chronic_disease,157:160:treatment	History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMP
NCT02516813	35:48:chronic_disease,66:90:chronic_disease,157:160:treatment,169:216:treatment	History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMP, use of percutaneous endoscopic gastrostomy (PEG) tubes
NCT02516813	1:16:clinical_variable,22:30:lower_bound,32:47:clinical_variable,54:62:lower_bound,64:92:clinical_variable	Life expectancy of ≥ 3 months (Phase Ia, Arm A) or ≥ 6 months (Phase Ia, Arm B and Phase Ib)
NCT02516813	42:57:clinical_variable,59:68:lower_bound,61:68:lower_bound,72:135:clinical_variable,137:146:lower_bound,205:212:clinical_variable	Liver function abnormality as defined by total bilirubin >1.5 × ULN or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >2.5 × ULN (except for subjects with liver involvement, who can have AST/ALT >5 × ULN)
NCT02516813	66:80:treatment	Measurable or evaluable disease by RECIST v1.1 (not required for ancillary cPoP part of the study)
NCT02516813	25:37:cancer,41:51:cancer,62:70:cancer,166:168:treatment,181:190:treatment,197:202:cancer,268:277:treatment	Phase Ia part: advanced solid tumors or metastases including lymphoma localized in the head and neck region or thorax with an indication for fractionated palliative RT (Arm A); or treatment-naïve SCCHN eligible for fractionated curatively intended RT with concurrent cisplatin (Arm B)
NCT02516813	16:25:treatment,46:51:cancer,69:87:treatment,102:116:treatment,161:166:cancer,232:241:treatment	Phase Ib part: treatment-naïve Stage III A/B NSCLC not eligible for surgical resection or concurrent chemoradiation (Arm A expansion cohort) or treatment-naïve SCCHN eligible for fractionated curatively intended RT with concurrent cisplatin (Arm B expansion cohort)
NCT02516813	1:9:treatment,36:45:upper_bound,78:84:cancer,178:187:treatment,208:213:cancer,258:277:cancer	Prior RT to the same region within 12 months (Phase Ia, Arm A; subjects with tumors localized in the head and neck region or thorax) or at any time previously (Phase Ia, Arm B; treatment-naïve subjects with SCCHN and Phase Ib; treatment-naïve subjects with Stage III A/B NSCLC or SCCHN)
NCT02516813	1:17:chronic_disease,34:50:clinical_variable,52:85:lower_bound	Renal impairment as evidenced by serum creatinine >1.5 × upper limit of normal (ULN)
NCT02516813	13:45:chronic_disease,70:87:chronic_disease,109:141:chronic_disease,150:197:clinical_variable,199:200:lower_bound	Significant cardiac conduction abnormalities, including a history of long QTc syndrome and/or pacemaker, or impaired cardiovascular function such as New York Heart Association classification score >2
NCT02516813	92:102:treatment,104:115:treatment,119:137:treatment,150:176:treatment,171:176:treatment,180:187:treatment,207:219:lower_bound,230:241:treatment,262:286:treatment,317:330:lower_bound,536:549:lower_bound	Subjects currently receiving (or unable to stop using prior to receiving the first dose of study drug) medications or herbal supplements known to be potent inhibitors of CYP3A or CYP2C19 must stop at least 1 week prior to taking MSC2490484A. Subjects receiving potent inducers of CYP3A or CYP2C19 must stop at least 3 weeks prior to taking MSC2490484A. Those receiving drugs mainly metabolized by CYP3A with a narrow therapeutic index as judged by the Investigator (and after optional consultation with the Sponsor) must stop at least one day prior to taking MSC2490484A
NCT02516813	104:115:treatment,119:137:treatment,171:186:treatment,187:194:treatment,198:205:treatment,226:238:lower_bound,260:265:treatment,297:310:lower_bound,344:381:treatment,402:415:lower_bound	Subjects currently receiving (or unable to stop using prior to receiving the first dose of trial drug) medications or herbal supplements known to be potent inhibitors of cytochrome P450 (CYP)3A or CYP2C19 (must stop at least 1 week prior), potent inducers of CYP3A or CYP2C19 (must stop at least 3 weeks prior), or drugs mainly metabolized by CYP3A with a narrow therapeutic index (must stop at least one day prior)
NCT02516813	30:40:treatment,44:66:treatment,95:107:lower_bound,115:130:treatment	Subjects currently receiving H2-blocker or proton pump inhibitors (or unable to stop at least 5 days prior to the first treatment)
NCT02516813	26:29:lower_bound,37:59:clinical_variable,79:82:lower_bound	Subjects where more than 10% of the total esophagus volume receives more than 50% of the prescribed RT dose
NCT02516813	17:22:cancer,23:31:treatment	Willing to have tumor biopsies collected in Ancillary cPoP
NCT02516241	1:17:chronic_disease,28:40:chronic_disease,42:53:chronic_disease,55:66:chronic_disease,71:105:chronic_disease	Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
NCT02516241	28:38:chronic_disease,42:64:chronic_disease,130:138:chronic_disease,142:150:chronic_disease,167:181:chronic_disease,197:215:chronic_disease,227:246:treatment,298:314:treatment,356:368:upper_bound,446:460:chronic_disease	Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion: • Patients with vitiligo or alopecia • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement • Any chronic skin condition that does not require systemic therapy • Patients without active disease in the last 3 years may be included but only after consultation with AstraZeneca • Patients with celiac disease controlled by diet alone may be included but only after consultation with AstraZeneca
NCT02516241	1:17:cancer,21:44:chronic_disease,94:102:treatment,116:129:lower_bound,146:161:treatment,196:212:cancer,241:244:treatment	Brain metastases or spinal cord compression unless the patient's condition is stable and off steroids for at least 14 days prior to the start of study treatment. Patients with suspected or known brain metastases at screening should have an MRI (preferred)/CT, preferably with IV contrast to access baseline disease status
NCT02516241	1:21:clinical_variable,48:57:upper_bound,139:140:lower_bound,184:244:clinical_variable,260:272:chronic_disease,275:286:clinical_variable,290:311:chronic_disease,342:351:lower_bound,352:365:chronic_disease	Creatinine clearance (calculated or measured) <60 mL/min calculated by Cockcroft-Gault equation (using actual body weight) or by measured 24-hour urine collection for determination • Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 audiometric hearing loss • CTCAE Grade ≥2 peripheral neuropathy • New York Heart Association ≥Class III heart failure
NCT02516241	25:53:treatment,61:68:upper_bound,94:122:treatment,174:184:treatment,186:193:treatment,195:211:treatment,216:240:treatment,246:271:treatment,275:299:treatment,303:320:treatment,335:340:upper_bound,348:358:treatment,379:387:treatment,441:462:treatment	Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion: • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection) • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
NCT02516241	12:43:treatment,65:89:treatment	History of allogenic organ transplantation that requires use of immunosuppressive agents
NCT02516241	37:65:treatment	Patients eligible or ineligible for cisplatin-based chemotherapy
NCT02516241	73:127:cancer,170:193:treatment	Patients with histologically or cytologically documented, unresectable, Stage IV transitional cell carcinoma of the urothelium who have not been previously treated with first-line chemotherapy
NCT02516241	19:42:treatment,80:137:treatment,139:148:treatment,150:160:treatment,165:186:treatment,198:229:treatment,243:268:treatment,272:285:treatment,319:332:lower_bound	Prior exposure to immune-mediated therapy, including but not limited to, other anti cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies, including therapeutic anticancer vaccines. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment
NCT02516241	12:35:treatment,43:56:upper_bound,43:50:upper_bound,78:80:treatment	Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP
NCT02516241	1:12:cancer,26:57:treatment	Tumor PD-L1 status, with Immunohistochemical (IHC) assay confirmed by a reference laboratory, must be known prior to randomization
NCT02515513	1:18:cancer	Pancreatic Cancer Patients who are potentially surgically resectable
NCT02515513	30:48:treatment	do not meet the criteria for surgical resection
NCT02508038	62:65:upper_bound,66:74:clinical_variable,80:100:treatment	1st complete remission, but very high-risk features (i.e., < 20% survival with conventional therapy)
NCT02508038	1:37:clinical_variable,40:71:upper_bound,76:79:age	ALT (alanine aminotransferase, SCPT) ≤ 5 x Upper LImit of Normal (ULN) for age
NCT02508038	15:23:lower_bound	Donor must be 18 years or older
NCT02508038	1:18:clinical_variable,24:27:lower_bound,31:65:treatment,69:83:treatment	Ejection fraction of > 40% by Multigated Acquisition Scan (MUGA) or echocardiogram
NCT02508038	19:39:treatment	Enrollment in any other clinical study from screening up to Day 100
NCT02508038	61:68:treatment	Failure to achieve Complete Response (CR) following initial therapy
NCT02508038	1:33:clinical_variable,36:52:lower_bound	Glomerular Filtration Rate (GFR) ≥ 60 ml/min/1.73m2
NCT02508038	1:10:chronic_disease,26:31:chronic_disease	HIV 1 & 2 antibody (Anti-HIV-1, 2 plus O)
NCT02508038	1:4:chronic_disease	HIV infection
NCT02508038	6:7:lower_bound,8:10:upper_bound	HTLV I/II antibody (Anti-HTLV I/II)
NCT02508038	1:15:treatment	Haploidentical by HLA-typing
NCT02508038	1:14:chronic_disease	Heart failure
NCT02508038	1:23:cancer,27:38:cancer	Hematologic malignancy or solid tumor
NCT02508038	1:37:treatment	Hepatitis B core antibody (Anti-HBc)
NCT02508038	1:12:chronic_disease	Hepatitis B surface antigen (HBsAg)
NCT02508038	1:12:chronic_disease	Hepatitis C antibody (Anti-HCV)
NCT02508038	59:74:treatment,116:125:upper_bound,167:197:treatment,199:226:treatment,257:269:cancer	High-risk refractory or relapsed ALL in patients for whom transplantation is deemed indicated (relapse occurring < 30 months from diagnosis, patients relapsing after previous allogeneic transplant, relapse after 2nd remission, primary induction failure or hypodiploidy)
NCT02508038	1:17:cancer,34:43:treatment	Hodgkin lymphoma relapsing after auto-HSCT
NCT02508038	50:54:clinical_variable,57:60:lower_bound	If measured, carbon monoxide diffusion capacity (DLCO) >50%
NCT02508038	31:49:pregnancy	If of reproductive potential, negative pregnancy test and willing to use effective birth control method
NCT02508038	57:76:treatment	Is free from communicable disease risks associated with xenotransplantation
NCT02508038	84:104:chronic_disease	Is free from risk factors for, and clinical evidence of, infection due to relevant communicable disease agents and diseases
NCT02508038	11:18:gender	Lactating females
NCT02508038	1:16:clinical_variable,22:30:lower_bound	Life expectancy of ≥ 3 months
NCT02508038	10:14:chronic_disease,26:30:chronic_disease,42:45:chronic_disease	MPX for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR)
NCT02508038	1:25:cancer,26:53:cancer	Myelodysplastic Syndrome/Myeloproliferative Syndrome
NCT02508038	1:4:treatment,9:24:chronic_disease,26:33:treatment	NAT for West Nile Virus (WNV-PCR)
NCT02508038	31:52:chronic_disease	Negative testing for relevant communicable diseases
NCT02508038	1:14:cancer	Neuroblastoma
NCT02508038	16:23:chronic_disease	No evidence of dyspnea at rest
NCT02508038	11:32:chronic_disease	No severe peripheral neuropathy
NCT02508038	4:23:treatment	No supplemental oxygen requirement
NCT02508038	1:21:cancer,32:47:treatment	Non-Hodgkin lymphoma relapsing after auto-HSCT
NCT02508038	1:13:cancer	Osteosarcoma
NCT02508038	67:85:treatment,87:100:treatment,105:117:treatment	Patient must have fully recovered from acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
NCT02508038	15:37:cancer,51:54:cancer	Patients with hematologic malignancy must have no HLA identical sibling or suitable unrelated donor OR time needed to find an acceptable unrelated donor match
NCT02508038	25:28:lower_bound,29:39:cancer,41:52:chronic_disease,56:67:cancer	Patients with more than one malignancy (hematologic or solid tumor)
NCT02508038	15:32:chronic_disease,52:60:chronic_disease,84:106:treatment	Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsant therapy
NCT02508038	15:26:cancer,79:88:treatment,123:126:lower_bound	Patients with solid tumor must have failed or have been ineligible to receive auto-HSCT or if auto-HSCT would not offer > 20% chance of cure
NCT02508038	1:9:pregnancy	Pregnant
NCT02508038	1:9:pregnancy,10:17:gender	Pregnant females
NCT02508038	32:52:cancer,129:138:treatment	Primary refractory or relapsed non-Hodgkin lymphoma unable to achieve 2nd remission or VGPR and therefore ineligible to receive auto-HSCT
NCT02508038	1:22:treatment	Prior organ allograft
NCT02508038	6:14:chronic_disease	RPR (Syphilis TP)
NCT02508038	10:26:cancer,132:189:treatment	Relapsed Hodgkin lymphoma unable to achieve 2nd remission or Very Good Partial Response (VGPR) and therefore ineligible to receive autologous hematopoietic stem cell transplant (auto-HSCT)
NCT02508038	13:42:cancer	Relapsed or primary refractory metastatic
NCT02508038	13:28:treatment,40:43:cancer,49:66:clinical_variable,69:72:upper_bound	Relapsed or primary therapy-refractory AML with bone marrow blast < 20%
NCT02508038	15:24:cancer,28:43:cancer,74:81:treatment,89:101:treatment	Relapsed with pulmonary or bone metastases and did not achieve a CR with surgery and/or chemotherapy
NCT02508038	21:41:chronic_disease,55:61:cancer,69:78:treatment,166:170:clinical_variable	Significant serious intercurrent illness unrelated to cancer or its treatment not covered by other exclusion criteria expected to significantly increase the risk of HSCT
NCT02508038	1:21:cancer,23:39:cancer,41:54:cancer,56:87:cancer,107:132:cancer	Soft tissue sarcomas (Rhabdomyosarcoma, Ewing sarcoma, Primitive Neuroectodermal Tumor or other high-risk extracranial solid tumors)
NCT02508038	34:48:upper_bound,49:63:treatment	Study enrollment no earlier than 3 months after preceding HSCT
NCT02508038	1:24:treatment	T. Cruzi - EIA (Chagas)
NCT02508038	1:16:clinical_variable,19:26:upper_bound	Total bilirubin < 3 mg/dL
NCT02508038	1:13:chronic_disease,23:39:chronic_disease	Uncontrolled, Serious Active Infection
NCT02508038	8:46:chronic_disease	active Central Nervous System (CNS) infection
NCT02508038	10:29:chronic_disease	signs of leukoencephalopathy
NCT02508038	14:40:chronic_disease	uncontrolled cardiac rhythm disturbance
NCT02507687	21:40:chronic_disease,44:63:chronic_disease,89:111:treatment	Diagnosis of either Open-Angle Glaucoma or Ocular Hypertension in each eye that require IOP lowering treatment
NCT02507687	36:49:treatment	Enrollment in other studies using Bimatoprost SR
NCT02507687	1:12:treatment,24:40:treatment,49:66:treatment,78:91:upper_bound	Eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months
NCT02495753	1:6:gender,18:35:treatment	Women undergoing cesarean delivery after labor at Barnes-Jewish Hospital
NCT02495753	31:37:allergy_name,41:50:allergy_name	known or suspected allergy to iodine or shellfish
NCT02495753	1:6:gender,19:49:chronic_disease	women with active herpes simplex virus infection
NCT02495415	14:21:lower_bound,44:79:treatment,86:89:chronic_disease,91:111:treatment,142:145:lower_bound,146:158:clinical_variable	A minimum of 6 weeks is required following prior large field radiation therapy (i.e. TBI, craniospinal therapy, whole abdomen, total lung, > 50% marrow space)
NCT02495415	18:23:cancer,87:105:treatment,113:119:treatment	Bone marrow with tumor cells seen on routine morphology (not by NSE staining only) of bilateral aspirate and/or biopsy on one bone marrow sample
NCT02495415	31:46:cancer,50:73:cancer	CNS lesions: A) Patients with CNS parenchymal or meningeal-based lesions that are present at study entry are NOT eligible due to concerns regarding toxicity attribution
NCT02495415	36:39:lower_bound,48:76:treatment	Diseases refractory/relapsed after one or more systemic cytotoxic therapies
NCT02495415	41:62:treatment,51:55:treatment,78:94:treatment,119:131:cancer	For patients with persistent disease, a biopsy of bone marrow, or bone, or a soft tissue site, must have demonstrated viable tumor
NCT02495415	46:73:treatment,81:87:upper_bound	Growth factor(s): Must not have received any hematopoetic growth factors within 7 days of study entry
NCT02495415	47:81:chronic_disease	Known history of, or positive test result for human immunodeficiency virus (HIV) infection
NCT02495415	35:38:lower_bound	Measurable is defined as at least one lesion 20 mm in at least one dimension
NCT02495415	12:17:cancer,21:24:treatment,28:35:treatment	Measurable tumor on MRI or CT scan
NCT02495415	1:17:treatment,60:76:treatment	Organ Transplant: Patients may NOT be the recipients of an organ transplant
NCT02495415	28:53:treatment,65:78:upper_bound	Participation in any other investigational treatment within the 6 weeks prior to enrollment or concurrent with this study
NCT02495415	64:76:treatment,78:84:treatment,94:125:treatment,127:146:treatment,224:238:treatment,242:250:treatment,252:261:treatment,263:272:treatment,286:298:treatment,300:314:treatment,316:321:treatment,323:335:treatment,340:354:treatment,356:368:treatment,370:384:treatment,386:400:treatment,402:411:treatment,413:425:treatment,427:434:treatment,440:450:treatment	Patients concurrently taking the following drugs are excluded: antioxidants, herbal or other alternative therapy medications, vitamin supplements (especially vitamins A, C, and E) other than at standard multivitamin doses, cyclosporine A or analogue; verapamil; tamoxifen or analogue, ketoconazole, chlorpromazine; RU486; indomethacin; or sulfinpyrazone, tetracycline, nalidixic acid, nitrofurantoin, phenytoin, sulfonamides, lithium, and amiodarone
NCT02495415	45:55:chronic_disease,59:72:treatment	Patients must have otherwise recovered from toxicities of prior therapy
NCT02495415	53:62:treatment,80:93:upper_bound	Patients must not have received small field (focal) radiation for a minimum of 2 weeks prior to study entry
NCT02495415	23:47:treatment,55:67:upper_bound	Patients who have had major non-biopsy surgery in the last 20 days
NCT02495415	28:40:treatment,48:55:upper_bound,65:86:treatment	Patients who have received chemotherapy within 3 weeks of first fenretinide treatment
NCT02495415	32:51:chronic_disease	Patients who have uncontrolled systemic infections
NCT02495415	18:41:clinical_variable,45:46:lower_bound,54:55:upper_bound,85:93:lower_bound	Patients with an ECOG performance status of 0, 1, or 2, and estimated survival of > 12 weeks
NCT02495415	29:61:chronic_disease	Patients with an identified familial hyperlipidemia disorder
NCT02495415	26:46:chronic_disease	Patients with any active hepatitis infections
NCT02495415	37:49:allergy_name	Patients with documented allergy to egg products
NCT02495415	37:49:allergy_name	Patients with documented allergy to soy products
NCT02495415	15:42:clinical_variable,45:48:lower_bound,61:81:chronic_disease,92:102:treatment	Patients with fasting serum triglycerides > 300 and/or with hypertriglyceridemia requiring medication
NCT02495415	33:50:chronic_disease,56:91:clinical_variable,97:106:lower_bound,112:126:clinical_variable,132:136:lower_bound	Patients with poorly controlled diabetes mellitus with fasting serum glucose concentration over 200 mg/dl or a hemoglobin A1C over 7.5%
NCT02495415	34:56:cancer,60:76:cancer,107:112:cancer,116:119:treatment,121:129:treatment	Patients with previously treated leptomeningeal disease or brain metastases without evidence of remaining tumor by PET, MRI scan, or spinal fluid
NCT02495415	28:40:chronic_disease	Patients with uncontrolled hypertension
NCT02495415	17:28:chronic_disease,45:64:treatment	Who have active CNS disease or a history of cranial irradiation are excluded due to concerns regarding toxicity attribution
NCT02495415	1:6:gender,11:23:pregnancy	Women who are pregnant
NCT02495415	1:22:chronic_disease	coagulation disorders
NCT02495415	5:14:treatment,59:62:lower_bound	for spiral CT, measurable is defined as 10 mm in at least one dimension
NCT02495415	7:52:chronic_disease,56:75:chronic_disease	other major medical illnesses of the cardiovascular or respiratory systems
NCT02495415	54:63:treatment	patient who tested positive subsequent to their last treatment regimen
NCT02495415	27:35:treatment,59:67:chronic_disease	patients currently taking steroids as prophylaxis against seizures
NCT02495415	72:90:treatment,92:105:treatment,110:128:treatment	patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
NCT02495415	43:55:upper_bound	patients who had a negative marrow within three months of study entry
NCT02495415	15:35:chronic_disease,52:62:treatment	patients with hypercholesterolemia with or without medication
NCT02495415	19:40:treatment,48:55:upper_bound,65:86:treatment	who have received investigational drugs within 6 weeks of first fenretinide treatment
NCT02495415	48:81:cancer	with histologically or cytologically confirmed Peripheral T-cell lymphoma (PTCL)
NCT02489591	12:21:allergy_name,25:52:allergy_name	Allergy to lidocaine or oxymetazoline hydrochloride
NCT02489591	77:95:chronic_disease	Any unstable cardiac condition (other than well controlled hypertension) or pulmonary problems
NCT02489591	1:15:chronic_disease	Claustrophobia
NCT02489591	1:27:chronic_disease,29:37:chronic_disease,39:49:chronic_disease,51:70:chronic_disease,74:84:chronic_disease	Concurrent sleep disorders (insomnia, narcolepsy, central sleep apnea or parasomnia)
NCT02489591	15:38:chronic_disease	Patients with Obstructive Sleep Apnea
NCT02489591	1:20:chronic_disease	Periodontal disease and/or insufficient number of teeth
NCT02489591	1:10:pregnancy	Pregnancy
NCT02489019	1:9:lower_bound	60 years and older
NCT02489019	1:4:age,15:17:upper_bound	Age less than 60
NCT02489019	26:44:treatment,49:68:treatment	Patients having combined general anesthesia and epidural anesthesia
NCT02489019	24:46:treatment	Patients scheduled for cardiovascular surgery
NCT02489019	57:72:treatment	Patients who will receive rapid sequence induction with succinylcholine
NCT02489019	31:65:clinical_variable,76:78:upper_bound,95:98:lower_bound	Patients with a pre-induction mean arterial blood pressure (MAP) less than 50 or greater than 150
NCT02489019	15:21:clinical_variable,35:41:lower_bound	Patients with weight greater than 125 kg
NCT02489019	16:34:treatment,61:84:treatment	Surgeries with general anesthesia alone or if combined with peripheral nerve blocks
NCT02486042	15:28:chronic_disease	Patients with liver disease as tested by LFTs
NCT02486042	23:31:upper_bound,55:61:upper_bound	less than or equal to 30 weeks gestation or less than 1500 g at birth
NCT02486042	3:12:upper_bound,13:24:clinical_variable	≤ 500 grams birthweight
NCT02484300	3:23:chronic_disease,36:51:chronic_disease,58:71:chronic_disease,73:89:chronic_disease,91:107:chronic_disease,118:135:chronic_disease	A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders
NCT02484300	25:29:clinical_variable,34:37:clinical_variable,40:43:upper_bound	Abnormal lung function (FEV1 and FVC < 80% predicted)
NCT02484300	1:5:age,6:8:lower_bound,9:17:upper_bound	Ages 18-70 years
NCT02484300	11:18:chronic_disease,39:51:chronic_disease,87:96:chronic_disease,108:114:chronic_disease,117:122:chronic_disease,124:134:chronic_disease,146:154:chronic_disease,157:170:chronic_disease,172:187:chronic_disease,206:214:chronic_disease	Any known cardiac (apart from treated hypertension with acceptable drugs, see below), pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular, hepatic disease, or patients with diabetes
NCT02484300	1:8:gender	Females
NCT02484300	63:66:clinical_variable,69:71:lower_bound	History of driving or other accidents due to sleepiness or an ESS > 18
NCT02484300	1:5:gender	Male
NCT02484300	11:13:lower_bound	More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day
NCT02484300	10:25:chronic_disease	No other sleep disorders
NCT02484300	1:34:treatment	Prior or current use of melatonin
NCT02484300	1:11:chronic_disease,14:16:lower_bound,17:37:clinical_variable	Severe OSA (≥30 apnea hypopnea index)
NCT02484300	17:23:lower_bound	Smokers (quit ≥ 1 year ago acceptable)
NCT02484300	23:30:lower_bound	Substantial alcohol (>3oz/day) or use of illicit drugs
NCT02484300	12:23:treatment	Use of any medications that may affect sleep or breathing
NCT02484300	8:37:treatment,39:83:treatment,85:99:treatment,164:172:treatment,183:225:treatment,228:265:treatment,303:322:treatment,324:332:treatment,340:352:treatment	Use of serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, ACE inhibitors or any drugs which interfere with the renin-Angiotensin system, Losartan (or other Angiotensin II type 1 receptor antagonists), non-specific calcium channel blockers (L channel specific are acceptable), anti-inflammatories, vitamins or any antioxidants
NCT02483468	1:9:upper_bound	3 months<
NCT02483468	9:20:treatment,32:39:chronic_disease	Current Medications that lower seizure threshold
NCT02483468	27:52:clinical_variable,53:57:lower_bound,60:68:lower_bound	ICD-9 Diagnosis code 724; BPI pain on average score>4/10; ≥3 months duration of pain
NCT02483468	1:6:allergy_name	Latex Allergy
NCT02483468	7:28:chronic_disease,47:55:chronic_disease	Other major medical problem (e.g., history of seizures)
NCT02483468	1:9:pregnancy	Pregnant
NCT02483468	14:33:chronic_disease	Prescription opiate use disorder
NCT02483468	1:22:chronic_disease,59:62:treatment	Psychiatric Condition Preventing successful engagement in CBT
NCT02483468	41:59:treatment	Unable or unwilling discontinue current behavioral therapy
NCT02483468	1:5:age,6:8:lower_bound,17:19:upper_bound	ages 18 through 65
NCT02483468	1:14:upper_bound,16:26:clinical_variable,28:29:lower_bound	past 6 months; COMM score >1
NCT02480114	14:24:treatment	Currently on gabapentin
NCT02480114	1:17:language_fluency	English speaking
NCT02480114	23:29:cancer,37:57:cancer	Histologically proven cancer of the head and neck cancer
NCT02480114	12:19:chronic_disease	History of seizure disorder
NCT02480114	20:51:treatment	Planned primary or adjuvant chemoradiation therapy
NCT02480114	24:34:treatment	Prior non-tolerance of gabapentin
NCT02479906	2:5:chronic_disease,34:38:clinical_variable,39:41:lower_bound,42:44:upper_bound	(MDD is not contraindicated when HDRS-21≤26)
NCT02479906	1:3:lower_bound,4:12:upper_bound,16:19:age	22-68 years of age
NCT02479906	44:75:chronic_disease	Any condition likely to be associated with increased intracranial pressure
NCT02479906	1:18:chronic_disease	Cerebral aneurysm
NCT02479906	22:25:lower_bound	Criteria D: at least 2/7 cognition & mood symptoms
NCT02479906	22:25:lower_bound	Criteria E: at least 2/6 arousal & reactivity symptoms
NCT02479906	23:26:lower_bound	Criterion B: at least 1/5 intrusion symptoms
NCT02479906	12:36:chronic_disease	History of cerebrovascular accident
NCT02479906	1:20:chronic_disease	Huntington's chorea
NCT02479906	1:5:clinical_variable,8:10:upper_bound	MMSE ≤ 24
NCT02479906	1:4:gender	Men
NCT02479906	1:19:chronic_disease	Multiple sclerosis
NCT02479906	1:19:pregnancy,41:44:age,45:50:gender	Negative pregnancy test in childbearing age women
NCT02479906	1:20:chronic_disease	Parkinson's disease
NCT02479906	71:92:chronic_disease,102:120:chronic_disease,122:148:chronic_disease,150:153:chronic_disease	Subject diagnosed according to the SCID I as suffering from any other major Axis I disorder, such as Psychotic Disorder, Bipolar affective disorder, OCD
NCT02479906	26:41:treatment	Subject has a history of cranial surgery
NCT02479906	26:34:chronic_disease,38:45:chronic_disease	Subject has a history of epilepsy or seizure
NCT02479906	38:49:chronic_disease,93:102:lower_bound	Subject has a history of significant head trauma with loss of consciousness for longer than 5 minutes
NCT02479906	38:50:chronic_disease	Subject has a history of significant hearing loss
NCT02479906	41:44:treatment	Subject has had previous treatment with TMS
NCT02479906	73:100:treatment,108:127:treatment,129:155:treatment,144:155:treatment,157:179:treatment,187:201:treatment,203:209:treatment,224:241:treatment,246:256:treatment,261:284:treatment	Subject has metallic particles in the eye or head (exclusive of mouth), implanted cardiac pacemaker or any intra-cardiac lines, implanted neurostimulators, intra-cranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps
NCT02479906	34:43:treatment	Subject is able to adhere to the treatment schedule
NCT02479906	25:39:treatment,62:66:lower_bound,70:79:clinical_variable	Subject is currently on Benzodiazepine at a dose higher than 3 mg of Lorazepam or equivalent
NCT02479906	39:61:treatment,107:120:upper_bound	Subject is currently participating in another clinical study or enrolled in another clinical study within 30 days prior to this study
NCT02479906	75:88:upper_bound	Subject with a history of substance abuse including alcoholism within the past 6 months (except nicotine and caffeine)
NCT02479906	23:39:chronic_disease,57:72:chronic_disease	Subject with unstable physical disease such as unstable cardiac disease
NCT02479906	37:44:treatment,70:90:chronic_disease	Subjects diagnosed according to the SCID II as suffering from Severe Personality Disorder
NCT02479906	29:50:chronic_disease	Subjects with a significant neurological disorder or insult
NCT02479906	18:31:clinical_variable,34:36:upper_bound	Subjects with an HDRS-21 score ≤ 26 at both Screening and Baseline visits
NCT02479906	33:37:chronic_disease,45:57:clinical_variable,60:62:lower_bound	Subjects with at least moderate PTSD with a CAPS-5 score ≥ 25 at both Screening and Baseline visits
NCT02479906	1:26:chronic_disease,34:43:upper_bound	Transient ischemic attack within two years
NCT02479906	1:6:gender,37:89:contraception_consent	Women of childbearing potential and not using a medically accepted form of contraception when sexually active
NCT02479906	1:6:gender	Women who are breast-feeding
NCT02479906	1:6:gender	women
NCT02479230	1:21:clinical_variable,24:55:upper_bound,59:67:upper_bound,83:98:cancer	Alkaline phosphatase < 2.5 upper limit of normal (ULN) (< 10 x ULN in presence of bone metastases)
NCT02479230	1:33:clinical_variable,36:69:upper_bound	Aspartate aminotransferase (AST) < 5.0 x normal institutional limits
NCT02479230	1:18:clinical_variable,21:30:upper_bound	Bilirubin (total) < 2.0 ml/dl
NCT02479230	1:11:clinical_variable,14:23:upper_bound	Creatinine < 1.5 mg/dl
NCT02479230	9:18:treatment	Current treatment on another clinical trial
NCT02479230	1:61:clinical_variable,62:63:lower_bound,64:65:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status 0-1
NCT02479230	1:17:clinical_variable,20:30:lower_bound	Hemoglobin (Hgb) ≥ 10.0 gm/dl
NCT02479230	26:39:cancer	Histologically confirmed breast cancer
NCT02479230	1:37:clinical_variable,40:43:upper_bound,75:91:treatment	International normalized ratio (INR) < 1.5, except for subjects receiving warfarin therapy
NCT02479230	7:41:chronic_disease,45:86:chronic_disease	Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
NCT02479230	31:38:chronic_disease,42:64:chronic_disease,158:168:treatment	Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
NCT02479230	38:54:cancer,73:81:treatment,137:145:lower_bound	Patients may have treated and stable brain metastases; they must be off steroids and must have had stable brain metastases for at least 6 months
NCT02479230	22:37:clinical_variable,43:51:lower_bound	Patients must have a life expectancy of > 3 months
NCT02479230	22:40:pregnancy	Patients must have a negative pregnancy test by urinalysis
NCT02479230	32:50:cancer	Patients must have evidence of metastatic disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease
NCT02479230	1:10:clinical_variable,13:25:lower_bound	Platelets > 100 x 10^9/L
NCT02479230	1:10:pregnancy	Pregnancy
NCT02479230	13:31:chronic_disease	Presence of bleeding diathesis
NCT02479230	1:18:treatment,64:72:lower_bound	Prior GEM therapy is acceptable as long as the last dose was ≥ 3 months from registration on this study
NCT02479230	1:14:clinical_variable,17:25:upper_bound	Serum calcium ≤ 12 mg/dl
NCT02479230	36:69:treatment	There is no limit to the number of prior systemic treatment regimens
NCT02479230	45:48:gender,53:58:gender	Use of an effective means of contraception (men and women) is mandated in subjects of child-bearing potential
NCT02479230	1:23:clinical_variable,26:38:lower_bound	White blood cell (WBC) > 3.0 x 10^9/L
NCT02479230	5:20:gender,61:79:pregnancy	all female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment
NCT02479230	1:16:gender,75:111:contraception_consent,133:140:treatment	female patients must be surgically sterile or be post-menopausal, or must agree to use effective contraception during the period of therapy
NCT02479230	1:16:gender,43:62:pregnancy,76:91:lower_bound	female subjects will be advised that they not become pregnant for at least one month after completing participation in the study
NCT02479230	32:40:treatment,60:69:treatment,73:83:chronic_disease	for subjects who are receiving warfarin for prophylaxis or treatment of thrombosis, INR values should be carefully monitored while patients are on study
NCT02479230	1:14:gender,23:86:contraception_consent,108:115:treatment	male patients must be surgically sterile or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
NCT02478684	11:31:chronic_disease	Any major congenital anomalies
NCT02478684	15:30:chronic_disease	Bleeding from placenta previa
NCT02478684	1:14:chronic_disease	Cord prolapse
NCT02478684	1:9:chronic_disease	Meconium
NCT02478684	27:29:lower_bound,34:46:upper_bound	Premature infants between 28 and 34 6/7 weeks
NCT02478684	1:30:chronic_disease	Suspected placental abruption
NCT02478684	1:21:chronic_disease	Terminal bradycardia
NCT02478255	1:8:chronic_disease,12:36:chronic_disease	Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
NCT02478255	30:41:treatment,83:88:lower_bound	Patient scheduled to undergo thoracic RT at Duke University to a dose of at least 20 Gy
NCT02478255	1:20:chronic_disease,61:68:upper_bound	Respiratory illness of a bacterial or viral etiology within 30 days of MRI
NCT02478255	31:49:chronic_disease	Subject has any form of known cardiac arrhythmia
NCT02478255	22:30:upper_bound	Subject is less than 18 years old
NCT02478255	12:20:pregnancy	Subject is pregnant
NCT02478255	76:95:chronic_disease	Subject meets all criteria above but does not have a clinical diagnosis of respiratory disease
NCT02477826	23:40:chronic_disease,44:61:chronic_disease,65:99:chronic_disease,111:137:chronic_disease	Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection
NCT02477826	1:61:clinical_variable,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1
NCT02477826	23:25:treatment,29:32:treatment,69:81:cancer	Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
NCT02477826	45:63:chronic_disease	Subjects with an active, known or suspected autoimmune disease
NCT02477826	25:64:cancer	Subjects with untreated Central nervous system (CNS) metastases
NCT02477826	11:25:cancer,29:41:cancer	recurrent NSCLC squamous or non-squamous histology
NCT02477826	9:42:treatment	with no prior systemic anticancer therapy
NCT02469662	1:9:lower_bound,13:16:age	18 years of age or older
NCT02469662	10:30:chronic_disease,32:46:chronic_disease,51:73:chronic_disease	Advanced rheumatoid arthritis, post-traumatic, or degenerative arthritis with incapacitating pain
NCT02469662	1:10:chronic_disease,49:58:chronic_disease,89:95:chronic_disease	Ankylosed joints, especially cases of bilateral ankylosis from causes other than active sepsis
NCT02469662	97:111:chronic_disease	Instability or loss of motion when the degree of joint or soft tissue damage precludes reliable osteosynthesis
NCT02469662	23:38:chronic_disease	Patient has a current major infection distant from the operative site
NCT02469662	61:70:chronic_disease	Patient has a currently active or history of repeated local infection at the surgical site
NCT02469662	32:38:chronic_disease	Patient has a history of prior sepsis
NCT02469662	25:53:chronic_disease	Patient has significant ipsilateral hand dysfunction
NCT02469662	176:183:treatment	Patient information available for each retrospective patient must, at minimum, include preoperative demographic information, preoperative physical exam information, the index surgery operative report, and details of the devices implanted
NCT02469662	28:72:treatment	Patient is a candidate for primary or revision total elbow arthroplasty
NCT02469662	12:32:pregnancy	Patient is known to be pregnant
NCT02469662	12:32:chronic_disease	Patient is mentally incompetent or unable to understand what participation in the study entails
NCT02469662	31:54:treatment,64:69:treatment,85:94:lower_bound	Patient must have undergone a total elbow replacement with the Nexel system between July 2013 and the date of the site initiation visit
NCT02469662	22:31:chronic_disease,35:78:chronic_disease	Patient suffers from paralysis or dysfunctional neuropathy at the elbow joint
NCT02465541	54:64:lower_bound	Ambulatory or able to engage in walking for at least 15 minutes
NCT02465541	25:47:chronic_disease,49:57:chronic_disease,59:77:chronic_disease,94:109:chronic_disease	Concurrent diagnosis of organic brain syndrome, dementia, mental retardation, or significant sensory deficit
NCT02465541	12:29:upper_bound	Currently (previous 6 months) engaged in structured exercise either aerobic or yoga based
NCT02465541	1:17:language_fluency	English speaking
NCT02465541	1:21:chronic_disease,29:42:chronic_disease,44:69:chronic_disease	Major mental illness (e.g., schizophrenia, major depressive disorder)
NCT02465541	10:35:cancer	No prior type I endometrial cancer diagnosis
NCT02465541	1:11:clinical_variable,15:20:chronic_disease,24:33:lower_bound	Overweight or obese (> 25 kg/m^2)
NCT02465541	23:83:cancer,85:99:cancer,121:142:treatment,147:156:treatment	Previous diagnosis of grade 1 or 2, stage I or II endometrioid endometrial cancers (type I cancers) as confirmed during surgical intervention for treatment
NCT02465541	26:32:cancer	Prior diagnosis of other cancer
NCT02465541	47:58:upper_bound	Sedentary lifestyle, as engaging in less than 100 minutes structured aerobic walking
NCT02465541	17:33:chronic_disease,58:79:chronic_disease,89:104:chronic_disease,118:142:chronic_disease,144:169:chronic_disease	Severe heart or systemic disease: evidence of documented myocardial infarction, chronic unstable angina, symptomatic congestive heart failure, uncontrolled hypertension
NCT02465541	8:31:chronic_disease,40:65:chronic_disease	Severe musculoskeletal disease: severe muscle or joint disorders due to disease or trauma, amputations, or any condition that significantly impair physical capabilities, as defined by the physician
NCT02460653	1:4:age,6:11:lower_bound,15:34:lower_bound,48:56:upper_bound	Age: 1 day (> 38 weeks GA neonate or older) to 17 years
NCT02460653	32:36:treatment,41:48:chronic_disease	All patients who are receiving HFNC for hypoxia
NCT02460653	69:89:treatment,93:112:treatment	Patient who the medical team feels may require urgent escalation of non-invasive therapy or imminent intubation
NCT02460653	20:31:upper_bound	Patients less than 3 kilograms
NCT02460653	20:28:upper_bound,29:44:clinical_variable	Patients less than 38 weeks gestational age
NCT02460653	18:35:chronic_disease,55:77:treatment	Patients who are immunocompromised and/or status post bone marrow transplant
NCT02460653	21:25:clinical_variable,28:31:lower_bound	Patients who are on FIO2 > 0.6 at the highest level of flow offered within the study
NCT02460653	19:43:chronic_disease	Patients who have congenital heart defects
NCT02458014	40:62:cancer	Active central nervous system (CNS) or extramedullary disease
NCT02458014	1:10:clinical_variable,33:42:upper_bound	Bilirubin less than or equal to 3.0 mg/dL
NCT02458014	1:21:clinical_variable,25:37:lower_bound	Creatinine clearance >= 30 ml/minute
NCT02458014	13:57:chronic_disease	Known to be human immunodeficiency virus positive (HIV+)
NCT02458014	1:30:treatment,38:52:upper_bound	Monoclonal antibodies therapy within 2 weeks before study entry
NCT02458014	26:36:cancer	No active or co-existing malignancy
NCT02458014	15:28:cancer,120:123:cancer,149:161:treatment,282:290:upper_bound,294:311:treatment,313:358:chronic_disease,396:412:lower_bound	Patients with B-lineage ALL in hematologic complete remission (CR) with molecular failure (i.e., had never achieved an MRD-negativity status before blinatumomab) or had a molecular relapse (i.e., became MRD positive after having been MRD negative) starting at any time point after 3 months of frontline therapy; molecular disease or minimal residual disease is defined by a value of at least of 1 x 10-4 (0.01%) by multicolor flow cytometry and/or by next generation sequencing (NGS)
NCT02458014	15:57:cancer,61:96:treatment,102:119:chronic_disease,178:190:treatment,305:319:upper_bound,323:340:treatment,342:359:chronic_disease,363:387:cancer,425:434:lower_bound	Patients with B-lineage acute lymphocytic leukemia (ALL) in hematologic complete remission (CR) with molecular failure (i.e., had never achieved an MRD-negativity status before blinatumomab) or had a molecular relapse (i.e., became MRD positive after having been MRD negative) starting at any time point after 3 months of frontline therapy; molecular disease or minimal residual disease is defined by a value of at least of 1 x 10^-4 (0.01%) by multicolor flow cytometry and/or by next generation sequencing (NGS)
NCT02458014	15:57:cancer,102:133:treatment,193:196:clinical_variable,242:246:lower_bound	Patients with Philadelphia chromosome positive (Ph+) ALL can be enrolled in CR1 or CR2 and beyond; a tyrosine kinase inhibitor (TKI) will be added at the discretion of the treating physician; MRD for these patients will be defined by PCR of 0.1% and above (International Scale)
NCT02458014	1:19:clinical_variable,23:24:lower_bound,32:33:upper_bound	Performance status of 0, 1, or 2
NCT02458014	1:9:pregnancy	Pregnant
NCT02458014	1:37:treatment,90:133:treatment,135:149:treatment,151:163:treatment,165:173:treatment,182:202:treatment,210:217:upper_bound	Radiotherapy and cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within 2 weeks before study entry
NCT02458014	1:16:clinical_variable,27:36:upper_bound	life expectancy less than 12 months
NCT02458014	9:14:gender	nursing women
NCT02445339	1:19:chronic_disease,21:58:clinical_variable,60:93:lower_bound	Acute liver injury (liver aminotransferase concentrations >5 times the upper limit of normal)
NCT02445339	33:49:treatment	Acute or chronic pain requiring opioid treatment
NCT02445339	1:5:age,6:8:lower_bound,9:11:upper_bound	Aged 18-80
NCT02445339	22:37:treatment,76:85:treatment,95:122:chronic_disease	Currently prescribed pharmacotherapy for alcohol dependence (not including treatment of acute alcohol withdrawal syndrome)
NCT02445339	1:28:language_fluency	English or Spanish speaking
NCT02445339	7:18:lower_bound,39:51:lower_bound	Have ≥2 days/week of heavy drinking (>4 drinks/day)
NCT02445339	1:38:language_fluency	Non-English Spanish speaking patients will not be enrolled initially until study documents have been translated, back translated, and approved by the Institutional Review Board (IRB)
NCT02445339	1:9:pregnancy	Pregnant
NCT02445339	42:52:allergy_name,56:63:allergy_name	Previous significant adverse reaction to naltrexone or diluent
NCT02445339	1:45:contraception_consent	not using effective methods of birth control
NCT02444689	1:24:chronic_disease,26:45:chronic_disease	Neurological impairment/ developmental delay
NCT02444689	18:46:treatment	New / changes in anti-hypertensive medication
NCT02444689	1:29:technology_access	No smart phone / smart phone data plan
NCT02444689	15:20:chronic_disease	Overweight or Obese
NCT02444689	1:10:pregnancy	Pregnancy
NCT02444689	20:44:chronic_disease,48:54:cancer	Prior diagnosis of congenital heart disease or cancer
NCT02444689	1:15:language_fluency	Speaks English
NCT02444689	54:67:upper_bound	medication known to affect blood pressure within the last 6 months
NCT02437110	1:4:chronic_disease	ALS diagnosed as probable, laboratory-supported probable or definite according to the World Federation of Neurology El Escorial revised criteria32 as determined by a neurologist with neuromuscular subspecialty training
NCT02437110	1:4:age,5:13:lower_bound	Age 18 years or older at the time of the screening visit
NCT02437110	1:31:clinical_variable,35:67:clinical_variable,81:116:lower_bound	Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3.0 times the upper limit of normal for the NIH Clinical Center
NCT02437110	1:16:clinical_variable,30:65:lower_bound	Creatine kinase greater than 3.0 times the upper limit of normal for the NIH Clinical Center
NCT02437110	1:9:chronic_disease	Dementia
NCT02437110	83:125:treatment,129:169:treatment	Dependence on daytime mechanical ventilation (invasive or non-invasive, including Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPap) at the time of the screening visit
NCT02437110	12:29:clinical_variable,55:69:lower_bound,98:101:treatment	Detectable HERV-K viral load in blood at a minimum of 1000 copies/ml as measured by quantitative PCR at the screening visit
NCT02437110	1:18:chronic_disease	Diabetes mellitus
NCT02437110	1:37:clinical_variable,39:46:upper_bound	Estimated glomerular filtration rate <60mg/dl
NCT02437110	1:11:clinical_variable,13:20:upper_bound	Hemoglobin <10mg/dL
NCT02437110	1:11:chronic_disease	Hemophilia
NCT02437110	29:40:treatment	History of having undergone gastrostomy at the time of screening
NCT02437110	62:65:chronic_disease,69:75:chronic_disease	History of positive test or positive result at screening for HIV or HTLV-1
NCT02437110	11:19:treatment,23:32:treatment,72:85:lower_bound	If taking riluzole or edaravone, must be on a stable dose for at least 30 days prior to the screening visit, or stopped taking riluzole or edaravone at least 30 days prior to the screening visit
NCT02437110	7:18:allergy_name	Known sulfonamide allergy
NCT02437110	1:3:clinical_variable,8:11:clinical_variable,13:48:lower_bound	PT and PTT >1.2 times the upper limit of normal for the NIH Clinical Center
NCT02437110	22:54:treatment,28:48:treatment,93:107:upper_bound	Participation in any other investigational drug trial or using investigational drug (within 12 weeks prior to Screening and thereafter)
NCT02437110	1:23:clinical_variable,28:44:upper_bound	Platelet concentration of <100,000/ (micro)l
NCT02437110	10:21:chronic_disease,42:53:chronic_disease	Positive Hepatitis B Surface Antigen and Hepatitis C Virus Antibody
NCT02437110	1:17:clinical_variable,19:36:clinical_variable,38:51:clinical_variable,53:66:clinical_variable,68:83:clinical_variable,85:98:clinical_variable,100:107:clinical_variable,112:118:clinical_variable,132:167:lower_bound	Serum creatinine, serum phosphorous, urine glucose, urine protein, total bilirubin, triglycerides, amylase, or lipase greater than 2.0 times the upper limit of normal for the NIH Clinical Center
NCT02437110	1:24:clinical_variable,35:42:upper_bound	Time from symptom onset less than 2 years
NCT02437110	10:25:chronic_disease,35:50:chronic_disease,54:91:chronic_disease,97:122:chronic_disease,132:143:chronic_disease,147:159:chronic_disease,173:183:cancer	Unstable medical disease (such as unstable angina or chronic obstructive pulmonary disease), or active infectious disease (such as Hepatitis C or tuberculosis), or current malignancy
NCT02437110	10:29:chronic_disease,41:50:chronic_disease,64:80:chronic_disease,88:95:upper_bound	Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit
NCT02437110	37:47:treatment,49:60:treatment,62:72:treatment,74:85:treatment,87:95:treatment,97:108:treatment,110:119:treatment,121:130:treatment,132:140:treatment,142:151:treatment,153:162:treatment,164:181:treatment,171:181:treatment,183:193:treatment,207:223:treatment,225:240:treatment,242:251:treatment,253:263:treatment,265:275:treatment,280:311:chronic_disease,313:326:treatment,328:341:treatment,343:352:treatment,356:366:treatment	Use of contraindicated medications: amiodarone, dronedarone, lovastatin, simvastatin, rifampin, rifapentine, rifabutin, cisapride, pimozide, midazolam, triazolam, dihydroergotamine, ergonovine, ergotamine, methylergonovine, St. John s wort, alfuzosin, salmeterol, sildenafil for pulmonary arterial hypertension, oxcarbazepine, phenobarbital, phenytoin or dofetilide
NCT02437110	71:81:treatment	competent caregiver who can and will be responsible for administering study drug
NCT02437110	5:17:treatment,29:43:upper_bound	had neuroimaging within the last 18 months
NCT02437110	35:53:pregnancy	hildbearing potential must have a negative pregnancy test at screening and be non-lactating
NCT02437110	6:36:pregnancy,73:81:lower_bound,106:145:contraception_consent,302:310:lower_bound	must not be able to become pregnant (e.g., post-menopausal for at least one year, surgically sterile, or using adequate methods of contraception) or breastfeed for the duration of the study. Adequate methods of contraception include: implanted contraception, intrauterine device in place for at least 3 months, or barrier method in conjunction with spermicide
NCT02435667	23:28:chronic_disease	Clinical diagnosis of HFpEF
NCT02435667	27:29:upper_bound	Current non-smokers with <15 pack year history
NCT02435667	1:18:clinical_variable,20:23:lower_bound	Ejection fraction ≥40%
NCT02435667	1:11:clinical_variable,14:21:upper_bound	Hemoglobin < 7.0 g/d
NCT02435667	1:13:pregnancy,14:19:gender	Non-pregnant women
NCT02435667	10:12:lower_bound,13:19:upper_bound,72:84:upper_bound,111:119:lower_bound	Patients 18-80 yrs old with a history stable (no medication changes in past 6 weeks (w/duration of diagnosis >6 months)
NCT02435667	13:33:chronic_disease	Significant cognitive impairment
NCT02435667	78:101:chronic_disease	individuals who are able to exercise (i.e. without orthopedic limitations or neuromuscular disorders)
NCT02416206	1:4:age,13:15:lower_bound,18:26:upper_bound	Age between 18 - 70 years
NCT02416206	66:70:treatment,88:96:lower_bound	Availability of Cryopreserved peripheral blood stem cells with a CD34 dose of at least 2x106/kg
NCT02416206	14:30:cancer	Diagnosis of Multiple Myeloma
NCT02416206	1:17:clinical_variable,20:23:lower_bound	Karnofsky status ≥ 70%
NCT02416206	19:37:chronic_disease,46:62:chronic_disease,63:78:chronic_disease,89:123:chronic_disease	Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
NCT02416206	36:66:chronic_disease	Patients who have any debilitating medical or psychiatric illness which would preclude their giving informed consent or their receiving optimal treatment and follow-up
NCT02416206	24:58:clinical_variable,60:63:upper_bound	Poor cardiac function: left ventricular ejection fraction <40%
NCT02416206	22:31:clinical_variable,33:42:lower_bound,55:64:chronic_disease,66:97:chronic_disease,100:103:clinical_variable,104:107:clinical_variable,110:116:lower_bound	Poor liver function: bilirubin >2.5 mg/dl (not due to hemolysis, Gilbert's or primary malignancy), AST/ALT > 3X ULN
NCT02416206	26:30:clinical_variable,32:35:clinical_variable,40:44:clinical_variable,46:49:upper_bound	Poor pulmonary function: FEV1, FVC, or DLCO <40% predicted
NCT02416206	22:32:clinical_variable,34:43:lower_bound,47:67:clinical_variable,70:79:upper_bound	Poor renal function: Creatinine >2.0 mg/dl or creatinine clearance < 40 mL/min (calculated creatinine clearance is permitted)
NCT02416206	8:16:upper_bound,43:55:treatment	Within 9 months of the start of induction chemotherapy and no evidence of relapse or progression
NCT02416206	1:6:gender,37:59:pregnancy,71:108:contraception_consent	Women of childbearing potential who currently are pregnant or who are not practicing adequate contraception
NCT02415660	112:121:treatment,142:143:lower_bound,144:156:upper_bound,221:222:lower_bound,223:235:upper_bound	Able to make one initial appointment at the Army Medical Department Center and School at Fort Sam Houston, one treatment visit approximately 2-3 days after the initial visit, and then a final outcome visit approximately 5-7 days after 2nd visit
NCT02415660	1:4:age,5:7:lower_bound,8:16:upper_bound	Age 18-64 years
NCT02415660	5:27:treatment,29:41:treatment,43:63:treatment,68:78:treatment,104:117:upper_bound	Any prior physical therapy, chiropractic, acupuncture treatment or injections for neck pain within the past 3 months
NCT02415660	1:8:gender,32:40:pregnancy	Females known or thought to be pregnant
NCT02415660	16:33:chronic_disease,43:70:treatment,75:78:treatment,110:122:chronic_disease,124:142:chronic_disease,146:170:treatment	History of any systemic disorder in which thoracic spine manipulation and TDN would be contraindicated (i.e. osteoporosis, bleeding disorders or anticoagulant medication use)
NCT02415660	12:34:treatment	History of cervical spine surgery
NCT02415660	1:41:language_fluency	Inability to read and understand English
NCT02415660	14:16:upper_bound,15:16:lower_bound,27:29:upper_bound,44:65:clinical_variable	No less than 10 points (0-50 range) on the Neck Disability Index
NCT02415660	18:33:chronic_disease,72:89:treatment	Prior history of whiplash injury resulting in neck pain which required medical treatment
NCT02415660	126:155:chronic_disease,162:171:chronic_disease,173:190:chronic_disease,192:207:chronic_disease,212:247:chronic_disease	Signs and symptoms consistent with nerve root compression (i.e. diminished upper extremity strength, sensation or reflexes), cervical artery insufficiency (i.e. nystagmus, gait disturbances, Horner Syndrome) or upper cervical ligament instability (i.e. Sharp-Purser, alar ligament, transverse ligament tests)
NCT02415387	30:40:cancer,48:53:cancer,57:83:cancer,85:92:chronic_disease,94:102:chronic_disease,112:125:chronic_disease,142:154:chronic_disease,156:183:chronic_disease,185:198:chronic_disease,200:210:chronic_disease,218:239:chronic_disease,250:270:chronic_disease,275:293:chronic_disease,381:398:chronic_disease,400:419:chronic_disease,421:446:chronic_disease,454:475:chronic_disease	A prior history of any other malignancy except basal or squamous cell skin cancers, strokes, diabetes, current heart disease or uncontrolled hypertension, peripheral vascular disease, liver disease, autoimmune and/or inflammatory diseases including rheumatoid arthritis and ulcerative colitis, and other medical conditions that would limit participation in the assessments (e.g., pulmonary disease, orthopedic problems, major psychiatric illness, major cognitive dysfunction, or an acute medical problem)
NCT02415387	5:10:gender	All women will be postmenopausal
NCT02415387	1:7:chronic_disease	Anemia
NCT02415387	1:11:treatment,36:44:treatment,56:63:treatment,74:85:treatment,91:108:treatment	Medication exclusions will include steroids as well as statins and other medications with anti-inflammatory actions
NCT02415387	1:6:gender,36:43:lower_bound,44:48:upper_bound,49:62:cancer,81:82:lower_bound,83:97:upper_bound,120:144:treatment,156:186:treatment,188:197:treatment,199:219:treatment	Women who have been diagnosed with stage I-IIIA breast cancer will be recruited 1-10 years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors)
NCT02415387	1:6:gender,27:42:treatment,54:70:upper_bound	Women who have received a typhoid vaccine within the last three years
NCT02409485	12:24:treatment,29:32:cancer	initiating radiotherapy for HNC
NCT02409485	13:28:clinical_variable,31:33:lower_bound	patient has Karnofsky score > 50 (ambulatory & capable of self-care)
NCT02409485	17:64:language_fluency	patient/partner cannot read or communicate using spoken English
NCT02409485	22:25:age,26:28:lower_bound	patient/partner is > age 18
NCT02409485	1:9:pregnancy,10:15:gender	pregnant women
NCT02408861	1:22:clinical_variable,27:34:upper_bound,43:56:upper_bound	AST (SGOT)/ALT (SGPT): =< 3 x ULN (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)
NCT02408861	1:53:clinical_variable,54:103:clinical_variable,108:115:upper_bound,124:137:upper_bound	AST (serum glutamic oxaloacetic transaminase [SGOT])/ALT (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN (within 2 weeks prior to enrollment)
NCT02408861	1:26:clinical_variable,30:40:lower_bound,49:62:upper_bound	Absolute neutrophil count >= 1,000/mm^3 (within 2 weeks prior to enrollment)
NCT02408861	1:15:clinical_variable,28:42:upper_bound	CD4 cell count of at least 100 cells/mm^3
NCT02408861	1:11:clinical_variable,14:21:upper_bound,25:52:clinical_variable,55:64:lower_bound,73:86:upper_bound	Creatinine < 1.5 UNL or creatinine clearance (CrCl) > 50 ml/min (within 2 weeks prior to enrollment)
NCT02408861	1:11:clinical_variable,15:45:upper_bound,49:53:clinical_variable,56:64:lower_bound,73:86:upper_bound	Creatinine: < 1.5 x upper normal limit (UNL) or CrCl > 50ml/min (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)
NCT02408861	1:61:clinical_variable,65:66:upper_bound,68:77:clinical_variable,81:84:lower_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
NCT02408861	16:31:clinical_variable,45:59:lower_bound,76:89:upper_bound	For Stratum 1: CD4+ cell count greater than 200 cells/mm^3 obtained within 2 weeks prior to enrollment at any United States (U.S.) laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent
NCT02408861	16:30:clinical_variable,39:42:lower_bound,43:57:upper_bound,74:87:upper_bound	For Stratum 2: CD4 cell count between 100-200 cells/mm^3 obtained within 2 weeks prior to enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent
NCT02408861	40:51:cancer,120:129:treatment,139:147:cancer,149:157:cancer,163:208:cancer	For participants in the 24 participant solid tumor cohort, only those histologies not known to respond to single agent nivolumab (such as pancreas, prostate, and microsatellite stable [MSS] colorectal cancer)
NCT02408861	1:4:chronic_disease,111:123:upper_bound,186:199:upper_bound	HIV viral load should be well suppressed, defined as below the limit of detection of the local assay or below 75 copies/mL by Food and Drug Administration (FDA)-approved assays, within 4 weeks prior to registration
NCT02408861	1:4:chronic_disease,1:16:chronic_disease,68:82:treatment,127:168:treatment	HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status
NCT02408861	1:11:clinical_variable,15:21:lower_bound,30:43:upper_bound	Hemoglobin >= 9 g/dL (within 2 weeks prior to enrollment)
NCT02408861	102:112:allergy_name,114:123:allergy_name,210:229:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or other agents used in study, or history of severe hypersensitivity reaction to any monoclonal antibody
NCT02408861	1:16:clinical_variable,41:54:upper_bound,97:140:clinical_variable	Leukocyte count: no lower limit (within 2 weeks prior to enrollment) (participants may receive granulocyte colony stimulating factor [GCSF] and transfusions to meet these parameters)
NCT02408861	1:11:upper_bound,15:25:lower_bound,34:47:upper_bound	Leukocytes >= 2,000/mm^3 (within 2 weeks prior to enrollment)
NCT02408861	48:57:treatment,62:65:chronic_disease,62:75:chronic_disease,87:113:treatment	Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management
NCT02408861	49:71:cancer,80:90:cancer	Participants must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
NCT02408861	64:67:lower_bound,123:132:clinical_variable,142:150:clinical_variable,174:187:clinical_variable,228:233:lower_bound,272:277:lower_bound,283:319:treatment,321:353:treatment,358:366:treatment	Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
NCT02408861	23:34:chronic_disease,55:78:chronic_disease,74:77:chronic_disease,135:146:chronic_disease,268:283:clinical_variable,290:313:upper_bound,319:329:clinical_variable,334:344:clinical_variable,356:395:upper_bound,401:452:clinical_variable,455:464:upper_bound,498:511:upper_bound	Participants who have hepatitis C (both reactive anti-hepatitis C virus [HCV] antibody and detectable HCV ribonucleic acid [RNA]) and hepatitis B (hepatitis B surface antigen [HBsAg] positive and anti-hepatitis B core [HBc]-total positive), may be enrolled, provided total bilirubin is =< 1.5 x institutional ULN, and AST (SGOT) and ALT (SGPT) must be =< 3 X institutional upper limit of normal, and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) < 100 IU/mL (if hepatitis B positive) within 2 weeks prior to enrollment
NCT02408861	42:64:treatment,76:89:upper_bound,105:133:treatment	Participants who have received any other investigational agents within the 4 weeks prior to enrollment; concurrent radiation therapy
NCT02408861	56:68:chronic_disease	Participants with clinical or radiographic evidence of pancreatitis
NCT02408861	1:10:clinical_variable,14:25:lower_bound,34:47:upper_bound	Platelets >= 75,000/mm^3 (within 2 weeks prior to enrollment)
NCT02408861	1:10:clinical_variable,15:26:lower_bound,81:89:cancer,98:111:upper_bound,153:157:clinical_variable	Platelets: >= 75,000/mm^3, unless decreased due to bone marrow involvement with lymphoma (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)
NCT02408861	1:14:treatment,19:37:cancer	Prior therapy for metastatic disease
NCT02408861	45:60:cancer	Repeat imaging demonstrates no new sites of bone metastases
NCT02408861	1:14:clinical_variable,18:26:lower_bound,35:48:upper_bound	Serum albumin >= 2.8 g/dL (within 2 weeks prior to enrollment)
NCT02408861	1:25:clinical_variable,28:37:upper_bound,46:59:upper_bound	Serum lipase and amylase < 1.5 x ULN (within 2 weeks prior to enrollment)
NCT02408861	1:25:clinical_variable,28:37:upper_bound,46:59:upper_bound,101:105:treatment	Serum lipase and amylase < 1.5 x ULN (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)
NCT02408861	1:12:cancer,31:46:clinical_variable,60:74:lower_bound,91:104:upper_bound	Solid Tumor Expansion Cohort: CD4+ cell count greater than 200 cells/mm^3 obtained within 2 weeks prior to enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent
NCT02408861	16:25:treatment,30:40:treatment,118:136:treatment,172:183:treatment,185:190:gender,187:190:gender,238:273:contraception_consent,275:318:contraception_consent,320:330:contraception_consent,443:452:pregnancy,457:471:upper_bound,489:509:treatment	The effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug
NCT02408861	33:53:treatment	The lesion being considered for palliative radiation is not a target lesion
NCT02408861	1:16:clinical_variable,20:67:upper_bound,71:78:upper_bound,97:114:chronic_disease,123:133:treatment,138:147:treatment,169:187:chronic_disease,289:304:clinical_variable,315:324:upper_bound,333:346:upper_bound	Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) =< 3 x ULN for subjects with Gilbert's disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation and must have a total bilirubin less than 3.0 mg/dL (within 2 weeks prior to enrollment)
NCT02408861	1:16:clinical_variable,20:67:upper_bound,75:82:upper_bound,105:122:chronic_disease,131:141:treatment,146:155:treatment,164:195:treatment,204:207:clinical_variable,211:214:clinical_variable,242:257:clinical_variable,268:277:upper_bound,287:300:upper_bound	Total bilirubin: =<1.5 x institutional upper limit of normal (ULN), or =< 3 x ULN for participants with Gilbert's disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without AST or ALT elevation, and must have a total bilirubin less than 3.0 mg/dL) (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)
NCT02408861	77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,183:201:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02408861	17:26:treatment,49:72:contraception_consent,89:103:upper_bound	WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 6 months after the last dose of investigational product
NCT02408861	19:50:treatment,67:78:allergy_name,87:96:treatment,182:198:clinical_variable	a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen)
NCT02408861	1:18:treatment	anabolic steroids
NCT02408861	50:66:allergy_name	delayed-type hypersensitivity reaction caused by contact allergen
NCT02408861	23:37:cancer,69:73:lower_bound,174:198:treatment,200:208:treatment,213:244:treatment	for participants with Kaposi sarcoma, the following apply: at least five measurable cutaneous KS lesions or any number of lesions with systemic unresectable disease with no previous local radiation, surgical, or intralesional cytotoxic therapy that would prevent response assessment
NCT02408861	1:4:gender,15:24:treatment,86:109:contraception_consent,126:140:upper_bound,158:181:treatment	men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product
NCT02408861	1:4:gender,45:73:contraception_consent,81:93:clinical_variable,107:118:upper_bound	men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year
NCT02408861	1:45:treatment	palliative (limited-field) radiation therapy
NCT02408861	45:70:treatment,155:162:treatment,170:177:treatment,207:214:lower_bound,262:270:upper_bound	participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment
NCT02408861	32:46:cancer,62:64:cancer,92:97:treatment,102:117:treatment,147:155:lower_bound,213:221:lower_bound	participants with uncontrolled Kaposi sarcoma are permitted (KS must be increasing despite HAART and HIV suppression for greater than or equal to 2 months, or stable KS despite HAART for greater than or equal to 3 months
NCT02408861	1:13:treatment,41:54:lower_bound	radiotherapy must be completed at least 4 weeks prior to registration
NCT02408861	39:52:upper_bound	scans must have been performed within 4 weeks prior to registration
NCT02408861	47:60:chronic_disease	the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection
NCT02408861	66:69:chronic_disease,141:152:treatment	the result must be obtained within 12 weeks prior to enrollment; PPD positive (or Quantiferon assay positive) participants are permitted if prophylaxis has been completed prior to enrollment
NCT02408861	8:25:treatment	use of anabolic steroids
NCT02408861	1:6:gender	women must not be breastfeeding
NCT02408861	1:6:gender,45:78:pregnancy,105:112:lower_bound,166:169:clinical_variable,179:193:upper_bound,222:231:treatment	women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropic [HCG]) within 72 hours prior enrollment and the start of nivolumab
NCT02408120	2:11:upper_bound,43:64:chronic_disease	<400 mg/dL without laboratory evidence of diabetic ketoacidosis
NCT02408120	1:21:clinical_variable,31:37:lower_bound	Blood glucose levels between >140 mg
NCT02408120	21:36:chronic_disease	Clinically relevant hepatic disease
NCT02408120	1:23:treatment	Corticosteroid therapy
NCT02408120	36:44:chronic_disease	Hyperglycemia without a history of diabetes
NCT02408120	18:42:chronic_disease,48:56:lower_bound	Known history of Type 2 diabetes mellitus for >3 months
NCT02408120	1:10:pregnancy	Pregnancy
NCT02408120	1:17:clinical_variable,20:29:lower_bound	Serum creatinine ≥ 3.5 mg/dL
NCT02408120	31:47:treatment	Subjects receiving continuous insulin infusion
NCT02408120	15:37:chronic_disease	Subjects with acute critical illness admitted to the ICU or expected to require ICU admission
NCT02408120	20:44:treatment	any combination of oral antidiabetic agents
NCT02408120	1:33:clinical_variable,35:37:upper_bound	glomerular filtration rate (GFR) <30
NCT02408120	1:16:treatment	insulin therapy
NCT02408120	1:24:treatment	non-insulin injectables
NCT02400554	4:12:lower_bound,16:19:age	Be 18 years of age or older
NCT02400554	41:51:lower_bound	Be able to walk unassisted for at least 10 minutes
NCT02400554	88:100:upper_bound	Have tried any tobacco, alcohol, or drugs OR ever felt out of control with any food in past 5 years
NCT02400554	18:23:gender	Self-identify as women
NCT02400554	1:6:gender,30:37:treatment,45:51:treatment,53:69:treatment,134:142:treatment,144:153:treatment	Women who are actively using opioids (i.e., heroin) methamphetamines and/or abusing prescription drugs not prescribed to them (e.g., Dilaudid, Oxycontin) or alcohol dependent (5+ bottles/glasses of alcohol a day)
NCT02400554	1:6:gender,19:38:chronic_disease	Women who exhibit serious psychiatric symptoms determined by CNO trained staff
NCT02400554	1:6:gender,21:29:chronic_disease,33:46:upper_bound,52:70:pregnancy	Women who have been suicidal in past 3 months, are currently pregnant, or are denied medical approval
NCT02398240	2:13:lower_bound,17:20:age	>29.99 years of age
NCT02398240	1:4:age,6:12:upper_bound	Age ≤1 year
NCT02398240	8:17:clinical_variable,20:51:upper_bound,65:75:clinical_variable,79:89:clinical_variable,91:98:upper_bound	Direct bilirubin < 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT (ALT) <3 x ULN
NCT02398240	1:18:clinical_variable,23:26:lower_bound,30:52:treatment,56:70:treatment	Ejection fraction of >50% by radionuclide angiogram or echocardiogram
NCT02398240	1:8:gender,17:25:pregnancy,36:39:treatment	Females who are pregnant (positive HCG)
NCT02398240	4:43:treatment,75:98:treatment,101:108:upper_bound,114:147:cancer	No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (<1000cGy) for superior vena cava (SVC) syndrome
NCT02398240	1:24:clinical_variable,34:37:age,41:61:age,63:80:lower_bound	Normal Serum creatinine based on age or creatinine clearance >60 ml/min/1.73 m2
NCT02398240	1:20:clinical_variable,22:25:lower_bound	Shortening fraction >27% by echocardiogram
NCT02398240	25:57:clinical_variable	equivalent radioisotope glomerular filtration rate (GFR) as determined by the institutional normal range
NCT02398240	12:20:lower_bound,22:37:clinical_variable,42:44:lower_bound	patients > 16 years, Karnofsky score of ≥60
NCT02398240	10:13:age,14:15:lower_bound,16:24:upper_bound,26:38:clinical_variable,43:45:lower_bound	patients age 1-16 years, Lansky score of ≥60
NCT02394028	4:17:upper_bound	</=8 weeks prior to screening
NCT02394028	76:94:chronic_disease,96:117:chronic_disease,119:138:chronic_disease,140:169:chronic_disease,171:197:chronic_disease,211:236:chronic_disease,242:262:chronic_disease	A history of, or current conditions affecting the digestive tract, such as ulcerative colitis, indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome
NCT02394028	57:80:treatment	Any major episode of infection requiring treatment with intravenous antibiotics
NCT02394028	5:49:treatment,57:118:treatment	Any prior treatment with anti-adhesion molecules (e.g., anti-mucosal addressin cell adhesion molecule [anti-MAdCAM-1])
NCT02394028	5:37:treatment,45:59:upper_bound	Any prior treatment with ustekinumab within 14 weeks prior to randomization
NCT02394028	1:35:chronic_disease	Chronic hepatitis B or C infection
NCT02394028	1:9:chronic_disease,21:23:chronic_disease	Fistulas related to CD
NCT02394028	28:70:treatment,82:93:treatment,95:106:treatment,112:122:treatment	Has received non-permitted inflammatory bowel disease (IBD) therapies (including natalizumab, vedolizumab, and efalizumab, as stated in the protocol)
NCT02394028	1:10:treatment,14:23:treatment	Ileostomy or colostomy
NCT02394028	14:32:chronic_disease	Intolerance, refractory disease
NCT02394028	31:33:chronic_disease,55:59:treatment	Moderately to severely active CD as determined by the CDAI
NCT02394028	9:16:treatment	Planned surgery for CD
NCT02394028	1:49:treatment,54:56:chronic_disease,86:95:chronic_disease	Treatment with antibiotics as adjunctive therapy for CD in the absence of documented infection
NCT02394028	1:31:contraception_consent	Use of effective contraception as defined by the protocol
NCT02394028	11:30:chronic_disease,67:109:treatment	active or latent tuberculosis (participants with prior history of Bacillus Calmette-Guérin [BCG] vaccination must pass protocol-defined screening criteria)
NCT02394028	1:17:treatment,25:32:upper_bound	anti-TNF therapy within 5 years from screening
NCT02394028	1:35:chronic_disease	human immunodeficiency virus (HIV)
NCT02394028	28:46:allergy_name,134:136:allergy_name,140:150:allergy_name	intolerance to one or more anti-TNF therapies are eligible to participate in the study provided they are intolerant or refractory to CS or IS therapy
NCT02394028	1:17:clinical_variable,21:34:upper_bound	oral antibiotics </=4 weeks prior to screening
NCT02389517	1:32:clinical_variable,36:48:lower_bound	Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
NCT02389517	7:16:chronic_disease,27:51:treatment,53:63:treatment,68:79:treatment,87:102:upper_bound	Acute infection requiring systemic anti-infectives, antivirals, or antifungals within two weeks prior to first dose
NCT02389517	1:50:contraception_consent,69:84:treatment,96:111:upper_bound,135:145:treatment	Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug
NCT02389517	5:32:cancer	Any measurable residual disease at the time of screening for the study
NCT02389517	24:43:cancer,132:141:treatment	Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
NCT02389517	33:39:lower_bound	Are postmenopausal for at least 1 year before the screening visit
NCT02389517	1:33:clinical_variable,38:68:clinical_variable,72:79:upper_bound	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
NCT02389517	1:10:clinical_variable,13:46:upper_bound	Bilirubin =<1.5 x upper limit of normal (ULN)
NCT02389517	1:32:clinical_variable,56:65:lower_bound,69:85:clinical_variable,92:98:upper_bound	Calculated creatinine clearance (by Cockroft-Gault) >= 50 ml/min or serum creatinine below 2 g/dL
NCT02389517	1:23:chronic_disease	Central nervous system involvement
NCT02389517	34:44:cancer,52:59:upper_bound,157:173:cancer	Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease
NCT02389517	1:9:clinical_variable,12:19:lower_bound,38:53:treatment	Diarrhea > grade 1 in the absence of anti-diarrheals
NCT02389517	1:61:clinical_variable,65:66:lower_bound,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
NCT02389517	13:16:cancer,60:86:treatment	Evidence of MRD at the time of screening for this study by multi-color flow cytometry (bone marrow procedure at screening required)
NCT02389517	34:59:treatment,84:102:treatment,111:123:treatment,128:147:chronic_disease,152:184:clinical_variable,185:188:lower_bound,193:195:upper_bound,196:220:chronic_disease,225:240:chronic_disease,244:265:chronic_disease,277:290:upper_bound	Evidence of current uncontrolled cardiovascular conditions, including uncontrolled cardiac conditions such as hypertension, or cardiac arrhythmias, or New York Heart Association stage III and IV congestive heart failure, or unstable angina or myocardial infarction within the past 6 months
NCT02389517	13:32:chronic_disease,36:48:treatment	Evidence of progressive disease on lenalidomide maintenance as per IMWG criteria
NCT02389517	1:16:gender	Female patients
NCT02389517	1:16:gender,45:69:pregnancy	Female patients who are lactating or have a positive serum pregnancy test during the screening period
NCT02389517	1:11:clinical_variable,15:21:lower_bound	Hemoglobin >= 8 g/dL
NCT02389517	23:31:allergy_name	History of allergy to mannitol
NCT02389517	29:46:allergy_name	Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
NCT02389517	7:36:chronic_disease,40:52:treatment,115:123:treatment	Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
NCT02389517	1:16:clinical_variable,30:38:lower_bound	Life expectancy of more than 3 months
NCT02389517	1:14:treatment,22:36:upper_bound	Major surgery within 14 days before enrollment
NCT02389517	1:14:gender	Male patients
NCT02389517	16:35:chronic_disease,39:51:treatment	No evidence of progressive disease on lenalidomide
NCT02389517	12:37:chronic_disease,46:78:chronic_disease,89:123:chronic_disease	Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
NCT02389517	18:39:treatment,68:90:treatment,126:133:upper_bound	Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
NCT02389517	16:23:lower_bound,24:45:clinical_variable,50:57:upper_bound	Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
NCT02389517	28:40:treatment,41:46:lower_bound,50:55:upper_bound	Patients must be receiving lenalidomide 10 mg or 15 mg and be able to tolerate dose escalation to 25 mg daily
NCT02389517	30:42:treatment,72:80:lower_bound,81:112:treatment,125:127:lower_bound,128:130:upper_bound,149:157:lower_bound	Patients must have initiated lenalidomide maintenance at approximately 3 months post autologous stem transplant (preferably 70-90 but not more than 120 days)
NCT02389517	29:41:treatment,58:66:lower_bound,101:109:upper_bound	Patients must have received lenalidomide maintenance for 3 months (+1 month window for a maximum of 4 months lenalidomide prior to enrollment)
NCT02389517	24:43:treatment,56:87:treatment,91:106:treatment,123:130:cancer,166:174:treatment,176:188:treatment	Patients who completed induction treatment followed by autologous stem cell transplant as initial therapy for symptomatic myeloma as per IMWG criteria and initiated Revlimid (lenalidomide) maintenance
NCT02389517	47:79:treatment,107:131:treatment	Patients who have already started or received multi-drug consolidation regimen post-transplant expect for lenalidomide maintenance
NCT02389517	1:15:clinical_variable,19:30:lower_bound	Platelet count >= 75 x 10^9/L
NCT02389517	1:13:treatment,21:35:upper_bound	Radiotherapy within 14 days before randomization
NCT02389517	1:55:clinical_variable,58:66:lower_bound,72:103:treatment	Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead electrocardiogram (ECG) during screening
NCT02389517	1:5:treatment,6:10:treatment,49:52:chronic_disease	SPEP/IFIX - negative and Freelite- negative but MRD-positive disease is allowed
NCT02389517	1:19:treatment,28:42:upper_bound,61:69:treatment	Systemic treatment, within 14 days before the first dose of ixazomib
NCT02389517	1:22:chronic_disease	Uncontrolled diabetes
NCT02389517	1:55:contraception_consent	agree to practice 2 effective methods of contraception
NCT02389517	84:87:cancer	available deoxyribonucleic acid (DNA) sample will be used for calibration step for MRD evaluation by gene sequencing
NCT02389517	15:38:cancer,42:59:cancer,121:130:treatment	patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
NCT02389309	1:32:clinical_variable,58:67:lower_bound	Absolute neutrophil count (ANC) greater than or equal to 1000/mm^3
NCT02389309	46:77:treatment,83:110:clinical_variable,113:121:upper_bound,134:153:clinical_variable,160:163:lower_bound,167:181:treatment,207:232:clinical_variable,237:254:clinical_variable,261:264:lower_bound	Adequate cardiac function defined as: normal 12 lead electrocardiogram (EKG) with corrected QT interval (QTc) < 450 msec, and either shortening fraction of >= 28% by echocardiogram and qualitatively normal left ventricular function, or ejection fraction of >= 55% by echocardiogram
NCT02389309	59:66:chronic_disease,107:121:clinical_variable,124:127:lower_bound	Adequate pulmonary function as defined as: no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
NCT02389309	1:4:age,5:6:lower_bound,12:19:upper_bound,32:36:gender,53:59:gender	Age 1 to < 2 years, 0.6 mg/dL (male) and 0.6 mg/dL (female)
NCT02389309	1:4:age,7:9:lower_bound,16:24:upper_bound,26:35:upper_bound,37:41:gender,58:64:gender	Age > 10 and < 13 years, 1.2 mg/dL (male) and 1.2 mg/dL (female)
NCT02389309	1:4:age,7:9:lower_bound,16:24:upper_bound,26:35:upper_bound,37:41:gender,47:56:upper_bound,58:64:gender	Age > 13 and < 16 years, 1.5 mg/dL (male) and 1.4 mg/dL (female)
NCT02389309	1:4:age,7:15:lower_bound,28:32:gender,49:55:gender	Age > 16 years, 1.7 mg/dL (male) and 1.4 mg/dL (female)
NCT02389309	1:4:age,7:8:age,15:22:upper_bound,34:38:gender,55:61:gender	Age > 2 and < 6 years, 0.8 mg/dL(male) and 0.8 mg/dL (female)
NCT02389309	1:4:age,7:8:lower_bound,15:23:upper_bound,36:40:gender,57:63:gender	Age > 6 and < 10 years, 1.0 mg/dL (male) and 1.0 mg/dL (female)
NCT02389309	20:27:gender,40:99:pregnancy,157:206:contraception_consent,241:255:lower_bound	All post-menarchal females must have a negative serum beta-human chorionic gonadotropin (beta HCG); sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least 6 months after
NCT02389309	1:11:treatment,13:20:treatment,22:31:treatment,33:43:treatment	Amiodarone, sotalol, ibutilide, dofetilide
NCT02389309	1:47:treatment,86:100:treatment	Angiotensin-converting enzyme (ACE) inhibitors: patients who are currently receiving ACE inhibitors
NCT02389309	1:9:treatment,18:29:treatment,34:56:treatment,98:106:treatment,161:167:treatment,169:176:treatment,240:254:upper_bound,258:271:upper_bound,276:285:treatment	Antacids: use of H2 blockers and proton pump inhibitors is not recommended; patients who require antacids should use short acting, locally active agents (e.g., Maalox, Mylanta etc.); however, these agents should not be taken within either 2 hours before or 2 hours after the dasatinib dose
NCT02389309	1:38:chronic_disease,6:31:chronic_disease,76:91:treatment,120:132:treatment,134:144:treatment,205:232:treatment	Anti-graft-versus-host disease (GVHD) or agents to prevent organ rejection post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant
NCT02389309	1:15:treatment,16:30:treatment,44:90:treatment,97:105:treatment,107:135:treatment	Anticoagulants/anti-platelets: patients on therapeutic (treatment) dose of anticoagulants (e.g. warfarin, low molecular-weight heparin)
NCT02389309	1:33:clinical_variable,38:68:clinical_variable,72:111:upper_bound	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal for age (ULN)
NCT02389309	1:10:clinical_variable,14:23:upper_bound	Bilirubin =< 1.5 x ULN
NCT02389309	10:17:treatment,144:156:lower_bound,169:178:treatment	Category I drugs that are generally accepted to have a risk of causing torsades de pointes including: (patients must discontinue drug at least 7 days prior to starting dasatinib)
NCT02389309	1:15:treatment,17:28:treatment,30:42:treatment,44:56:treatment,58:66:treatment	Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
NCT02389309	1:10:treatment,12:20:treatment,22:32:treatment,34:41:treatment,43:54:treatment,56:67:treatment,69:81:treatment,83:95:treatment,97:109:treatment,111:122:treatment	Cisapride, bepridil, droperidol, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, sparfloxacin, lidoflazine
NCT02389309	1:24:treatment,90:97:treatment,142:157:treatment,279:290:upper_bound,295:308:treatment,320:332:upper_bound	Concomitant medications: the following drugs need to be stopped at the time of beginning therapy: patient cannot be on liver enzyme inducing anticonvulsants; patients must not have received growth factors to support the number or function of white cells or platelets within the past 7 days and pegfilgrastim within the past 14 days
NCT02389309	1:21:clinical_variable,25:70:clinical_variable,73:91:lower_bound,95:111:clinical_variable,121:124:age	Creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70 ml/min/1.73 m^2 OR serum creatinine based on age/gender
NCT02389309	15:26:clinical_variable,28:40:treatment,42:56:treatment,58:69:treatment,71:82:treatment,84:95:treatment,101:110:treatment	Drugs prolong QT interval; erythromycin, clarithromycin, pentamidine, ondansetron, granisetron, and methadone
NCT02389309	1:11:clinical_variable,25:33:lower_bound,35:46:treatment,82:94:lower_bound	Hemoglobin greater than 8.0 g/dL (transfusion independent; no transfusion for >= 7 days prior to study enrollment)
NCT02389309	32:64:allergy_name	History of hypersensitivity to any component of the formulation
NCT02389309	28:52:treatment,54:65:treatment,67:89:treatment,122:130:treatment,194:207:treatment,318:330:lower_bound,343:352:treatment	Inducers and Inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4): patients required to be on any CYP3A4/5 inhibitors or inducers will be excluded (with the exception of dexamethasone, but all efforts should be made to reduce the dose of dexamethasone); patients must discontinue drug at least 7 days prior to starting dasatinib
NCT02389309	1:29:clinical_variable,33:35:lower_bound,64:67:age,74:99:clinical_variable,119:123:age	Karnofsky performance status >= 50 for patients >= 16 years of age and a Lansky performance status >= 50 for patients aged < 16 years
NCT02389309	1:16:clinical_variable,29:37:lower_bound	Life expectancy: must be >= 12 weeks
NCT02389309	24:35:treatment,45:72:treatment,80:87:upper_bound	Must not have received bevacizumab or other monoclonal antibody therapy within 4 weeks of study the entry
NCT02389309	24:55:treatment,68:77:treatment,110:117:upper_bound,145:155:clinical_variable,180:187:upper_bound	Must not have received oral tyrosine kinase inhibitors (other than dasatinib) or other similar agents within 3 weeks of the study entry and all toxicities must have resolved to < grade 2 prior to enrollment
NCT02389309	66:77:cancer,132:144:cancer,164:182:cancer,187:207:cancer	Patients must have had a previous histological verification of a solid tumor at the original diagnosis and/or recurrence including brain tumors; for patients with brain stem gliomas and optic pathway tumors, the requirement for histological evaluation may be waived
NCT02389309	33:46:treatment,52:61:treatment,66:78:treatment	Patients must not have received prior therapy with dasatinib and temsirolimus for any indication
NCT02389309	38:60:chronic_disease,73:81:chronic_disease,85:103:chronic_disease,111:124:upper_bound,126:151:chronic_disease,165:166:lower_bound,215:228:upper_bound,230:251:chronic_disease,255:270:chronic_disease,293:319:clinical_variable,320:329:lower_bound,341:365:chronic_disease,375:393:chronic_disease,404:414:treatment,416:440:chronic_disease,486:513:chronic_disease,536:554:chronic_disease,556:582:chronic_disease,593:613:chronic_disease,646:673:chronic_disease,713:736:chronic_disease,746:769:chronic_disease,771:795:chronic_disease,800:819:chronic_disease,822:844:clinical_variable,848:875:treatment,879:887:lower_bound	Patients with clinically significant cardiovascular disease: history of ischemic or hemorrhagic stroke within past 6 months; uncontrolled hypertension, on at least 2 repeated determinations on separate days within past 3 months; myocardial infarction or unstable angina within past 6 months; New York Heart Association grade III or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris within past 6 months; clinically significant peripheral vascular disease within past 6 months; pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within past 6 months; diagnosed congenital long QT syndrome; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
NCT02389309	34:57:chronic_disease,66:74:upper_bound,97:122:chronic_disease,135:158:chronic_disease,165:188:treatment	Patients with evidence of recent intratumoral hemorrhage (within 3 months of study enrollment), gastrointestinal bleeding, history of coronary artery disease or on anticoagulation therapy
NCT02389309	21:55:chronic_disease	Patients with known human immunodeficiency virus (HIV)
NCT02389309	1:10:clinical_variable,36:47:lower_bound,96:108:lower_bound	Platelets greater than or equal to 75,000/mm^3 (transfusion independent; no transfusion for >= 7 days prior to study enrollment)
NCT02389309	1:9:pregnancy	Pregnant
NCT02389309	1:10:treatment,12:24:treatment,26:38:treatment	Quinidine, procainamide, disopyramide
NCT02389309	1:19:treatment,30:37:lower_bound,42:51:treatment,55:62:upper_bound,67:83:treatment	Radiotherapy (XRT): at least 4 weeks for focal XRT or 8 weeks for craniospinal XRT must have elapsed prior to study entry
NCT02389309	1:18:clinical_variable,23:48:clinical_variable,59:66:upper_bound	Serum cholesterol and serum triglyceride levels must be < grade 2
NCT02389309	1:27:treatment,38:45:lower_bound,56:70:treatment,75:83:upper_bound,88:102:treatment	Stem cell transplant (SCT): at least 8 weeks following autologous SCT and 12 weeks for allogeneic SCT
NCT02389309	1:8:treatment,19:26:lower_bound,37:44:treatment,95:127:treatment	Surgery: at least 2 weeks following surgery including brain and spine provided post-operative magnetic resonance imaging (MRI) shows no active bleeding
NCT02389309	64:76:cancer,132:144:lower_bound,288:291:lower_bound,373:378:lower_bound	The patient must have a stable clinical (neurologic in case of brain tumors) exam and be on a stable dose of steroids for at least 1 week prior to study entry; the patient should have a measurable and/or evaluable disease; measurable disease which is defined as the presence of at least one lesion that can be accurately measured in two dimensions (each measures at least 10 mm) or evaluable disease which is defined as at least one lesion that can be accurately measured in at least one dimension (measure at least 10 mm)
NCT02389309	61:83:chronic_disease,94:106:treatment,117:136:treatment,138:157:chronic_disease	Uncontrolled current illness including, but not limited to, uncontrolled infection, need for hemodialysis, need for ventilatory support, psychiatric illness/social situations that would limit compliance with study requirements
NCT02389309	10:17:lower_bound	at least 3 weeks must have elapsed from the last dose
NCT02389309	16:21:gender	breast-feeding women
NCT02389309	34:41:treatment,43:54:treatment,56:67:treatment,69:77:treatment,91:119:treatment,174:188:clinical_variable,230:236:lower_bound,262:271:treatment	patients are not allowed to take aspirin, clopidogrel, ticlopidine, Aggrenox; patients on prophylactic anticoagulation may be enrolled and treated on study as long as their platelet count is monitored closely and maintained at > 75,000 while they are receiving dasatinib
NCT02389309	36:51:treatment,55:75:treatment,127:139:chronic_disease	patients must not be receiving any anti-thrombotic or anti-platelet agents; patient cannot be on drugs that cause significant prolonged QT (category I drug)
NCT02389309	1:16:treatment,29:38:treatment,42:54:treatment	prior treatment with either dasatinib or temsirolimus
NCT02389309	56:85:treatment,113:133:treatment	the patient's disease must be considered refractory to conventional/standard therapy, or a disease for which no conventional therapy exists and is progressive
NCT02383979	36:46:treatment	Cooperative, patient scheduled for amputation, with time and availability to do fMRI prior to their operative date
NCT02383979	50:54:treatment	Cooperative, with time and availability to do an fMRI
NCT02383979	10:13:age,14:22:lower_bound	Subjects age 18 years or older
NCT02383979	10:13:age,14:22:lower_bound,26:28:upper_bound	Subjects age 18 years to 30
NCT02383979	22:26:treatment	Subjects who opt for fMRI portion of the study are willing and/or able to tolerate fMRI
NCT02383979	30:34:treatment	Willing and able to tolerate fMRI
NCT02383979	20:34:treatment	Willing to perform mirror therapy for 14 days prior and post-operative procedure
NCT02383979	29:45:treatment	inability to cooperate with physical therapy
NCT02383979	15:29:chronic_disease	patients with claustrophobia will be excluded from participating in the fMRI portion of this study
NCT02383979	34:48:treatment,41:48:treatment,61:70:chronic_disease	possessing a contraindication to mirror therapy for example blindness or inability to position properly for the therapy
NCT02383979	1:32:chronic_disease,105:124:chronic_disease,128:146:chronic_disease	primary central nervous disease such as status post cerebral vascular accident with persistent deficit, Alzheimer's disease or Multiple Sclerosis
NCT02383979	15:34:treatment	scheduled for elective amputation
NCT02379819	1:4:clinical_variable,96:99:lower_bound	CNC word recognition equal to or better than that in the ear to be implanted but not more than 80% correct
NCT02379819	53:65:chronic_disease	Moderately severe to profound mid to high frequency hearing loss in the contralateral ear
NCT02379819	20:32:chronic_disease	Normal to moderate hearing loss in the low frequencies with severe to profound mid to high frequency hearing loss in the ear to be implanted
NCT02379819	31:43:chronic_disease,47:55:lower_bound	duration of sever to profound hearing loss of 30 years or greater
NCT02379819	1:27:language_fluency	non-native English speaker
NCT02379377	1:11:clinical_variable,16:20:lower_bound	Liver mass (>= 1 cm) with arterial phase contrast enhancement and early washout on subsequent phases by CT
NCT02379377	1:11:clinical_variable,15:19:lower_bound,63:80:cancer,82:89:cancer,91:101:cancer,103:128:cancer	Liver mass (≥ 1 cm) that has suggestive imaging findings of a benign liver mass (adenoma, hemangioma, focal nodular hyperplasia)
NCT02379377	1:11:clinical_variable,15:19:lower_bound,31:57:cancer,59:77:cancer	Liver mass (≥ 1 cm) that is a non-HCC primary malignancy (cholangiocarcinoma)
NCT02379377	1:11:clinical_variable,15:19:lower_bound,29:35:treatment,43:61:cancer,74:91:cancer,104:121:cancer	Liver mass (≥ 1 cm) that is biopsy proven metastatic disease (metastatic colorectal cancer, metastatic pancreatic cancer)
NCT02379377	47:50:cancer	Patients with a known infiltrative variant of HCC
NCT02379377	29:39:cancer,58:79:treatment,87:97:upper_bound	Patients with a known prior malignancy who have received systemic chemotherapy within five years
NCT02379377	33:50:chronic_disease,52:79:clinical_variable,82:91:lower_bound	Patients with poorly controlled diabetes mellitus (fasting blood glucose level > 200 mg/dL)
NCT02379377	1:9:pregnancy	Pregnant
NCT02379377	34:58:clinical_variable,61:70:lower_bound	Suggestive imaging findings plus alpha-feto protein (AFP) > 200 mg/dL
NCT02379377	1:6:cancer	Tumor confirmed by arteriography
NCT02379377	1:33:cancer	basal cell carcinoma of the skin
NCT02379377	1:32:cancer	carcinoma in situ of the cervix
NCT02379377	15:29:cancer,43:61:cancer	patients with liver mass(es) proven to be metastatic disease
NCT02379377	7:10:cancer	prior HCC
NCT02374333	1:4:cancer,34:41:treatment,76:90:treatment	ALL without curative options for therapy, including those not eligible for allogeneic SCT
NCT02374333	8:19:chronic_disease,23:34:chronic_disease	Active hepatitis B or hepatitis C infection
NCT02374333	38:42:clinical_variable,45:48:lower_bound	Adequate cardiac function defined as LVSF ≥ 28% confirmed by ECHO
NCT02374333	1:28:clinical_variable,30:36:clinical_variable,40:55:clinical_variable,57:59:lower_bound	Adequate performance status (Lansky or Karnofsky score ≥50)
NCT02374333	1:28:clinical_variable,42:49:upper_bound,50:57:chronic_disease	Adequate pulmonary function defined as < Grade 3 hypoxia
NCT02374333	1:4:age,5:6:lower_bound,10:18:upper_bound	Age 1 to 24 years
NCT02374333	18:41:chronic_disease	Any uncontrolled active medical disorder that would preclude participation as outlined
NCT02374333	15:23:lower_bound,29:39:treatment,41:49:upper_bound,53:61:treatment	Are more than 4 months from transplant (6 months at infusion)
NCT02374333	1:10:clinical_variable,12:21:upper_bound	Bilirubin <2.0 mg/dl
NCT02374333	7:15:cancer	CD19+ leukemia
NCT02374333	1:13:chronic_disease,37:44:treatment,110:122:chronic_disease	CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity
NCT02374333	19:36:treatment,165:180:treatment	Concurrent use of systemic steroids at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion
NCT02374333	1:11:clinical_variable,14:23:upper_bound,38:49:upper_bound,54:57:age	Creatinine < 2.5 mg/dl and less than 2.5x normal for age
NCT02374333	1:28:cancer,38:52:cancer,95:111:cancer,118:133:treatment,155:169:treatment	Diffuse large cell lymphoma or other high-grade NHL, previously identified as CD19+ including residual disease after primary therapy and not eligible for autologous SCT
NCT02374333	1:18:clinical_variable,21:29:lower_bound	Expected survival > 12 weeks
NCT02374333	1:7:gender,65:98:pregnancy,121:129:upper_bound	Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
NCT02374333	32:45:treatment,36:45:treatment,180:198:treatment	For those patients who require leukapheresis for T cell collection (i.e. no previously collected product exists), adequate venous access for apheresis or eligible for appropriate catheter placement, and no other contraindications for leukapheresis
NCT02374333	1:4:chronic_disease	HIV infection
NCT02374333	16:20:chronic_disease,36:53:treatment	Have no active GVHD and require no immunosuppression
NCT02374333	1:5:gender	Male
NCT02374333	120:127:treatment	Patient may be in any complete response, or patient may have active disease but responding or stable after most recent therapy
NCT02374333	61:73:treatment	Patients previously treated with B cell directed engineered cell therapy
NCT02374333	1:9:pregnancy	Pregnant
NCT02374333	13:20:lower_bound,21:22:upper_bound,42:54:chronic_disease	Presence of grade 2-4 acute or extensive chronic GVHD
NCT02374333	1:9:treatment,22:31:treatment	Steroids for disease treatment at times other than cell collection or at the time of infusion
NCT02374333	14:30:chronic_disease	Uncontrolled active infection
NCT02374333	7:16:treatment,21:25:chronic_disease	Under treatment for GVHD
NCT02374333	32:46:treatment,50:66:treatment	Use of physiologic replacement hydrocortisone or inhaled steroids
NCT02374333	114:128:treatment	beyond 1st CR with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT
NCT02374333	1:7:gender	female
NCT02374333	11:16:gender	lactating women
NCT02374333	1:9:cancer	lymphoma
NCT02374333	36:54:treatment	partial response or no response to prior cell therapy
NCT02374333	16:36:treatment	relapsed after prior autologous SCT
NCT02374333	16:34:treatment	relapsed after prior cell therapy
NCT02374333	26:51:cancer,69:87:treatment,105:115:treatment,119:133:treatment,182:188:upper_bound,224:233:treatment	subjects with documented CD19+ B cell malignancies and no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to <2 year survival) with currently available therapies will be enrolled
NCT02347527	12:17:chronic_disease	Overweight/obese adults
NCT02339233	1:4:chronic_disease,8:12:chronic_disease,21:28:chronic_disease	HIV or AIDS related illness
NCT02339233	10:18:lower_bound	at least one-year post injury
NCT02339233	1:15:chronic_disease,17:28:chronic_disease,30:37:chronic_disease,41:54:chronic_disease	cardiovascular, respiratory, bladder or renal disease unrelated to SCI
NCT02339233	1:13:chronic_disease	dysautonomia that would contraindicate standing
NCT02339233	1:12:chronic_disease	hypovolemia
NCT02339233	18:26:lower_bound,30:33:age	must be at least 18 years of age
NCT02339233	48:64:upper_bound	must not have received botox injections in the prior six months
NCT02339233	27:37:chronic_disease	no clinically significant depression
NCT02339233	12:46:treatment	no current anti-spasticity medication regimen
NCT02339233	12:39:chronic_disease	no painful musculoskeletal dysfunction, unhealed fracture, contracture, pressure sore
NCT02339233	1:14:chronic_disease	pressure sore that might interfere with training
NCT02339233	1:14:chronic_disease,16:19:clinical_variable,20:26:upper_bound	severe anemia (Hgb<8 g/dL)
NCT02339233	34:57:chronic_disease	stable medical condition without cardiopulmonary disease
NCT02339233	1:24:chronic_disease	urinary tract infection that might interfere with stand or step training
NCT02337465	1:34:clinical_variable,37:39:lower_bound	Karnofsky performance status (PS) ≥ 70
NCT02337465	15:28:treatment,39:66:treatment	Patients with prostatectomy receiving post-operative radiotherapy
NCT02337465	15:49:chronic_disease	Patients with uncontrolled inter-current illness
NCT02337465	1:7:cancer,31:37:treatment,41:53:treatment	cancer involving the liver by biopsy or radiographic criteria
NCT02337465	1:16:cancer,20:26:treatment,74:91:treatment	prostate cancer by biopsy, with the intent of undergoing definitive dose radiation therapy to targets within the liver, or prostate
NCT02337465	1:38:chronic_disease	psychiatric illness/social situations that would limit compliance with study requirements
NCT02332915	1:4:age,5:7:lower_bound,11:19:upper_bound	Age 21 to 90 years
NCT02332915	1:6:gender	Males
NCT02332915	1:19:language_fluency	Speaker of English since childhood
NCT02332915	1:7:chronic_disease,33:41:lower_bound,42:53:chronic_disease	Stroke survivor who is at least 6 months post-stroke
NCT02332915	1:8:gender	females
NCT02332915	12:36:chronic_disease,46:52:chronic_disease	history of speech/language problems prior to stroke
NCT02332915	1:23:chronic_disease,35:41:chronic_disease	neurological condition other than stroke
NCT02332915	1:26:chronic_disease	untreated psychopathology
NCT02332668	8:26:chronic_disease,45:63:treatment,67:79:upper_bound	Active autoimmune disease that has required systemic treatment in past 2 years
NCT02332668	1:17:chronic_disease,28:44:treatment	Active infection requiring systemic therapy
NCT02332668	10:18:cancer,71:82:cancer,86:94:cancer	Advanced melanoma or PD-L1-positive advanced, relapsed, or refractory solid tumor or lymphoma
NCT02332668	15:39:treatment	Any number of prior treatment regimens
NCT02332668	9:17:lower_bound,23:31:upper_bound,35:38:age	Between 6 months and <18 years of age
NCT02332668	45:52:treatment,94:115:treatment,154:176:treatment	Currently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device
NCT02332668	14:30:chronic_disease,44:68:treatment,90:115:treatment	Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy
NCT02332668	1:20:gender,55:96:contraception_consent	Female participants of childbearing potential must be willing to use 2 methods of contraception or be surgically sterile
NCT02332668	1:20:gender,61:94:pregnancy	Female participants of childbearing potential should have a negative urine or serum pregnancy test
NCT02332668	35:46:chronic_disease,61:69:treatment	Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
NCT02332668	15:37:treatment	Has undergone solid organ transplant at any time
NCT02332668	1:17:chronic_disease	Hepatitis B or C
NCT02332668	67:94:cancer,98:106:cancer	Histologically- or cytologically-documented, locally-advanced, or metastatic solid malignancy or lymphoma that is incurable
NCT02332668	47:54:treatment	History or current evidence of any condition, therapy, or laboratory abnormality
NCT02332668	1:35:chronic_disease	Human immunodeficiency virus (HIV)
NCT02332668	1:16:clinical_variable,18:20:lower_bound,39:47:lower_bound,51:54:age	Karnofsky score ≥50 for participants >16 years of age
NCT02332668	14:53:cancer,61:85:cancer	Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
NCT02332668	18:28:cancer,68:77:treatment,100:132:cancer,134:169:cancer,173:190:cancer	Known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ
NCT02332668	18:37:chronic_disease,39:41:chronic_disease,43:64:chronic_disease	Known history of active tuberculosis (TB; Bacillus tuberculosis)
NCT02332668	7:18:chronic_disease	Known psychiatric or substance abuse disorders that would interfere with the requirements of the study
NCT02332668	1:18:clinical_variable,20:22:lower_bound,45:53:lower_bound,74:82:upper_bound,86:89:age	Lansky Play Scale ≥50 for participants from 6 months up to and including 16 years of age
NCT02332668	1:18:gender,50:98:contraception_consent,131:147:treatment,156:164:upper_bound	Male participants of reproductive potential must agree to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study medication
NCT02332668	30:65:treatment,67:78:lower_bound,128:160:chronic_disease	Participants who have had an allogeneic hematopoietic transplant >5 years ago are eligible as long as there are no symptoms of Graft Versus Host Disease [GVHD]
NCT02332668	19:32:cancer,43:73:treatment	Participants with neuroblastoma with only metaiodobenzylguanidine (MIBG)-positive evaluable disease may be enrolled
NCT02332668	1:9:pregnancy	Pregnant
NCT02332668	1:19:treatment,27:34:upper_bound,53:62:treatment	Prior radiotherapy within 2 weeks of start of study treatment
NCT02332668	1:35:treatment,46:67:treatment	Prior systemic anti-cancer therapy including investigational agent
NCT02332668	1:14:treatment	Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent
NCT02332668	17:24:treatment,32:39:upper_bound,66:76:treatment	Received a live vaccine within 30 days of planned start of study medication
NCT02332668	28:35:lower_bound,40:53:allergy_name,72:82:allergy_name	Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients
NCT02332668	12:29:treatment,34:39:cancer	Tissue (or lymph node biopsy for rrcHL participants) available from an archival tissue sample
NCT02332668	1:9:cancer	Tumor(s) involving the brain stem
NCT02332668	72:86:upper_bound,110:120:treatment	abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication
NCT02332668	9:16:lower_bound,22:30:upper_bound,34:37:age,42:47:cancer	between 3 years and <18 years of age for rrcHL participants
NCT02332668	93:107:upper_bound,125:141:treatment	expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of study medication
NCT02332668	23:30:treatment	for which no standard therapy exists
NCT02332668	23:30:treatment	for which no standard therapy is considered appropriate
NCT02332668	12:34:treatment	has failed prior standard therapy
NCT02332668	38:80:allergy_name	known severe hypersensitivity to any component or analog of the trial treatment, that might confound the results of the trial
NCT02332668	22:27:lower_bound,52:57:lower_bound	measurement must be >15 mm in longest diameter or >10 mm in short axis] for rrcHL participants
NCT02332668	97:104:lower_bound,108:111:age	on day of signing informed consent/assent (the first 3 participants dosed in Part 1 are to be ≥ 6 years of age)
NCT02332668	1:57:treatment,69:81:upper_bound	prior allogeneic hematopoietic stem cell transplantation within the last 5 years
NCT02332668	1:20:treatment,30:39:treatment,41:48:treatment,53:99:treatment,104:111:chronic_disease,115:138:chronic_disease	replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable
NCT02332668	6:34:treatment,39:62:cancer	with potentially curative therapy, or in situ cervical cancer
NCT02332668	8:20:upper_bound	within 7 days prior to the date of allocation/randomization
NCT02332668	8:22:upper_bound,60:70:treatment	within 72 hours prior to receiving the first dose of study medication
NCT02332369	1:10:chronic_disease	Amblyopia
NCT02332369	1:9:chronic_disease	Aniridia
NCT02332369	116:139:treatment	Capsular bag tearing beyond the point where the surgeon thinks it is in the best interest of the patient to have a capsular ring implanted
NCT02332369	1:10:chronic_disease,18:25:chronic_disease	Cataracts due to rubella
NCT02332369	1:21:chronic_disease	Congenital cataracts
NCT02332369	1:16:chronic_disease	Corneal disease
NCT02332369	1:9:chronic_disease	Diabetes
NCT02332369	1:22:chronic_disease	Flat anterior chamber
NCT02332369	1:13:chronic_disease	Iris atrophy
NCT02332369	1:7:chronic_disease	Iritis
NCT02332369	1:15:chronic_disease	Microphthalmia
NCT02332369	1:20:chronic_disease	Ocular inflammation
NCT02332369	1:14:chronic_disease	Optic atrophy
NCT02332369	1:34:clinical_variable,40:48:lower_bound	Preoperative intraocular pressure over 21 mm Hg
NCT02332369	14:30:chronic_disease	Preoperative ocular infection
NCT02332369	1:21:chronic_disease	Retinal degeneration
NCT02332369	1:19:chronic_disease	Retinal detachment
NCT02332369	13:29:treatment,37:44:treatment	Significant zonular didlysis during surgery
NCT02332369	1:9:chronic_disease	Vitritis
NCT02332369	180:206:chronic_disease,208:224:chronic_disease,226:232:chronic_disease	patient has observed or suspected weakened, torn, missing or otherwise compromised zonules (torn or missing estimated not to exceed one-third of the capsular bag diameter) due to Pseudoexfoliation Syndrome, Marfans Syndrome, trauma or other zonular compromising condition
NCT02332369	21:29:lower_bound	patient is at least 21 years old
NCT02332369	18:56:treatment	patient requires cataract surgery with IOL implantation
NCT02332369	1:8:chronic_disease	uveitis
NCT02329652	1:27:chronic_disease,36:51:chronic_disease	Active untreated infection such as decubitus ulcer
NCT02329652	1:4:age,7:15:lower_bound	Age > 16 years
NCT02329652	1:46:clinical_variable	American Spinal Injury Impairment Scale (AIS) grade A, B, C, or D
NCT02329652	1:43:clinical_variable,47:50:lower_bound	Biceps/brachialis/brachioradialis strength of 2/5 or higher on Manual Muscle Test
NCT02329652	1:19:pregnancy	Currently pregnant
NCT02329652	14:47:chronic_disease	Diagnosis of cervical level spinal cord injury, either complete or incomplete
NCT02329652	36:50:treatment	Disorder or condition that require MRI monitoring
NCT02329652	1:4:chronic_disease	HIV
NCT02329652	12:24:chronic_disease	History of coagulopathy
NCT02329652	11:21:upper_bound	Less than six months post-injury
NCT02329652	32:39:treatment	Medically stable - cleared for surgery
NCT02329652	7:30:chronic_disease	Other neurological conditions
NCT02329652	13:16:chronic_disease,37:70:treatment	Progressive SCI In subjects who are undergoing bilateral implantation
NCT02329652	10:13:lower_bound	at least two of the following muscles: left/right gluteus maximus, left/right erector spinae, left/right quadratus lumborum
NCT02329652	1:38:chronic_disease	chronic obstructive pulmonary disease
NCT02329652	1:9:chronic_disease	diabetes or any condition which requires frequent blood pressure monitoring or frequent venipuncture
NCT02329652	1:43:chronic_disease	diabetes with peripheral nerve involvement
NCT02329652	1:13:chronic_disease	hypertension
NCT02329652	1:19:chronic_disease	multiple sclerosis
NCT02329652	1:29:treatment	neuroprosthesis implantation delayed until criteria met
NCT02329652	1:29:treatment,54:62:pregnancy	neuroprosthesis implantation delayed until no longer pregnant
NCT02329652	1:10:chronic_disease	pneumonia
NCT02329652	1:29:chronic_disease	severe autonomic dysreflexia
NCT02329652	8:19:chronic_disease	severe bradycardia
NCT02329652	8:31:chronic_disease	severe cardiopulmonary disease
NCT02329652	1:11:lower_bound	six months or more post-injury
NCT02329652	39:60:chronic_disease	subjects should not have a history of autonomic dysreflexia
NCT02329652	1:24:chronic_disease	urinary tract infection
NCT02327403	1:4:clinical_variable,12:29:upper_bound	ACR in the previous 6 months
NCT02327403	1:4:age,6:14:upper_bound	Age <18 years
NCT02327403	1:8:chronic_disease	EBV IgG negative
NCT02327403	1:11:treatment	Everolimus
NCT02327403	13:37:treatment,39:51:treatment,55:65:treatment	Maintenance immunosuppression of CNI (cyclosporine or tacrolimus)
NCT02327403	1:5:gender	Male
NCT02327403	1:12:clinical_variable,14:24:lower_bound	Proteinuria ≥1 gram/day in spot urine protein/creatinine ratio
NCT02327403	1:10:treatment	Sirolimus
NCT02327403	14:41:chronic_disease	active acute antibody-mediated rejection
NCT02327403	8:32:chronic_disease,34:37:chronic_disease	active acute cellular rejection (ACR; higher than borderline)
NCT02327403	1:24:treatment,26:38:treatment,40:43:treatment,47:50:treatment,64:72:treatment	antiproliferative agent (azathioprine, MMF or MPA) with either steroids or not
NCT02327403	1:5:clinical_variable,7:16:lower_bound	eGFR ≥30 ml/min
NCT02327403	1:5:clinical_variable,6:15:upper_bound	eGFR<30 ml/min
NCT02327403	1:7:gender	female adult
NCT02327403	1:18:treatment,41:49:lower_bound	kidney transplant recipients older than 18 years old
NCT02327403	12:26:treatment	patient on mTOR inhibitor
NCT02327403	17:20:chronic_disease,22:34:treatment,38:48:treatment,54:62:treatment	patient only on CNI (cyclosporine or tacrolimus) and steroids
NCT02327403	11:15:chronic_disease	recurrent FSGS
NCT02327403	2:16:lower_bound,17:32:treatment	≥6 months after transplantation
NCT02324439	1:32:clinical_variable,58:67:lower_bound,130:139:clinical_variable,165:176:lower_bound,201:217:clinical_variable,243:250:lower_bound	Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, equivalent to Common Toxicity Criteria (CTCAE v4.0) Grade 1. Platelets greater than or equal to 100,000/mcl (CTCAE v4.0 Grade 0-1). Hemoglobin (Hgb) greater than or equal to 9.0g/dl (CTCAE v4.0 Grade 2)
NCT02324439	1:10:clinical_variable,33:42:upper_bound,65:113:clinical_variable,118:138:clinical_variable,141:150:upper_bound	Bilirubin less than or equal to 1.5 x ULN (CTCAE v4.0 Grade 1). Serum glutamate oxaloacetate transaminase (SGOT) and alkaline phosphatase ≤ 2.5 x ULN (CTCAE v4.0 Grade 1)
NCT02324439	1:11:clinical_variable,34:78:upper_bound	Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN), CTCAE v4.0 Grade 1
NCT02324439	1:9:treatment,66:79:chronic_disease,81:116:chronic_disease,118:127:chronic_disease,129:143:chronic_disease,147:152:chronic_disease,154:183:chronic_disease	Flaxseed supplementation may be contraindicated in patients with acute abdomen, esophageal stricture or perforation, dysphagia, GI obstruction or ileus, acute intestinal inflammation or unexplained abdominal pain. Patients with any of these conditions will be excluded from this trial as the high fiber content of flaxseed may make these conditions worse
NCT02324439	57:64:upper_bound	Patient has received other investigational drugs within 28 days before enrollment
NCT02324439	29:43:treatment,44:57:treatment,86:93:treatment,95:115:treatment,117:137:treatment,143:151:treatment	Patients concurrently using anticoagulants/antiplatelets on a DAILY BASIS, including aspirin, Clopidogrel (Plavix), Ticlopidine (Ticlid), and Coumadin
NCT02324439	49:82:allergy_name	Patients unable to tolerate and/or allergies to flaxseed or flaxseed preparations
NCT02324439	18:26:pregnancy	Patients who are pregnant
NCT02324439	34:46:treatment,50:62:treatment,75:85:cancer	Patients who have received prior radiotherapy or chemotherapy for another malignancy
NCT02324439	15:66:clinical_variable,69:70:lower_bound	Patients with Gynecologic Oncology Group (GOG) performance status > 2
NCT02324439	30:32:cancer,43:71:cancer,73:98:cancer,102:123:cancer,145:163:treatment,211:219:upper_bound,237:253:treatment	Patients with a diagnosis of OC including epithelial ovarian carcinoma, primary peritoneal cancer or fallopian tube cancer who are currently in clinical remission as determined by the PI or co-I and are within 4 months of completion of cancer treatment
NCT02324439	44:68:chronic_disease,78:96:chronic_disease,181:195:treatment	Patients with a diagnosis of/problems with von Willebrand's disease or other bleeding disorders (as flaxseed may slow blood clotting; the risk of bruising or bleeding in people on anticoagulants or with bleeding disorders may be a concern)
NCT02324439	28:54:chronic_disease,70:86:chronic_disease,101:118:chronic_disease	Patients with a history of inflammatory bowel disease, problems with chronic diarrhea or history of bowel obstruction
NCT02324439	28:49:chronic_disease,141:160:treatment	Patients with a history of uncontrolled diabetes (as flaxseed can lower blood glucose levels and might have additive effects when used with anti-diabetic drugs)
NCT02324439	26:46:chronic_disease	Patients with concurrent uncontrolled illness
NCT02324439	15:29:cancer,58:76:cancer	Patients with ovarian cancer of low malignant potential (borderline cancers)
NCT02324439	34:53:chronic_disease	Patients with serious medical or psychiatric illness
NCT02324439	1:15:chronic_disease	Renal function
NCT02324439	1:6:gender,45:63:pregnancy	Women of childbearing potential must have a negative pregnancy test
NCT02324439	63:81:treatment,86:107:treatment	patients of any stage who are in remission who have undergone surgical debulking and adjuvant chemotherapy
NCT02323191	21:60:cancer,78:102:treatment,106:132:treatment,169:183:upper_bound	Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening (within 28 days before C1D1) and prior radiographic assessments
NCT02323191	50:61:allergy_name,98:110:allergy_name	Allergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulation
NCT02323191	14:33:treatment,45:57:treatment,61:77:treatment,86:99:upper_bound	Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the exceptions provided in the protocol
NCT02323191	1:54:clinical_variable,55:56:lower_bound,60:61:upper_bound	Eastern Cooperative Oncology Group performance status 0 or 1
NCT02323191	39:59:chronic_disease,161:183:chronic_disease,193:251:chronic_disease,253:274:chronic_disease,286:299:upper_bound,310:321:chronic_disease,326:341:chronic_disease,346:363:chronic_disease,375:404:chronic_disease,432:444:chronic_disease	Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of symptomatic bronchospasm)
NCT02323191	12:46:chronic_disease	History of human immunodeficiency virus (HIV)
NCT02323191	15:40:chronic_disease	History of or active autoimmune disease
NCT02323191	1:23:cancer	Leptomeningeal disease
NCT02323191	1:16:clinical_variable,50:58:lower_bound	Life expectancy of greater than or equal to (>=) 16 weeks
NCT02323191	1:25:pregnancy,38:50:upper_bound,60:69:treatment,87:92:gender,130:139:upper_bound	Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women less than or equal to (<=) 12 months post-menopause
NCT02323191	21:39:chronic_disease,53:68:chronic_disease,82:96:upper_bound	Participant has had pulmonary embolism or any other thrombo-embolic event within 6 months prior to study entry
NCT02323191	31:55:cancer,67:85:upper_bound	Participants has a history of hematological malignancy within the last 5 years prior to study entry
NCT02323191	86:126:cancer,128:142:cancer,144:158:cancer,160:174:cancer,179:198:cancer	Participants must have histologically confirmed diagnosis of locally advanced and/or metastatic triple negative breast cancer, ovarian cancer, bladder cancer, gastric cancer, or soft tissue sarcoma
NCT02323191	26:37:chronic_disease,46:57:chronic_disease,62:81:chronic_disease	Participants with active hepatitis B, active hepatitis C, or active tuberculosis
NCT02323191	19:29:cancer,84:102:upper_bound	Participants with metastases to the brain stem, midbrain, pons, medulla, or within 10 millimeter (mm) of the optic apparatus (optic nerves and chiasm)
NCT02323191	1:15:clinical_variable,36:46:clinical_variable,68:77:lower_bound	Postmenopausal state is defined as amenorrhea for greater than (>) 12 months
NCT02323191	1:9:pregnancy	Pregnant
NCT02323191	1:22:treatment,26:45:treatment,66:73:lower_bound,94:104:treatment	Prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first receipt of study drug
NCT02323191	23:35:treatment,37:49:treatment,61:82:treatment,94:107:treatment,143:144:upper_bound	Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade <=1 severity (Common Terminology Criteria for Adverse Events [CTCAE] v4.03, or later versions)
NCT02323191	1:10:treatment,25:54:treatment	Treatment with systemic immunosuppressive medications
NCT02323191	11:16:gender	lactating women
NCT02323126	1:32:clinical_variable,34:45:upper_bound	Absolute Neutrophil Count (ANC) <1.5 x 109/L
NCT02323126	1:33:clinical_variable	Aspartate aminotransferase (AST)
NCT02323126	101:110:treatment,112:121:treatment	Documented progression of disease according to RECIST v1.1 following primary standard of care (e.g. erlotinib, gefitinib)
NCT02323126	93:109:treatment	Documented progression of disease according to RECIST v1.1 following standard of care (e.g. platinum doublet)
NCT02323126	1:24:clinical_variable,27:28:upper_bound	ECOG performance status ≤ 2
NCT02323126	1:11:cancer,12:17:cancer,19:33:cancer	EGFR T790M NSCLC (adenocarcinoma)
NCT02323126	1:5:clinical_variable,16:21:cancer	EGFR wild-type NSCLC
NCT02323126	1:17:clinical_variable,19:25:upper_bound	Hemoglobin (Hgb) <9 g/dL
NCT02323126	43:63:allergy_name	History of allergy or hypersensitivity to nivolumab components
NCT02323126	1:10:clinical_variable,12:23:upper_bound	Platelets <100 x 109/L
NCT02323126	1:67:treatment	Previous treatment with a c-MET inhibitor or HGF-targeting therapy (applies only to Group 2)
NCT02323126	1:17:clinical_variable,19:28:lower_bound	Serum creatinine >1.5 x ULN
NCT02323126	1:13:clinical_variable	Serum lipase > ULN
NCT02323126	1:16:clinical_variable,18:51:lower_bound	Total bilirubin >1.5 x upper limit of normal (ULN)
NCT02323126	1:13:cancer,126:134:clinical_variable	Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e. EGFR T790M positivity post progression on EGFR TKI for Group 1; cMet status for Group 2) must be provided for analysis
NCT02323126	1:31:clinical_variable,33:40:lower_bound	alanine aminotransferase (ALT) >3 x ULN
NCT02323126	53:71:chronic_disease	any known or suspected, current or past history of, autoimmune disease
NCT02323126	30:43:clinical_variable,45:48:lower_bound,49:58:upper_bound	asymptomatic serum amylase > CTCAE Grade 2 (1.5-2.0 x ULN)
NCT02323126	1:17:chronic_disease	brain metastases
NCT02323126	29:101:contraception_consent	child bearing potential who refuse or are not able to use a highly effective method of contraception
NCT02323126	29:47:treatment,60:75:treatment,78:89:lower_bound,90:100:treatment	condition requiring chronic systemic treatment with either corticosteroids(> 10 mg daily prednisone equivalent)
NCT02323126	24:51:treatment	have been treated with prior PD-1 and PD-L1 agents
NCT02323126	62:78:cancer	histologically documented locally advanced, recurrent and/or metastatic NSCLC
NCT02323126	33:67:chronic_disease,77:118:chronic_disease	history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
NCT02323126	1:26:chronic_disease	interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
NCT02323126	24:44:clinical_variable,46:53:upper_bound	measured or calculated creatinine clearance <75% LLN
NCT02323126	7:36:treatment,44:51:upper_bound,55:64:treatment	other immunosuppressive medications within 14 days of treatment start
NCT02323126	19:36:chronic_disease,40:57:chronic_disease,78:95:chronic_disease	positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
NCT02323126	1:9:pregnancy	pregnant
NCT02323126	20:23:lower_bound,38:55:treatment	received more than one prior line of EGFR TKI therapy1 (applies only to Group 1)
NCT02323126	25:42:treatment,59:69:treatment,84:88:lower_bound,129:145:treatment,153:165:treatment	require emergent use of systemic steroids, chronic use of prednisone (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or radiotherapy
NCT02323100	1:9:lower_bound	18 years or older
NCT02323100	38:68:lower_bound,72:104:clinical_variable,106:136:clinical_variable,146:155:chronic_disease	Abnormal liver function, defined as ≥3x upper limit of normal (ULN) of aspartate aminotransferase (AST), alanine aminotransferase (ALT) or known cirrhosis
NCT02323100	1:34:chronic_disease,42:49:upper_bound,53:81:chronic_disease,92:115:treatment,123:130:upper_bound	Acute upper respiratory infection within 2 weeks or acute pulmonary exacerbation requiring intravenous antibiotics within 4 weeks of Screening Visit
NCT02323100	15:32:treatment,37:52:chronic_disease,60:69:treatment,71:81:treatment,83:100:treatment,102:114:treatment,116:121:treatment,123:131:treatment,140:147:upper_bound	Any change in chronic therapies for CF lung disease (e.g., Ibuprofen, Pulmozyme®, hypertonic saline, Azithromycin, TOBI®, Cayston®) within 4 weeks of Study Day 1
NCT02323100	5:35:treatment,5:25:treatment,43:50:upper_bound,74:86:upper_bound	Any investigational drug or device within 30 days of Screening or within 6 half-lives of the investigational drug (whichever is longer)
NCT02323100	24:31:chronic_disease,33:38:chronic_disease,42:56:chronic_disease	Clinically significant cardiac, liver or kidney disease
NCT02323100	24:26:chronic_disease	Confirmed diagnosis of CF based on the following criteria
NCT02323100	16:36:treatment,38:58:treatment,81:115:treatment,126:133:upper_bound	Current use of ivacaftor (Kalydeco), lumacaftor/ivacaftor combination, or other corrector or potentiator (Symdeko) less than 30 days from Screening
NCT02323100	1:5:clinical_variable,19:22:lower_bound,44:47:age	FEV1 greater than 30% predicted normal for age, gender, height (Hankinson standards) pre or post-bronchodilator at Screening
NCT02323100	26:37:treatment,41:70:treatment	History of or listed for solid organ or hematological transplantation
NCT02323100	31:88:contraception_consent	If of childbearing potential, agree to use one highly effective method of contraception from the time of consent through the Visit 4 study visit, per section 9.1.13 of the protocol
NCT02323100	1:5:gender	Male
NCT02323100	1:19:pregnancy,29:34:gender	Negative pregnancy test for women of child-bearing potential
NCT02323100	1:18:clinical_variable,36:39:lower_bound	Oxygen saturation by pulseoximetry 90% or greater breathing ambient air or regular oxygen regimen at screening and day 1
NCT02323100	1:9:pregnancy,11:28:pregnancy	Pregnant, planned pregnancy or breast feeding
NCT02323100	1:17:chronic_disease	Seizure disorder
NCT02323100	1:14:treatment,22:29:upper_bound	Sinus surgery within 6 weeks of Screening Visit
NCT02323100	13:47:treatment,94:112:treatment	Subjects on chronic inhaled antibiotic therapy are eligible if they can continue their usual antibiotic regimen, or remain on their off-cycle period, for the duration of study drug exposure
NCT02323100	8:52:treatment	Taking pancreatic enzyme replacement therapy (PERT)
NCT02323100	1:7:gender	female
NCT02301260	1:30:language_fluency	English as a primary language
NCT02301260	24:49:chronic_disease	a current diagnosis of Major Depressive Disorder
NCT02301260	18:26:treatment,30:45:treatment	currently taking steroids or benzodiazepines
NCT02301260	14:32:chronic_disease	diagnosis of Multiple Sclerosis
NCT02301260	24:43:chronic_disease,45:61:chronic_disease,63:76:chronic_disease,81:90:chronic_disease	history of significant psychiatric illness (bipolar disorder, schizophrenia, or psychosis)
NCT02301260	33:42:upper_bound	most recent exacerbation within one month
NCT02272556	1:4:clinical_variable,7:16:lower_bound	ALT > 2.5 x ULN
NCT02272556	1:4:age,5:7:lower_bound,8:10:upper_bound	Age 18-55
NCT02272556	1:4:bmi,5:7:lower_bound,8:17:upper_bound	BMI 18-45 kg/m^2
NCT02272556	1:19:chronic_disease	Bleeding Disorders
NCT02272556	1:11:clinical_variable,14:23:lower_bound	Creatinine > 1.5 mg/dL
NCT02272556	19:26:treatment,34:47:upper_bound	Current or recent steroid use in last 3 months
NCT02272556	1:4:clinical_variable,7:15:upper_bound	Hgb < 10 mg/dL
NCT02272556	7:29:chronic_disease	Known Neurological Disorders
NCT02272556	1:11:cancer	Malignancy
NCT02272556	1:10:pregnancy,12:38:pregnancy	Pregnancy, actively seeking pregnancy, or breastfeeding
NCT02272556	1:10:chronic_disease,16:21:treatment,35:44:treatment,46:58:treatment,60:67:treatment,100:118:chronic_disease,120:123:bmi,126:135:lower_bound,190:199:upper_bound	Type 2 DM with HbA1C treated with metformin, sulfonylurea, insulin, or combination OR age-matched, non-diabetic obese (BMI > 30 kg/m^2) OR age-matched lean, healthy control subjects (BMI < 25 kg/m^2)
NCT02272556	1:26:chronic_disease	Uncontrolled Hypertension
NCT02272556	1:32:chronic_disease	Untreated Psychiatric Disorders
NCT02272556	11:26:chronic_disease	Untreated thyroid disease
NCT02267772	100:117:clinical_variable,131:135:lower_bound,151:155:upper_bound	This will be defined as the presence of uterine contractions documented on the tocodynanometer and cervical dilation greater than 2 cm, but less than 6 cm
NCT02267772	22:27:gender,50:57:treatment,69:82:upper_bound	We will also exclude women who have received any opioids within the last 24 hours
NCT02267772	22:35:allergy_name,102:118:chronic_disease,120:140:chronic_disease,154:174:chronic_disease,182:194:chronic_disease,196:206:chronic_disease,208:218:clinical_variable,221:224:lower_bound	contraindications to acetaminophen including reported elevated liver function tests, hepatic injury, hepatic disorder, active liver disease, alcoholism, chronic malnutrition, known coagulapathy, hemorrhage, creatinine > 1.0, or known allergy or hypersensitivity to acetaminophen
NCT02267772	11:19:upper_bound	less than 16 weeks gestation
NCT02267772	11:19:upper_bound,23:26:age	less than 18 years of age
NCT02267772	1:9:pregnancy,10:15:gender,29:37:lower_bound,41:50:pregnancy,119:137:chronic_disease,139:153:chronic_disease,155:167:chronic_disease,169:182:chronic_disease,184:199:chronic_disease,203:211:chronic_disease,235:244:treatment,250:272:treatment,307:324:treatment	pregnant women greater than 16 weeks of pregnancy who present with pain due to a maternal medical condition including sickle cell crisis, pyelonephritis, pancreatitis, cholecystitis, nephrolithiasis or headache and who are warranting treatment with intravenous medication for pain control as part of their routine treatment
NCT02267772	1:9:pregnancy,10:15:gender,29:37:lower_bound,41:50:pregnancy,134:143:treatment,206:223:treatment	pregnant women greater than 24 weeks of pregnancy who present with uterine contractions, but are not in labor and who are warranting treatment with intravenous medication for pain control as part of their routine treatment
NCT02267772	1:9:pregnancy,10:15:gender,29:37:lower_bound,41:50:pregnancy	pregnant women greater than 34 weeks of pregnancy who present with uterine contractions and are in the first stage of labor and who are warranting treatment with intravenous medication for pain control as part of their routine treatment
NCT02267772	30:34:upper_bound	the cervix remains less than 2 cm dilated and has not changed after 1 hour after re-examining her cervix
NCT02267772	6:12:clinical_variable,23:28:upper_bound	with weight less than 50 kg
NCT02267772	1:6:gender	women
NCT02266745	1:12:clinical_variable,23:34:upper_bound	AST and ALT are each ≤5 × the ULN
NCT02266745	1:32:clinical_variable,34:43:lower_bound	Absolute neutrophil count (ANC) ≥1,500/mm3
NCT02266745	1:17:chronic_disease,19:24:chronic_disease,29:45:chronic_disease,56:72:treatment	Active bacterial, viral, or fungal infection requiring systemic therapy
NCT02266745	1:38:clinical_variable,40:53:upper_bound	Alanine aminotransferase (ALT [SGPT]) ≤2.5 × the ULN
NCT02266745	5:27:treatment,35:48:upper_bound,66:76:treatment	Any cytotoxic chemotherapy within 21 days prior to initiation of study drug
NCT02266745	5:34:treatment,36:68:treatment,102:116:upper_bound	Any immunomodulatory drug therapy, anti-neoplastic hormonal therapy (unless dose has been stable for 3 months prior to Baseline and will remain stable during the trial)
NCT02266745	1:40:clinical_variable,42:55:upper_bound	Aspartate aminotransferase (AST [SGOT]) ≤2.5 × the ULN
NCT02266745	24:42:chronic_disease	Clinically significant hearing impairment, as judged by the Principal Investigator
NCT02266745	1:63:clinical_variable,67:68:lower_bound,69:70:upper_bound	Eastern Collaborative Oncology Group (ECOG) Performance Status of 0-1 (Appendix 1)
NCT02266745	41:61:treatment	Evaluable disease, either measurable on physical examination
NCT02266745	7:35:chronic_disease,39:73:chronic_disease	Known human immunodeficiency virus or acquired immunodeficiency syndrome related illness
NCT02266745	1:16:clinical_variable,18:26:upper_bound	Life expectancy <12 weeks
NCT02266745	1:14:treatment,22:35:upper_bound,53:63:treatment	Major surgery within 28 days prior to initiation of study drug
NCT02266745	61:66:gender,124:127:age,167:177:chronic_disease,183:198:upper_bound	Negative serum β hCG (human chorionic gonadotropin) test in women of childbearing potential (defined as women ≤50 years of age, or >50 years of age with a history of amenorrhea for ≤12 months prior to study entry)
NCT02266745	35:46:cancer,57:73:treatment	Pathologically confirmed advanced solid tumor for which standard therapy proven to provide clinical benefit does not exist or is no longer effective
NCT02266745	1:10:clinical_variable,12:23:lower_bound	Platelets ≥100,000/mm3
NCT02266745	45:63:treatment,87:95:chronic_disease,123:130:upper_bound	Presence of an acute or chronic toxicity of prior chemotherapy, with the exception of alopecia, that has not resolved to ≤Grade 1, as determined by National Cancer Institute Common Toxicity Criteria for Adverse Effects (CTCAE) v 4.0 (http://evs.nci.nih.gov/ftp1/CTCAE/About.html)
NCT02266745	10:20:chronic_disease	Previous malignancy
NCT02266745	1:13:treatment,21:34:upper_bound	Radiotherapy within 28 days prior to baseline
NCT02266745	22:23:lower_bound,24:64:treatment,69:87:cancer	Receipt of more than 3 prior regimens of cytotoxic chemotherapy for metastatic disease unless prior approval is granted by the Sponsor
NCT02266745	12:24:treatment,29:33:lower_bound	Receipt of radiotherapy to >25 % of bone marrow
NCT02266745	1:14:clinical_variable,16:25:lower_bound	Serum albumin ≥3.0 gm/dL
NCT02266745	1:17:clinical_variable,19:28:upper_bound	Serum creatinine ≤1.5 mg/dL
NCT02266745	8:25:chronic_disease	Severe liver dysfunction (Child-Pugh Class B or C)
NCT02266745	146:160:upper_bound	Subjects with a history of esophageal bleeding have varices that have been sclerosed or banded and no bleeding episodes have occurred during the prior 6 months
NCT02266745	23:35:cancer,39:57:cancer	Subjects with primary liver cancer or hepatic metastasis
NCT02266745	1:16:clinical_variable	Total bilirubin is no higher than the ULN
NCT02266745	1:16:clinical_variable,18:55:upper_bound	Total bilirubin ≤1.5 × the upper limit of normal (ULN)
NCT02266745	14:38:chronic_disease,40:81:clinical_variable,82:83:lower_bound,87:88:upper_bound,99:120:chronic_disease,122:146:chronic_disease,148:195:treatment,197:222:chronic_disease,227:245:chronic_disease,253:267:upper_bound,285:295:treatment	Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug
NCT02266745	10:30:chronic_disease,65:105:clinical_variable,110:118:lower_bound,123:128:gender,133:141:lower_bound,146:153:gender	Unstable cardiac dysrhythmias or persistent prolongation of the corrected QT interval (QTc) (Fridericia) to >450 msec for males or >470 msec for females
NCT02266745	1:16:treatment,18:27:lower_bound,28:38:treatment,57:80:treatment,71:80:treatment,88:102:treatment,111:124:upper_bound,142:152:treatment	corticosteroids >20 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug
NCT02266745	44:56:cancer	imaging by Response Evaluation Criteria in Solid Tumors (RECIST v1.1, Appendix 2)
NCT02266745	1:26:treatment	immunosuppressive therapy
NCT02266745	13:18:cancer	informative tumor marker(s)
NCT02266745	1:30:clinical_variable,32:41:lower_bound	measured creatinine clearance ≥60 mL/min
NCT02266745	1:36:cancer,40:79:cancer,92:97:cancer,115:130:treatment,141:154:lower_bound	non-squamous-cell carcinoma of skin or carcinoma in-situ of the uterine cervix, unless the tumor was treated with curative intent more than 2 years prior to study entry
NCT02264678	16:37:chronic_disease	A diagnosis of ataxia telangiectasia
NCT02264678	1:5:age,15:17:lower_bound	Aged at least 18
NCT02264678	17:24:allergy_name	Bad reaction to AZD6738
NCT02264678	22:31:treatment,37:45:allergy_name	Contra-indicated for treatment with MEDI4736
NCT02264678	37:48:allergy_name	Contra-indicated for treatment with carboplatin
NCT02264678	22:45:treatment	Contra-indicated for treatment with olaparib
NCT02264678	13:22:treatment,28:42:treatment	No previous treatment with PARP inhibitor
NCT02264678	22:35:treatment	Prior exposure to an ATR inhibitor
NCT02264678	22:58:cancer	Second or third line triple negative breast cancer (TNBC)
NCT02264678	22:49:cancer	Second or thrid line HER2 negative breast cancer
NCT02264678	19:41:cancer	The presence of a solid malignant tumour that is not considered appropriate for further standard treatment
NCT02264678	10:32:cancer,63:84:cancer	advanced gastric adenocarcinoma (including GEJ) patients with ATM deficient tumours
NCT02264678	10:32:cancer,44:47:cancer,78:85:cancer	advanced gastric adenocarcinoma (including GEJ) patients with ATM proficient tumours
NCT02264678	34:60:cancer	advanced recurrent or metastatic non-small cell lung cancer
NCT02264678	1:38:cancer	head and neck squamous cell carcinoma
NCT02264678	22:28:cancer,38:42:lower_bound,80:82:treatment,86:94:treatment	patients must have a tumour at least 1 cm in size that can be measured using a CT or MRI scan
NCT02264678	13:32:cancer,38:59:cancer	second line lung adenocarcinoma with ATM deficient tumours
NCT02257424	10:34:clinical_variable,37:44:lower_bound,60:74:treatment	Abnormal cardiac valve morphology (≥grade 2) documented by echocardiogram
NCT02257424	5:32:treatment,23:32:treatment,60:68:chronic_disease	All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed in Eligibility Criteria #4) must be Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03, 2009) at the time of starting treatment
NCT02257424	30:50:treatment	Any number and type of prior anticancer therapies
NCT02257424	1:5:treatment,9:23:treatment	BRAF or MEK inhibitors
NCT02257424	165:185:treatment,192:196:clinical_variable,197:199:lower_bound,200:204:upper_bound,212:226:clinical_variable,231:241:clinical_variable,254:266:clinical_variable,278:299:treatment,306:314:treatment,339:356:treatment,379:394:treatment,403:439:treatment,441:448:treatment,454:464:treatment	Current use of a prohibited medication as described in Section 6.3.8 of the protocol for Potential for Drug-Drug Interaction: apply moisturizing creams frequently, topical keratolytics (e.g. urea 20-40 % cream, salicylic acid 6%, tazarotene 0.1% cream, fluorouracil 5% cream), clobetasol propionate 0.05% ointment for erythematous areas, topical lidocaine 2%, and / or systemic pain medication such as nonsteroidal anti-inflammatory drugs, codeine, and pregabalin for pain
NCT02257424	11:19:lower_bound,20:44:chronic_disease,59:85:clinical_variable	Current ≥ Class II congestive heart failure as defined by New York Heart Association
NCT02257424	51:60:chronic_disease,64:73:chronic_disease	Due to risk of disease exacerbation patients with porphyria or psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbations
NCT02257424	108:118:treatment,140:165:allergy_name	Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)
NCT02257424	12:36:chronic_disease,48:69:chronic_disease,74:89:chronic_disease,92:112:treatment,117:125:treatment,133:147:upper_bound	History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
NCT02257424	12:37:chronic_disease,49:60:chronic_disease	History of interstitial lung disease or chronic pneumonitis
NCT02257424	12:22:cancer,61:68:upper_bound	History of malignancy other than disease under study within 3 years of study enrollment
NCT02257424	12:22:cancer	History of malignancy with confirmed activating RAS mutation at any time
NCT02257424	7:30:chronic_disease,35:68:chronic_disease	Known Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection
NCT02257424	16:25:pregnancy,38:50:upper_bound,94:99:gender	Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women
NCT02257424	45:60:treatment,106:136:chronic_disease,171:193:chronic_disease,203:237:treatment	Patients must be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
NCT02257424	27:35:lower_bound,39:42:age	Patients must be at least 18 years of age
NCT02257424	23:46:clinical_variable,50:51:lower_bound,55:56:upper_bound	Patients must have an ECOG performance status of 0 or 1
NCT02257424	40:53:treatment,55:59:treatment,61:71:treatment,73:79:treatment,90:102:treatment,112:125:lower_bound,152:173:treatment,183:196:lower_bound	Patients must have discontinued active immunotherapy (IL-2, interferon, CTLA-4, etc.) or chemotherapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study
NCT02257424	58:86:cancer,125:144:treatment	Patients must have histologically confirmed diagnosis of Stage IV metastatic melanoma positive for BRAF V600E or V600K by a CLIA approved assay
NCT02257424	37:71:treatment,106:122:lower_bound	Patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry
NCT02257424	20:38:treatment,49:54:cancer,61:78:treatment,82:104:treatment	Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
NCT02257424	20:80:treatment,87:96:treatment,98:111:treatment,113:126:treatment,128:137:treatment,141:154:treatment,163:170:upper_bound,197:206:treatment	Patients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks of the start of the study treatment
NCT02257424	35:75:treatment	Patients that are asymptomatic on low dose maintenance hormone replacement delivered at a stable dose for prior toxicities
NCT02257424	76:89:treatment	Patients who are known to be experiencing an objective partial response to immunotherapy at the time of study enrollment
NCT02257424	14:26:pregnancy	Patients who are pregnant
NCT02257424	39:61:chronic_disease	Patients with a previously documented retinal vein occlusion
NCT02257424	15:31:cancer,45:66:treatment,93:101:upper_bound	Patients with brain metastases treated with whole brain radiation that have been stable for 2 months
NCT02257424	15:43:treatment	Patients with intra-cardiac defibrillators
NCT02257424	40:49:chronic_disease,80:101:chronic_disease,168:177:treatment	Patients with known serious concurrent infection or medical illness, including psychiatric disorders, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety
NCT02257424	48:72:cancer	Subjects with a history of completely resected non-melanoma skin cancer
NCT02257424	26:45:chronic_disease,51:64:lower_bound	Subjects with controlled atrial fibrillation for >30 days prior to randomization
NCT02257424	24:43:chronic_disease	Subjects with moderate valvular thickening
NCT02257424	1:6:gender,12:52:contraception_consent,58:71:upper_bound,105:114:treatment,140:154:lower_bound,172:187:treatment,328:330:upper_bound,391:399:contraception_consent,401:412:contraception_consent,417:438:contraception_consent,534:544:contraception_consent,610:629:contraception_consent,637:645:contraception_consent,647:656:contraception_consent,658:671:contraception_consent,673:694:contraception_consent,700:710:contraception_consent,757:779:contraception_consent,787:806:contraception_consent,888:898:treatment	Women must use an effective method of contraception from 14 days prior to randomization, throughout the treatment period, and for at least 6 months after the last dose of study treatment as directed by their physician. Effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, or intra-uterine devices). At the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.) Hormonal-based methods (e.g., oral contraceptives) are NOT permitted as contraception due to potential drug-drug interactions with dabrafenib
NCT02257424	15:31:cancer,45:56:treatment,60:67:treatment,95:108:upper_bound,250:261:treatment	patients with brain metastases treated with gamma knife or surgery are allowed to participate after 3 weeks have elapsed since their procedure . Demonstration of brain stability by an imaging study after the procedure is required for gamma knife or CNS surgery patients
NCT02257424	44:62:chronic_disease,63:71:chronic_disease	subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis]
NCT02257424	31:43:cancer	subjects with indolent second malignancies
NCT02257424	21:39:chronic_disease	subjects with known Gilbert's syndrome
NCT02257424	46:49:chronic_disease,57:60:chronic_disease	subjects with laboratory evidence of cleared HBV and/or HCV
NCT02256631	1:26:clinical_variable,86:102:upper_bound,153:169:upper_bound	Absolute neutrophil count: for infants less than or equal to 24 hours old, less than 4,000 cells/mm^3; for infants greater than 24 hours old, less than 1,250 cells/mm^3
NCT02256631	18:21:age	Allowable infant age at the time of enrollment is dependent on the Dose Group and Cohort
NCT02256631	21:40:treatment,48:56:upper_bound,117:122:treatment,124:131:treatment,136:141:treatment,142:147:treatment	Any requirement for supplemental oxygen beyond 24 hours of life or requiring supplemental oxygen at the time of the VRC01, VRC01LS, or VRC07-523LS dose
NCT02256631	22:25:chronic_disease,66:69:lower_bound	At increased risk of HIV acquisition defined as documentation of one or more of the following risk factors
NCT02256631	1:13:clinical_variable,39:45:lower_bound	Birth weight greater than or equal to 2.0 kg
NCT02256631	12:17:chronic_disease,27:32:gender	Born to an HIV-1-infected woman who meets all maternal inclusion/exclusion criteria listed above
NCT02256631	18:31:chronic_disease	Documentation of HIV infection
NCT02256631	18:33:chronic_disease	Documentation of HIV-1 infection is defined as positive results from two samples collected at different time points. All samples tested must be whole blood, serum, or plasma. For this protocol, the results for sample #2 may be pending at the time of enrollment. Results documented in the clinical record from past testing may be used to satisfy the criteria for documentation of HIV-1 infection. More information on this criterion can be found in the protocol
NCT02256631	25:48:chronic_disease,101:104:chronic_disease	Documented or suspected serious medical illness or immediate life-threatening condition (other than HIV infection) in the mother that may interfere with the ability to complete study requirements, as judged by the examining clinician
NCT02256631	33:48:chronic_disease,50:76:chronic_disease,91:117:chronic_disease	Documented or suspected serious medical illness, serious congenital anomaly, or immediate life-threatening condition in the infant that may interfere with the ability to complete study requirements, as judged by the examining clinician
NCT02256631	43:51:upper_bound,55:58:age,100:107:treatment,111:122:treatment,149:163:upper_bound	Dose Groups 4 and 5 (Cohort 1): Less than 72 hours of age, and anticipated availability to receive VRC01LS or VRC07-523LS immunization at less than 72 hours after birth
NCT02256631	65:68:age,110:117:treatment,121:145:treatment	Dose Groups 4 and 5 (Cohort 2): Less than or equal to 5 days of age, and anticipated availability to receive VRC01LS or VRC07-523LS immunization no more than 5 days after birth
NCT02256631	1:16:clinical_variable,92:100:lower_bound	Gestational age, by best obstetrical, ultrasound, or infant exam, greater than or equal to 36 weeks
NCT02256631	26:34:lower_bound,38:41:age	Greater than or equal to 18 years of age
NCT02256631	1:11:clinical_variable,22:31:upper_bound	Hemoglobin less than 12.0 g/dL
NCT02256631	20:48:treatment,56:65:pregnancy	Mother received no antiretroviral therapy (ART) during pregnancy
NCT02256631	47:50:chronic_disease,51:54:clinical_variable,141:148:upper_bound	Mother with any detectable viral replication (HIV RNA above the limit of detection) at last measurement prior to delivery determined within 30 days of delivery
NCT02256631	43:56:chronic_disease	Mother with documented* 2-class resistant HIV infection, which may include historical documentation of lack of response
NCT02256631	1:15:clinical_variable,26:44:upper_bound	Platelet count less than 100,000 cells/mm^3
NCT02256631	28:47:treatment	Prior participation in any HIV-1 vaccine trial
NCT02256631	46:54:lower_bound	Prolonged rupture of membranes (greater than 12 hours)
NCT02256631	40:57:treatment,61:84:treatment,97:106:pregnancy	Receipt of any other active or passive HIV immunotherapy or investigational product during this pregnancy
NCT02256631	22:57:treatment,61:84:treatment,106:113:treatment	Receipt of any other active or passive HIV immunotherapy or investigational product other than the study vaccine
NCT02256631	52:66:treatment,71:96:treatment,132:165:treatment,220:239:treatment	Receipt of or anticipated need for blood products, immunoglobulin, or immunosuppressive therapy. This includes infants who require hepatitis B immunoglobulin (HBIG) but does not require exclusion of infants who receive hepatitis B vaccine in the newborn period
NCT02256631	1:43:clinical_variable,44:76:clinical_variable,102:124:lower_bound,128:131:age	Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) greater than or equal to 1.25 times upper limit of age adjusted normal
NCT02256631	1:6:gender,67:123:treatment,116:121:treatment	Women who have a documented history of virologic failure while on non-nucleoside reverse transcriptase inhibitors (NNRTIs) but who had no resistance testing at the time of viral failure will be considered to have NNRTI-documented resistance
NCT02256631	29:32:treatment,72:79:lower_bound,112:121:pregnancy	mother began or reinitiated ART (after an interruption of greater than 14 days), during the third trimester of pregnancy
NCT02240069	125:135:treatment	Capable and willing to record symptom data and wood stove usage data, as well as complete pulmonary function testing (i.e., spirometry)
NCT02232165	22:28:cancer,37:54:cancer	A known diagnosis of cancer (except basal cell cancer)
NCT02232165	1:20:clinical_variable,23:31:lower_bound	Acute traumatic SCI > 24 hours old
NCT02232165	10:17:chronic_disease,19:28:chronic_disease,30:37:chronic_disease,41:54:chronic_disease	Advanced cardiac, pulmonary, hepatic or liver disease
NCT02232165	1:4:age,30:38:lower_bound	Age greater than or equal to 16 years
NCT02232165	38:52:allergy_name	Allergy or other contraindication to norepinephrine
NCT02232165	1:22:chronic_disease	Central cord syndrome, defined as ASIA C or D with mean lower extremity score greater than upper extremity score
NCT02232165	1:25:chronic_disease	Isolated sensory deficit, motor intact
NCT02232165	26:49:chronic_disease,65:89:chronic_disease,91:94:treatment,113:121:treatment	Known uncorrected severe coronary artery disease or evidence of active coronary ischemia (ECG changes, positive troponin)
NCT02232165	48:67:chronic_disease	Motor complete or incomplete (ASIA A, B, or C) acute traumatic SCI involving spinal levels between C0 and T12
NCT02232165	69:84:upper_bound	Patients who have a history of substance abuse or dependency within 12 months prior to the study
NCT02232165	13:46:clinical_variable,48:49:lower_bound	Polytrauma: Abbreviated Injury Severity Score >3 in any area other than head
NCT02232165	31:42:chronic_disease,52:80:chronic_disease	Pre-existing and active major psychiatric or other chronic neurological disease
NCT02232165	1:10:pregnancy	Pregnancy
NCT02232165	60:68:upper_bound	Randomization and initiation of management protocol within 24 hours of injury
NCT02232165	1:26:chronic_disease,73:81:lower_bound,94:102:lower_bound,103:112:clinical_variable,122:146:treatment	Uncontrolled hypertension, defined as blood pressure persistently above 220 mmHg systolic or 120 mmHg diastolic, despite antihypertensive therapy
NCT02232165	47:68:clinical_variable,70:77:lower_bound	he former will be operationally defined using NCI Toxicity Criteria (Grade 2 or higher)
NCT02231073	1:5:age,6:8:lower_bound,9:17:upper_bound	Aged 50-90 years old
NCT02231073	78:90:chronic_disease	Capable of following directions. iPD subjects: UK Brain Bank criteria, i.e., bradykinesia
NCT02231073	22:31:treatment,37:51:chronic_disease	Contraindications to MRI scans (eg, claustrophobia, metal in body)
NCT02231073	39:42:age,57:60:chronic_disease,65:77:chronic_disease	Control subjects: Will be matched for age and gender to iPD and parkinsonism groups
NCT02231073	12:14:chronic_disease	Idiopathic PD subjects: Same as above and deep brain stimulation electrodes
NCT02231073	32:37:upper_bound	Inability to stand or walk for 2 min without an assistive device
NCT02231073	4:19:chronic_disease,23:33:chronic_disease,37:69:chronic_disease,82:116:chronic_disease,120:132:chronic_disease	No musculoskeletal or peripheral or central nervous system disorders (other than idiopathic Parkinson disease (iPD) or parkinsonism) that could significantly affect balance or gait
NCT02231073	1:13:chronic_disease,112:132:chronic_disease	Parkinsonism subjects: Gait characterized by slow short steps, shuffling gait and may be wide-based, with FoG, postural instability
NCT02231073	1:13:chronic_disease,24:56:chronic_disease,65:95:chronic_disease,97:120:chronic_disease,122:143:chronic_disease,148:165:chronic_disease	Parkinsonism subjects: iPD and Parkinson plus syndromes such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Syndrome, or Cerebellar Ataxia
NCT02231073	19:29:treatment	Recent changes in medication
NCT02231073	13:19:chronic_disease,45:53:treatment	Significant tremor that would interfere withMRI scan
NCT02231073	31:39:treatment	Unilateral onset, response to levodopa
NCT02231073	32:43:chronic_disease,45:62:chronic_disease,68:88:chronic_disease,102:108:chronic_disease,110:120:chronic_disease,122:132:chronic_disease,136:162:chronic_disease	at least one of the following: rest tremor, muscular rigidity, and postural instability not cause by visual, vestibular, cerebellar or proprioceptive dysfunction
NCT02231073	56:64:lower_bound	participating in a vigorous exercise program more than 2 x/week
NCT02223520	39:56:treatment	Allergies to any agent used in either treatment regimen
NCT02223520	42:48:lower_bound	Neonate has anticipated stay longer than 5 days in the NICU
NCT02223520	29:38:chronic_disease	Parent(s) test positive for S. aureus at screening
NCT02223520	61:83:chronic_disease	admitted from home and had admission screening cultures for S. aureus colonization that were negative
NCT02223520	14:20:lower_bound,24:27:age	greater than 7 days of age
NCT02213497	1:11:clinical_variable,14:21:lower_bound,22:38:clinical_variable,41:76:upper_bound	Hemoglobin > 10 g/dL serum creatinine < 1.5 times the upper limit of normal
NCT02213497	18:26:lower_bound,30:33:age	Patient must be >18 years of age
NCT02213497	52:63:chronic_disease,65:70:chronic_disease,72:79:chronic_disease,84:102:chronic_disease	Patients must be surgical candidates with adequate hematologic, renal, hepatic and pulmonary function
NCT02213497	23:46:clinical_variable,50:51:lower_bound,52:53:upper_bound	Patients must have an ECOG Performance Status of 0-1
NCT02213497	20:29:clinical_variable,32:44:upper_bound	Patients must have bilirubin < 1.5 × normal
NCT02213497	41:50:cancer,51:55:cancer	Patients with AJCC 7th edition clinical stage IIB-IIIC
NCT02213497	41:55:cancer	Patients with a histologic diagnosis of adenocarcinoma of the esophagus located distal to the carina
NCT02213497	15:29:clinical_variable,40:54:lower_bound,58:71:lower_bound,103:122:treatment,163:165:treatment,169:189:treatment	Patients with primary tumors exceeding 8 cm in length or 5 cm in width ( length should be measured by endoscopic findings, width should be measured by diagnostic CT or CT portion of PET/CT)
NCT02213497	23:29:cancer	Patients with primary tumors located at or above the carina
NCT02213497	1:9:pregnancy,10:15:gender,17:50:pregnancy	Pregnant women, women planning to become pregnant and women that are nursing
NCT02213497	23:35:cancer,47:61:upper_bound,74:92:cancer,96:116:cancer,118:134:cancer,138:155:cancer	Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
NCT02213497	1:4:clinical_variable,7:15:lower_bound	WBC > 3000/mm3
NCT02213497	1:6:gender,49:99:contraception_consent,106:124:contraception_consent,126:129:contraception_consent,131:138:contraception_consent,171:183:treatment	Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive, IUD, condoms or other barrier methods etc.). Hysterectomy or menopause must be clinically documented
NCT02213497	1:10:clinical_variable,13:24:lower_bound	platelets > 100,000 mm3
NCT02213497	1:10:clinical_variable,15:18:clinical_variable,21:54:upper_bound	serum AST and ALT < 2 times the upper limit of normal
NCT02204956	13:16:age	18 years of age
NCT02204956	1:43:treatment	Mini-Mental State Examination (MMSE: [45])
NCT02204956	22:30:chronic_disease	current diagnosis of dementia
NCT02204956	22:40:chronic_disease,44:61:chronic_disease	current diagnosis of mental retardation or autistic disorder
NCT02204956	32:33:lower_bound	current smoker (i.e., at least 5 cigarettes/day when not hospitalized)
NCT02204956	41:75:treatment	medical contraindication for the use of nicotine replacement therapy (NRT)
NCT02204956	1:66:technology_access	no access to a telephone or inability to communicate by telephone
NCT02204956	211:214:lower_bound	patient's inability to provide consent for study participation due to his/her inability to demonstrate an understanding of study procedures as contained in the statement of informed consent, after no more than two explanations
NCT02204956	1:10:pregnancy,30:54:pregnancy,62:70:upper_bound	pregnancy, breastfeeding, or plans to become pregnant within 6 months
NCT02200445	16:31:chronic_disease,35:61:chronic_disease	A diagnosis of Crohn's disease or Inflammatory Bowel Disease
NCT02200445	16:18:chronic_disease	A diagnosis of UC made by standard clinical, radiological, endoscopic and histological criteria
NCT02200445	3:21:pregnancy,98:104:gender,131:134:age	A negative pregnancy test in the 2 weeks prior to anticipated commencement of the study drug, in female subjects of child-bearing age
NCT02200445	10:17:chronic_disease	Abnormal thyroid function tests
NCT02200445	1:4:age,5:7:lower_bound,8:16:upper_bound	Age 18-70 years
NCT02200445	16:43:allergy_name	Allergy to any component of the study drug
NCT02200445	1:15:treatment,47:67:treatment	Corticosteroid dependency (inability to taper oral corticosteroids without a recurrence of disease activity) is also included in this category
NCT02200445	1:11:clinical_variable,14:60:lower_bound	Creatinine ≥ 1.5x institutional upper limit of normal (ULN)
NCT02200445	55:58:lower_bound,59:79:treatment,154:174:treatment,176:199:treatment,201:213:treatment,221:237:treatment,244:282:treatment	Failure to tolerate or failure to respond to at least one conventional therapy with the intention of inducing or maintaining remission (examples include oral corticosteroids, oral 5-aminosalicylates, azathioprine and/or 6-mercaptopurine, or a tumor necrosis factor (TNF) antagonist
NCT02200445	18:37:treatment,45:52:upper_bound,116:123:upper_bound,144:155:treatment,159:169:treatment	First dose of an anti-TNF medication within 4 weeks of anticipated study commencement, or a subsequent dose within 2 weeks of commencement; or ciclosporin or tacrolimus within 2 weeks of anticipated study commencement
NCT02200445	12:29:cancer,33:42:chronic_disease	History of colorectal cancer or dysplasia
NCT02200445	1:10:treatment,12:27:treatment,31:49:treatment,55:77:treatment	Ileostomy, proctocolectomy or subtotal colectomy with ileorectal anastomosis
NCT02200445	1:11:cancer,23:35:upper_bound	Malignancy within the last 5 years
NCT02200445	1:4:gender,9:14:gender,46:96:contraception_consent,104:113:treatment,122:138:upper_bound	Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment
NCT02200445	1:22:chronic_disease,30:40:clinical_variable,44:45:lower_bound,46:48:upper_bound	Moderate to severe UC with a Mayo score of 6-12
NCT02200445	29:46:chronic_disease	Positive screening test for tuberculosis (TB)
NCT02200445	10:18:treatment,23:26:chronic_disease,28:51:chronic_disease,55:58:chronic_disease	Positive serology for HIV, hepatitis B virus (HBV) or HCV
NCT02200445	25:46:chronic_disease	Positive stool test for Clostridium difficile
NCT02200445	1:9:pregnancy,23:28:gender	Pregnant or lactating women
NCT02200445	19:23:treatment	Prior exposure to IL-2
NCT02200445	18:48:treatment,56:68:upper_bound	Received another investigational new drug (IND) within 5 half-lives of that agent before the planned commencement of SC IL-2
NCT02200445	27:35:treatment,37:47:treatment,51:63:treatment,81:96:chronic_disease,98:116:chronic_disease,118:129:chronic_disease,131:137:chronic_disease,142:177:chronic_disease	Requirement for immediate surgical, endoscopic or radiological intervention for toxic megacolon, massive hemorrhage, perforation, sepsis, or intra-abdominal or perianal abscess
NCT02200445	17:40:treatment	Stable doses of concomitant medications
NCT02200445	1:16:clinical_variable,7:16:clinical_variable,19:28:lower_bound,30:33:clinical_variable,36:56:lower_bound,58:61:clinical_variable,129:147:chronic_disease	Total bilirubin > 2.0 mg/dL, ALT > 2x institutional ULN, GGT > 2x institutional ULN. Elevated unconjugated bilirubin related to Gilbert's syndrome is allowed
NCT02200445	22:28:chronic_disease,44:70:chronic_disease,72:76:clinical_variable,77:86:lower_bound,90:92:upper_bound	Uncontrolled cardiac angina or symptomatic congestive cardiac failure (NYHA Class III or IV)
NCT02200445	14:19:chronic_disease,65:86:chronic_disease	Unspecified (IBD-U, a diagnostic classification formerly termed indeterminate colitis
NCT02193932	54:86:treatment	Patients who meet the regular exclusion criteria for Magnetic Resonance Imaging (MRI) studies per the prescreening form reviewed with all patients prior to exams
NCT02193932	42:49:chronic_disease	Patients with overt symptoms or signs of anxiety than cannot cooperate during the recording inside the scanner, unless consent is given for the procedure to be performed with sedation by the anesthesia department
NCT02193932	1:20:chronic_disease	Refractory epilepsy cases, referred by the service of Neurology
NCT02191969	1:21:language_fluency	Able to read English (required for CGA and other surveys administered)
NCT02191969	57:77:lower_bound	Already walking or engaging in other physical activity >120 minutes per week as documented via subject self-report
NCT02191969	14:22:lower_bound,23:26:upper_bound,27:49:cancer,62:98:treatment,62:71:treatment	Diagnosis of stage II-III colon or rectal cancer planned for treatment with adjuvant chemotherapy scheduled as part of standard treatment
NCT02191969	25:43:chronic_disease	One or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention
NCT02191969	15:34:cancer,45:60:treatment,84:100:treatment	Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy
NCT02191969	3:6:age,7:15:lower_bound,26:29:age	≥ Age 60 years (no upper age limit)
NCT02179853	12:27:chronic_disease,36:42:chronic_disease,44:61:chronic_disease,63:69:chronic_disease,84:100:chronic_disease	History of chronic disease, except asthma, atopic dermatitis, autism or controlled seizure disorder
NCT02179853	32:40:allergy_name	History of hypersensitivity to anakinra
NCT02179853	12:44:chronic_disease	History of tuberculosis (TB) or TB exposure
NCT02179853	17:21:age,22:29:lower_bound,33:41:upper_bound	Infant or child aged 1 month to 17 years
NCT02179853	1:6:gender,54:63:pregnancy,64:87:contraception_consent	Males engaging in sexual activity that could lead to pregnancy willing to use a condom
NCT02179853	16:23:gender,25:43:pregnancy,77:107:contraception_consent	Post-menarchal females: Negative pregnancy test at screening and willing to use two forms of contraception during the study
NCT02179853	11:26:treatment,38:52:upper_bound	Use of an IL-1 antagonist within the 3 months prior to enrollment
NCT02167022	1:3:lower_bound,7:16:upper_bound,20:23:age	12 to 36 months of age
NCT02167022	1:41:treatment	Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study
NCT02167022	14:26:chronic_disease,30:48:chronic_disease	Diagnosis of CP secondary to neuronal migration
NCT02167022	1:58:clinical_variable,59:60:lower_bound,69:72:upper_bound	Gross Motor Function Classification System (GMFCS) levels I, II and III
NCT02167022	1:19:chronic_disease,59:83:treatment,177:186:chronic_disease,255:261:cancer,263:278:chronic_disease	Medical conditions that may prevent the administration of rehabilitation therapies at the intensity required by the study, or that may compromise the study ability to maintain blindness, or that have a co-morbidity not typically associated with CP (i.e. cancer, cystic fibrosis)
NCT02167022	18:20:chronic_disease,50:53:age,57:66:lower_bound	The diagnosis of CP is often uncertain under the age of 12 months. The cutoff at 36 months is to have a population of young children when the brain is most plastic and most susceptible to reorganization
NCT02167022	118:126:upper_bound,154:169:clinical_variable	insult to the central nervous system that caused the motor dysfunction must have occurred during gestation or within one year after birth independent of gestational age
NCT02167022	1:11:chronic_disease	spastic CP confirmed by a pediatric neurologist or pediatric rehabilitation specialist
NCT02166905	1:32:clinical_variable,36:44:lower_bound	Absolute neutrophil count (ANC) >= 1,000/uL
NCT02166905	66:88:chronic_disease	Additional exclusion criteria for exploratory cohort ONLY: Known pulmonary hypertension
NCT02166905	104:114:treatment	Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug (i.e., any significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the patient's risk by participating in this study)
NCT02166905	5:34:clinical_variable,30:33:clinical_variable	Any human leukocyte antigen (HLA) type; (historic HLA typing is permitted)
NCT02166905	1:13:treatment,15:32:treatment,37:50:treatment,58:71:upper_bound,91:101:treatment,103:110:upper_bound,115:127:treatment	Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study drug (6 weeks for nitrosoureas)
NCT02166905	13:31:treatment,91:106:treatment,108:122:treatment,126:163:treatment,169:201:treatment	Concomitant systemic treatment with chronic use (based on the investigator's judgment) of corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs, and other platelet inhibitory agents
NCT02166905	38:56:cancer,58:72:cancer,85:105:cancer,112:124:treatment,156:180:cancer	Eligible patients will be women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after chemotherapy with no evidence of disease or minimal residual disease for primary or recurrent disease; this may or may not be measurable; these patients would normally enter a period of observation after standard management
NCT02166905	46:68:chronic_disease,146:153:treatment	Evidence of current drug or alcohol abuse or psychiatric impairment, which in the Investigator's opinion will prevent completion of the protocol therapy or follow-up
NCT02166905	9:69:clinical_variable,76:77:upper_bound	Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
NCT02166905	29:38:treatment	Have been informed of other treatment options
NCT02166905	1:17:clinical_variable,21:27:lower_bound	Hemoglobin (Hgb) >= 8 g/dL
NCT02166905	19:39:chronic_disease,57:65:treatment,75:93:treatment	History of severe autoimmune disorders requiring use of steroids or other immunosuppressives
NCT02166905	7:18:chronic_disease,20:31:chronic_disease,36:70:treatment	Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
NCT02166905	1:16:clinical_variable,19:27:lower_bound	Life expectancy > 6 months
NCT02166905	1:18:chronic_disease	Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
NCT02166905	1:19:cancer,97:109:treatment	Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available
NCT02166905	7:24:chronic_disease,32:50:chronic_disease,61:72:treatment,74:92:chronic_disease	Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)
NCT02166905	18:82:treatment,90:103:upper_bound	Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug
NCT02166905	28:61:treatment,54:61:treatment,97:107:treatment,111:122:treatment,201:218:lower_bound,219:225:treatment,314:321:upper_bound	Patients may have received previous NY-ESO-1 vaccine therapy; patients who received maintenance paclitaxel or bevacizumab are eligible for enrollment provided they have discontinued therapy (at least 4 weeks for prior taxane or prior bevacizumab) prior to randomization and recovered from toxicities to less than grade 2
NCT02166905	42:87:contraception_consent,95:109:contraception_consent,118:127:treatment	Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment
NCT02166905	1:16:clinical_variable,20:30:lower_bound	Platelets (PLT) >= 100,000/uL
NCT02166905	1:9:pregnancy	Pregnant
NCT02166905	1:86:clinical_variable,90:171:clinical_variable,175:182:upper_bound	Serum aspartate aminotransferase (serum glutamic oxaloacetic transaminase [SGOT]/AST) or serum alanine aminotransferase (serum glutamate pyruvate transaminase [SGPT]/ALT) =< 3 x ULN
NCT02166905	1:17:clinical_variable,21:28:upper_bound	Serum creatinine =< 2 x ULN
NCT02166905	31:65:treatment,60:64:treatment,118:128:treatment,130:139:treatment,141:155:treatment,164:177:upper_bound	Subjects being treated with a monoamine oxidase inhibitor (MAOI), or drug which has significant MAOI activity (e.g., Meperidine, linezolid, methylene blue) within 3 weeks prior to screening
NCT02166905	38:75:treatment,77:85:treatment,87:98:treatment,100:130:treatment,150:164:treatment,166:179:treatment,181:191:treatment,193:205:treatment,207:219:treatment,221:231:treatment	Subjects who are currently receiving therapy with a potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer or inhibitor (e.g. clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir)
NCT02166905	40:50:treatment	The ability to swallow and retain oral medication
NCT02166905	1:16:clinical_variable,20:53:upper_bound	Total bilirubin =< 1.5 x upper limit of normal (ULN)
NCT02166905	1:6:cancer,43:69:treatment	Tumor expression of NY-ESO-1 or LAGE-1 by immunohistochemistry (IHC) and/or reverse transcriptase polymerase chain reaction (RTPCR)
NCT02166905	8:35:treatment,46:79:treatment,91:101:treatment,103:113:treatment,119:131:treatment	Use of UDP glucuronosyltransferase 1 family, polypeptide A9 (UGT1A9) inhibitor including: diclofenac, imipramine, and ketoconazole
NCT02166905	9:24:gender	nursing female patients
NCT02163317	1:43:clinical_variable	Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control (CDC)
NCT02163317	7:16:chronic_disease,20:36:chronic_disease,47:70:treatment	Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
NCT02163317	1:10:treatment,28:35:upper_bound	Bone scan completed within 90 days
NCT02163317	1:38:chronic_disease,61:80:chronic_disease,121:134:treatment	Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
NCT02163317	1:17:clinical_variable,20:22:lower_bound,23:26:upper_bound	Clinical stage a ≤ T1-T2a (American Joint Committee on Cancer [AJCC] 7th edition)
NCT02163317	1:61:clinical_variable,76:77:lower_bound,81:82:upper_bound,90:103:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status must be level 0 or 1 within 60 days prior to registration
NCT02163317	13:31:cancer	Evidence of distant metastases
NCT02163317	1:15:clinical_variable,18:24:upper_bound	Gleason scores ≤ 7(3+4)
NCT02163317	1:22:chronic_disease,45:53:chronic_disease,61:80:chronic_disease	Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters
NCT02163317	37:50:upper_bound,60:71:treatment	PSA should not be obtained prior to 30 days after stopping finasteride
NCT02163317	37:44:upper_bound,60:71:treatment	PSA should not be obtained prior to 90 days after stopping dutasteride
NCT02163317	1:4:clinical_variable,35:48:upper_bound,49:64:treatment	PSA should not be obtained within 10 days after prostate biopsy
NCT02163317	1:26:treatment,36:89:treatment,97:106:treatment,108:118:treatment,123:139:treatment,147:156:treatment,159:173:treatment,181:190:treatment,192:204:treatment,207:216:treatment,224:248:treatment,254:287:treatment	Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., diethylstilbestrol [DES]), or surgical castration (orchiectomy)
NCT02163317	1:46:treatment,51:66:cancer	Previous or concurrent cytotoxic chemotherapy for prostate cancer
NCT02163317	1:28:treatment,30:52:treatment,57:78:treatment	Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
NCT02163317	1:25:treatment,27:40:treatment,43:54:treatment,59:99:treatment,104:119:cancer	Previous radical surgery (prostatectomy), cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer
NCT02163317	1:32:clinical_variable,35:43:upper_bound,51:64:upper_bound	Prostate specific antigen (PSA) ≤ 10 ng/mL within 90 days prior to registration
NCT02163317	1:20:cancer	Regional lymph node involvement
NCT02163317	1:17:clinical_variable,20:65:upper_bound,59:65:clinical_variable,77:97:upper_bound	Serum creatinine ≤ 1.5 times upper limit of institutional normal (normal: ≤ 1.17 mL/min/1.73 m^2)
NCT02163317	1:33:chronic_disease,45:58:upper_bound	Transmural myocardial infarction within the last 6 months
NCT02163317	1:16:chronic_disease,24:48:chronic_disease,59:74:treatment,86:99:upper_bound	Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
NCT02163317	8:19:treatment,27:40:upper_bound	Use of dutasteride within 90 days prior to registration
NCT02163317	8:19:treatment,27:40:upper_bound	Use of finasteride within 30 days prior to registration
NCT02163317	23:26:treatment	be able to undergo an MRI with contrast
NCT02163317	39:54:treatment,48:54:treatment,76:89:clinical_variable	have a histological evaluation of the prostate biopsy with assignment of a Gleason score to the biopsy material
NCT02163317	46:76:cancer	have a histologically confirmed diagnosis of adenocarcinoma of the prostate
NCT02163317	42:84:treatment,92:105:upper_bound	have a history/physical examination with digital rectal examination of the prostate within 90 days prior to screening
NCT02163317	1:35:chronic_disease	human immunodeficiency virus (HIV) testing
NCT02163317	22:25:treatment	unable to undergo an MRI with contrast
NCT02163317	107:108:lower_bound,117:126:upper_bound,139:156:treatment	willing and able to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire (baseline, 6, 12 and 24 months post end of radiation therapy)
NCT02152995	50:73:clinical_variable,77:85:lower_bound	A QT interval corrected for heart rate using the Bazett's formula (QTcB) >= 480 msec
NCT02152995	3:20:cancer,33:44:treatment	A metastatic lesion that is not radioiodine-avid on a diagnostic radioiodine scan performed prior to enrollment in the current study
NCT02152995	3:14:treatment,20:37:cancer,90:111:treatment,112:120:lower_bound	A radioiodine-avid metastatic lesion which remained stable in size or progressed despite radioiodine treatment 6 months or more prior to entry in the study; there are no size limitations for the index lesion used to satisfy this entry criterion
NCT02152995	28:58:treatment,169:191:chronic_disease,195:225:treatment,229:235:treatment	Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
NCT02152995	1:32:clinical_variable,36:48:lower_bound	Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
NCT02152995	1:8:clinical_variable,12:20:lower_bound	Albumin >= 2.5 g/dL
NCT02152995	11:20:treatment,48:126:clinical_variable,130:131:upper_bound	All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grade =< 1
NCT02152995	58:68:treatment	Animal reproductive studies have not been conducted with trametinib
NCT02152995	1:33:clinical_variable,38:68:clinical_variable,72:95:upper_bound	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
NCT02152995	26:31:cancer,48:62:cancer,74:84:cancer	Availability of archival tumor tissue from the thyroid cancer primary or metastasis (a tissue block or a minimum of 30 unstained slides would be required; patients with less archival tissue available may still be eligible for the study after discussion with the MSK principal investigator)
NCT02152995	126:140:cancer,134:139:cancer,142:155:cancer,177:187:cancer,196:209:cancer,267:274:cancer	COHORT A: Confirmation in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) has an neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) or Kirsten rat sarcoma viral oncogene homolog (KRAS) or Harvey rat sarcoma viral oncogene homolog (HRAS) mutation at G12, G13, or Q61; this group of patients will also be referred to as RAS MUT
NCT02152995	30:49:chronic_disease,106:124:treatment,132:141:upper_bound	COHORT A: Patients must have progressive disease, defined as the presence of new or growing lesion(s) on radiologic imaging within 14 months of study enrollment and/or new/worsening disease related symptoms within 14 months of study enrollment
NCT02152995	1:21:treatment,27:42:treatment	Concurrent treatment with bisphosphonates
NCT02152995	1:11:clinical_variable,15:24:upper_bound,28:59:clinical_variable,39:59:clinical_variable,89:98:lower_bound	Creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min
NCT02152995	18:39:treatment	Current use of a prohibited medication
NCT02152995	1:61:clinical_variable,65:66:upper_bound,68:77:clinical_variable,81:84:lower_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
NCT02152995	1:4:chronic_disease,26:60:treatment,105:149:treatment	HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with trametinib
NCT02152995	108:118:allergy_name,123:133:allergy_name,140:165:allergy_name,172:200:allergy_name	Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO) or to thyrotropin alpha (Thyrogen)
NCT02152995	1:11:clinical_variable,15:21:lower_bound	Hemoglobin >= 9 g/dL
NCT02152995	12:36:chronic_disease,48:69:chronic_disease,74:89:chronic_disease,92:112:treatment,117:125:treatment,133:147:upper_bound	History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
NCT02152995	20:30:cancer	History of another malignancy
NCT02152995	12:37:chronic_disease,41:52:chronic_disease	History of interstitial lung disease or pneumonitis
NCT02152995	24:43:chronic_disease	History or evidence of cardiovascular risk
NCT02152995	44:68:chronic_disease,87:120:clinical_variable	History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
NCT02152995	68:79:chronic_disease	History or evidence of current clinically significant uncontrolled arrhythmias
NCT02152995	7:25:cancer	Known cardiac metastases
NCT02152995	7:41:chronic_disease,43:66:chronic_disease,71:94:chronic_disease	Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
NCT02152995	1:42:clinical_variable	Left ventricular ejection fraction (LVEF) < LLN
NCT02152995	1:35:clinical_variable,84:105:treatment,109:144:treatment	Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
NCT02152995	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 3 months
NCT02152995	4:16:treatment,9:16:treatment,20:36:treatment,44:69:treatment,84:97:upper_bound	No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed < 4 weeks prior to the initiation of therapy on this protocol
NCT02152995	4:35:treatment,28:35:treatment,38:51:upper_bound	No external beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol
NCT02152995	4:21:treatment,14:21:treatment,35:49:upper_bound	No prior RAI therapy is allowed < 6 months prior to initiation of therapy on this protocol
NCT02152995	11:20:treatment,25:39:cancer	No recent treatment for thyroid cancer
NCT02152995	1:18:treatment	Other anti-cancer therapy while on study
NCT02152995	45:53:treatment	Patients must agree to undergo two separate biopsies of a malignant lesion
NCT02152995	62:79:cancer	Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants); confirmation of thyroid carcinoma will be done at Memorial Sloan-Kettering (MSK)
NCT02152995	60:63:lower_bound,224:229:lower_bound,235:258:treatment,268:273:lower_bound,279:293:treatment,295:327:treatment,332:340:treatment	Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan, magnetic resonance imaging (MRI), or calipers by clinical exam
NCT02152995	58:68:treatment,98:108:treatment	Patients unable to follow a low iodine diet or requiring medication with high content in iodide (amiodarone)
NCT02152995	23:53:treatment,67:89:treatment,97:105:upper_bound	Patients who received iodinated intravenous contrast as part of a radiographic procedure within 3 months of study registration
NCT02152995	15:43:treatment	Patients with intra-cardiac defibrillators
NCT02152995	1:10:clinical_variable,14:26:lower_bound	Platelets >= 100 x 10^9/L
NCT02152995	1:22:clinical_variable,23:59:clinical_variable,64:97:clinical_variable,101:124:upper_bound	Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x institutional ULN
NCT02152995	1:4:treatment	RAI-refractory disease on structural imaging
NCT02152995	26:40:cancer,44:60:cancer,64:87:chronic_disease	Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
NCT02152995	39:40:lower_bound,130:147:treatment,139:147:treatment,237:242:cancer,261:267:treatment,662:677:treatment	The goal will be to have a minimum of 6 patients from Cohort A and 3 patients from Cohort B attempt to have one or both of these research biopsies done (for a total of 9 patients total); accrual may be limited only to subjects for whom tumor is accessible for biopsy and attempt at biopsy is considered safe if continued enrollment of those who are not candidates for biopsy make it impossible to reach the accrual goals for research biopsies described above (e.g., if 19 [of 25] patients are accrued to Cohort A without any biopsies having been obtained within the cohort, then all further subjects who are registered to that cohort must qualify for attempted research biopsy in order to be enrolled into the study
NCT02152995	26:29:lower_bound,30:54:treatment	The presence of at least one fluorodeoxyglucose (FDG) avid lesion
NCT02152995	1:16:clinical_variable,20:67:upper_bound	Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
NCT02152995	1:34:treatment,48:74:clinical_variable,77:85:lower_bound,93:102:clinical_variable,105:112:lower_bound,143:168:treatment	Treatment-refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy
NCT02152995	14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,142:157:chronic_disease,167:177:chronic_disease,182:201:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02152995	8:35:treatment,43:50:upper_bound,55:70:upper_bound,112:119:lower_bound,168:178:treatment	Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib and during the study
NCT02152995	1:9:chronic_disease	alopecia
NCT02152995	20:23:chronic_disease,28:31:chronic_disease,32:41:chronic_disease	chronic or cleared HBV and HCV infection
NCT02152995	9:24:treatment	grade 2 prior treatment related toxicities may be allowed after discussion with the principal investigator
NCT02152995	1:19:treatment	megestrol [Megace] if used as an appetite stimulant
NCT02152995	1:4:gender,52:87:contraception_consent,153:167:upper_bound,182:192:treatment	men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of trametinib administration
NCT02152995	1:29:treatment	palliative radiation therapy to non-target lesions
NCT02152995	41:48:upper_bound	patients who have been disease-free for 3 years
NCT02152995	48:72:cancer	patients with a history of completely resected non-melanoma skin cancer
NCT02152995	26:45:clinical_variable,52:65:lower_bound,69:82:treatment	patients with controlled atrial fibrillation for > 30 days prior to randomization
NCT02152995	24:46:cancer	patients with indolent secondary malignancies
NCT02152995	1:9:pregnancy,10:15:gender	pregnant women
NCT02152995	21:36:treatment,57:69:chronic_disease	prophylactic use of bisphosphonates in patients without bone disease
NCT02152995	51:59:treatment	subjects who would have been excluded from having biopsies done due to the above reasons
NCT02152995	41:44:treatment,49:57:treatment	these potential risks may also apply to RAI and thyrogen
NCT02152995	1:34:clinical_variable,35:54:treatment	thyroid-stimulating hormone [TSH] suppressive therapy
NCT02152995	1:10:treatment,14:26:chronic_disease	treatment of osteoporosis
NCT02152995	1:6:gender,3:6:gender,47:82:contraception_consent,84:92:contraception_consent,96:127:contraception_consent,129:139:contraception_consent	women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
NCT02152995	1:6:gender,46:64:pregnancy,77:90:upper_bound	women of child-bearing potential must have a negative pregnancy test within 2 weeks prior study registration
NCT02149823	1:3:lower_bound,6:9:age,12:14:upper_bound	18 ≤ age ≤ 65
NCT02149823	24:38:chronic_disease,42:54:chronic_disease	Clinically significant cardiovascular or neurological conditions
NCT02149823	26:39:upper_bound	Current substance abuse (last 6 months) or past dependence on stimulants
NCT02149823	40:43:chronic_disease	Currently meets DSM-IV-TR criteria for MDD
NCT02149823	23:32:chronic_disease	Currently meets for a psychotic episode
NCT02149823	18:30:treatment,40:60:treatment	Currently taking psychotropic or other systemic medications
NCT02149823	1:3:clinical_variable,4:6:lower_bound	IQ≥80
NCT02149823	1:21:language_fluency	Non-English speaking
NCT02149823	24:27:clinical_variable	clinically significant EKG abnormalities, or serious general medical illness
NCT02149823	1:8:treatment,30:46:treatment	opioids or other potentially neurotoxic drugs
NCT02149823	1:9:pregnancy	pregnant or lactating
NCT02149823	1:23:chronic_disease	traumatic brain injury
NCT02149823	14:26:chronic_disease	uncontrolled hypertension
NCT02141919	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT02141919	18:31:cancer,55:65:cancer	All histology of renal cancers are included including oncocytoma
NCT02141919	15:29:cancer	Biopsy proven Renal neoplasm
NCT02141919	11:21:clinical_variable,23:26:lower_bound,30:48:clinical_variable,53:56:lower_bound,110:118:upper_bound	Growth of renal mass >4mm in radiographic scans or >2mm in two different scans must be demonstrated within a one year period
NCT02141919	25:43:cancer	No clinical evidence of metastatic disease
NCT02141919	1:11:clinical_variable,14:17:upper_bound	Renal mass ≤ 3cm
NCT02141919	36:64:treatment,80:83:treatment,87:99:treatment	Subjects may not have received any treatment for the renal mass before such as RFA or cryoablation
NCT02141919	10:30:pregnancy	Subjects must not be pregnant during the course of SABR
NCT02141919	42:61:treatment	Subjects must not have received previous abdominal radiation
NCT02140554	1:2:upper_bound,3:11:chronic_disease	4 priapism episodes that require a visit to a medical facility (without inpatient admission) are sufficient to meet criterion
NCT02140554	10:23:chronic_disease	Advanced liver disease
NCT02140554	37:47:allergy_name	Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells
NCT02140554	16:44:chronic_disease	Any history of severe cerebral vasculopathy
NCT02140554	22:32:cancer,36:61:chronic_disease	Any prior or current malignancy or immunodeficiency disorder
NCT02140554	1:26:clinical_variable,30:57:clinical_variable,59:67:lower_bound	Baseline prothrombin time or partial thromboplastin time >1.5× ULN
NCT02140554	5:7:lower_bound,13:15:upper_bound,19:22:age	Be ≥12 and ≤50 of age at time of consent
NCT02140554	35:44:chronic_disease,46:51:chronic_disease,53:59:chronic_disease,64:83:chronic_disease	Clinically significant and active bacterial, viral, fungal, or parasitic infection
NCT02140554	14:39:chronic_disease	Diagnosis of sickle cell disease (SCD), with either βS/βS or βS/β0 or βS/β+ genotype
NCT02140554	26:46:chronic_disease	Diagnosis of significant psychiatric disorder of the subject that, in the Investigator's judgment, could seriously impede the ability to participate in the study
NCT02140554	42:45:chronic_disease,147:154:lower_bound,147:148:lower_bound,256:264:lower_bound,292:313:treatment	For the purposes of this study, a severe VOE is defined as an event with no medically determined cause other than a vaso-occlusion, requiring a ≥ 24-hour hospital or Emergency Room (ER) observation unit visit or at least 2 visits to a day unit or ER over 72 hours with both visits requiring intravenous treatment
NCT02140554	49:69:upper_bound,147:150:treatment	Have been treated and followed for at least the past 24 months prior to Informed Consent in medical center(s) that maintained detailed records on SCD history
NCT02140554	25:41:treatment,38:40:treatment	Have either experienced hydroxyurea (HU) failure at any point in the past or must have intolerance to HU (defined as patient being unable to continue to take HU per PI judgement)
NCT02140554	13:16:chronic_disease	Have severe SCD
NCT02140554	51:75:chronic_disease	Immediate family member with a known or suspected Familial Cancer Syndrome
NCT02140554	14:22:upper_bound,26:29:age,37:40:treatment,113:125:treatment	In subjects <18 years of age, these MRI findings are exclusionary, unless in the opinion of the Investigator, a liver biopsy could provide additional data to confirm eligibility and would be safe to perform
NCT02140554	51:76:clinical_variable,82:89:upper_bound,93:99:upper_bound,116:128:treatment,135:149:clinical_variable,152:162:upper_bound,172:185:chronic_disease	Inadequate bone marrow function, as defined by an absolute neutrophil count of < 1000/µL (< 500/µL for subjects on HU treatment) or a platelet count < 120,000/µL (without hypersplenism)
NCT02140554	1:29:clinical_variable,35:37:lower_bound,40:48:lower_bound,52:55:age	Karnofsky performance status of ≥ 60 (≥16 years of age)
NCT02140554	1:4:treatment,35:44:chronic_disease,58:66:chronic_disease,93:102:chronic_disease,107:131:clinical_variable,133:140:lower_bound,159:171:treatment,185:193:lower_bound,197:200:age	MRI findings suggestive of active hepatitis, significant fibrosis, inconclusive evidence of cirrhosis, or liver iron concentration ≥15 mg/g require follow-up liver biopsy in subjects ≥18 years of age
NCT02140554	1:33:treatment,79:88:chronic_disease	Magnetic Resonance Imaging (MRI) of the liver demonstrating clear evidence of cirrhosis
NCT02140554	18:69:treatment,77:84:upper_bound	Participation in another clinical study with an investigational drug within 30 days of Screening
NCT02140554	18:50:treatment,93:113:treatment	Patients needing curative anticoagulation therapy during the period of conditioning through platelet engraftment
NCT02140554	12:34:clinical_variable	Persistent aspartate transaminase
NCT02140554	26:66:chronic_disease,68:73:chronic_disease,78:83:chronic_disease,86:109:chronic_disease,114:131:chronic_disease	Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV)
NCT02140554	1:10:pregnancy	Pregnancy
NCT02140554	21:42:treatment	Prior receipt of an allogeneic transplant
NCT02140554	18:30:treatment	Prior receipt of gene therapy
NCT02140554	19:34:treatment	Unable to receive RBC transfusion
NCT02140554	3:28:clinical_variable,33:35:lower_bound,38:46:upper_bound,50:53:age	a Lansky performance status of ≥60 (<16 years of age)
NCT02140554	1:30:clinical_variable,33:43:lower_bound,53:72:treatment	abnormal transcranial Doppler [≥200 cm/sec] needing chronic transfusion
NCT02140554	12:34:contraception_consent	absence of adequate contraception for fertile subjects
NCT02140554	37:45:treatment,60:78:treatment,99:125:treatment	any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients
NCT02140554	31:37:gender	breastfeeding in a postpartum female
NCT02140554	1:23:clinical_variable,25:59:lower_bound	direct bilirubin value >3× the upper limit of normal (ULN)
NCT02140554	60:63:chronic_disease,118:119:lower_bound,127:131:chronic_disease,139:154:upper_bound	in the setting of appropriate supportive care measures for SCD (e.g.,pain management plan) have experienced at least 4 severe VOEs in the 24 months prior to informed consent
NCT02140554	1:10:chronic_disease,14:22:chronic_disease	occlusion or stenosis in the polygon of Willis
NCT02140554	10:28:chronic_disease	overt or hemorrhagic stroke
NCT02140554	35:49:treatment	patients on prophylactic doses of anticoagulants
NCT02140554	13:29:chronic_disease	presence of Moyamoya disease
NCT02140554	49:55:cancer,64:87:cancer	previously treated, non-life threatening, cured tumors such as squamous cell carcinoma of the skin
NCT02140554	1:9:chronic_disease	priapism does not require hospital admission but does require a medical facility visit
NCT02140554	27:40:chronic_disease	suspected of arising from liver disease
NCT02138669	15:32:chronic_disease,34:44:chronic_disease,48:72:chronic_disease	Patients with collagen vascular, autoimmune or immunodeficiency disease
NCT02138669	1:9:pregnancy	Pregnant
NCT02138669	9:17:lower_bound,21:24:age	Who are 21 years of age or older
NCT02138669	12:29:clinical_variable,33:36:lower_bound	Who have a corneal thickness of 450 microns or greater at the proposed incision site
NCT02138669	10:33:treatment	Who have corneal transplantation as the only remaining option to improve their functional vision
NCT02138669	1:27:treatment	amiodarone HCL (Cordarone)
NCT02138669	1:18:chronic_disease	corneal dystrophy
NCT02138669	1:24:treatment	isotretinoin (Accutane)
NCT02138669	1:35:chronic_disease	recurrent corneal erosion syndrome
NCT02138669	12:29:clinical_variable,33:44:upper_bound	who have a corneal thickness of 449 microns or less at the proposed incision site
NCT02133573	54:69:clinical_variable,72:77:upper_bound,81:83:lower_bound,84:92:upper_bound,110:130:treatment	History of preterm birth or short cervix (defined as cervical length ≤ 25 mm at 18-24 weeks GA necessitating progesterone therapy
NCT02133573	49:61:allergy_name,114:140:allergy_name,142:170:allergy_name,172:179:allergy_name,183:206:allergy_name,208:224:allergy_name,226:250:allergy_name,252:271:allergy_name,273:282:allergy_name	Known sensitivity or listed contraindication to progesterone (known allergy or hypersensitivity to progesterone, severe hepatic dysfunction, undiagnosed vaginal bleeding, mammary or genital tract carcinoma, thrombophlebitis, thromboembolic disorders, cerebral hemorrhage, porphyria)
NCT02133573	1:47:language_fluency	Language other than English spoken in the home
NCT02133573	51:65:chronic_disease	Major genetic or extra-cardiac anomaly other than 22q11 deletion
NCT02133573	31:63:treatment	Maternal contraindication for magnetic resonance imaging (MRI)
NCT02133573	17:29:treatment,37:44:upper_bound	Maternal use of progesterone within 30 days of enrollment
NCT02133573	30:33:chronic_disease,35:54:chronic_disease,66:73:treatment,79:107:treatment,117:125:upper_bound,136:156:clinical_variable,153:155:clinical_variable,177:185:upper_bound	Mother carrying a fetus with CHD (maternal-fetal dyad) requiring surgery with cardiopulmonary bypass (CPB) prior to 44 weeks corrected gestational age (GA) identified prior to 28 weeks GA
NCT02133573	30:41:treatment,65:77:treatment,84:97:treatment,99:108:treatment,110:122:treatment,126:137:treatment	Prescription or ingestion of medications known to interact with progesterone (e.g. Bromocriptine, Rifamycin, Ketoconazole or Cyclosporin)
NCT02133573	62:69:treatment	Subjects with a known history of non-compliance with medical therapy
NCT02125786	1:28:clinical_variable,30:34:clinical_variable,37:38:upper_bound	Adequate performance status (ECOG < 3)
NCT02125786	23:44:cancer,49:52:age,55:62:upper_bound	Any patient with both metastatic ependymoma and age < 3 years at the time of enrollment
NCT02125786	32:49:treatment,66:74:lower_bound	Interval from start of initial radiation therapy to enrollment > 9 months
NCT02125786	10:14:age,15:16:lower_bound,17:25:upper_bound	Patients aged 1-21 years at the time of enrollment
NCT02125786	1:9:pregnancy,10:15:gender,67:84:treatment	Pregnant women are excluded from enrollment on this study because radiation therapy is an agent with the potential for teratogenic or abortifacient effects
NCT02125786	1:31:treatment	Prior craniospinal irradiation
NCT02125786	13:36:cancer,49:66:treatment	Progressive intracranial ependymoma after prior focal irradiation
NCT02125786	39:61:treatment	research participant does not require mechanical ventilation
NCT02112565	1:26:clinical_variable,30:44:lower_bound	Absolute neutrophil count >= 1,500 cells/µL
NCT02112565	8:21:chronic_disease,32:53:chronic_disease,61:78:upper_bound,80:115:chronic_disease,119:130:chronic_disease,148:172:chronic_disease	Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease or heart block, or uncontrolled congestive heart failure
NCT02112565	1:33:clinical_variable,29:32:clinical_variable,34:64:clinical_variable,60:63:clinical_variable,68:77:upper_bound,70:77:upper_bound,101:117:cancer	Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; AST/ALT =< 5 x ULN if liver metastasis is present
NCT02112565	1:61:clinical_variable,65:66:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 2
NCT02112565	1:11:clinical_variable,15:29:lower_bound	Leukocytes >= 3,000 cells/µL
NCT02112565	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 3 months by physician assessment
NCT02112565	62:76:gender	Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only)
NCT02112565	52:68:cancer,103:116:lower_bound,135:144:treatment	Patients may be enrolled with a history of treated brain metastases that are clinically stable for >= 4 weeks prior to start of study treatment
NCT02112565	41:63:treatment,72:107:treatment	Patients may not be receiving any other investigational agents; use of over-the-counter herbal medications
NCT02112565	126:137:cancer	Patients must have histologically or cytologically confirmed (at original diagnosis or subsequent recurrence or progression) solid tumor that is metastatic, unresectable, progressive, or recurrent, and for which standard curative or palliative measures do not exist or are no longer effective
NCT02112565	33:51:treatment,55:64:treatment,71:84:upper_bound,103:112:treatment	Patients must not have received prior chemotherapy or radiation for < 4 weeks prior to start of study treatment
NCT02112565	42:53:chronic_disease	Patients with a history of noninfectious pneumonitis will be excluded during the dose-escalation phase of the trial
NCT02112565	91:107:chronic_disease,112:149:chronic_disease	Patients with uncontrolled undercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02112565	1:10:clinical_variable,14:31:lower_bound	Platelets >= 100, 000 cells/µL
NCT02112565	1:22:clinical_variable,23:59:clinical_variable,61:105:clinical_variable,109:118:upper_bound	Prothrombin time (PT)/international normalized ratio (INR)/ activated partial thromboplastin time (aPTT) =< 1.5 x ULN
NCT02112565	1:17:clinical_variable,21:30:upper_bound,45:65:clinical_variable,69:78:lower_bound	Serum creatinine =< 1.5 mg/dL or a measured creatinine clearance >= 50 mL/min
NCT02112565	1:16:clinical_variable,20:61:upper_bound	Total bilirubin =< 1.5 times the upper limit of normal (ULN)
NCT02112565	1:6:gender,3:6:gender,47:82:contraception_consent,84:92:contraception_consent,96:127:contraception_consent,131:141:contraception_consent,172:182:upper_bound	Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation
NCT02112565	5:28:treatment,60:73:lower_bound,86:101:treatment	any prior radiation therapy must have been administered >= 4 weeks prior to start of study treatment
NCT02112565	67:76:treatment,95:110:treatment	the patient must be recovered from the acute toxic effects of the treatment prior to start of study treatment
NCT02106650	1:4:clinical_variable,6:13:lower_bound	ANC ≥1000/µL
NCT02106650	1:78:clinical_variable,69:72:clinical_variable,80:151:clinical_variable,142:145:clinical_variable,157:188:clinical_variable,184:187:clinical_variable,190:222:upper_bound,237:243:upper_bound,283:291:cancer	Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT), and gamma-glutamyltransferase (GGT) ≤2.5 xupper limit of normal (ULN) (AST/ALT/GGT ≤5 xULN if documented hepatic involvement with lymphoma)
NCT02106650	1:11:clinical_variable,13:22:upper_bound,26:57:clinical_variable,59:68:lower_bound	Creatinine ≤2.0 mg/dL or calculated creatinine clearance ≥50 mL/min
NCT02106650	1:61:clinical_variable,63:64:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status ≤2
NCT02106650	1:8:gender,42:104:contraception_consent,118:132:contraception_consent,139:154:treatment,181:188:lower_bound,222:229:treatment,233:243:treatment,282:348:pregnancy,361:374:upper_bound	Females of childbearing potential are to agree to practice a medically acceptable contraceptive regimen (including a barrier method) from study treatment initiation until at least 30 days after the last administration of Folotyn or leucovorin, whichever is last, and are to have a negative urine beta human chorionic gonadotropin (β-HCG) pregnancy test within 14 days prior to the first day of study treatment
NCT02106650	1:14:gender,22:68:contraception_consent,80:89:treatment,116:123:lower_bound	Male patients are to agree to use a barrier method of contraception from study treatment initiation until at least 90 days after the last administration of Folotyn
NCT02106650	1:15:clinical_variable,17:27:lower_bound	Platelet count ≥100,000/µL
NCT02106650	1:16:clinical_variable,18:27:upper_bound	Total bilirubin ≤1.5 mg/dL
NCT02106650	1:30:chronic_disease,43:60:chronic_disease,71:86:chronic_disease,152:161:treatment	active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment
NCT02106650	10:18:lower_bound,22:25:age	at least 18 years of age
NCT02106650	1:25:chronic_disease,26:35:lower_bound,36:38:upper_bound,56:115:clinical_variable	congestive heart failure Class III/IV according to the New York Heart Association (NYHA) Functional Classification
NCT02106650	16:42:cancer,53:57:chronic_disease,62:66:cancer,88:97:treatment	diagnosed with hematological malignancies including PTCL and CTCL and are eligible for treatment with a dose of 30 mg/m^2
NCT02106650	5:18:treatment,26:39:upper_bound	had major surgery within 14 days prior to enrollment
NCT02106650	26:33:treatment,41:49:upper_bound	had previous exposure to Folotyn within 6 months of study enrollment
NCT02106650	47:54:treatment,72:79:lower_bound,101:118:treatment	has recovered from the toxic effects of prior therapy, and is at least 30 days from the most recent cytotoxic therapy, prior to enrollment
NCT02106650	21:55:chronic_disease	known, uncontrolled human immunodeficiency virus (HIV)-positive diagnosis
NCT02106650	1:9:pregnancy	pregnant
NCT02106650	10:36:treatment	received prophylactic CNS treatment are eligible
NCT02106650	13:52:cancer,74:83:treatment	symptomatic central nervous system (CNS) metastases or lesions for which treatment is required
NCT02106650	14:26:chronic_disease	uncontrolled hypertension
NCT02106650	10:31:treatment,33:42:treatment,47:54:treatment,62:75:upper_bound,85:94:treatment	used any investigational drugs, biologics, or devices within 14 days prior to study treatment or plans to use any of these during the course of the study
NCT02106312	1:4:age,23:31:lower_bound	Age above or equal to 18 years
NCT02106312	1:25:treatment,50:56:treatment,73:83:treatment,85:93:treatment,98:108:treatment,115:122:treatment	Anticoagulant medication of any kind; especially Ascal®(and derivates), coumarines (Sintrom® and Marcoumar®), all heparin and heparin-like formulations
NCT02106312	1:7:treatment,15:18:chronic_disease,34:70:treatment,96:111:cancer,123:145:cancer,233:248:cancer,310:315:treatment,363:384:treatment	Biopsy proven MLS (including the reciprocal chromosomal translocation t(12;16)(q13;p11); A the primary sarcoma in case of non-metastatic disease for management is with curative intent (regimen to be chosen = 18 x 2 GY) B in case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 GY in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes (see paragraph 10 for radiobiological considerations)
NCT02106312	1:42:clinical_variable	ECOG (Eastern Cooperative Oncology Group)
NCT02106312	1:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	PS (Performance Status) 0-2
NCT02106312	102:120:clinical_variable,124:125:lower_bound,126:133:upper_bound,146:153:treatment	Patients must be able (physically, mentally and socially) to complete a series of RT, followed by an observation period of 4-6 weeks and undergo surgery
NCT02106312	1:10:pregnancy	Pregnancy
NCT02106312	1:38:treatment	Prior radiotherapy to the target area
NCT02106312	13:37:treatment	patients on anticoagulant medication as described above may take part in the dose reduction part of the study, but the repeat biopsies may not be taken
NCT02101944	3:9:lower_bound,13:31:chronic_disease,66:81:clinical_variable	> 200 mg of monoclonal protein in the urine on screening 24-hour electrophoresis
NCT02101944	3:9:gender,64:69:gender,98:110:treatment,114:136:treatment	A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
NCT02101944	1:32:language_fluency,36:43:lower_bound	Absolute neutrophil count (ANC) >= 1000/uL
NCT02101944	1:7:chronic_disease,10:16:lower_bound,54:70:clinical_variable,73:80:upper_bound	Anemia > 2 g/dL below the lower limit of normal or a hemoglobin value < 10 g/dL
NCT02101944	1:33:clinical_variable,38:68:clinical_variable,71:114:upper_bound	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the institutional upper limit of normal
NCT02101944	1:13:chronic_disease,15:28:chronic_disease,37:47:chronic_disease,51:71:chronic_disease	Bone lesions: lytic lesions, severe osteopenia or pathologic fractures
NCT02101944	6:19:gender	Both men and women of all races and ethnic groups are eligible for this study
NCT02101944	1:61:clinical_variable,43:61:clinical_variable,65:66:upper_bound,68:77:clinical_variable,81:84:lower_bound,199:215:cancer	Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) is required for eligibility; those patients with lower performance status based solely on bone pain secondary to multiple myeloma
NCT02101944	98:105:cancer	Evidence of any end organ damage criteria listed below (at any time) attributed to the patient's myeloma
NCT02101944	1:8:gender,54:68:pregnancy,72:87:pregnancy,124:133:lower_bound,134:159:treatment	Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to starting therapy and prior to beginning another cycle
NCT02101944	1:14:chronic_disease,16:29:clinical_variable,32:42:lower_bound	Hypercalcemia: serum calcium > 11.5 mg/dL
NCT02101944	42:49:cancer,138:157:cancer	Patient must have relapsed or refractory myeloma that fits or did fit International Myeloma Working Group (IMWG) diagnostic criteria for symptomatic myeloma
NCT02101944	89:96:treatment,114:127:lower_bound,137:146:treatment	Patients must agree not to donate blood, sperm/ova during the course of taking protocol therapy and for at least 4 weeks after stopping treatment
NCT02101944	52:60:pregnancy,72:77:gender,140:158:treatment,167:181:upper_bound	Patients must be able to avoid direct contact with pregnant or nursing women, infants and immunocompromised individuals during the days of reolysin treatment and for two days after
NCT02101944	52:80:treatment,85:105:treatment,129:140:treatment,177:185:upper_bound,191:221:treatment	Patients must have been previously treated with an immunomodulatory drug (IMiD) and proteasome inhibitor, must be refractory to carfilzomib defined as progression on or within 2 months of a carfilzomib-containing therapy, and must be progressing
NCT02101944	30:64:chronic_disease,85:96:chronic_disease,100:101:chronic_disease	Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections
NCT02101944	32:60:treatment	Patients previously treated on clinical trial with reolysin
NCT02101944	32:72:treatment	Patients who are receiving any other therapeutic investigational agents
NCT02101944	23:35:treatment,39:51:treatment,59:72:upper_bound	Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study
NCT02101944	27:51:cancer,178:186:clinical_variable,192:198:upper_bound	Patients with a currently active second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, shorten survival to < 1 year, or confound data interpretation
NCT02101944	1:22:chronic_disease,28:42:chronic_disease,44:56:chronic_disease,58:72:chronic_disease,74:104:chronic_disease,110:139:chronic_disease	Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein), and skin changes (POEMS) syndrome
NCT02101944	1:15:clinical_variable,19:25:lower_bound,30:41:treatment	Platelet count >= 75,000 and transfusion independent
NCT02101944	1:9:pregnancy,10:15:gender	Pregnant women are excluded from this study; breastfeeding should be discontinued
NCT02101944	13:44:cancer	Presence of clonal bone marrow plasma cells
NCT02101944	7:46:treatment,36:46:treatment,112:125:lower_bound	Prior autologous and/or allogeneic transplant is permitted although transplant must have occurred greater than 90 days prior to registration
NCT02101944	1:16:treatment,7:16:treatment,49:56:lower_bound,99:122:treatment,216:223:upper_bound	Prior radiation is permitted; however, at least 2 weeks must have elapsed since the completion of prior radiation therapy and patients must have recovered from all radiation-associated toxicities to no greater than grade 1 at the time of registration
NCT02101944	1:20:chronic_disease,22:38:clinical_variable,41:48:lower_bound	Renal insufficiency: serum creatinine > 2 mg/dL
NCT02101944	1:38:clinical_variable,42:50:lower_bound,85:123:clinical_variable	Serum immunoglobulin free light chain >= 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
NCT02101944	1:25:clinical_variable,29:38:lower_bound,42:65:treatment	Serum monoclonal protein >= 500 mg/dL by protein electrophoresis
NCT02101944	1:16:clinical_variable,19:28:upper_bound	Total bilirubin < 1.5 mg/dL
NCT02101944	77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
NCT02101944	1:6:gender,3:6:gender,47:82:contraception_consent,84:92:contraception_consent,96:127:contraception_consent,129:139:contraception_consent,150:163:lower_bound,201:208:lower_bound,248:255:treatment	Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) starting 28 days prior to starting the study until at least 90 days following discontinuation of the trial therapy
NCT02101944	1:22:chronic_disease,40:48:upper_bound	myocardial infarction in the preceding 6 months
NCT02101944	27:96:treatment,81:95:treatment,104:114:treatment,138:143:upper_bound,280:292:lower_bound,302:311:treatment	patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg by mouth daily or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least 7 days prior to study treatment
NCT02101944	1:20:chronic_disease	psychiatric illness/social situations that would limit compliance with study requirements
NCT02101944	10:15:gender,16:31:pregnancy,23:31:pregnancy	should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
NCT02100956	162:181:chronic_disease,233:249:chronic_disease	Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the Principal Investigator, would place the subject at increased risk (active gynecologic disease in which increased tone would be detrimental e.g., uterine fibroids with ongoing bleeding), compromise the subject's compliance with study procedures, or compromise the quality of the dat
NCT02100956	1:17:chronic_disease,24:32:lower_bound	Neuropathic pain for > 6 months
NCT02100956	1:10:pregnancy	Pregnancy
NCT02100956	1:7:clinical_variable,22:32:upper_bound	Weight < or equal to 240 pounds
NCT02100956	9:33:treatment	chronic intrathecal drug therapy
NCT02100956	1:22:treatment,29:37:lower_bound,61:79:lower_bound,80:88:treatment	oral opioid treatment for > 3 months at a current dose of > 100 milligram (mg) morphine per day or equivalent
NCT02100956	47:57:allergy_name,61:70:allergy_name	significant reaction to any ingredient of the study drug or lidocaine
NCT02094625	48:58:cancer	(inclusive) at time of diagnosis of underlying malignancy
NCT02094625	50:57:treatment,172:181:treatment,200:209:treatment,213:240:treatment,246:286:treatment	Are anticipated to be able to comply with end-of-therapy audiology assessment (note that hearing assessments are performed per routine clinical care in children receiving cisplatin and consist of an audiogram or auditory brainstem response, and distortion-product otoacoustic emissions
NCT02094625	13:14:lower_bound,19:27:upper_bound,31:34:age	Are between 1 and 21 years of age
NCT02094625	1:10:treatment,35:40:upper_bound	Cisplatin must be delivered over <3 day
NCT02094625	1:21:chronic_disease,28:43:cancer,52:68:cancer	Disseminated disease (e.g. lepto-meningeal spread, tumor metastases)
NCT02094625	52:64:allergy_name	Documented hypersensitivity or allergy to previous NAC infusion
NCT02094625	37:47:cancer,55:72:treatment,100:103:lower_bound,114:123:treatment	Have a new diagnosis of a localized malignancy with a planned treatment course to include at least two cycles of cisplatin
NCT02094625	67:79:treatment,97:114:treatment	Hepatic, biliary, cardiac, or bone marrow function inadequate for chemotherapy as per patient's treatment regimen
NCT02094625	1:26:clinical_variable,28:31:upper_bound	Karnofsky or Lansky score <50%
NCT02094625	1:37:chronic_disease,154:173:chronic_disease,195:205:treatment,223:238:treatment,274:290:upper_bound	Moderate or Severe Persistent Asthma as defined by the latest recommendations from the National Heart Lung and Blood Institute definition includes daily asthma exacerbation with need for rescue medication) or an overnight hospitalization for asthma exacerbation within the previous 28 days
NCT02094625	52:66:cancer,68:83:cancer,85:97:cancer	Most common but not exclusive diagnoses consist of hepatoblastoma, medulloblastoma, osteosarcoma
NCT02094625	9:18:treatment,44:51:upper_bound,57:63:upper_bound	Planned cisplatin dose to be infused over ≤6 hours for ≤2 days per cycle
NCT02094625	1:10:pregnancy	Pregnancy or breast-feeding mothers
NCT02094625	34:43:clinical_variable,53:62:lower_bound,67:77:lower_bound	Total cumulative dose of planned cisplatin must be >200 mg/m2 (or 6.67 mg/kg equivalent for infants requiring weight-based dosing
NCT02094625	32:42:chronic_disease,106:127:clinical_variable,129:132:upper_bound,192:212:chronic_disease	no preexisting risk of serious arrhythmia as defined by (a) normal sinus rhythm on electrocardiogram and corrected QT interval <500 and (b) no previous history of congenital arrhythmia (e.g. Wolf-Parkinson-White)
NCT02073292	12:28:chronic_disease,58:80:chronic_disease	Absence of focal neurologic signs or symptoms related to thoracic radiculopathy
NCT02073292	1:4:age,5:7:lower_bound	Age 18 or older
NCT02073292	46:54:lower_bound	Chronic thoracic spine mediated back pain of 3 months duration or longer
NCT02073292	40:57:chronic_disease,62:81:chronic_disease,99:109:chronic_disease,145:165:treatment	Concomitant medical (e.g. uncontrolled cardiac condition) or psychiatric illness (e.g., untreated depression) likely to endanger the patient or compromise treatment outcomes
NCT02073292	60:75:treatment,80:96:treatment	Failure to respond to conservative measures in the form of oral medication and physical therapy
NCT02073292	1:11:cancer	Malignancy
NCT02073292	11:14:lower_bound,49:57:upper_bound,102:131:treatment,172:181:treatment,209:220:treatment	More than 50% reduction in their pain less than 2 months duration following a series of 2 diagnostic thoracic medial branch blocks of the affected joints using 1 ml of 1% lidocaine in the first procedure and bupivacaine 0.5 % in the second time
NCT02073292	1:10:pregnancy	Pregnancy
NCT02073292	1:28:chronic_disease	Systemic or local infection
NCT02073292	11:23:chronic_disease	Untreated coagulopathy
NCT02073097	1:26:clinical_variable,29:37:lower_bound	Absolute neutrophil count ≥ 1,500/mc
NCT02073097	8:32:chronic_disease,34:60:clinical_variable,61:70:lower_bound,74:76:upper_bound,91:99:chronic_disease,174:195:chronic_disease,203:220:upper_bound	Active congestive heart failure (New York heart Association Class III or IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within four months prior to enrollment
NCT02073097	27:68:clinical_variable,71:74:lower_bound,90:104:treatment,108:143:treatment	Adequate cardiac function left ventricular ejection fraction (LVEF) > 50% as assessed by echocardiogram or MUGA (Multi Gated Acquisition Scan)
NCT02073097	1:4:age,7:9:lower_bound	Age ≥ 60 (1 point
NCT02073097	1:31:clinical_variable,33:77:clinical_variable,81:122:upper_bound	Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 X institutional upper limit of normal
NCT02073097	1:16:clinical_variable,17:20:lower_bound,24:26:upper_bound	Ann Arbor stage III or IV (1 point)
NCT02073097	1:33:clinical_variable,35:82:clinical_variable,85:126:upper_bound	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≤ 2.5 X institutional upper limit of normal
NCT02073097	1:21:clinical_variable,24:33:lower_bound	Creatinine clearance ≥ 45 mL/min calculated by Cockcroft-Gault
NCT02073097	1:24:clinical_variable,27:28:lower_bound	ECOG performance status ≥ 2 (1 point)
NCT02073097	1:61:clinical_variable,43:61:clinical_variable,64:65:upper_bound,89:90:upper_bound,188:195:treatment	Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; performance status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated
NCT02073097	1:11:clinical_variable,14:22:lower_bound	Hemoglobin ≥ 7.0 g/dl
NCT02073097	102:113:allergy_name,131:137:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or other agents (R-CHOP) used in this study
NCT02073097	1:35:chronic_disease,57:91:treatment	Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCT02073097	7:35:chronic_disease,51:59:cancer	Known central nervous system (CNS) involvement by lymphoma
NCT02073097	1:28:clinical_variable,31:62:lower_bound	Lactate dehydrogenase (LDH) > upper limit of normal (1 point)
NCT02073097	7:19:cancer,31:43:upper_bound,74:97:cancer,101:106:cancer,110:146:cancer,160:175:cancer,182:198:treatment	Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin, or low-risk prostate cancer after curative therapy
NCT02073097	36:43:upper_bound,45:75:treatment,83:106:treatment,115:121:treatment,174:189:cancer,272:274:treatment,282:294:treatment,296:310:treatment,315:333:treatment,335:344:treatment,363:376:upper_bound	Patients may have received brief (<15 days) treatment with glucocorticoids and/or 1 cycle of chemotherapy such as R-CHOP [or some component(s) thereof] for the diagnosis of B-cell lymphoma provided they had all necessary staging tests performed prior to R-CHOP including CT and/or PET/CT scans, echocardiogram and bone marrow biopsy. Treatment must occur within 60 days prior to enrollment
NCT02073097	45:82:cancer,76:81:cancer,119:136:cancer,138:157:cancer,162:184:cancer,193:219:cancer	Patients must have histologically confirmed diffuse large B-cell lymphoma (DLBCL); patients with previously diagnosed indolent lymphoma (follicular lymphoma and marginal zone lymphoma but not small lymphocytic lymphoma) who have transformed to DLBCL are eligible only if they have not previously been treated for indolent lymphoma. For the Phase II study, patients must have non-GC DLBCL as determined by Hans Algorithm
NCT02073097	38:60:treatment	Patients who are receiving any other investigational agents
NCT02073097	43:132:ethnicity	Patients who are reported to be of direct Asian-Pacific (China, Japan, Taiwan, Singapore, Republic of Korea, and Thailand) ancestry
NCT02073097	64:80:chronic_disease,88:101:upper_bound,111:120:treatment	Patients who have had major surgical procedures or significant traumatic injury within 28 days prior to study treatment
NCT02073097	90:105:lower_bound	Patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier
NCT02073097	90:106:chronic_disease,111:130:chronic_disease	Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02073097	1:15:clinical_variable,18:29:lower_bound	Platelet count ≥ 100,000/mcL
NCT02073097	1:9:pregnancy	Pregnant
NCT02073097	16:27:treatment,99:122:treatment,171:176:gender,173:176:gender,217:252:contraception_consent,254:292:contraception_consent,296:306:contraception_consent,308:321:upper_bound,339:348:treatment,398:412:upper_bound,444:449:gender,450:465:pregnancy,457:465:pregnancy,609:612:gender,668:681:lower_bound,699:710:treatment	The effects of Carfilzomib on the developing human fetus are unknown. For this reason and because chemotherapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 2 weeks prior to initiation of treatment, for the duration of study participation and for 3 months after completing treatment. Should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately. Men must agree to refrain from sperm donation for at least 90 days after the last dose of carfilzomib
NCT02073097	1:16:clinical_variable,66:83:chronic_disease	Total bilirubin within normal institutional limits unless due to Gilbert's disease
NCT02073097	15:20:gender,118:129:treatment	breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib
NCT02073097	3:4:lower_bound,5:21:cancer	≥ 2 extranodal sites (1 point)
NCT02061293	21:34:chronic_disease,38:62:chronic_disease,102:125:chronic_disease	A family history of schizophrenia or schizoaffective disorder (first or second degree relatives), or bipolar disorder type 1 (first degree relatives)
NCT02061293	32:42:allergy_name,46:61:allergy_name	Allergy or hypersensitivity to psilocybin or diphenhydramine
NCT02061293	30:46:treatment,37:46:treatment	Are not participating in any formal treatment for alcohol dependence (12-step meetings are not considered treatment)
NCT02061293	1:8:treatment,10:25:treatment,27:33:treatment,38:46:treatment,59:73:upper_bound	Cocaine, psychostimulant, opioid, or cannabis dependence (past 12 months)
NCT02061293	1:21:chronic_disease,23:60:clinical_variable,63:65:upper_bound	Cognitive impairment (Folstein Mini Mental State Exam score < 26)
NCT02061293	67:79:upper_bound	Current non-medical use of cocaine, psychostimulants, or opioids (past 30 days)
NCT02061293	14:36:chronic_disease,38:51:chronic_disease,53:77:chronic_disease,79:95:chronic_disease,105:129:chronic_disease,139:169:chronic_disease	Exclusionary psychiatric conditions (schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, current post-traumatic stress disorder, current suicidality or history of medically serious suicide attempt)
NCT02061293	92:102:treatment	Have a family member or friend who can pick them up and stay with them overnight after the psilocybin administration sessions
NCT02061293	15:16:lower_bound,44:56:upper_bound	Have at least 4 heavy drinking days in the past 30 days
NCT02061293	126:146:chronic_disease,148:167:chronic_disease,185:194:chronic_disease	High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support)
NCT02061293	12:24:treatment,57:68:upper_bound,74:85:lower_bound	History of hallucinogen use disorder, or any use in the past 1 year, or >25 lifetime uses
NCT02061293	1:6:gender	Males
NCT02061293	79:95:chronic_disease,111:134:chronic_disease,136:159:chronic_disease,161:174:chronic_disease,176:201:chronic_disease,209:220:lower_bound,247:271:chronic_disease,273:279:chronic_disease,281:296:chronic_disease,298:319:chronic_disease,321:343:chronic_disease,345:371:chronic_disease,373:406:chronic_disease,411:435:chronic_disease	Medical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, uncontrolled hypertension (above 165/95 mmHg at screening), history of cerebrovascular accident, asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction)
NCT02061293	14:24:treatment,69:86:treatment,94:109:treatment,111:125:treatment,127:143:treatment,145:155:treatment,178:190:treatment,194:213:treatment,215:222:treatment,224:239:treatment	Need to take medication with significant potential to interact with study medications (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants)
NCT02061293	1:10:pregnancy	Pregnancy or lactation
NCT02061293	9:12:treatment,46:54:chronic_disease,56:77:chronic_disease	Serious ECG abnormalities (e.g., evidence of ischemia, myocardial infarction)
NCT02061293	33:46:clinical_variable,60:61:lower_bound,167:174:upper_bound	Significant alcohol withdrawal (CIWA-Ar score greater than 7. Patients presenting at screening in withdrawal may be referred for detoxification and reassessed within 30 days)
NCT02061293	1:4:age,5:7:lower_bound,8:10:upper_bound	age 25-65
NCT02061293	1:8:gender	females
NCT02061293	6:10:chronic_disease	with SCID (DSM-IV) diagnosis of alcohol dependence who
NCT02056873	41:50:treatment	(If the subject chooses not to have the treatment, they cannot participate in the study
NCT02056873	42:45:treatment	(Subjects not required to participate in HRT but it will be highly encouraged, and must be completed prior to start of this study's protocol
NCT02056873	10:53:treatment,65:79:chronic_disease,81:94:chronic_disease,96:102:chronic_disease,104:122:chronic_disease,124:145:chronic_disease,150:168:chronic_disease,230:237:treatment	Abnormal brain magnetic resonance imaging (MRI) scan, including severe atrophy, hydrocephalus, stroke, structural lesions, demyelinating lesions, or infectious lesions that would potentially confound the outcome or safety of the surgery as judged by the study neurosurgeon
NCT02056873	26:33:chronic_disease,41:54:upper_bound	Any attempt or intent of suicide in the last 6 months
NCT02056873	50:53:treatment,57:79:cancer,120:140:treatment	Any previous neurological intervention including DBS or ablative brain lesions, any metal in the head, and any type of implanted stimulator
NCT02056873	1:9:chronic_disease,13:34:chronic_disease	Dementia or cognitive dysfunction that will place the subject at risk for worsening cognition, and/or may impact the ability to cooperate with tasks involved in the study
NCT02056873	31:74:treatment	History of noncompliance with previous medical and psychosocial treatment efforts
NCT02056873	4:14:treatment,53:67:treatment,117:129:treatment	If medication trials resulted in discontinuation of TS medications, the subject must be stabilized for 3 months off TS medicines
NCT02056873	35:50:treatment,35:60:treatment,162:178:treatment	If tic is focal or addressable by botulinum toxin treatment, the study neurologist will offer to administer a trial of botulinum toxin prior to consideration of surgical therapy
NCT02056873	17:27:treatment,28:38:treatment	Multiple failed medication treatments of inadequate dose or duration
NCT02056873	43:69:treatment,71:74:lower_bound,75:85:upper_bound	Must be at minimum a single trial with an alpha-2 adrenergic agonist (0.1-0.3 mg/day)
NCT02056873	36:47:treatment	Must be willing to keep TS related medications stable and unchanged throughout the trial
NCT02056873	24:46:treatment,47:88:treatment,90:93:treatment	Must have been offered habit reversal therapy/cognitive behavioral intervention therapy (HRT) if subject did not have it prior to enrollment
NCT02056873	42:108:treatment	Must have been stabilized for 1 month on TS medication without a dose change prior to surgical intervention
NCT02056873	13:22:chronic_disease	Presence of psychotic features
NCT02056873	39:62:chronic_disease,64:77:chronic_disease,79:93:chronic_disease,103:123:chronic_disease,125:146:chronic_disease,192:199:treatment	Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney disease, chronic neurological disease, hematological disease, or frailty that impacts tolerability of the surgery as judged by the screening physicians
NCT02056873	54:67:upper_bound	Significant substance abuse or dependence within the last 6 months
NCT02056873	1:3:cancer	TS must be causing incapacitation with severe distress, self-injurious behavior, and/or quality of life disruption
NCT02056873	12:22:treatment,158:159:lower_bound,280:281:lower_bound,282:290:upper_bound,294:305:treatment,311:319:upper_bound,323:331:treatment,333:344:treatment,348:356:upper_bound,363:375:treatment,377:380:lower_bound,381:389:upper_bound	TS must be medication refractory. Criteria to determine if medication refractory is the exact criteria stated by Mink et. al TSA DBS Guidelines published in 2006: Subjects must have been treated by a psychiatrist or neurologist experienced in TS with therapeutic doses of either 1-4 mg/day of haloperidol or 2-8 mg/day of pimozide, risperidone (1-3 mg/day), and aripiprazole (2.5-5 mg/day)
NCT02056873	43:60:chronic_disease,72:74:chronic_disease,79:89:treatment,98:116:chronic_disease,122:136:treatment	The presence of only simple motor tics, a movement disorder other than TS, or medication related movement disorders from TS medications
NCT02056873	65:76:treatment	Those who improve significantly will be excluded from receiving DBS surgery)
NCT02056873	23:30:chronic_disease,32:42:chronic_disease,44:60:chronic_disease,71:98:chronic_disease	Untreated or unstable anxiety, depression, bipolar disorder, or other Axis I psychiatric disorder
NCT02056873	1:6:gender,38:50:pregnancy,54:72:pregnancy,74:89:pregnancy	Women of child-bearing potential who are pregnant or planning pregnancy (urine pregnancy test required)
NCT02056873	1:39:clinical_variable,49:54:lower_bound,68:77:lower_bound,79:97:clinical_variable,107:109:lower_bound	Yale Global Tic Severity Scale (YGTSS) must be ≥35/50 for at least 12 months; Motor Tic subscore must be ≥15
NCT02055053	1:4:age,5:7:lower_bound	Age 18 or older
NCT02055053	1:4:age,15:21:upper_bound	Age less than 18 yrs
NCT02055053	12:29:allergy_name	Allergy to local anesthetics
NCT02055053	17:29:treatment,33:45:treatment	Conversion from laparoscopic to open surgery
NCT02055053	36:45:treatment	History of Chronic pain or ongoing treatment for chronic pain
NCT02055053	20:44:chronic_disease	with unilateral or bilateral inguinal herna for laparoscopic repair
NCT02046330	1:54:clinical_variable,67:69:lower_bound	24-item Hamilton Depression Rating Scale (HDRS) score of at least 21 on the first 17 items
NCT02046330	24:34:lower_bound,48:64:clinical_variable,82:89:lower_bound,115:122:lower_bound	A recurrent (equal or >4 episodes) or chronic (episode duration equal or higher >2 years) course AND a minimum of 5 years since the onset of the first depressive episode
NCT02046330	28:35:lower_bound,93:108:treatment,123:124:lower_bound	Adequate trials (equal or >6 weeks at the maximum recommended or tolerated dose) of primary antidepressants from at least 3 different classes
NCT02046330	1:4:age,5:7:lower_bound,10:18:upper_bound	Age 22 - 65 years
NCT02046330	22:25:treatment,28:29:lower_bound,30:50:treatment	An adequate trial of ECT (>6 bilateral treatments), or inability to tolerate an adequate ECT trial
NCT02046330	33:46:treatment,49:51:lower_bound	An adequate trial of individual psychotherapy (>20 sessions with an experienced psychotherapist)
NCT02046330	56:88:treatment	Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI)
NCT02046330	36:57:chronic_disease,69:77:chronic_disease	Any current clinically significant neurological disorder, including dementia or medical illness affecting brain function
NCT02046330	5:21:treatment,84:93:treatment	Any previous surgery to destroy the region of the brain that will be the target of treatment
NCT02046330	46:49:treatment,123:138:treatment,140:157:treatment,159:184:treatment,194:216:treatment,218:227:pregnancy,251:265:chronic_disease,268:277:chronic_disease,279:291:chronic_disease,388:395:treatment	Any surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/or inability to undergo presurgical MRI (cardiac pacemaker, implantable defibrillator or other implantable stimulator, pregnancy, metal in body, severe claustrophobia), infection, coagulopathy, inability to undergo an awake operation, significant cardiac or other medical risk factors for surgery
NCT02046330	31:49:chronic_disease,51:67:chronic_disease,69:82:chronic_disease,87:111:chronic_disease	Current or past non-affective psychotic disorder, Bipolar Disorder, Schizophrenia, or Schizoaffective disorder
NCT02046330	1:42:clinical_variable,46:48:upper_bound	Global Assessment of Function (GAF) score of 45 or less
NCT02046330	19:39:chronic_disease,200:231:chronic_disease	History of severe personality disorder, where, based on the judgment of the investigators, the personality disorder will interfere with the patient's ability to complete the follow-up protocol, e.g. borderline personality disorder
NCT02046330	18:25:chronic_disease	Imminent risk of suicide
NCT02046330	1:32:chronic_disease	Major Depression Disorder (MDD) diagnosed by Structured Clinical Interview for DSM-IV (SCID I/DSM-IV), judged to be of disabling severity
NCT02046330	82:98:treatment,108:116:chronic_disease	Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal or other self-injurious behavior)
NCT02046330	56:69:upper_bound	No alcohol and/or substance abuse or dependence in the past 6 months
NCT02046330	15:35:treatment	No changes in medication treatment during participation in study
NCT02046330	29:52:treatment,66:73:lower_bound	On a stable drug regimen of psychotropic medication for at least 6 weeks at the time of entry into the study
NCT02046330	18:58:treatment,70:87:upper_bound	Participation in another drug, device, or biologics trial within the preceding 30 days
NCT02046330	38:54:chronic_disease	Patients who suffer from generalized anxiety disorder
NCT02046330	1:10:pregnancy	Pregnancy
NCT02046330	35:44:treatment	Presence of a condition requiring diathermy
NCT02046330	43:47:treatment	Presence of a condition requiring routine MRIs
NCT02046330	33:36:treatment	Refusal of an adequate trial of ECT
NCT02046330	15:28:treatment	Subject is on anticoagulant medication
NCT02046330	34:51:clinical_variable,56:65:upper_bound	Terminal illness associated with expected survival of <12 months
NCT02046330	25:32:lower_bound,128:142:treatment,158:159:lower_bound,201:208:treatment,210:212:treatment,214:224:treatment,226:238:treatment,240:255:treatment,257:266:treatment,273:302:treatment	adequate trials ( equal>4 weeks at the usually recommended or maximum tolerated dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant)
NCT02046330	1:34:contraception_consent	not using effective contraception
NCT02046330	1:6:gender,23:26:age	women of childbearing age
NCT02035085	2:10:lower_bound,14:17:age	>18 years of age
NCT02035085	1:15:chronic_disease	Claustrophobic
NCT02035085	13:31:cancer	Evidence of metastatic disease
NCT02035085	1:7:gender	Female
NCT02035085	15:36:treatment	High risk for surgical intervention because of comorbidities
NCT02035085	11:20:upper_bound	Less than 18 months disease-free interval
NCT02035085	1:11:treatment,16:33:treatment,38:54:cancer	Lumpectomy and radiation therapy for breast carcinoma
NCT02035085	1:17:treatment	Metallic implant
NCT02035085	1:19:pregnancy	Negative pregnancy test
NCT02035085	16:34:cancer	No evidence of metastatic disease
NCT02035085	20:27:treatment	Patient is fit for surgery as determined by preoperative medical clearance workup performed by an independent primary care physician
NCT02035085	10:48:treatment,56:63:upper_bound	Received treatment with an investigational drug within 30 days of screening
NCT02035085	19:22:treatment	Unable to undergo MRI
NCT02033616	1:41:cancer	Active central nervous system metastases at the time of treatment
NCT02033616	1:17:chronic_disease,111:125:chronic_disease,129:147:chronic_disease	Active infection or other active medical condition that could be eminently life-threatening, including active blood clotting or bleeding diathesis
NCT02033616	24:39:cancer,119:134:upper_bound	Diagnosis of any other invasive cancer or other disease process which is considered to be life-threatening within the next five years
NCT02033616	1:24:clinical_variable,38:39:lower_bound,41:56:clinical_variable,67:70:upper_bound	ECOG performance status greater than 1 (Karnofsky score less than 70%)
NCT02033616	1:31:clinical_variable,33:48:clinical_variable,52:54:lower_bound,55:59:upper_bound	ECOG performance status of 0-1 (Karnofsky score of 70-100%)
NCT02033616	16:29:treatment,94:119:treatment	Have undergone leukapheresis from which sufficient provided PBMC were obtained to produce an investigational treatment
NCT02033616	7:25:chronic_disease,27:43:chronic_disease,89:114:treatment	Known autoimmune disease, immunodeficiency, or disease process that involves the use of immunosuppressive therapy
NCT02033616	27:33:allergy_name	Known hypersensitivity to GM-CSF
NCT02033616	15:38:chronic_disease,42:45:chronic_disease	Known to have active hepatitis B or C or HIV
NCT02033616	18:33:chronic_disease,50:72:chronic_disease,87:111:treatment	Known underlying cardiac disease associated with myocardial dysfunction that requires active medical treatment
NCT02033616	53:126:cancer,128:142:cancer,155:172:cancer,189:207:treatment,250:271:treatment,291:307:treatment,315:330:treatment	Patients must previously have been staged as having stage III [intraperitoneal (IP)] or Stage IV (distant metastatic) ovarian, fallopian tube, or primary peritoneal cancer, have undergone surgical debulking, and have initiated or completed standard adjuvant chemotherapy, which may include intravenous (IV) and/or IP chemotherapy using standard regimens
NCT02033616	28:44:cancer,73:98:treatment,136:147:treatment,151:161:treatment,238:247:treatment	Patients with one or a few brain metastases that have been treated with stereotactic radiotherapy consisting of a single dose, such as Gamma Knife or Cyberknife, are allowed to be included in the study, but need wait one week after such treatment
NCT02033616	46:53:upper_bound	Received another investigational drug within 28 days of the first dose or are planning to receive another investigational drug while receiving this investigational treatment
NCT02033616	82:107:cancer	Successful establishment of an autologous epithelial ovarian, fallopian tube, or primary peritoneal cancer cell line by AIVITA Biomedical, Inc
NCT02033616	8:27:treatment,13:19:cancer,83:99:treatment,104:112:cancer,116:129:cancer,150:160:lower_bound	taking anti-cancer therapy for cancer other than ovarian (such as continuation of hormonal therapy for prostate or breast cancer diagnosed more than five years earlier)
NCT02033616	7:16:treatment,40:67:chronic_disease	under treatment for arterial or venous peripheral vascular disease
NCT02033616	1:16:chronic_disease,28:66:chronic_disease	unstable angina related to atherosclerotic cardiovascular disease
NCT02033486	11:17:gender	Any adult female volunteers of any race or ethnic background
NCT02033486	7:15:upper_bound,28:36:lower_bound	Under 30 years old or over 80 years old
NCT02033486	13:17:age,21:23:lower_bound,27:29:upper_bound	between the ages of 30 to 80
NCT02033486	1:9:pregnancy,24:43:pregnancy	pregnant or thinks she may become pregnant
NCT02033486	16:39:treatment	presenting for breast cancer treatment
NCT02030015	1:4:age,6:14:upper_bound	Age: 17 years or less at time of enrollment
NCT02030015	16:23:gender	Breast-feeding females
NCT02030015	15:38:chronic_disease	Children with severe renal impairment will not be enrolled
NCT02030015	29:37:lower_bound	Patients who are older than 17 years will not be enrolled
NCT02030015	15:22:gender,31:39:pregnancy	Post-pubertal females who are pregnant
NCT02030015	33:77:chronic_disease	Subjects must have a documented infantile or juvenile gangliosidosis disease
NCT02030015	33:42:allergy_name	Subjects who have an allergy to miglustat or any of the components within the drug product
NCT02030015	62:71:pregnancy	who are unwilling to use highly-effective methods to prevent pregnancy
NCT02025959	38:41:age,45:53:lower_bound	exclude any hospital staff under the age of 18 years old from this study as well as hospital patients and non-hospital staff
NCT02025959	68:71:age,75:87:lower_bound	subjects must be University of Chicago hospital employees over the age of 18 years old
NCT02025426	1:4:age,6:12:lower_bound	Age ≥18 yrs
NCT02025426	12:25:allergy_name,29:38:allergy_name	Allergy to phenylephrine or ephedrine, or any other standardized medication
NCT02025426	23:44:chronic_disease	Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection
NCT02025426	1:3:chronic_disease,10:27:treatment	CD under spinal anesthesia
NCT02025426	1:17:language_fluency	English speaking
NCT02025426	1:7:clinical_variable,10:13:upper_bound	Height < 5'0
NCT02025426	14:19:gender	Non-laboring women
NCT02025426	13:41:treatment,45:70:treatment	Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants
NCT02025426	1:14:chronic_disease	Pre-eclampsia (mild, or severe)
NCT02025426	8:23:chronic_disease,27:36:pregnancy	Severe Cardiac disease in pregnancy with marked functional limitations (NYHA Class III and IV)
NCT02025426	73:80:upper_bound	Subject enrollment in another study involving a study medication within 30 days of CD
NCT02013778	8:21:chronic_disease,29:36:upper_bound	Active GI hemorrhage within 2 weeks of study enrollment
NCT02013778	1:4:age,5:13:upper_bound	Age 18 years old
NCT02013778	1:8:clinical_variable,25:34:clinical_variable,44:47:clinical_variable	Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5
NCT02013778	1:19:chronic_disease,23:38:treatment	Ascites refractory to medical therapy
NCT02013778	1:35:clinical_variable,36:37:lower_bound,41:42:upper_bound	Child-Turcotte-Pugh Classification A or B
NCT02013778	39:42:treatment	Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)
NCT02013778	31:34:treatment,38:42:treatment	Contraindication to receiving HCQ or TACE
NCT02013778	1:11:clinical_variable,23:26:clinical_variable,37:40:clinical_variable	Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L
NCT02013778	1:51:clinical_variable,52:53:lower_bound,56:57:upper_bound	Eastern Clinical Oncology Group performance status 0 or1
NCT02013778	37:46:treatment	Participation in another concurrent treatment protocol
NCT02013778	24:48:cancer,134:137:cancer,141:147:treatment,155:159:lower_bound,300:303:treatment,307:309:treatment,313:319:clinical_variable,400:409:chronic_disease,417:436:chronic_disease,442:470:clinical_variable,484:493:lower_bound	Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL
NCT02013778	27:59:treatment	Patient not candidate for orthotopic liver transplantation at the Hospital of the University of Pennsylvania based on review of patient imaging and history at multidisciplinary Hepatic Tumor Conference at the Hospital of the University of Pennsylvania
NCT02013778	1:11:treatment	Prior TACE
NCT02013778	10:13:cancer	Unilobar HCC
NCT02013778	1:6:gender,11:23:pregnancy	Women who are pregnant
NCT01999179	2:10:lower_bound,14:17:age	>18 years of age
NCT01999179	59:67:upper_bound	Anticipated replacement of central venous catheter within 3 months
NCT01999179	19:32:lower_bound	Catheter removal >1 month prior to enrollment
NCT01999179	1:21:clinical_variable,23:32:lower_bound	Creatinine clearance >30 ml/min
NCT01999179	9:20:chronic_disease	Current hematologic
NCT01999179	30:44:chronic_disease,55:89:chronic_disease,105:140:chronic_disease,161:184:chronic_disease,189:208:chronic_disease,212:226:treatment	Known underlying higher risk thrombophilias including antiphospholipid antibody syndrome, antithrombin, protein C or protein S deficiencies, or homozygosity or compound heterozygosity for prothrombin G20210A or Factor V R506Q mutations
NCT01999179	75:82:lower_bound	Major bleeding or clinically relevant non-major bleeding in the preceding 60 days
NCT01999179	55:70:treatment	Participation in another clinical trial that requires anticoagulation
NCT01999179	1:15:clinical_variable,17:23:lower_bound	Platelet count >50,000
NCT01999179	16:28:treatment	Treatment with thrombolysis
NCT01999179	33:45:treatment,66:81:treatment	Underlying medical condition or chemotherapy requiring long-term anticoagulation
NCT01999179	17:34:chronic_disease,88:98:treatment,100:102:treatment,106:116:treatment	Upper extremity venous thrombosis associated with an indwelling catheter documented by ultrasound, CT or venography
NCT01999179	8:21:treatment,33:61:treatment	Use of anticoagulant other than low-molecular weight heparin
NCT01999179	1:23:cancer,13:23:cancer,35:47:treatment,49:56:treatment,58:67:treatment,71:87:treatment	solid tumor malignancy undergoing chemotherapy, surgery, radiation or hormonal therapy for malignancy
NCT01993810	1:32:clinical_variable,36:52:lower_bound,69:82:upper_bound	Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 obtained within 30 days prior to registration
NCT01993810	1:43:chronic_disease,144:178:chronic_disease	Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
NCT01993810	52:70:cancer	Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup
NCT01993810	1:38:chronic_disease,61:80:chronic_disease,106:117:cancer,158:171:treatment,179:186:upper_bound	Chronic obstructive pulmonary disease exacerbation or other respiratory illness other than the diagnosed lung cancer requiring hospitalization or precluding study therapy within 30 days before registration
NCT01993810	1:28:chronic_disease	Exudative pleural effusions are excluded, regardless of cytology
NCT01993810	1:27:treatment,28:62:treatment,63:92:treatment,112:125:upper_bound	Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration
NCT01993810	1:46:clinical_variable,50:59:lower_bound,66:69:lower_bound,96:110:treatment,118:125:upper_bound	Forced expiratory volume in one second (FEV1) >= 0.8 liter or >= 35% predicted with or without bronchodilator within 90 days prior to registration
NCT01993810	1:11:clinical_variable,15:23:lower_bound,42:53:treatment,87:103:clinical_variable,148:161:upper_bound	Hemoglobin >= 9.0 g/dl (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is acceptable), obtained within 30 days prior to registration
NCT01993810	53:79:cancer	Histologically or cytologically proven diagnosis of non-small cell lung cancer
NCT01993810	37:50:upper_bound,77:95:clinical_variable	History/physical examination within 30 days prior to registration including resting heart rate
NCT01993810	48:52:clinical_variable,56:60:clinical_variable,67:92:upper_bound	It is highly recommended but not required that SGOT or SGPT be =< 1.5 upper limit of normal
NCT01993810	48:63:clinical_variable,70:95:upper_bound	It is highly recommended but not required that total bilirubin be =< 1.5 upper limit of normal
NCT01993810	1:38:treatment,81:101:treatment,123:136:upper_bound	Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration
NCT01993810	45:52:treatment,102:116:treatment	Patients who develop local recurrence after surgery and rendered candidate for definitive concurrent chemoradiation
NCT01993810	28:46:treatment,54:55:upper_bound,66:88:treatment,99:107:upper_bound,111:127:treatment	Patients who have received systemic treatment (up to 4 cycles of induction chemotherapy, or up to 6 months of targeted therapy)
NCT01993810	95:108:upper_bound,153:158:cancer,178:185:chronic_disease	Patients who meet the criterion above without oxygen (O2), but who need acute (started within 10 days prior to registration) supplemental oxygen due to tumor-caused obstruction/hypoxia are eligible, provided the amount of the O2 needed has been stable
NCT01993810	27:43:cancer,64:69:cancer,70:83:cancer	Patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor
NCT01993810	21:28:treatment	Patients who refuse surgery
NCT01993810	15:45:chronic_disease	Patients with non-malignant pleural effusion
NCT01993810	39:61:cancer,65:70:cancer,89:98:treatment	Patients with prior history of either small cell lung cancer or NSCLC regardless of the treatment received
NCT01993810	1:22:clinical_variable,26:33:upper_bound	Peripheral neuropathy =< grade 1 at the time of registration
NCT01993810	1:10:clinical_variable,14:32:lower_bound,49:56:upper_bound	Platelets >= 100,000 cells/mm^3 obtained within 30 days prior to registration
NCT01993810	1:10:pregnancy	Pregnancy
NCT01993810	16:26:cancer,64:71:lower_bound	Prior invasive malignancy unless disease free for a minimum of 3 years
NCT01993810	1:19:treatment,47:53:cancer,86:103:treatment	Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
NCT01993810	1:28:treatment,43:49:cancer,64:65:lower_bound,76:98:treatment,112:120:lower_bound,124:140:treatment	Prior systemic chemotherapy for the study cancer, if more than 4 cycles of induction chemotherapy or more than 6 months of targeted therapy
NCT01993810	1:17:clinical_variable,20:29:clinical_variable,33:64:clinical_variable,68:77:lower_bound,85:98:upper_bound,132:155:clinical_variable	Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 mL/min within 30 days prior to registration estimated by the Cockcroft-Gault formula
NCT01993810	1:47:clinical_variable,51:95:clinical_variable,103:116:upper_bound	Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) within 30 days prior to registration
NCT01993810	1:16:clinical_variable,20:23:upper_bound,31:44:upper_bound	Total bilirubin =< 1.5 within 30 days prior to registration
NCT01993810	1:33:chronic_disease,45:58:upper_bound	Transmural myocardial infarction within the last 6 months
NCT01993810	1:26:clinical_variable,29:32:lower_bound,40:53:upper_bound	Unintentional weight loss > 10% within 30 days prior to registration
NCT01993810	1:16:chronic_disease,24:48:chronic_disease,59:74:treatment,86:99:upper_bound	Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
NCT01993810	43:50:treatment,60:71:treatment	When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative
NCT01993810	1:6:gender,37:54:gender,78:91:contraception_consent	Women of childbearing potential and male participants must practice adequate contraception
NCT01993810	1:6:gender,45:69:pregnancy,82:95:upper_bound	Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration
NCT01993810	1:26:clinical_variable,27:28:lower_bound,29:30:upper_bound,38:51:upper_bound	Zubrod performance status 0-1 within 30 days prior to registration
NCT01993810	88:97:treatment	for patients who are clearly nonresectable, the case can be determined by the treating radiation oncologist and/or a medical oncologist or pulmonologist
NCT01993810	1:4:gender	men who are sexually active
NCT01993810	46:74:treatment,87:100:upper_bound	non-operable disease will be determined by a multi-disciplinary treatment team within 60 days prior to registration
NCT01993810	1:68:contraception_consent	not willing/able to use medically acceptable forms of contraception
NCT01993810	1:19:treatment,36:42:cancer	prior chemotherapy for a different cancer
NCT01993810	1:12:cancer,17:49:cancer,51:62:cancer,64:70:cancer	skin cancer and in situ carcinomas of the breast, oral cavity, cervix, and other organs and are permissible
NCT01993810	1:6:gender	women of childbearing potential
NCT01993719	76:88:upper_bound	A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2 years)
NCT01993719	1:26:clinical_variable,40:50:lower_bound,74:84:treatment	Absolute neutrophil count greater than 1000/mm(3) without the support of filgrastim
NCT01993719	8:27:chronic_disease,46:70:treatment,73:94:chronic_disease,121:138:chronic_disease	Active systemic infections, (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnesses
NCT01993719	1:4:age,30:38:lower_bound	Age greater than or equal to 65 years old
NCT01993719	13:37:chronic_disease,47:87:chronic_disease	Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease)
NCT01993719	30:34:clinical_variable,57:60:upper_bound	Any patient known to have an LVEF less than or equal to 45%
NCT01993719	32:36:clinical_variable,37:38:lower_bound,45:46:upper_bound	Clinical performance status of ECOG 0, 1 or 2
NCT01993719	24:30:chronic_disease,38:61:chronic_disease,92:111:chronic_disease,113:136:chronic_disease,148:172:chronic_disease,187:209:chronic_disease,213:223:chronic_disease	Clinically significant atrial and or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or history of ischemic heart disease or chest pain
NCT01993719	12:36:chronic_disease,55:64:treatment	Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system
NCT01993719	12:36:treatment	Concurrent systemic steroid therapy
NCT01993719	30:49:cancer	Confirmation of diagnosis of metastatic melanoma by the Laboratory of Pathology of NCI
NCT01993719	12:16:clinical_variable,39:42:upper_bound	Documented FEV1 less than or equal to 60% predicted tested in patients
NCT01993719	12:16:clinical_variable,42:45:upper_bound	Documented LVEF of less than or equal to 45%
NCT01993719	26:34:lower_bound,38:41:age,68:76:upper_bound	Greater than or equal to 18 years of age and less than or equal to 70 years of age
NCT01993719	1:11:clinical_variable,14:22:lower_bound	Hemoglobin > 8.0 g/dl
NCT01993719	12:38:treatment,42:59:chronic_disease	History of coronary revascularization or ischemic symptoms
NCT01993719	69:94:allergy_name	History of severe immediate hypersensitivity reaction to any of the agents used in this study
NCT01993719	12:31:cancer,46:49:lower_bound	Measurable metastatic melanoma with at least one lesion that is resectable for TIL generation and at least one other lesion that can be measured by RECIST criteria
NCT01993719	11:21:lower_bound,50:72:treatment,110:129:treatment,180:187:upper_bound,227:235:chronic_disease,239:247:chronic_disease,295:310:treatment	More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). Patients must have progressive disease after prior treatment
NCT01993719	29:54:treatment,66:78:upper_bound,124:131:upper_bound	Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less
NCT01993719	34:67:contraception_consent,124:135:upper_bound,142:151:treatment	Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
NCT01993719	34:56:treatment	Patients who are receiving other investigational agents
NCT01993719	15:16:upper_bound,26:42:cancer,62:66:upper_bound,70:78:clinical_variable	Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic
NCT01993719	1:15:clinical_variable,41:54:lower_bound	Platelet count greater than or equal to 100,000/mm(3)
NCT01993719	18:21:chronic_disease,50:59:treatment,146:162:chronic_disease	Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus are less responsive to the experimental treatment and more susceptible to its toxicities.)
NCT01993719	1:14:clinical_variable,37:72:upper_bound	Serum ALT/AST less than or equal to 2.5 times the upper limit of normal
NCT01993719	7:17:clinical_variable,40:49:upper_bound	Serum Creatinine less than or equal to 1.6 mg/dl
NCT01993719	13:36:chronic_disease	Symptoms of respiratory dysfunction
NCT01993719	1:16:clinical_variable,39:48:upper_bound,74:92:chronic_disease,109:124:clinical_variable,135:144:upper_bound	Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dl
NCT01993719	1:4:clinical_variable,30:40:lower_bound	WBC greater than or equal to 3000/mm(3)
NCT01993719	1:6:gender,46:64:pregnancy,122:131:treatment	Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
NCT01993719	1:6:gender,42:50:pregnancy,120:129:treatment	Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
NCT01989585	3:14:clinical_variable,50:71:clinical_variable,75:83:lower_bound,97:122:clinical_variable	A QT interval corrected for heart rate using the Bazett's formula QTcB >= 480 msec on screening electrocardiography (ECG)
NCT01989585	14:65:chronic_disease	A history of glucose-6-phosphate dehydrogenase (G6PD) deficiency
NCT01989585	28:43:treatment,89:119:chronic_disease,154:176:chronic_disease,180:195:treatment	Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
NCT01989585	1:34:clinical_variable,39:46:lower_bound,62:76:treatment,126:139:chronic_disease,140:148:chronic_disease	Abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study
NCT01989585	10:26:clinical_variable,30:40:lower_bound	Absolute neutrophil count >= 1 x 10^9/L
NCT01989585	1:12:treatment,14:28:treatment,30:43:treatment,45:59:treatment	Antibiotics: clarithromycin, telithromycin, troleandomycin
NCT01989585	1:12:treatment,14:23:treatment,44:52:treatment,54:63:treatment,65:76:treatment	Antibiotics: rifamycin class agents (e.g., rifampin, rifabutin, rifapentine)
NCT01989585	1:15:treatment,19:38:treatment,66:73:treatment	Anticoagulants or antiplatelet agents except for low-dose, 81 mg aspirin
NCT01989585	1:16:treatment,18:31:treatment,33:46:treatment,48:61:treatment,63:72:treatment,76:87:treatment	Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, s-mephenytoin
NCT01989585	1:16:treatment,18:28:treatment	Antidepressants: nefazodone
NCT01989585	1:12:treatment,14:26:treatment,28:40:treatment,42:54:treatment,56:68:treatment	Antifungals: itraconazole, ketoconazole, posaconazole, voriconazole
NCT01989585	1:15:treatment,17:26:treatment,28:38:treatment,40:50:treatment	Antiretroviral: ritonavir, saquinavir, atazanavir
NCT01989585	1:33:clinical_variable,35:81:clinical_variable,83:113:clinical_variable,115:159:clinical_variable,164:205:upper_bound	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
NCT01989585	72:90:treatment,212:227:treatment,229:233:treatment,235:253:treatment,255:268:treatment,270:299:treatment,301:308:treatment,310:322:treatment,327:334:treatment	Because the composition, pharmacokinetics (PK), and metabolism of many herbal supplements are unknown, the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)
NCT01989585	12:21:treatment,12:42:treatment,27:42:treatment,127:134:treatment,136:148:treatment,238:263:treatment	Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis
NCT01989585	29:39:treatment,55:66:treatment,70:88:treatment	Current use of a prohibited medication; the following medications or non-drug therapies are prohibited
NCT01989585	47:63:chronic_disease,79:102:treatment,126:136:treatment,153:164:treatment,166:175:treatment,177:186:treatment,188:196:treatment,208:222:treatment,224:229:treatment,234:252:treatment,328:355:treatment,365:372:treatment,417:445:treatment,447:454:treatment,482:494:upper_bound,611:626:treatment,631:641:chronic_disease,690:699:upper_bound,715:730:clinical_variable,746:757:lower_bound,767:774:upper_bound,829:859:treatment	Due to the expected dose-limiting toxicity of thrombocytopenia, the following concomitant medications are not allowed during navitoclax administration: clopidogrel, ibuprofen, tirofiban, warfarin, and other anticoagulants, drugs, or herbal supplements that affect platelet function are excluded, with the exception of low-dose anticoagulation medications (such as heparin) that are used to maintain the patency of a central intravenous catheter; aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention may resume a low dose (i.e., maximum 100 mg QD) of aspirin if platelet counts are stable (>= 50,000/mm^3) through 6 weeks of navitoclax administration; all decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitor
NCT01989585	1:61:clinical_variable,65:66:upper_bound,68:77:clinical_variable,81:84:lower_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
NCT01989585	1:11:clinical_variable,15:21:lower_bound	Hemoglobin >= 9 g/dl (patients may be transfused to this level)
NCT01989585	12:15:chronic_disease,19:22:chronic_disease,82:90:chronic_disease,94:113:chronic_disease,101:113:chronic_disease,128:144:chronic_disease,167:184:chronic_disease,200:214:chronic_disease,218:236:chronic_disease	History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes)
NCT01989585	12:36:chronic_disease,48:69:chronic_disease,74:89:chronic_disease,92:112:treatment,117:125:treatment,133:147:upper_bound,151:164:treatment	History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
NCT01989585	102:112:allergy_name,114:124:allergy_name,129:139:allergy_name,161:186:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)
NCT01989585	20:30:cancer,83:84:lower_bound,107:112:cancer,183:200:cancer,332:340:cancer,344:358:cancer,362:378:treatment,462:486:cancer,517:539:cancer,606:625:cancer,723:729:cancer	History of another malignancy; exception: patients who have been disease-free for 3 years (depending upon tumor type studied or clinical setting, 3 or 5 years can be used; e.g., for advanced melanoma and pancreatic studies 3 years is more appropriate due to aggressiveness of the disease, while 5 years can be more appropriate for prostate or ovarian cancer or adjuvant setting when life expectancy is longer), or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent secondary malignancies, are eligible; consult the CTEP medical monitor if unsure whether second malignancies meet the requirements specified above; exception: patients with history of RAS mutation-positive tumors are not eligible regardless of interval from the current study; prospective RAS testing is not required; however, if the results of previous RAS testing are known, they must be used in assessing eligibility
NCT01989585	25:37:chronic_disease,41:52:chronic_disease	History of interstitial lung disease or pneumonitis
NCT01989585	37:65:chronic_disease,69:101:chronic_disease	History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
NCT01989585	35:43:lower_bound,44:68:chronic_disease,87:120:clinical_variable	History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
NCT01989585	68:79:chronic_disease,117:136:chronic_disease,143:156:lower_bound	History or evidence of current clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for > 30 days prior to randomization are eligible)
NCT01989585	1:35:chronic_disease,31:34:chronic_disease,57:91:treatment,69:91:treatment,133:144:treatment,477:511:treatment,522:532:clinical_variable,539:547:lower_bound	Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy that predict to interact with any of the study drugs are ineligible because of the potential for pharmacokinetic interactions with the study drugs; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; it is not necessary to conduct HIV testing at screening; patients who are HIV-positive with undetectable viral loads, not on interacting antiretroviral therapy, and have CD4 counts above 300/mm^3 may be eligible after discussion with the principal investigator
NCT01989585	1:15:chronic_disease,17:28:treatment	Hyperlipidemia: gemfibrozil
NCT01989585	18:41:chronic_disease,37:40:chronic_disease,46:69:chronic_disease,65:68:chronic_disease	Known history of hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); it is not necessary to conduct HBV and HCV testing at screening
NCT01989585	1:35:clinical_variable,84:105:treatment	Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
NCT01989585	1:11:clinical_variable,15:24:lower_bound	Leukocytes >= 3,000/mcL
NCT01989585	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 3 months
NCT01989585	16:24:treatment,26:41:treatment	Miscellaneous: bosentan, St. John's wort
NCT01989585	16:26:treatment	Miscellaneous: conivaptan
NCT01989585	7:26:treatment,42:51:treatment,60:78:treatment	Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)
NCT01989585	32:49:clinical_variable,63:71:upper_bound	Patients must have a corrected QT (QTc) interval of less than 480 msec
NCT01989585	68:76:cancer	Patients must have histologically confirmed, BRAF-mutant (V600E/K) melanoma (molecularly confirmed using validated, commercially available assay performed in a Clinical Laboratory Improvement Act [CLIA]-approved laboratory) that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective
NCT01989585	60:63:lower_bound,224:229:lower_bound,235:258:clinical_variable,268:273:lower_bound,286:315:treatment,317:349:treatment,354:362:treatment	Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
NCT01989585	39:49:treatment,81:87:upper_bound	Patients must not have received prior navitoclax, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression
NCT01989585	24:35:treatment,59:76:treatment,59:107:treatment,152:169:treatment,176:191:treatment,199:214:treatment,220:284:treatment,288:330:treatment	Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A or CYP2C8 are ineligible; current use of, or intended ongoing treatment with: herbal remedies (e.g., St. John's wort), or strong inhibitors or inducers of permeability-glycoprotein (Pgp) or breast cancer resistance protein 1 (Bcrp1) should also be excluded
NCT01989585	38:60:treatment,85:106:treatment,114:121:upper_bound,183:190:lower_bound,245:254:treatment	Patients who are receiving any other investigational agents have received any other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study treatment and during the study
NCT01989585	23:36:treatment,38:50:treatment,54:66:treatment,74:87:upper_bound,109:119:treatment,124:158:treatment,196:223:treatment,240:256:treatment,261:276:treatment,289:307:upper_bound,325:335:treatment,343:353:treatment,355:376:treatment,413:425:upper_bound,460:469:treatment,471:480:treatment,508:521:upper_bound	Patients who have had immunotherapy, chemotherapy or radiotherapy within 14 days prior to the first dose of navitoclax, or prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks prior to first dose of dabrafenib and/or trametinib; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatment; biologics will not be allowed within 30 days prior to, or during, navitoclax administration
NCT01989585	1:10:clinical_variable,14:25:lower_bound	Platelets >= 100,000/mcL
NCT01989585	35:45:treatment,64:70:treatment,77:105:treatment,116:142:treatment,188:198:treatment,251:308:treatment,317:334:treatment,343:353:treatment,355:362:treatment,368:378:treatment,388:423:treatment,483:494:treatment,528:584:treatment,601:613:upper_bound,621:645:treatment	Preclinical studies indicate that navitoclax is metabolized by CYP3A4, is a moderate inhibitor of CYP2C8, and is a strong inhibitor of CYP2C9; there is also evidence of interactions with dabrafenib; therefore, caution should be exercised when dosing navitoclax concurrently with CYP2C8 and CYP2C9 substrates; common CYP2C8 substrates include paclitaxel, statins, and glitazones, whereas CYP2C9 substrates include phenytoin; when possible, investigators should switch to alternative medications or monitor the patients closely; CYP3A inhibitors such as ketoconazole and clarithromycin are not allowed 7 days prior to the first dose of navitoclax or during navitoclax administration
NCT01989585	1:9:pregnancy,10:15:gender,53:63:treatment,65:75:treatment,81:91:treatment,237:246:treatment,270:281:treatment	Pregnant women are excluded from this study because navitoclax, dabrafenib, and trametinib may have teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued if the mother is treated with the study drugs
NCT01989585	1:17:treatment,19:33:treatment,39:52:treatment	Prior navitoclax, BRAF inhibitor, and MEK inhibitor is prohibited; (exceptions for Phase I are described above)
NCT01989585	1:14:treatment,7:14:treatment,160:181:treatment,189:202:treatment,204:220:treatment,210:220:treatment,276:282:upper_bound	Prior therapy is allowed; for patients enrolled in the Phase I portion of the study, patients may have received any number of prior lines of therapy including treatment with a BRAF and/or MEK inhibitor; prior navitoclax use will not be allowed, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression
NCT01989585	1:14:treatment,114:133:treatment,145:159:treatment,161:171:treatment,173:182:treatment,194:218:treatment,223:235:treatment,245:261:treatment,263:277:treatment,285:306:treatment	Prior therapy is allowed; for patients enrolled in the Phase II portion of the study, patients may have received prior immunotherapy (including high-dose IL-2, ipilimumab, nivolumab, and other anti-PD1/PDL1 antibodies) or chemotherapy; however prior navitoclax, BRAF inhibitor and/or MEK inhibitor therapy will not be allowed
NCT01989585	1:22:clinical_variable,23:59:clinical_variable,64:97:clinical_variable,100:133:upper_bound	Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.3 x upper limit of normal (ULN)
NCT01989585	1:17:clinical_variable,21:30:upper_bound,34:54:clinical_variable,58:76:lower_bound	Serum creatinine =< 1.5 mg/dL OR creatinine clearance >= 50 mL/min/1.73 m^2
NCT01989585	1:25:treatment,29:35:treatment	Strong inducers of CYP3A or CYP2C8
NCT01989585	1:37:treatment	Strong inhibitors of CYP3A or CYP2C8
NCT01989585	33:49:treatment,58:74:chronic_disease,102:114:upper_bound	Subject has a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within 1 year prior to the first dose of study drug
NCT01989585	16:26:treatment,28:38:treatment,44:54:treatment,115:120:gender,117:120:gender,201:236:contraception_consent,238:269:contraception_consent,274:284:contraception_consent,286:308:contraception_consent,479:493:upper_bound,544:549:gender,550:565:pregnancy,557:565:pregnancy	The effects of navitoclax, dabrafenib, and trametinib on the developing human fetus are unknown; for this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (barrier method of birth control, or abstinence; hormonal contraception is not allowed due to drug-drug interactions which can render hormonal contraceptives ineffective) prior to study entry, for the duration of study participation, and for 4 months after completion of study drug administration; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately
NCT01989585	1:16:clinical_variable,120:136:clinical_variable	Total bilirubin =< 1.5 x institutional upper limit of normal OR > 1.5 x institutional upper limit of normal allowed if direct bilirubin is within normal range
NCT01989585	1:34:treatment,48:74:clinical_variable,77:85:lower_bound,93:102:clinical_variable,105:112:lower_bound,143:168:treatment	Treatment-refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy
NCT01989585	14:34:chronic_disease,77:101:chronic_disease,115:139:chronic_disease,141:165:chronic_disease,167:185:chronic_disease,187:208:chronic_disease,213:232:chronic_disease,233:250:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirements
NCT01989585	129:136:lower_bound,152:180:treatment,189:197:chronic_disease,234:247:treatment,254:265:chronic_disease,266:280:chronic_disease,282:303:chronic_disease,305:317:chronic_disease,329:348:treatment	Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v. 5.0) grade 2 or higher from previous anti-cancer therapy, except alopecia or an endocrine toxicity related to immunotherapy (e.g. thyroiditis/hypothyroidism, adrenal insufficiency, hypophysitis) requiring replacement therapy, at the time of randomization
NCT01989585	95:98:chronic_disease,102:105:chronic_disease,192:212:clinical_variable,215:222:lower_bound	Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as evidence of new optic disc cupping, evidence of new visual field defects, and intraocular pressure > 21 mmHg
NCT01986075	1:4:age,5:7:lower_bound,8:10:upper_bound	Age 18-60
NCT01986075	1:16:bmi,18:21:bmi,25:32:upper_bound	Body Mass Index (BMI) < 18kg/m2. (amphetamine may produce weigh loss thus a minimum BMI cut-off is being used for study inclusion)
NCT01986075	1:26:chronic_disease	Coronary vascular disease
NCT01986075	28:51:treatment	Currently being prescribed psychotropic medication by another physician
NCT01986075	1:29:clinical_variable,33:52:lower_bound	Elevated transaminase levels (> 3x the normal limit)
NCT01986075	33:53:allergy_name,55:66:allergy_name	History of allergic reaction to candidate medication (amphetamine)
NCT01986075	12:20:chronic_disease,34:55:chronic_disease,60:82:chronic_disease	History of seizures, unexplained loss of consciousness, or traumatic brain injury
NCT01986075	26:42:chronic_disease,44:57:chronic_disease,65:83:chronic_disease	Meets DSM-V criteria for bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse
NCT01986075	19:22:chronic_disease,61:72:clinical_variable,105:132:chronic_disease,302:317:treatment,321:334:treatment	Participants with MDD, with symptom severity that exceeds a HAM-D score of 20, and/or any other current Axis I psychiatric disorder as defined by DSM-V supported by the MINI that in the investigator's judgment are unstable, would be disrupted by study medication, or are likely to require specialized pharmacotherapy or psychotherapy during the study period
NCT01986075	1:10:pregnancy	Pregnancy
NCT01986075	1:28:chronic_disease,78:103:chronic_disease,105:120:chronic_disease,122:143:chronic_disease	Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension, acute hepatitis, uncontrolled diabetes
NCT01986075	23:32:lower_bound	Used cocaine at least four days in the past month
NCT01986075	28:43:gender,47:81:contraception_consent	failure in sexually active female patients to use adequate contraceptive methods
NCT01985087	1:26:clinical_variable,29:45:lower_bound	Absolute neutrophil count > 1,500/microliter
NCT01985087	1:11:clinical_variable,50:70:clinical_variable,73:90:lower_bound,109:126:clinical_variable	Creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels about institutional normal
NCT01985087	1:4:chronic_disease,41:63:treatment,142:154:treatment	HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with temozolomide
NCT01985087	102:114:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide
NCT01985087	37:49:cancer,107:114:lower_bound,191:201:cancer	Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy
NCT01985087	32:39:cancer,89:101:upper_bound,103:126:cancer,132:142:cancer,146:181:cancer	Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
NCT01985087	1:29:clinical_variable,32:34:lower_bound,36:40:clinical_variable,43:44:upper_bound	Karnofsky performance status > 60 (ECOG < 2)
NCT01985087	1:11:clinical_variable,14:30:lower_bound	Leukocytes > 3,000/microliter
NCT01985087	31:59:treatment,63:70:treatment	Participants may not have had chemotherapy wafer placement at surgery
NCT01985087	24:32:lower_bound,36:39:age	Participants must be > 70 years of age
NCT01985087	49:61:cancer,62:73:cancer	Participants must have histologically confirmed glioblastoma/gliosarcoma
NCT01985087	24:39:clinical_variable,53:61:lower_bound	Participants must have life expectancy greater than 6 months
NCT01985087	36:49:treatment,54:77:cancer,88:97:treatment,101:113:treatment	Participants must not have had any prior therapy for glioblastoma multiforme including radiation or chemotherapy
NCT01985087	1:10:clinical_variable,13:31:lower_bound	Platelets > 100,000/microliter
NCT01985087	1:54:clinical_variable	Total bilirubin within normal institutional limits 12
NCT01985087	1:6:cancer,7:73:clinical_variable	Tumor o6-methylguanine-DNA-methyltransferase promoter methylation status must be determined
NCT01985087	1:38:clinical_variable,39:74:clinical_variable,77:118:upper_bound	aspartate aminotransferase test(SGOT)/alanine aminotransferase test(SGPT) < 2.5 X institutional upper limit of normal
NCT01973283	7:13:cancer,14:23:treatment	Acute cancer treatment
NCT01973283	13:14:lower_bound	Anyone with 1 or more characteristics of frailty
NCT01973283	25:28:treatment,45:58:upper_bound	Currently followed by a PCP (had an eval in last 6-months)
NCT01973283	72:91:upper_bound	Diagnosis of substance abuse or dependence (last 12 months), excluding Nicotine dependence
NCT01973283	1:26:chronic_disease,33:38:chronic_disease,40:46:chronic_disease,48:57:chronic_disease	End stage medical illness (e.g. liver, kidney, pulmonary)
NCT01973283	1:5:clinical_variable,6:8:lower_bound,15:41:chronic_disease,48:51:chronic_disease,53:62:chronic_disease	HRSD>16 and a DSM-IV depressive disorder (e.g. MDD, Dysthymia)
NCT01973283	44:56:allergy_name,60:70:allergy_name,132:156:lower_bound,182:205:lower_bound	History of allergic or adverse reaction to escitalopram or duloxetine, or non-response to adequate trial of escitalopram (at least 4 weeks at dose of 20 mg) or duloxetine (at least 4 weeks at dose of 90mg)
NCT01973283	12:21:chronic_disease,25:43:chronic_disease,47:63:chronic_disease	History of psychosis or psychotic disorder or bipolar disorder
NCT01973283	1:17:clinical_variable,20:22:upper_bound,41:49:chronic_disease	Mini Mental Exam < 24 or a diagnosis of dementia
NCT01973283	37:52:chronic_disease	Patient is considered a significant risk of suicide
NCT01973283	86:100:treatment,122:131:treatment,178:196:treatment,202:205:treatment	Subject is considered based on history to be unlikely to respond to the single agent antidepressant (i.e., subjects with treatment resistant depression, including subjects with previous treatment with ECT)
NCT01972919	1:4:clinical_variable,8:11:clinical_variable,14:39:upper_bound	ALT or AST < 3 x upper limit of normal
NCT01972919	1:25:treatment,50:63:upper_bound	Abdominal/pelvic CT scan with IV contrast within 21 days prior to study entry
NCT01972919	18:20:clinical_variable,21:39:treatment,100:102:clinical_variable,130:138:treatment,146:159:upper_bound	Abdominal/pelvic MR prior to radiation with perfusion and diffusion- weighted sequences and MR and CT sim for radiation planning Pet scan within 21 days prior to study entry, Functional renal study
NCT01972919	20:36:treatment	Ability to swallow oral medications
NCT01972919	1:32:clinical_variable,35:50:lower_bound	Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
NCT01972919	7:16:chronic_disease,20:36:chronic_disease,47:70:treatment	Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
NCT01972919	1:4:age,7:9:lower_bound	Age ≥ 18
NCT01972919	1:21:clinical_variable,24:49:upper_bound	Alkaline phosphatase < 3 x upper limit of normal
NCT01972919	5:18:clinical_variable,26:39:upper_bound	Any major surgery within 28 days prior to study entry
NCT01972919	16:21:chronic_disease,25:46:chronic_disease	Any unresolved bowel or bile duct obstruction
NCT01972919	1:14:treatment,19:24:treatment,32:45:upper_bound	Chest CT scan, or X-ray within 21 days prior to study entry
NCT01972919	1:38:chronic_disease,39:51:treatment,61:80:chronic_disease,127:134:treatment,142:149:upper_bound	Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration
NCT01972919	1:27:cancer,29:46:cancer,50:68:chronic_disease	Distant metastatic disease, second malignancy or peritoneal seeding
NCT01972919	1:22:clinical_variable,25:34:upper_bound	Fasting blood glucose < 160 mg/dl
NCT01972919	1:11:clinical_variable,14:22:lower_bound,41:52:treatment,86:89:clinical_variable	Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.)
NCT01972919	86:99:upper_bound	History/physical examination, including collection of weight and vital signs, within 28 days prior to study entry
NCT01972919	25:27:treatment	Inability to undergo an MR of the abdomen/pelvis
NCT01972919	1:46:treatment,83:95:treatment	Major resection of the stomach or small bowel that could affect the absorption of capecitabine
NCT01972919	1:25:pregnancy,54:67:upper_bound	Negative serum pregnancy test (if applicable) within 14 days prior to study entry
NCT01972919	35:44:treatment	Participation in another clinical treatment trial while on study
NCT01972919	53:69:cancer,71:85:cancer	Pathologically confirmed (histologic or cytologic), locally advanced, adenocarcinoma of the pancreas; patients must have unresectable disease based on institutional standardized criteria of unresectability or medical inoperability
NCT01972919	33:41:lower_bound,45:72:treatment	Patients must have had at least 4 months of prior systemic chemotherapy
NCT01972919	36:46:chronic_disease	Patients with and without regional adenopathy are eligible
NCT01972919	1:10:clinical_variable,13:30:lower_bound	Platelets ≥ 100,000 cells/mm3
NCT01972919	1:10:pregnancy,14:19:gender,16:19:gender,82:149:contraception_consent,200:214:upper_bound,224:234:treatment	Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during the course of the study and for women, for 3 months after the last study drug administration
NCT01972919	28:40:allergy_name,44:55:allergy_name	Prior allergic reaction to capecitabine or gemcitabine
NCT01972919	1:19:treatment,47:53:cancer,86:103:treatment	Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
NCT01972919	1:17:clinical_variable,20:29:upper_bound	Serum creatinine ≤ 1.5 mg/dl
NCT01972919	1:16:clinical_variable,19:28:upper_bound	Total bilirubin < 3.0 mg/dL
NCT01972919	1:33:chronic_disease,41:55:upper_bound	Transmural myocardial infarction within 3 months prior to study entry
NCT01972919	14:36:chronic_disease	Uncontrolled malabsorption syndrome significantly affecting gastrointestinal function
NCT01972919	1:16:chronic_disease,24:48:chronic_disease,86:99:upper_bound	Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
NCT01972919	1:6:gender,37:54:gender	Women of childbearing potential and male participants who are sexually active must practice adequate contraception
NCT01972919	1:26:clinical_variable,27:28:lower_bound,29:30:upper_bound,38:44:upper_bound	Zubrod performance status 0-1 within 1 week of study entry
NCT01970345	21:30:chronic_disease	Active or suspected neoplasia
NCT01970345	1:13:chronic_disease,14:26:chronic_disease	Cardiomegaly/valvulopathy
NCT01970345	1:22:chronic_disease	Hepatic insufficiency
NCT01970345	23:28:allergy_name	History of allergy to IGF-1
NCT01970345	1:26:chronic_disease	Intracranial hypertension
NCT01970345	1:46:language_fluency	Language delay (lack of fluent phrase speech) reflected by use of ADOS Module 1 or 2
NCT01970345	25:49:chronic_disease	Meet DSM-5 criteria for Autism Spectrum Disorder confirmed by the Autism Diagnostic Interview-Revised (ADI-R)
NCT01970345	19:38:treatment,19:29:treatment,52:70:lower_bound,143:148:treatment	Must be on stable medication regimens for at least three months prior to enrollment, assuming the concomitant medication is safe for use with IGF-1
NCT01970345	105:125:treatment	Patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with IGF-1
NCT01970345	1:20:chronic_disease	Renal insufficiency
NCT01970345	13:16:age,13:17:age,21:22:lower_bound,23:31:upper_bound	between the ages of 5-12 years of age
NCT01968109	10:11:lower_bound	At least 1 lesion with measurable disease at baseline
NCT01968109	1:19:chronic_disease	Autoimmune disease
NCT01968109	29:41:treatment,71:97:treatment	Availability of an existing tumor biopsy sample (and consent to allow pre-treatment tumor biopsy)
NCT01968109	1:24:clinical_variable,33:34:lower_bound,39:40:upper_bound	ECOG performance status between 0 and 2
NCT01968109	1:13:chronic_disease,15:25:chronic_disease,43:51:chronic_disease	Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
NCT01968109	63:71:cancer,73:80:cancer,86:89:cancer	For Dose Expansion: all of the above in escalation except for cervical, ovarian, and CRC
NCT01968109	36:44:cancer,46:53:cancer,55:62:cancer,67:90:cancer,92:105:cancer,107:114:cancer,119:140:cancer,150:172:treatment,174:191:cancer,183:191:cancer,214:219:cancer,221:241:cancer,251:253:treatment,285:323:treatment,369:439:treatment	For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4
NCT01968109	1:44:cancer,48:60:cancer,66:80:cancer	Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease
NCT01968109	45:48:lower_bound,58:75:treatment	Progressed, or been intolerant to, at least one standard treatment regimen, except for subjects in 1st line cohorts
NCT01968109	14:28:cancer	Uncontrolled CNS metastases
NCT01967238	13:28:chronic_disease,30:42:treatment,46:67:treatment	(either the influenza virus, pneumococcal or meningococcal vaccine)
NCT01967238	24:32:chronic_disease,36:62:chronic_disease	(mild illness, such as diarrhea or mild respiratory infection with or without fever, and local infections do not apply)
NCT01967238	1:3:lower_bound,4:12:upper_bound,16:19:age	18-80 years of age
NCT01967238	104:120:chronic_disease,124:142:chronic_disease	Any clinically significant abnormality on medical history or physical examination including history of immunodeficiency or autoimmune disease
NCT01967238	100:108:chronic_disease,110:133:chronic_disease,135:156:chronic_disease,158:168:cancer	Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation
NCT01967238	11:24:chronic_disease,39:66:chronic_disease,83:105:chronic_disease	Confirmed HIV infection, positive for hepatitis B surface antigen or positive for hepatitis C antibodies
NCT01967238	18:35:treatment,45:73:treatment,84:106:treatment,111:132:treatment	Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications
NCT01967238	36:42:chronic_disease,44:48:chronic_disease,52:69:chronic_disease,103:124:chronic_disease	Documented previous infection with dengue, zika or chikungunya virus or no history of dengue, zika or chikungunya infection
NCT01967238	1:4:allergy_name	Egg allergy
NCT01967238	1:7:gender	Female
NCT01967238	5:12:treatment,58:92:chronic_disease	For Flumist participants: Close contact with person with severely compromised immune system requiring isolation
NCT01967238	5:12:treatment	For Flumist participants: Current illness that limits delivery to nasal airway
NCT01967238	12:35:chronic_disease	History of Guillain-Barre syndrome
NCT01967238	12:28:chronic_disease	History of seizure disorder for Flumist group participants only
NCT01967238	4:12:pregnancy	Is pregnant
NCT01967238	1:5:gender	Male
NCT01967238	95:107:upper_bound	Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study
NCT01967238	28:50:allergy_name	Prior allergic reaction to commercial vaccination
NCT01967238	14:31:treatment,42:49:upper_bound,74:86:treatment,91:112:treatment,123:130:upper_bound	Received the influenza vaccine less than 1 month ago and/or received the pneumococcal and meningococcal vaccine less than 4 years ago
NCT01967238	38:46:upper_bound	Unable to continue participation for 12 weeks
NCT01967238	40:60:treatment	Willing to receive a single dose of an FDA-approved vaccine
NCT01954316	5:13:lower_bound,17:20:age	Are 18 years of age or older
NCT01954316	8:23:clinical_variable,37:45:lower_bound	Have a life expectancy greater than 3 months
NCT01954316	6:28:chronic_disease,39:60:chronic_disease,69:77:upper_bound	Have active angina pectoris or recent myocardial infarction (within 6 months)
NCT01954316	55:65:chronic_disease	Have active, acute, or chronic clinically significant infections
NCT01954316	49:68:chronic_disease	Have additional uncontrolled serious medical or psychiatric illness
NCT01954316	9:69:clinical_variable,73:74:lower_bound,78:79:upper_bound	Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
NCT01954316	102:117:treatment,119:145:chronic_disease	Have any medical condition that could impair the administration of oral agents including significant bowel resection, inflammatory bowel disease or uncontrolled nausea or vomiting
NCT01954316	6:33:chronic_disease,37:40:clinical_variable,57:65:lower_bound	Have chronic atrial fibrillation or QTc of greater than 470 msec, as calculated by Bazett's correction formula
NCT01954316	27:51:chronic_disease,82:134:clinical_variable,145:149:clinical_variable,152:155:upper_bound	Have clinical symptomatic congestive heart failure defined at >= Class II of the New York Heart Association functional classification system or LVEF < 50% at baseline
NCT01954316	10:23:treatment,31:38:upper_bound	Have had major surgery within 21 days of starting therapy
NCT01954316	50:56:cancer,120:138:treatment	Have histologic or cytological proof of advanced cancer that has progressed and for which there is no further standard anticancer therapy available in the opinion of the investigator
NCT01954316	15:27:treatment,29:41:treatment,43:61:treatment,65:90:treatment,101:111:lower_bound,127:138:treatment,142:153:treatment,184:194:treatment,248:264:treatment	Have received radiotherapy, chemotherapy, biological therapy or investigational treatment less than four weeks (six weeks for nitrosourea or mitomycin C) prior to first dose of study medication or have not recovered from all acute toxicities from prior treatments
NCT01954316	19:38:chronic_disease	Have uncontrolled severe hypertension
NCT01954316	7:40:cancer	Known central nervous system metastasis
NCT01954316	1:25:pregnancy,36:50:upper_bound	Negative serum pregnancy test with 72 hours prior to start of study drug
NCT01954316	74:93:treatment	Patients being treated with certain drugs not acceptable while receiving CFI-400945 fumarate
NCT01954316	39:47:treatment	Patients being treated with full dose warfarin
NCT01954316	28:42:treatment,50:63:upper_bound,91:110:treatment	Patients who have received growth factors within 14 days prior to initiation of dosing of CFI-400945 fumarate
NCT01954316	26:46:chronic_disease,50:67:chronic_disease,116:144:treatment,148:180:treatment	Patients with history of deep vein thrombosis or pulmonary embolus who are being treated with therapeutic doses of low molecular weight heparin or prophylactic dose anticoagulants may be enrolled
NCT01954316	16:36:treatment,44:51:upper_bound,64:71:treatment	Placement of a venous access device within 21 days of starting therapy
NCT01954316	1:14:gender,49:101:contraception_consent,147:154:lower_bound,194:204:treatment	Women and men of child producing potential must agree to use highly effective means of contraception during study participation, and for at least 30 days after the last administration of study medication
NCT01954316	1:6:gender,11:23:pregnancy	Women who are pregnant or nursing
NCT01948739	1:4:age,13:15:lower_bound,16:24:upper_bound	Age between 18-75 years
NCT01948739	14:33:chronic_disease,38:56:chronic_disease	Diagnosis of unilateral cortical and subcortical stroke confirmed by brain CT or MRI scan
NCT01948739	1:31:language_fluency	English-language comprehension and cognitive ability sufficient to give informed consent and to cooperate with the intervention
NCT01948739	21:37:chronic_disease,39:51:chronic_disease	No condition (e.g., severe arthritis, central pain) that would interfere with valid administration of the motor function tests
NCT01948739	15:56:treatment,64:80:upper_bound,110:133:treatment,137:163:treatment	No history of neurolytic procedure to the affected limb in the past four months and no planned alteration in upper-extremity therapy or medication for muscle tone during the course of the study
NCT01948739	32:38:chronic_disease	No previous clinically defined stroke
NCT01948739	1:10:pregnancy	Pregnancy
NCT01948739	53:65:cancer,67:74:chronic_disease,76:82:chronic_disease,86:115:chronic_disease	Previous history of or MRI findings consistent with brain tumors, strokes, trauma or arterial venous malformations
NCT01948739	13:27:chronic_disease,21:27:chronic_disease,50:56:lower_bound,82:90:lower_bound	Subacute or chronic stroke; interval of at least 3month and interval of at least 6 months from stroke to time of enrollment
NCT01948739	11:21:chronic_disease	Untreated depression that may affect motivation to participate in the study
NCT01948739	17:28:chronic_disease,45:51:chronic_disease,53:80:clinical_variable,93:94:lower_bound,113:116:upper_bound	Upper-extremity hemiparesis associated with stroke (manual muscle testing score of at least 2, but no more than 4/5 in the elbow and wrist flexors)
NCT01948739	1:4:age,5:7:lower_bound,8:10:upper_bound	age 18-65
NCT01947673	13:29:chronic_disease	any serious systemic disease that might influence survival
NCT01947673	1:22:chronic_disease	autonomic dysfunction
NCT01947673	22:46:chronic_disease	clinical evidence of congestive heart failure
NCT01947673	1:18:clinical_variable,25:28:upper_bound	ejection fraction below 35%
NCT01947673	1:22:chronic_disease,26:50:chronic_disease,62:77:upper_bound	myocardial infarction or cerebrovascular accident within the past six months
NCT01947673	1:22:chronic_disease	peripheral neuropathy
NCT01947673	1:10:pregnancy	pregnancy
NCT01947673	8:14:chronic_disease,20:29:clinical_variable,31:37:upper_bound	severe anemia with hgb level <8 g/dL
NCT01947673	1:8:treatment,20:33:upper_bound	surgery within the past 3 months
NCT01921634	29:40:treatment,58:71:chronic_disease	Appendix removed at time of laparoscopy for treatment of endometriosis and/or pelvic pain
NCT01921634	1:20:chronic_disease,41:54:chronic_disease	Chronic pelvic pain and/or diagnosis of endometriosis
NCT01921634	1:17:language_fluency	English Speaking
NCT01921634	1:21:language_fluency	Non-English speaking
NCT01921634	1:22:treatment	Previous appendectomy
NCT01921634	1:6:gender	Women
NCT01921634	1:4:age,5:7:lower_bound,8:16:upper_bound	age 18-51 years of age
NCT01905709	10:15:lower_bound,45:48:clinical_variable,66:67:lower_bound,68:74:upper_bound,86:96:treatment,128:138:treatment,146:155:treatment,157:169:treatment,171:182:treatment	At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g., rifaximin, nitazoxanide, fidaxomicin)
NCT01905709	10:13:lower_bound,33:36:chronic_disease	At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity
NCT01905709	41:48:treatment,50:60:treatment	Moderate CDI not responding to standard therapy (vancomycin) for at least a week
NCT01905709	8:30:chronic_disease,36:51:chronic_disease,71:87:treatment,102:106:treatment	Severe C. difficile infection with toxic megacolon, not responding to standard therapy or the use of IVIg
NCT01905709	36:39:chronic_disease	Subject has recurrent or relapsing CDI
NCT01905709	21:29:lower_bound	Subject is at least 18 years old
NCT01905709	12:20:pregnancy	Subject is pregnant
NCT01882153	14:20:chronic_disease	Diagnosis of autism based on DSM-IV-TR criteria
NCT01882153	20:23:chronic_disease	Has a diagnosis of ASD
NCT01882153	38:44:chronic_disease,70:79:chronic_disease,81:94:chronic_disease,96:115:chronic_disease,117:135:chronic_disease,137:152:chronic_disease	Have a medical diagnosis that causes autism like symptomology (e.g., Fragile X, Down syndrome, Angelman's syndrome, tuberous sclerosis, Rett's disorder)
NCT01882153	1:6:gender	Males
NCT01882153	111:128:chronic_disease	Receiving or will receive a parent delivered intervention to alleviate symptoms related to their diagnosis of autistic disorder
NCT01882153	1:4:age,19:22:lower_bound,27:38:upper_bound	age range between 1.6 and 17.11 years of age
NCT01882153	13:17:age,13:16:age,21:24:lower_bound,29:40:upper_bound	between the ages of 1.6 and 17.11 years of age
NCT01882153	1:8:gender	females
NCT01882153	37:40:lower_bound,41:48:chronic_disease	medically unstable (e.g., more than one seizure a month)
NCT01874860	1:4:age,30:38:lower_bound	Age greater than or equal to 18 years
NCT01874860	9:18:treatment,24:50:treatment	Current treatment with tyrosine kinase inhibitors
NCT01874860	14:24:cancer,28:48:cancer	Diagnosis of colorectal or head and neck cancer
NCT01874860	18:26:pregnancy	Patients who are pregnant
NCT01874860	1:26:treatment,38:46:upper_bound	Prior cetuximab treatment within the 6 months of study initiation
NCT01874860	21:24:lower_bound,33:42:treatment	Receipt of at least one dose of cetuximab during the study time period
NCT01871766	1:2:lower_bound,3:11:upper_bound,15:18:age	0-21 years of age
NCT01871766	36:51:clinical_variable,54:87:upper_bound,92:95:age	Adequate liver function defined as total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
NCT01871766	1:4:age,7:15:upper_bound	Age < 22 years (eligible until 22nd birthday)
NCT01871766	1:21:clinical_variable,25:41:clinical_variable,44:59:lower_bound	Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.732
NCT01871766	1:20:gender	Female participants who are breast feeding must agree to stop breast feeding
NCT01871766	1:20:gender,23:31:lower_bound,35:38:age,69:83:pregnancy,87:102:pregnancy,115:129:upper_bound,143:152:treatment	Female participants ≥ 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment
NCT01871766	1:8:gender,46:54:pregnancy	Females of child-bearing potential cannot be pregnant or breast-feeding
NCT01871766	12:21:cancer,23:31:cancer,33:45:cancer,47:55:cancer,57:73:cancer,78:92:cancer,98:116:cancer	High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or anaplastic RMS with metastatic disease at diagnosis (stage 4)
NCT01871766	23:49:allergy_name,53:67:allergy_name	History of allergy to Optison(TM) contrast agent or blood products
NCT01871766	15:27:treatment,46:63:upper_bound,82:88:treatment,92:110:treatment	Initiation of chemotherapy is planned within 6 weeks (42 days) of the definitive biopsy or surgical resection
NCT01871766	11:20:cancer,22:30:cancer,32:51:cancer	Low-risk: Embryonal, botryoid, spindle cell tumors only (Subset 1: Stage 1, Group I; Stage 1 Group I; Stage 1 Group III orbital only; Stage 2 Group I; Stage 2 Group II) (Subset 2: Stage 1 Group III non orbit; Stage 3 Group I, II)
NCT01871766	45:67:cancer	Newly diagnosed participants with localized rhabdomyosarcoma (RMS)
NCT01871766	82:104:cancer	Newly diagnosis or suspected diagnosis of previously untreated participants with rhabdomyosarcoma (RMS)
NCT01871766	16:22:chronic_disease,24:46:chronic_disease	No evidence of active, uncontrolled infection
NCT01871766	29:47:treatment,51:84:treatment,96:104:treatment,151:156:cancer,157:166:treatment	Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma (excluding steroids) unless an emergency situation requires local tumor treatment
NCT01871766	110:126:upper_bound,189:201:treatment	Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol
NCT01871766	53:62:clinical_variable,83:92:upper_bound	Participants with biliary or hepatic primaries with bilirubin values greater than 1.5 x ULN may be enrolled on study if all other eligibility criteria are met
NCT01871766	48:53:cancer	Participants with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract
NCT01871766	30:47:treatment	Patients requiring emergency radiation therapy are eligible for enrollment on this study
NCT01871766	36:46:clinical_variable,50:51:lower_bound,59:60:lower_bound	Performance level corresponding to ECOG score of 0, 1, or 2
NCT01871766	1:43:clinical_variable,46:52:lower_bound	Peripheral absolute neutrophil count (ANC) ≥ 750/μL
NCT01871766	1:15:clinical_variable,18:27:lower_bound	Platelet count ≥ 75,000/μL (transfusion independent)
NCT01871766	1:13:treatment,15:33:treatment	Prior biopsy, surgical resection and lymph node sampling is allowed
NCT01871766	1:17:chronic_disease,27:30:age	Serum creatinine based on age and gender
NCT01871766	60:98:contraception_consent,106:113:treatment,131:144:lower_bound,145:154:treatment	Sexually active patients of childbearing potential must be willing to use effective contraception during therapy and for at least 1 month after treatment is completed
NCT01871766	5:29:clinical_variable,64:72:upper_bound	The Lansky performance score should be used for participants < 16 years
NCT01871766	20:38:treatment,54:59:cancer	Undergoing upfront surgical resection of the primary tumor
NCT01871454	71:81:cancer,87:99:treatment,101:122:treatment	A reasonable attempt should be made to make a pathologic diagnosis of malignancy (ie. bronchoscopy, CT guided lung biopsy)
NCT01871454	1:4:age,9:17:lower_bound	Age >/= 18 years
NCT01871454	46:53:upper_bound	CT scan of the chest with IV contrast within 8 weeks of registration
NCT01871454	1:13:treatment,21:28:upper_bound,50:54:treatment	Chemotherapy within 4 weeks of the initiation of SABR
NCT01871454	1:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	ECOG performance status 0-1
NCT01871454	1:5:clinical_variable,7:10:upper_bound,28:32:clinical_variable	FEV1 <20% predicted and/or DLCO <20% predicted
NCT01871454	44:63:cancer,77:112:treatment,129:150:treatment	Histologically proven diagnosis of a prior thoracic malignancy treated with thoracic external beam radiotherapy with or without systemic chemotherapy
NCT01871454	1:14:treatment,65:78:cancer	Loco-regional is defined as recurrence within the region of the primary tumor or adjacent draining lymph node regions
NCT01871454	1:25:pregnancy,38:51:upper_bound,72:77:gender	Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
NCT01871454	24:45:treatment	No previously reported thoracic radiotherapy
NCT01871454	70:85:cancer	Pathologic or clinical diagnosis of a new or loco-regional recurrent lung malignancy
NCT01871454	21:42:treatment,60:72:treatment	Plans to administer systemic chemotherapy overlapping with radiotherapy
NCT01871454	1:9:pregnancy,10:15:gender	Pregnant women
NCT01871454	1:31:clinical_variable,69:76:upper_bound	Pulmonary function test (PFTs), including diffusion capacity within 8 weeks of registration
NCT01871454	28:35:upper_bound	Whole body PET scan within 8 weeks of registration
NCT01871454	1:6:gender	Women of childbearing potential
NCT01871454	11:16:gender	lactating women
NCT01871454	1:18:gender,48:105:contraception_consent	male participants who are sexually active must agree to use a medically effective means of birth control
NCT01856049	5:13:pregnancy,14:19:gender	Any pregnant woman
NCT01856049	15:18:age	regardless of age
NCT01856049	30:34:chronic_disease	with a prenatal diagnosis of HLHS
NCT01851369	1:10:clinical_variable,11:20:clinical_variable,43:82:upper_bound,106:122:cancer	AST(SGOT)/ALT(SGPT) less than or equal to 3 X institutional upper limit of normal; 5.0 x ULN in cases of liver metastases
NCT01851369	102:107:cancer,108:116:treatment	Ability to understand and the willingness to sign a written informed consent document and to undergo tumor biopsies in the expansion phase
NCT01851369	1:26:clinical_variable,40:49:lower_bound	Absolute neutrophil count greater than 1,500/mcL
NCT01851369	20:27:lower_bound,29:46:cancer,55:57:upper_bound,58:68:cancer,72:95:cancer	Adequately managed stage 0 (carcinoma in situ), I, or II basal cell or squamous cell carcinoma from which the patient is currently in complete remission
NCT01851369	20:27:lower_bound,31:33:upper_bound,54:61:cancer,65:80:cancer	Adequately managed stage I or II well differentiated thyroid or prostate cancer is also eligible, wherein the patient is not required to be in complete remission
NCT01851369	1:4:age,17:25:lower_bound	Age greater than18 years
NCT01851369	11:17:cancer,67:78:upper_bound	Any other cancer from which the patient has been disease-free for three years
NCT01851369	1:24:clinical_variable,35:36:upper_bound,70:71:upper_bound	ECOG performance status less than 2 (Phase I), less than or equal to 1(Phase II)
NCT01851369	1:4:chronic_disease,26:60:treatment,117:123:treatment	HIV-positive patients on combination antiretroviral therapy are ineligible because of possible PK interactions with TRC102
NCT01851369	1:11:clinical_variable,37:44:lower_bound,72:84:upper_bound	Hemoglobin greater than or equal to 10 g/dL without transfusion within 1 week prior to enrollment
NCT01851369	102:108:allergy_name,112:115:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or TMZ
NCT01851369	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 3 months
NCT01851369	75:81:treatment,108:139:treatment	Patients enrolling in the expansion cohorts must have disease amenable to biopsy and be willing to undergo pre-and post-treatment biopsies
NCT01851369	61:72:treatment	Patients must be able to swallow whole tablets or capsules; nasogastric or G-tube administration is not allowed
NCT01851369	34:46:treatment,48:65:treatment,70:86:treatment,112:119:lower_bound,124:136:lower_bound,189:196:lower_bound,201:213:treatment,217:228:treatment,273:280:lower_bound,317:327:treatment,390:396:lower_bound,402:430:treatment,522:552:treatment	Patients must have completed any chemotherapy, radiation therapy, or biologic therapy greater than or equal to 4 weeks (or 5 half-lives, whichever is shorter) prior to entering the study (6 weeks for nitrosoureas or mitomycin C). Patients must be greater than or equal to 2 weeks since any prior administration of a study drug in a Phase 0 or equivalent study and greater than or equal to 1 week from palliative radiation therapy. Patients must have recovered to eligibility levels from prior toxicity or adverse events. Treatment with bisphosphonates is permitted
NCT01851369	47:69:treatment	Patients who are actively receiving any other investigational agents
NCT01851369	22:38:cancer,42:66:cancer,152:176:clinical_variable,226:233:lower_bound,252:259:treatment,264:288:treatment	Patients with active brain metastases or carcinomatous meningitis are excluded from this clinical trial. Patients with treated brain metastases, whose brain metastatic disease has remained stable for greater than or equal to 4 weeks without requiring steroid and anti-seizure medications are eligible to participate
NCT01851369	35:47:cancer,81:88:treatment,140:149:treatment	Phase I: histologically confirmed solid tumors that have progressed on standard therapy known to prolong survival or for which no standard treatment options exist
NCT01851369	31:43:cancer	Phase II only: No other prior malignancies are allowed
NCT01851369	30:47:cancer,59:75:chronic_disease,118:131:treatment,152:180:treatment	Phase II only: patients with colorectal cancer with known MSI-high disease who have not previously been treated with immunotherapy or who have refused treatment with immunotherapy
NCT01851369	36:61:cancer,76:79:lower_bound,89:96:treatment,98:103:cancer,143:172:cancer,187:190:lower_bound	Phase II: histologically confirmed colorectal adenocarcinoma post at least two lines of therapy, NSCLC post at least two lines of therapy, or granulosa cell ovarian cancer post at least one line of therapy. Patients must have measurable disease
NCT01851369	1:10:clinical_variable,36:47:lower_bound	Platelets greater than or equal to 100,000/mcL
NCT01851369	1:9:pregnancy,10:15:gender,72:82:treatment,72:83:treatment,219:228:treatment	Pregnant women are excluded from this study because the effects of the study drugs on the developing fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
NCT01851369	7:16:clinical_variable,38:61:upper_bound	Total bilirubin less than or equal to1.5 X institutional ULN
NCT01851369	84:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, serious untreated infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT01851369	1:21:clinical_variable,47:64:lower_bound,83:100:clinical_variable,114:123:lower_bound	creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels greater than 1.5 mg/dL
NCT01851369	1:16:clinical_variable,34:57:upper_bound	creatinine less than or equal to 1.5 X institutional ULN
NCT01849146	33:42:treatment	12 weeks from the completion of radiation
NCT01849146	1:8:lower_bound,34:47:treatment,49:67:treatment,75:82:treatment,84:102:treatment,104:115:treatment	2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., Tarceva, hydroxychloroquine, bevacizumab, etc.)
NCT01849146	1:8:upper_bound,16:44:treatment	3 weeks from a non-nitrosourea chemotherapy
NCT01849146	1:8:lower_bound,18:90:treatment	4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents
NCT01849146	1:8:upper_bound,16:40:treatment	6 weeks from a nitrosourea chemotherapy
NCT01849146	1:26:clinical_variable,30:39:lower_bound	Absolute neutrophil count >= 1,500/mcL
NCT01849146	1:45:clinical_variable,46:79:clinical_variable,83:124:upper_bound	Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
NCT01849146	1:33:clinical_variable,34:82:clinical_variable,83:113:clinical_variable,114:160:clinical_variable,164:203:upper_bound	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal
NCT01849146	1:11:clinical_variable,54:74:clinical_variable,78:96:lower_bound,115:132:clinical_variable	Creatinine =< institutional upper limit of normal OR creatinine clearance >= 60 ml/min/1.73 m^2 for patients with creatinine levels above institutional normal
NCT01849146	1:11:clinical_variable,15:21:lower_bound	Hemoglobin >= 9 g/dL
NCT01849146	1:35:chronic_disease,57:91:treatment,136:164:treatment	Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD1775 (MK-1775)
NCT01849146	1:10:clinical_variable,14:25:lower_bound	Platelets >= 100,000/mcL
NCT01849146	1:9:pregnancy,10:15:gender,53:70:treatment	Pregnant women are excluded from this study because AZD1775 (MK-1775) has potential for teratogenic or abortifacients effects
NCT01849146	1:16:clinical_variable	Total bilirubin =< institutional upper limit of normal
NCT01849146	1:6:gender,45:69:pregnancy	Women of childbearing potential must have a negative serum pregnancy test prior to study entry
NCT01849146	17:31:treatment	able to swallow whole capsules
NCT01849146	1:45:treatment,67:76:treatment	enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol
NCT01849146	66:89:treatment,91:103:treatment,105:118:treatment,122:349:treatment,354:370:treatment,381:392:cancer	going on Arm 1 or combination dose cohort must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor
NCT01849146	43:75:treatment,43:52:treatment,92:104:treatment,114:121:lower_bound,139:152:lower_bound	going on Arm 2 must have received planned treatment with radiation therapy and concomitant temozolomide at least 28 days but no more than 49 days prior to starting treatment on this study
NCT01849146	6:38:treatment,46:53:upper_bound,66:75:treatment	have magnetic resonance imaging (MRI) within 21 days of starting treatment
NCT01849146	20:30:cancer,57:62:cancer,66:101:cancer,105:136:cancer,138:144:cancer,149:156:cancer	have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder
NCT01849146	34:46:cancer,90:107:treatment,112:124:treatment	have prior histologically proven glioblastoma that is progressive or recurrent following radiation therapy +/- chemotherapy
NCT01849146	23:35:cancer	histologically proven glioblastoma
NCT01849146	102:114:allergy_name,118:135:allergy_name	history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or AZD1775 (MK-1775) are ineligible
NCT01849146	24:46:treatment,64:70:upper_bound,94:103:treatment	maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the start of treatment
NCT01849146	15:30:treatment,32:40:treatment,80:87:treatment,89:93:treatment	may not be on anti-coagulants (warfarin, etc.) other than low-molecular weight heparin (LMWH)
NCT01849146	33:81:treatment,83:113:treatment,118:170:treatment	may not be on drugs known to be moderate or potent inhibitors/inducers of CYP3A4, sensitive substrates of CYP3A4, or substrates of CYP3A4 with narrow therapeutic windows
NCT01849146	56:68:cancer,72:75:treatment,83:90:upper_bound,103:112:treatment	measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within 21 days of starting treatment
NCT01849146	13:41:clinical_variable,45:48:lower_bound	must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
NCT01849146	13:18:cancer,87:96:treatment,113:125:cancer	must have a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of glioblastoma completed and signed by a pathologist
NCT01849146	11:25:treatment	ndergoing repeat surgery that is clinically indicated as determined by their care providers
NCT01849146	21:43:treatment	receiving any other investigational agents are ineligible
NCT01849146	35:48:treatment	recovered from severe toxicity of prior therapy
NCT01849146	14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease	uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible
NCT01849146	21:43:treatment	unlimited number of prior therapy regimens
NCT01810588	1:15:cancer	Acute leukemia in first remission at high-risk for recurrence
NCT01810588	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT01810588	1:16:chronic_disease	Aplastic anemia
NCT01810588	1:29:chronic_disease	Chronic lymphocytic leukemia, relapsed or with poor prognostic features
NCT01810588	1:29:cancer	Chronic myelogenous leukemia in chronic
NCT01810588	1:35:chronic_disease	Chronic myeloproliferative disease
NCT01810588	13:37:chronic_disease,41:50:chronic_disease	Evidence of chronic active hepatitis or cirrhosis
NCT01810588	1:19:chronic_disease	Hemoglobinopathies
NCT01810588	1:16:clinical_variable,42:45:lower_bound	Karnofsky (KPS) Performance status of >= 70%
NCT01810588	1:16:clinical_variable	Life expectancy is severely limited by concomitant illness or uncontrolled infection
NCT01810588	1:17:cancer	Multiple myeloma
NCT01810588	1:25:cancer	Myelodysplastic syndrome
NCT01810588	7:29:chronic_disease,41:62:treatment	Other hematological disorder in need of allogeneic transplant
NCT01810588	1:9:pregnancy	Pregnant
NCT01810588	35:71:cancer	Previously Relapsed or refractory acute leukemia (myeloid or lymphoid)
NCT01810588	25:43:cancer,47:63:cancer	Recurrent or refractory malignant lymphoma or Hodgkin lymphoma
NCT01810588	20:61:clinical_variable	Severely decreased Left Ventricular Ejection Fraction (LVEF)
NCT01810588	14:25:chronic_disease	Uncontrolled HIV disease
NCT01810588	22:34:cancer	accelerated phase or blast-crisis
NCT01810588	1:33:cancer	blastoid dendritic cell neoplasm
NCT01807091	1:3:lower_bound,4:7:upper_bound	10-19% blasts in marrow by morphology or flow cytometry or blood
NCT01807091	1:4:cancer,6:40:cancer,64:67:cancer	AML (acute promyelocytic leukemia [APL] excepted) or high-risk MDS
NCT01807091	46:87:clinical_variable,91:94:lower_bound	Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of 45% or greater, by multiple gated acquisition (MUGA) or echocardiogram
NCT01807091	51:63:chronic_disease,65:74:chronic_disease,76:92:chronic_disease	Afebrile with clear chest imaging and no signs of active viral, bacterial, fungal infection unless determined to be, at the discretion of the investigator, not clinically significant in the context of this study
NCT01807091	1:12:clinical_variable,16:22:upper_bound	Blast count =< 10,000
NCT01807091	1:11:clinical_variable,14:17:lower_bound	Fibrinogen > 200
NCT01807091	26:36:upper_bound	Patient must live within 30 minutes of the treating physician's office during outpatient treatment
NCT01807091	27:57:treatment	The benefits/risks of the induction chemotherapy regimen will be reviewed
NCT01807091	1:40:clinical_variable,43:47:upper_bound,67:75:clinical_variable,87:99:treatment	Treatment-related mortality (TRM) score < 9.21 corresponding to a TRM rate of 3% when chemotherapy of similar intensity as proposed here is administered to inpatients
NCT01807091	48:59:chronic_disease,63:78:chronic_disease,82:106:chronic_disease	no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure
NCT01804634	1:7:lower_bound,8:16:upper_bound	1 year-50 years
NCT01804634	3:11:lower_bound,44:52:treatment	> 6 months must have elapsed from start of last BMT
NCT01804634	1:4:clinical_variable,6:9:clinical_variable,15:35:clinical_variable,38:45:upper_bound	ALT, AST, and Alkaline Phosphatase < 5 x ULN
NCT01804634	1:4:age,6:15:lower_bound	Age >0.5 years
NCT01804634	11:22:cancer,17:22:cancer,27:46:cancer,39:46:cancer,66:69:upper_bound	Any other solid tumor and soft tissue sarcoma with an estimated <10% chance of survival will be considered on a case by case basis at the departmental tumor board and/or sarcoma meeting
NCT01804634	1:10:clinical_variable,13:22:upper_bound	Bilirubin ≤ 3.0 mg/dL
NCT01804634	1:8:chronic_disease	Cardiac
NCT01804634	1:36:cancer	Desmoplastic small round cell tumor
NCT01804634	1:5:clinical_variable,7:10:clinical_variable,12:16:clinical_variable,18:36:clinical_variable,40:43:lower_bound,69:79:clinical_variable	FEV1, FVC, DLCO (diffusion capacity) > 50% predicted (corrected for hemoglobin)
NCT01804634	40:75:treatment,79:100:treatment	Failure to achieve at least a PR after induction therapy with COG ANBL0532 or standard chemotherapy
NCT01804634	5:8:chronic_disease	For CMV seronegative recipients, a CMV seronegative donor
NCT01804634	26:35:clinical_variable,36:42:clinical_variable,43:45:lower_bound,46:49:upper_bound	Good performance status (Karnofsky/Lansky 60-100)
NCT01804634	1:4:chronic_disease	HIV-positive
NCT01804634	1:4:treatment	HLA-mismatched donors will be prioritized over HLA-matched to maximize an allogeneic benefit
NCT01804634	1:8:chronic_disease	Hepatic
NCT01804634	74:81:treatment	It is expected that patients will have received upfront standard of care therapy for their respected disease
NCT01804634	1:35:clinical_variable,54:57:lower_bound	Left ventricular ejection fraction at rest must be ≥ 35%
NCT01804634	7:26:chronic_disease	Major ABO incompatibility
NCT01804634	1:25:cancer	Metastatic Ewing Sarcoma
NCT01804634	7:26:chronic_disease	Minor ABO incompatibility
NCT01804634	1:14:cancer	Neuroblastoma
NCT01804634	1:13:cancer	Osteosarcoma with metastatic disease beyond the lungs
NCT01804634	40:42:upper_bound	Patients (Parents/guardians for those <18) and donors must be able to sign consent forms
NCT01804634	61:72:treatment,73:78:treatment,79:92:treatment,96:99:treatment	Patients must be recovered from the acute toxicities of any prior chemo/radio/immunotherapy or BMT
NCT01804634	58:67:treatment	Patients must be willing to participate in all stages of treatment
NCT01804634	52:66:treatment	Patients who relapse after either single or tandem autologous BMT are eligible
NCT01804634	16:17:lower_bound,29:36:clinical_variable,51:60:treatment,62:74:treatment,78:99:treatment,101:110:treatment	Patients with >5 identified lesions on the end of induction (COG ANBL0532 or standard chemotherapy) MIBG scan
NCT01804634	131:144:chronic_disease	Patients with high risk disease as defined in Appendix 1 who do not meet eligibility requirements/organ function requirements for myeloablative conditioning
NCT01804634	131:144:cancer	Patients with high risk disease as defined in Appendix 1 whose autologous peripheral blood stem cell product is contaminated with neuroblastoma or who do not have an autologous product available
NCT01804634	100:107:lower_bound	Patients with measurable disease must have stable disease by RECIST criteria on two scans at least 6 weeks apart
NCT01804634	10:35:treatment	Positive leukocytotoxic crossmatch
NCT01804634	15:37:treatment,43:55:treatment,59:80:treatment	Refractory to induction chemotherapy with COG ANBL0532 or standard chemotherapy
NCT01804634	1:17:clinical_variable,42:45:age	Serum creatinine within normal range for age
NCT01804634	1:25:cancer	Stage 4 rhabdomyosarcoma
NCT01804634	55:58:lower_bound	The donor and recipient must be identical at at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1
NCT01804634	14:19:chronic_disease,21:30:chronic_disease,35:52:chronic_disease	Uncontrolled viral, bacterial, or fungal infections
NCT01804634	1:6:gender,47:59:pregnancy,61:65:clinical_variable	Women of childbearing potential who currently are pregnant (HCG+)
NCT01804634	49:66:clinical_variable,72:75:upper_bound	be classified as high risk defined by having an expected survival of < 10%
NCT01804634	1:21:cancer	ganglioneuroblastoma
NCT01804634	1:20:clinical_variable,23:26:lower_bound	shortening fraction > 25%
NCT01804634	13:46:contraception_consent	who are not practicing adequate contraception
NCT01804634	6:21:cancer,38:47:treatment	with lung metastases not amenable to resection
NCT01799135	37:78:treatment	Adequate renal function to tolerate intravenous gadolinium contrast injection
NCT01799135	30:65:treatment,70:75:cancer	Deemed to be a candidate for stereotactic body radiation therapy for NSCLC
NCT01799135	26:52:cancer	Histologically confirmed non-small cell lung cancer
NCT01799135	1:20:treatment,24:45:treatment	Implanted pacemaker or cardiac defibrillator
NCT01799135	16:33:cancer,37:55:cancer	No evidence of nodal involvement or distant metastases
NCT01799135	1:9:pregnancy	Pregnant or breastfeeding
NCT01799135	1:28:treatment,32:39:treatment	Prior thoracic radiotherapy or surgery
NCT01799135	1:6:cancer,15:19:lower_bound,24:28:upper_bound	Tumor between 1 cm and 6 cm
NCT01783535	1:23:clinical_variable,34:35:upper_bound,43:58:upper_bound	ECOG Performance Score must be ≤ 2 within two weeks prior to registration
NCT01783535	28:54:cancer,95:120:cancer,146:159:treatment,171:183:treatment,308:319:treatment	Newly diagnosed, untreated intraocular retinoblastoma. Participants previously diagnosed with unilateral retinoblastoma treated surgically, with focal therapy or needing chemotherapy who develop asynchronous involvement of the contralateral eye, or patients with unilateral retinoblastoma treated only with enucleation or focal therapy who develop asynchronous involvement of the contralateral eye, will be eligible for study
NCT01783535	24:47:chronic_disease,62:78:clinical_variable,84:90:upper_bound,95:98:age	Participants must have adequate renal function as defined by serum creatinine ≤ to 3X ULN for age
NCT01783535	66:75:clinical_variable,81:111:upper_bound,117:121:clinical_variable,126:130:clinical_variable,136:142:upper_bound	Participants must have an adequate liver function, as defined by bilirubin ≤ to 3X upper limit of normal (ULN), and SGOT and SGPT ≤ to 3X ULN
NCT01783535	31:49:chronic_disease	Participants must not have an invasive infection at time of protocol entry
NCT01783535	13:31:cancer	Presence of metastatic disease or gross (residual) orbital involvement
NCT01777035	1:40:clinical_variable,43:45:lower_bound	Baseline Barthel Index Functional Score > 70, functional at home
NCT01777035	1:15:chronic_disease,29:48:chronic_disease	Cardiac arrest as cause for respiratory failure
NCT01777035	10:31:cancer	Elevated intracranial pressure
NCT01777035	1:3:clinical_variable,6:8:lower_bound,12:20:upper_bound	MV > 24, < 96 hours
NCT01777035	1:10:pregnancy	Pregnancy
NCT01777035	18:41:chronic_disease	Rapidly changing neurological conditions
NCT01777035	8:29:chronic_disease	Severe chronic pain syndrome on admission
NCT01777035	1:19:chronic_disease	Terminal condition
NCT01777035	1:23:chronic_disease,25:48:chronic_disease,50:66:chronic_disease	Traumatic brain injury, multiple limb fractures, pelvic fractures
NCT01777035	1:16:clinical_variable,19:27:upper_bound	life expectancy < 6 months
NCT01773707	1:22:clinical_variable,25:46:upper_bound	2 hour plasma glucose <140 mg/dL (7.8 mmol/L)
NCT01773707	41:45:treatment,48:71:lower_bound	30, 60, 90 minute plasma glucose during OGTT ≥ 200 mg/dL (11.1 mmol/L)
NCT01773707	31:39:chronic_disease	Abnormal Glucose Tolerance or Diabetes
NCT01773707	5:20:chronic_disease,29:71:chronic_disease	Are immunodeficient or have clinically significant chronic lymphopenia
NCT01773707	14:22:pregnancy,40:67:pregnancy,75:83:upper_bound	Be currently pregnant or lactating, or anticipate getting pregnant within 3 months of the last study drug administration
NCT01773707	13:17:age,13:16:age,21:22:lower_bound,23:31:upper_bound,76:77:lower_bound	Between the ages of 1-45 years at the time of enrollment in TN01 and age ≥ 6 at time of randomization in this trial
NCT01773707	1:23:clinical_variable,26:48:upper_bound	Fasting plasma glucose < 110 mg/dL (6.1 mmol/L)
NCT01773707	17:20:chronic_disease,66:68:bmi	Have a positive PPD test result or history of previously treated TB, or positive interferon-gamma release assay (IGRA) test
NCT01773707	9:25:chronic_disease	Have an active infection at time of randomization
NCT01773707	18:38:chronic_disease	Have evidence of active EBV infection
NCT01773707	44:47:chronic_disease,49:60:chronic_disease,125:146:chronic_disease	Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B core antibody or surface antigen), or Hepatitis C infection
NCT01773707	38:51:chronic_disease	Have serological evidence of current CMV infection
NCT01773707	1:30:treatment	Insulin autoantibodies (mIAA)
NCT01773707	51:58:upper_bound,73:80:upper_bound	Normal glucose tolerance by OGTT confirmed within 7 weeks (no more than 52 days) of baseline (visit 0)
NCT01773707	22:46:treatment	Require use of other immunosuppressive agents
NCT01773707	28:43:chronic_disease,45:49:chronic_disease,51:63:chronic_disease,68:93:chronic_disease,103:114:cancer,116:126:cancer,131:147:chronic_disease	These include pre-existing cardiac disease, COPD, neurological, or blood count abnormalities (such as lymphopenia, leukopenia, or thrombocytopenia)
NCT01760005	52:63:upper_bound	Alcohol or drug dependence currently or within the past 1 year
NCT01760005	1:14:treatment,27:31:clinical_variable,35:41:upper_bound,43:50:treatment	Anticoagulants except low dose (≤ 325 mg) aspirin
NCT01760005	12:15:lower_bound,57:60:age,92:101:treatment,112:134:treatment,179:187:upper_bound	Are within -15 to + 10 years of the predicted or actual age of cognitive symptom onset for treatment arms. For Cognitive Run-In (CRI): includes participants who are younger than 15 years prior to the expected age of cognitive symptom onset, in addition to those 15 years younger and no more than 10 years older than expected or actual age of cognitive symptom onset
NCT01760005	9:11:lower_bound,12:20:upper_bound,24:27:age	Between 18-80 years of age
NCT01760005	28:53:chronic_disease,62:70:chronic_disease,72:102:clinical_variable,106:107:lower_bound,108:109:upper_bound	Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1
NCT01760005	24:74:treatment,86:101:upper_bound	Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months
NCT01760005	12:18:cancer,30:42:upper_bound,51:71:cancer,73:100:cancer,102:117:cancer,121:138:cancer,180:192:lower_bound	History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years
NCT01760005	47:69:chronic_disease,71:94:chronic_disease,96:114:chronic_disease,118:133:chronic_disease,138:167:chronic_disease	History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders
NCT01760005	35:54:chronic_disease,123:168:chronic_disease	Individuals who know they have an Alzheimer's disease-causing mutation or are unaware of their genetic status and have an autosomal dominant Alzheimer's disease (ADAD) mutation in their family
NCT01760005	1:34:pregnancy,43:78:pregnancy	Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial
NCT01760005	13:23:treatment,25:39:treatment,41:64:treatment	Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan
NCT01760005	109:121:treatment,132:147:treatment,152:161:pregnancy	Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy
NCT01757418	1:2:lower_bound,3:14:upper_bound	8-13.99 years for Phase 2
NCT01757418	2:11:lower_bound,12:19:clinical_variable	>300 mg/dL protein in spot urinalysis
NCT01757418	1:4:age,5:7:lower_bound,8:16:upper_bound	Age 12-65 years for Phase 1
NCT01757418	1:18:chronic_disease,38:43:clinical_variable,46:53:lower_bound,68:90:chronic_disease	Concomitant acute process, including fever > 38.5° C with clinical suspicion of infection
NCT01757418	26:60:treatment	Current participation in another investigational drug study
NCT01757418	9:18:treatment,24:43:treatment	Current treatment with chronic transfusion
NCT01757418	25:44:chronic_disease,46:48:chronic_disease,52:76:chronic_disease	Documented diagnosis of sickle cell disease (SS or S-β thalassemia genotype)
NCT01757418	1:3:clinical_variable,6:13:lower_bound	Hb > 10 g/dL
NCT01757418	1:3:clinical_variable,5:11:upper_bound	Hb< 5 g/dl
NCT01757418	1:14:clinical_variable,17:23:lower_bound	Increased ALT > 2X ULN
NCT01757418	11:17:chronic_disease,38:58:treatment,62:88:treatment	Increased stroke risk as assessed by transcranial Doppler or magnetic resonance imaging (all subjects undergo testing)
NCT01757418	7:21:chronic_disease	Known IgA deficiency
NCT01757418	1:10:pregnancy	Pregnancy
NCT01757418	7:17:chronic_disease	Prior thromboses
NCT01757418	1:17:clinical_variable,19:28:lower_bound	Serum creatinine ≥1.3 mg/dL
NCT01757418	1:41:treatment,49:66:upper_bound	Vaccination with a live attenuated virus in the preceding 6 weeks
NCT01757418	1:3:clinical_variable,6:9:lower_bound	ct > 30%
NCT01757418	9:17:treatment	current estrogen use
NCT01757418	18:32:allergy_name	known allergy to gamma globulin
NCT01757418	33:50:chronic_disease	known condition associated with renal dysfunction
NCT01754779	6:19:clinical_variable,21:28:lower_bound,32:37:gender	24hr urine calcium >250mg/d in women
NCT01754779	2:9:lower_bound,13:16:gender,26:36:treatment	>300mg/d in men prior to indapamide use
NCT01754779	1:15:chronic_disease	Hypercalciuric CaP stone formers
NCT01754779	1:15:chronic_disease	Hypocitraturic CaP stone formers
NCT01754779	22:30:clinical_variable,37:41:lower_bound	elevated pH as 24-hr urine pH above 6.40
NCT01754779	6:8:clinical_variable,13:17:lower_bound,36:59:chronic_disease	high pH as >6.40 in the absence of urinary tract infection
NCT01754779	1:14:clinical_variable,16:23:upper_bound	urine citrate <320mg/d
NCT01734512	20:23:chronic_disease	A known history of HIV seropositivity
NCT01734512	1:4:age,6:7:lower_bound,13:21:upper_bound	Age ≥3 and ≤21 years
NCT01734512	1:12:cancer,25:47:cancer	Astrocytoma, Low Grade (Fibrillary astrocytoma, WHO Grade 2) - 10065886
NCT01734512	1:12:cancer,25:46:cancer	Astrocytoma, Low Grade (Low-grade Astrocytoma, NOS, WHO Grade 2) - 10003571
NCT01734512	79:89:treatment,103:110:upper_bound,114:117:age	Because no dosing or adverse event data are currently available on the use of everolimus in patients <3 years of age,
NCT01734512	55:68:treatment,94:103:treatment,109:119:treatment	Close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus
NCT01734512	1:16:gender,73:81:pregnancy,100:118:pregnancy	Female patients of child bearing potential must not be breastfeeding or pregnant as evidenced by a negative pregnancy test
NCT01734512	1:4:chronic_disease,26:60:treatment	HIV-positive patients on combination antiretroviral therapy
NCT01734512	1:14:chronic_disease	Hepatitis B/C blood test must be done at screening for all patients
NCT01734512	1:4:clinical_variable,6:9:upper_bound,12:27:treatment,79:87:treatment,111:122:treatment,128:135:lower_bound	INR ≤1.5. (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of LMW heparin for >2 weeks at time of randomization)
NCT01734512	44:68:chronic_disease,116:126:treatment,134:152:chronic_disease,167:173:chronic_disease,175:183:chronic_disease,185:193:chronic_disease,195:217:chronic_disease,221:242:treatment	Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection
NCT01734512	1:25:clinical_variable,32:40:upper_bound,44:47:age,53:55:lower_bound	Lansky Performance score (if ≤ 16 years of age) of ≥50 by the time of registration
NCT01734512	1:16:clinical_variable,33:40:lower_bound	Life expectancy of greater than 8 weeks
NCT01734512	21:30:clinical_variable,37:45:lower_bound,49:52:age	Patient must have a Karnofsky (if ≥ 16 years of age)
NCT01734512	23:32:treatment,34:46:treatment,54:66:treatment	Patients may have had treatment (chemotherapy and/or radiotherapy) for any number of relapses prior to this recurrence
NCT01734512	23:30:treatment,62:71:treatment	Patients may not have therapy for this recurrence (including radiation)
NCT01734512	51:54:clinical_variable,57:66:lower_bound,68:82:clinical_variable,88:99:lower_bound,105:115:clinical_variable,118:125:lower_bound,143:150:treatment	Patients must have adequate bone marrow function (ANC ≥ 1,000/mm3, platelet count of ≥ 100,000/mm3, and hemoglobin ≥ 9 gm/dL) before starting therapy
NCT01734512	45:53:clinical_variable,56:69:upper_bound,74:83:clinical_variable,86:99:upper_bound,117:124:treatment	Patients must have adequate liver function (SGPT/ALT ≤ 2.5 times ULN and bilirubin ≤ 1.5 times ULN) before starting therapy
NCT01734512	45:61:clinical_variable,64:91:upper_bound,96:99:age,103:106:clinical_variable,109:126:lower_bound,144:151:treatment	Patients must have adequate renal function (serum creatinine ≤ 1.5 times institutional ULN for age or GFR ≥ 70 ml/min/1.73 m2) before starting therapy
NCT01734512	20:37:clinical_variable,39:48:upper_bound,53:66:clinical_variable,69:78:upper_bound,95:102:treatment	Patients must have cholesterol level <350 mg/dL and triglycerides < 400 mg/dL before starting therapy
NCT01734512	60:63:lower_bound,64:70:clinical_variable,115:118:lower_bound,133:136:treatment	Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least two dimensions on MRI
NCT01734512	58:61:age,71:85:treatment	Patients must have normal pulmonary function testing for age based on pulse oximetry
NCT01734512	72:79:lower_bound,83:85:upper_bound,86:98:clinical_variable	Patients must have radiographic progressive or recurrent confirmed WHO grade I or II astrocytomas, that was confirmed histologically
NCT01734512	48:88:treatment,98:119:lower_bound,154:166:lower_bound,170:181:treatment	Patients must have received their last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6)weeks of nitrosourea
NCT01734512	73:89:clinical_variable,92:104:upper_bound	Patients must have received their last dose of other investigational or biological agent > 7 days prior to study entry
NCT01734512	52:64:treatment,68:83:treatment,87:100:cancer,117:142:lower_bound	Patients must have received their last fraction of craniospinal or focal radiation to primary tumor or other sites >12 weeks (3 months) prior to registration
NCT01734512	41:51:treatment,55:78:treatment	Patients receiving any other concurrent anticancer or investigational therapy
NCT01734512	20:27:treatment,29:47:treatment,53:68:treatment,80:103:treatment	Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
NCT01734512	20:42:treatment	Patients receiving concomitant medication that may interfere with study outcome
NCT01734512	29:71:treatment,79:87:upper_bound	Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
NCT01734512	48:51:treatment	Patients who do not have measurable disease on MRI
NCT01734512	51:65:treatment	Patients who have been previously treated with an mTOR inhibitor
NCT01734512	32:43:chronic_disease,63:74:chronic_disease	Patients who test positive for Hepatitis C antibodies and the Hepatitis B antigen
NCT01734512	43:53:allergy_name,63:73:allergy_name,80:89:allergy_name,91:103:allergy_name	Patients with a known hypersensitivity to everolimus or other rapamycins (e.g. sirolimus, temsirolimus)
NCT01734512	134:141:treatment	Patients with any clinically significant unrelated systemic illness that would compromise the patient's ability to tolerate protocol therapy
NCT01734512	78:85:treatment	Patients with inability to return for follow-up visits to assess toxicity to therapy
NCT01734512	35:41:cancer	Patients with primary spinal cord tumors
NCT01734512	1:22:cancer	Pilocytic Astrocytoma - 90600112
NCT01734512	53:56:treatment	Progressive or recurrent disease should be based on MRI according to the definition below
NCT01734512	1:8:treatment,12:35:treatment	Topical or inhaled corticosteroids
NCT01734512	14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease,202:219:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT01734512	66:91:treatment,113:124:clinical_variable,127:135:upper_bound,140:153:clinical_variable,156:164:upper_bound,181:188:treatment	the patient can only be included after initiation of appropriate lipid lowering medication and documentation of cholesterol < 350mg/dL and triglycerides < 400mg/dl before start of therapy
NCT01734512	1:6:gender,3:6:gender,47:82:contraception_consent	women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
NCT01730118	8:22:chronic_disease,24:33:chronic_disease,37:53:chronic_disease,64:73:treatment	Active systemic viral, bacterial or fungal infection requiring treatment
NCT01730118	33:35:lower_bound	Adults greater than or equal to 18
NCT01730118	1:4:age,30:38:lower_bound	Age greater than or equal to 18 years
NCT01730118	10:14:clinical_variable,18:35:treatment,61:64:lower_bound	Baseline LVEF by 2D Echocardiogram greater than or equal to 53%
NCT01730118	23:33:clinical_variable,44:53:upper_bound,55:59:clinical_variable,64:68:clinical_variable,91:120:upper_bound,125:140:clinical_variable,163:172:upper_bound,174:181:clinical_variable,271:289:cancer	Chemistry parameters: Creatinine less than 1.5 mg/dL, SGOT and SGPT less than or equal to 3X the upper limits of normal and total bilirubin less than or equal to 1.5 mg/dl, Alk PO4 less than or equal to 3X the upper limits of normal (except for patients with documented metastatic disease to bone and/or liver)
NCT01730118	23:33:clinical_variable,51:55:clinical_variable,60:64:clinical_variable,87:93:upper_bound,101:110:clinical_variable,133:141:upper_bound,146:153:clinical_variable,220:238:cancer	Chemistry parameters: Creatinine less than mg/dL, SGOT and SGPT less than or equal to 3X ULN, total bilirubin less than or equal to 1.5X ULN and Alk PO4 less than or equal to 3X ULN (except for patients with documented metastatic disease to bone and/or liver)
NCT01730118	24:43:chronic_disease,71:84:clinical_variable,95:101:chronic_disease,103:127:chronic_disease,129:150:chronic_disease,152:163:chronic_disease,197:206:treatment,229:241:treatment	Clinically significant cardiac dysfunction defined as a history of >= NYHA Class II symptoms, angina, congestive heart failure, myocardial infarction, arrhythmias or cardiac dysfunction requiring treatment or discontinuation of chemotherapy
NCT01730118	12:23:treatment,32:41:lower_bound,44:54:lower_bound,59:80:cancer,85:95:cancer,120:130:treatment,139:148:lower_bound	Cumulative doxorubicin dose >= 400mg/m^2 (>450 mg/m^2 for malignant soft tissue and bone tumor patients) or cumulative epirubicin dose >= 800mg/m^2
NCT01730118	26:32:lower_bound,50:58:treatment,62:100:treatment,105:115:cancer	Greater than or equal to 1 week since receipt of standard or investigational HER2- directed therapy for metastatic or recurrent disease
NCT01730118	26:32:lower_bound,51:76:treatment,81:99:cancer	Greater than or equal to 1 week since standard or investigational treatment for metastatic disease
NCT01730118	26:33:lower_bound,46:74:treatment	Greater than or equal to 6 weeks s/p primary surgery with curative intent
NCT01730118	25:28:clinical_variable,32:47:lower_bound,49:52:clinical_variable,56:70:lower_bound,72:82:clinical_variable,86:95:lower_bound,97:100:clinical_variable,104:120:lower_bound,122:136:clinical_variable,140:151:lower_bound,153:155:clinical_variable,156:159:clinical_variable,179:212:upper_bound	Hematologic parameters: ANC >= 1000 cells/mm^3, ALC >= 300 cells/mm^3, Hemoglobin >= 9.0 gm/dL, WBC >= 2,500 cells/mm^3, platelet count >= 75,000/mm^3, PT/PTT less than or equla to1.5X the upper limits of normal
NCT01730118	25:28:clinical_variable,32:47:lower_bound,49:52:clinical_variable,56:70:lower_bound,72:91:clinical_variable,94:103:lower_bound,105:108:clinical_variable,111:125:lower_bound,127:141:clinical_variable,144:155:lower_bound,157:163:clinical_variable	Hematologic parameters: ANC >= 1000 cells/mm^3, ALC >= 300 cells/mm^3, absolute Hemoglobin >=9.0 gm/dL, WBC >=2500 cells/mm3, platelet count >=75,000/mm^3, PT/PTT 1.5X the upper limits of normal
NCT01730118	32:36:clinical_variable,58:73:treatment,79:98:treatment	History of changes in baseline LVEF that occurred during prior treatment with anti-HER2 treatment
NCT01730118	30:51:treatment,55:67:treatment	May or may not have received adjuvant radiotherapy or chemotherapy based on pathologic risk per NCCN guidelines
NCT01730118	30:41:treatment,70:82:treatment	May or may not have received neoadjuvant cisplatin-based combination chemotherapy per NCCN guidelines
NCT01730118	10:36:treatment,39:62:treatment,68:89:treatment,92:130:treatment,141:164:treatment	Naive to trastuzumab (Herceptin(TM)), pertuzumab (Perjeta(TM)) and lapatinib (Tykerb(TM)), ado-trastuzumab emtansine (Kadcyla(TM)) or other HER2-directed therapies
NCT01730118	28:31:chronic_disease,45:49:chronic_disease	Negative serology for anti-HIV-1/2 and anti-HTLV 1/2
NCT01730118	10:18:treatment,23:40:chronic_disease,78:95:treatment,105:114:chronic_disease	Negative serology for hepatitis B and C unless the result is consistent with prior vaccination or prior infection with full recovery
NCT01730118	1:24:clinical_variable,28:34:gender	Negative serum beta HCG if female and of childbearing potential
NCT01730118	1:24:pregnancy	Negative serum beta HCG if of childbearing potential
NCT01730118	22:36:cancer,40:54:cancer,70:75:cancer,104:120:cancer,160:176:chronic_disease,180:187:treatment,191:200:treatment,261:272:chronic_disease,287:296:lower_bound	Patients with active CNS metastases or leptomeningeal involvement by tumor (patients with a history of brain metastases who have been successfully treated for brain metastasis by surgery or radiation and who have not had any evidence of the new or progressive CNS disease fot more than 12 months are eligible)
NCT01730118	15:28:cancer,66:69:treatment,80:90:clinical_variable,101:104:lower_bound,117:120:upper_bound	Patients with breast cancer that is known to be HER2 1+ or 2+ by IHC or with a Vysis FISH result of 1.8 - less than 2.2
NCT01730118	15:28:cancer,30:37:cancer,39:64:cancer,74:81:cancer,96:100:clinical_variable,128:145:clinical_variable,148:151:lower_bound	Patients with breast cancer, gastric, gastroesophageal junction or other cancers with 1+ to 3+ HER2/neu expression by IHC or a Vysis FISH result > 2.2
NCT01730118	26:53:chronic_disease,105:114:treatment,142:170:treatment	Patients with inadequate bilateral peripheral venous or central venous catheter access for the required apheresis to allow generation of the autologous AdHER2 DC vaccine product
NCT01730118	15:22:cancer,24:32:cancer,34:39:cancer,41:48:cancer,49:74:cancer,76:95:cancer,97:107:cancer,109:116:cancer,118:139:cancer,144:170:cancer,180:192:cancer,234:237:clinical_variable,248:258:clinical_variable,291:294:lower_bound	Patients with ovarian, cervical, colon, gastric/gastroesophageal junction, non-small cell lung, renal cell, bladder, malignant soft tissue and bone tumor prostate cancer or other solid tumors that is known to be HER2 1+, 2+ or 3+ by IHC OR have a Vysis FISH result greater than or equal to 1.8
NCT01730118	1:19:clinical_variable,21:25:clinical_variable,26:27:lower_bound,28:29:upper_bound	Performance Status: ECOG 0-1
NCT01730118	1:18:clinical_variable,20:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	Perormance Status: ECOG 0-1
NCT01730118	1:9:pregnancy,10:15:gender,53:69:treatment,97:108:treatment	Pregnant women are excluded from this study because AdHER DC vaccine may have the potential for teratogenic or abortifacient effects
NCT01730118	14:33:chronic_disease,52:61:treatment,121:135:cancer	Recurrent or progressive disease on prior standard therapies with known clinical benefit with the exception of adjuvant bladder cancer population
NCT01730118	26:44:cancer,68:72:clinical_variable,73:91:treatment	Recurrent or progressive metastatic disease after standard of care HER2-targeted therapies
NCT01730118	27:36:treatment,40:60:treatment,65:104:cancer	Stable, concurrent use of tamoxifen or aromatase inhibitors for hormone receptor positive breast cancer
NCT01730118	27:36:treatment,40:60:treatment,91:104:cancer	Stable, concurrent use of tamoxifen or aromatase inhibitors for hormone receptor positive breast cancer are allowed
NCT01730118	21:31:treatment	Status-post primary cystectomy with curative intent
NCT01730118	1:6:cancer,7:16:cancer,18:21:cancer,23:26:cancer,28:31:cancer,76:81:cancer	Tumor stage T3a, T3b, T4a, T4b and any node positive disease regardless of tumor stage
NCT01730118	1:7:cancer,17:21:clinical_variable,22:23:lower_bound,32:33:upper_bound,38:41:clinical_variable,52:69:clinical_variable,83:86:lower_bound	Tumors that are HER2 1+, 2+ or 3+ by IHC or have a Vysis FISH result greater than 1.8
NCT01730118	21:33:treatment,43:67:treatment,75:81:upper_bound	Use of any standard chemotherapy or other investigational agent(s) within 1 week of study enrollment
NCT01730118	8:39:treatment,47:54:upper_bound,105:139:treatment	Use of systemic corticosteroid therapy within 2 weeks of study enrollment, including patients receiving replacement corticosteroid therapy
NCT01730118	16:40:gender,44:71:contraception_consent,77:96:contraception_consent,98:112:contraception_consent,114:133:contraception_consent,138:145:contraception_consent,172:184:upper_bound,212:225:treatment	Willingness of female and male subjects to use effective contraception e.g. oral contraceptives, barrier device, intrauterine device, or condoms, during the study and for three months following the last dose of study vaccine
NCT01730118	16:31:gender,35:62:contraception_consent	Willingness of female subjects to use effective contraception
NCT01730118	6:10:cancer,12:26:cancer	with HER2+ bladder cancer in the adjuvant setting (adjuvant bladder cancer patients)
NCT01730118	32:43:cancer,74:84:cancer,85:97:cancer,121:139:treatment,172:189:treatment	with malignant soft tissue and bone tumors and recurrent or progressive, metastatic solid tumors who have progressed on standard therapies with known benefit but for whom anti-HER2 therapy is not clinically indicated
NCT01722240	1:4:age,5:7:lower_bound,8:16:upper_bound	Age 18-75 years
NCT01722240	1:4:bmi,5:7:lower_bound,8:16:upper_bound	BMI 20-40 kg/m2
NCT01722240	30:51:chronic_disease,53:68:chronic_disease,70:92:treatment,94:101:treatment,105:125:treatment,134:153:upper_bound	Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks
NCT01722240	1:4:chronic_disease,8:24:chronic_disease	HIV or Hepatitis B or C positive status
NCT01722240	1:6:clinical_variable,20:24:upper_bound	HbA1c of less than 8.5%
NCT01722240	1:16:chronic_disease,18:30:clinical_variable,33:47:lower_bound,52:61:chronic_disease	Hepatic disease (transaminase > 3 times normal) or cirrhosis
NCT01722240	1:17:chronic_disease,19:29:clinical_variable,32:47:upper_bound	Renal impairment (serum eGFR < 30ml/min/1.73m2)
NCT01722240	1:16:chronic_disease,44:60:treatment,82:94:treatment	Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII; also known as insulin pump)
NCT01722240	1:16:chronic_disease,31:39:upper_bound	Type 1 diabetes for less than 6 months
NCT01722240	63:70:upper_bound	Use of an investigational agent or therapeutic regimen within 30 days of study
NCT01722240	12:25:chronic_disease	history of gastroparesis
NCT01722240	12:39:chronic_disease,43:57:chronic_disease	history of medullary thyroid carcinoma or MEN 2 syndrome
NCT01722240	12:24:chronic_disease	history of pancreatitis
NCT01722240	39:46:treatment	multiple (four or more) injections of insulin per day
NCT01722240	1:20:chronic_disease	non-cardiac disease
NCT01722240	1:10:pregnancy	pregnancy
NCT01720147	14:32:treatment	Able to take enteral medication
NCT01720147	5:8:age	All age groups, including adults
NCT01720147	14:16:chronic_disease,27:35:treatment,39:56:treatment	Diagnosis of FA proven by DEB test or molecular testing
NCT01720147	20:32:treatment,36:51:treatment,88:97:treatment	Patients receiving cyclosporine or digoxin therapy or are unable to discontinue either treatment due to medical reasons
NCT01720147	18:26:pregnancy,62:71:pregnancy,80:129:contraception_consent	Patients who are pregnant or breastfeeding or are at risk of pregnancy and are unable to use acceptable methods of birth control during the length of the study
NCT01720147	28:53:treatment,63:75:treatment,92:99:upper_bound	Patients who have received quercetin supplementation or other antioxidants within the last 30 days
NCT01720147	41:55:cancer,59:67:cancer	Patients with morphological evidence of myelodysplasia or leukemia
NCT01720147	1:14:chronic_disease,25:33:treatment	Renal failure requiring dialysis
NCT01720147	1:16:clinical_variable,19:26:lower_bound,34:38:clinical_variable,40:43:lower_bound	Total bilirubin > 3 mg/dl and/or SGPT >200 at time of enrollment
NCT01712048	10:13:age,15:23:lower_bound,47:67:treatment,71:96:chronic_disease	Patients age >18 years that are scheduled for endoscopic resection of large colo-rectal lesions who consent to this study
NCT01712048	31:38:cancer,79:82:treatment	Patients with lesions showing adenoma invasion into the muscularis propria on EUS
NCT01712048	27:30:lower_bound,31:50:clinical_variable,53:57:lower_bound	Patients without at least one colo-rectal lesions ≥ 20mm
NCT01685411	2:10:upper_bound,14:17:age	<45 years of age
NCT01685411	2:10:upper_bound,14:17:age,35:43:lower_bound,58:99:treatment	<45 years of age who are at least 6 months after initial hematopoietic stem cell transplant (HSCT)
NCT01685411	14:48:cancer,50:78:cancer,82:112:cancer	Diagnosis of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and current in complete remission
NCT01685411	1:29:clinical_variable,31:34:lower_bound	Karnofsky performance status >70%
NCT01685411	1:6:gender,23:26:age,39:57:pregnancy	Women of childbearing age must have a negative pregnancy test
NCT01685411	38:46:upper_bound	active uncontrolled infection within one week of study enrollment
NCT01685411	39:75:contraception_consent	all sexually active participants must agree to use effective contraception during study treatment
NCT01685411	1:8:chronic_disease,10:44:clinical_variable,46:49:lower_bound,53:79:treatment	cardiac: left ventricular ejection fraction >45% by echocardiogram (ECHO/MUGA)
NCT01685411	14:48:treatment	eligible for TBI containing preparative regimen
NCT01685411	26:35:treatment,67:95:treatment	have received sufficient radiation treatment to be ineligible for total body irradiation (TBI) containing preparative therapy
NCT01685411	34:49:chronic_disease,57:69:chronic_disease,71:78:chronic_disease	hepatic: no clinical evidence of hepatic failure (e.g., coagulopathy, ascites)
NCT01685411	11:17:gender	lactating female
NCT01685411	1:9:pregnancy	pregnant
NCT01685411	8:28:clinical_variable,30:47:lower_bound	renal: creatinine clearance >40 mL/min/1.73m^2
NCT01684397	36:46:treatment	Ability to swallow and retain oral medication
NCT01684397	1:32:clinical_variable,36:48:lower_bound	Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
NCT01684397	1:31:clinical_variable,36:68:clinical_variable	Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN
NCT01684397	104:114:treatment	Any condition which in the investigator's opinion deems the subject an unsuitable candidate to receive study drug
NCT01684397	1:7:treatment,25:64:cancer,70:80:cancer	Biopsy/pathology-proven clear cell renal cell carcinoma (CCRCC) with metastases
NCT01684397	27:43:treatment,73:90:treatment	Concurrent use of another anti-cancer drug including an investigational anti-cancer agent
NCT01684397	1:21:treatment,25:33:treatment	Coronary angioplasty or stenting
NCT01684397	1:39:treatment	Coronary artery bypass grafting (CABG)
NCT01684397	1:28:clinical_variable,31:39:lower_bound	Corrected QT interval (QTc) > 480 msec
NCT01684397	13:28:chronic_disease,32:49:chronic_disease	Evidence of active bleeding or bleeding disorder
NCT01684397	9:69:clinical_variable,73:74:upper_bound	Have an Eastern Cooperative Oncology Group (ECOG) performance status =< 1
NCT01684397	1:11:clinical_variable,15:23:lower_bound	Hemoglobin >= 10 gm/dL
NCT01684397	33:58:chronic_disease	History of any of the following cardio-vascular condition
NCT01684397	12:37:chronic_disease,48:80:chronic_disease	History of cerebrovascular accidents including transient ischemic attacks (TIA)
NCT01684397	12:38:chronic_disease	History of deep vein thrombosis (DVT)
NCT01684397	24:62:chronic_disease	History of symptomatic chronic congestive heart failure (CHF)
NCT01684397	1:40:clinical_variable,45:89:clinical_variable,92:101:upper_bound	International normalization ratio (INR) and activated partial thromboplastin time (aPTT) < 1.2 x ULN
NCT01684397	1:14:treatment,22:35:upper_bound,39:48:treatment,52:65:treatment,85:98:upper_bound	Major surgery within 28 days prior to treatment or major surgery planned during the next 6 months
NCT01684397	1:27:chronic_disease	Myocardial infarction (MI)
NCT01684397	1:33:clinical_variable,37:40:lower_bound,45:80:treatment,84:98:treatment	Normal cardiac ejection fraction (> 50%) by multi gated acquisition scan (MUGA) or echocardiogram
NCT01684397	1:10:clinical_variable,14:26:lower_bound	Platelets >= 100 x 10^9/L
NCT01684397	1:9:pregnancy	Pregnant
NCT01684397	1:30:treatment,35:61:cancer,72:80:treatment,84:106:treatment	Prior VEGF targeted therapies for renal cell carcinoma (RCC) including adjuvant or neoadjuvant treatments
NCT01684397	13:34:treatment,42:55:upper_bound	Received an investigational agent within 30 days prior to enrollment
NCT01684397	23:47:treatment	Subjects currently on anti-coagulation therapy
NCT01684397	33:39:cancer,47:59:upper_bound	Subjects diagnosed with another cancer in the past 3 years
NCT01684397	42:85:contraception_consent,93:101:contraception_consent,105:136:contraception_consent,138:148:contraception_consent	Subjects of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
NCT01684397	26:55:clinical_variable,59:79:clinical_variable,87:94:upper_bound	Subjects should not have packed red blood cells (PRBC) or platelet transfusion within 14 days of the screening
NCT01684397	21:37:cancer	Subjects with known brain metastases
NCT01684397	13:46:chronic_disease	Symptomatic peripheral arterial disease (PAD)
NCT01684397	1:16:clinical_variable,20:47:upper_bound	Total bilirubin =< upper limit of normal (ULN)
NCT01684397	45:56:treatment	Unable to discontinue the use of prohibited medications
NCT01684397	14:26:chronic_disease,28:56:clinical_variable,59:68:lower_bound,72:84:clinical_variable,90:98:lower_bound	Uncontrolled hypertension (systolic blood pressure [BP] > 150 mm Hg or diastolic BP of > 90 mm Hg)
NCT01684397	77:93:chronic_disease,110:147:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic or psychiatric illness/social situations that would limit compliance with study requirements
NCT01684397	1:16:chronic_disease	Unstable angina
NCT01684397	1:21:cancer,25:48:cancer,89:98:treatment	basal cell carcinoma or squamous cell carcinoma, of skin which were completely cured by resection
NCT01684397	9:24:gender	nursing female subjects
NCT01684397	5:90:treatment,97:181:treatment	one prior therapy with high dose IL-2 or anti-programmed cell death (PD)-1 compound alone or in combination with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) targeting drug
NCT01684397	1:24:chronic_disease,32:45:upper_bound	pulmonary embolism (PE) in the past 6 months
NCT01684397	31:43:upper_bound,91:97:upper_bound,120:148:treatment	the 3 values have to be below 150/90 mm Hg for eligibility and can only be obtained after 2 days of the last change in anti-hypertensive medication
NCT01684397	8:17:treatment,55:57:clinical_variable	use of clonidine is not permissible for adjusting the BP during this period
NCT01676753	3:4:lower_bound,14:58:treatment	> 2 lines of prior chemotherapy in the metastatic setting
NCT01676753	1:32:clinical_variable,35:44:lower_bound	Absolute neutrophil count (ANC) ≥ 1,500 /μL
NCT01676753	1:33:clinical_variable,35:39:clinical_variable,45:73:clinical_variable,75:79:clinical_variable,83:92:upper_bound,85:92:upper_bound,107:123:cancer	Aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase ALT (SGPT) ≤ 2.5 x ULN, ≤ 5 x ULN if liver metastasis
NCT01676753	24:42:chronic_disease	Clinically significant cardiac arrhythmia
NCT01676753	24:48:chronic_disease,50:65:chronic_disease	Clinically significant congestive heart failure, unstable angina pectoris
NCT01676753	20:35:treatment,39:61:treatment	Concomitant use of bisphosphonates or RANK-ligand inhibitors is allowed
NCT01676753	14:30:chronic_disease,47:70:treatment,142:159:upper_bound,204:219:treatment	Congenitally long QT syndrome, and/or current anti-arrhythmic therapy, a n d / o r has received any marketed or experimental compound in the last 1 week prior to entering the study with known effects of QT prolongation (Refer to AZCERT website)
NCT01676753	1:15:gender,54:87:pregnancy,93:98:clinical_variable,106:120:upper_bound,226:241:pregnancy	Female patient of childbearing potential must have a negative serum or urine pregnancy test β-hCG within 72 hours prior to first doses of study medication . If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
NCT01676753	1:7:gender,62:101:contraception_consent,138:146:upper_bound,176:186:treatment	Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication
NCT01676753	16:28:treatment,36:43:upper_bound,70:77:treatment	Has received a live vaccine within 30 days of planned start of study therapy
NCT01676753	1:11:clinical_variable,14:20:lower_bound	Hemoglobin ≥ 9 g/dL
NCT01676753	27:37:cancer,71:84:cancer,93:95:clinical_variable,100:102:clinical_variable,104:107:upper_bound,105:106:lower_bound,145:149:clinical_variable,159:162:clinical_variable,173:175:upper_bound,180:184:clinical_variable,186:189:upper_bound	Histologically documented metastatic or locally advanced unresectable breast cancer that is ER and PR <10% expression and does not over-express HER2 protein (IHC 0, 1+, or 2+ and FISH <2.0)
NCT01676753	90:114:cancer	Histologically or cytologically documented, incurable, unresectable locally advanced, or metastatic breast cancer
NCT01676753	1:22:chronic_disease,34:47:upper_bound,66:77:treatment	Myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator
NCT01676753	1:34:clinical_variable,37:46:upper_bound	Partial thromboplastin time (PTT) ≤ 1.2 x ULN
NCT01676753	28:44:chronic_disease,69:94:treatment,106:141:treatment,153:189:treatment,218:233:treatment,238:244:chronic_disease,246:283:chronic_disease,285:302:chronic_disease,325:341:treatment,396:408:upper_bound,426:441:treatment	Patient has a diagnosis of immunodeficiency or is receiving ongoing immunosuppressive therapy, including systemic or enteric corticosteroids except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, chronic obstructive pulmonary disease, allergic rhinitis). Patient must be off systemic steroid or any other form of immunosuppressive therapy within 7 days prior to first dose of trial treatment
NCT01676753	61:68:treatment	Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
NCT01676753	69:82:chronic_disease	Patient has a history or current evidence of clinically significant heart disease
NCT01676753	23:51:cancer	Patient has a primary central nervous system tumor
NCT01676753	24:49:chronic_disease,98:123:chronic_disease	Patient has history of interstitial lung disease or known history of, or any evidence of active, noninfectious pneumonitis
NCT01676753	24:39:chronic_disease,41:53:chronic_disease,94:102:allergy_name,106:126:allergy_name,136:174:allergy_name,184:211:allergy_name	Patient has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or prior allogeneic bone marrow transplantation or prior solid organ transplantation
NCT01676753	26:40:cancer,48:72:cancer	Patient has known active CNS metastases and/or carcinomatous meningitis
NCT01676753	37:57:chronic_disease	Patient has known history of active Hepatitis A, B, or C
NCT01676753	43:82:allergy_name	Patient has known hypersensitivity to the components of study drug or its analogs
NCT01676753	19:30:chronic_disease,34:59:chronic_disease	Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
NCT01676753	55:89:treatment	Patient is currently participating in a study with an investigational compound or device
NCT01676753	34:52:chronic_disease,71:89:treatment,93:105:upper_bound,125:149:treatment,151:166:treatment,170:193:treatment,202:221:treatment,229:238:treatment,240:247:treatment,252:298:treatment,303:337:chronic_disease	Patient is diagnosed with active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Note: replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
NCT01676753	24:58:chronic_disease	Patient is known to be Human Immunodeficiency Virus (HIV)-positive
NCT01676753	12:26:gender,32:40:lower_bound,44:47:age	Patient is male or female and ≥18 years of age on the day of signing informed consent
NCT01676753	12:20:pregnancy	Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
NCT01676753	27:33:treatment	Patient must consent to a biopsy of a site of disease unless the only site of disease is lung/pleura, bone, or deemed unsafe by the principal investigator
NCT01676753	19:37:clinical_variable,41:42:lower_bound,43:44:upper_bound,52:74:clinical_variable,79:94:clinical_variable,97:105:lower_bound	Patient must have performance status of 0-1 on the ECOG Performance Scale and life expectancy > 3 months
NCT01676753	21:33:treatment,41:47:upper_bound,94:106:treatment,114:121:upper_bound,125:137:upper_bound,172:184:treatment,186:197:treatment,201:212:treatment,215:246:clinical_variable,258:283:treatment,291:298:upper_bound,418:433:treatment,454:461:upper_bound,474:484:chronic_disease,489:497:chronic_disease	Patient who has had radiotherapy within 1 week (or unresolved radiation-related toxicities), chemotherapy within 2 weeks or 5 half-lives, whichever is longer (6 weeks for nitrosoureas, mitomycin C or bevacizumab), anti-cancer monoclonal antibody for direct anti-neoplastic treatment within 3 weeks, or who has not recovered from toxicity due to previous agents administered. If the patient has residual toxicity from prior treatment, toxicity must be ≤ Grade 1 (except for neuropathy and alopecia)
NCT01676753	20:27:upper_bound,28:57:treatment,33:57:treatment,214:232:treatment	Patients less than 2 weeks post major surgical procedure (all surgical wounds must be fully healed). For the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia
NCT01676753	20:36:treatment,51:79:treatment	Patients requiring warfarin therapy are excluded, low molecular weight heparin is permitted
NCT01676753	45:56:treatment,97:103:lower_bound,116:128:lower_bound,190:200:treatment	Patients who have discontinued any of these medications must have a wash-out period of at least 5 days or at least 5 half-lives of the drug (whichever is longer) prior to the first dose of dinaciclib (Refer to Appendix 2 Drugs that interact strongly with CYP3A4)
NCT01676753	47:62:allergy_name	Patients who have known allergic reactions to IV contrast dye despite standard prophylaxis
NCT01676753	22:33:treatment,50:79:treatment	Patients who require medications that are strong CYP3A4 inhibitors or inducers
NCT01676753	1:10:clinical_variable,13:24:lower_bound	Platelets ≥ 100,000 /μL
NCT01676753	1:22:clinical_variable,23:59:clinical_variable,62:67:upper_bound,68:71:clinical_variable	Prothrombin time (PT)/International Normalized Ratio (INR) ≤ 1.2 x ULN
NCT01676753	1:17:clinical_variable,19:27:lower_bound	QTc prolongation >480 msec (Bazett's Formula)
NCT01676753	1:10:clinical_variable,13:35:lower_bound	Serum LDH > 1.5x institutional ULN
NCT01676753	1:17:clinical_variable,21:52:clinical_variable,55:88:upper_bound	Serum creatinine or calculated creatinine clearance ≤ 1.5 x upper limit of normal (ULN)
NCT01676753	13:22:clinical_variable,31:34:clinical_variable	Serum total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 x ULN
NCT01676753	3:12:lower_bound,31:48:clinical_variable,51:74:lower_bound	≥ 60 mL/min for patients with creatinine levels > 1.5 x institutional ULN
NCT01670877	1:4:clinical_variable,6:18:lower_bound	ANC ≥1.5 x 10^9/L
NCT01670877	1:4:clinical_variable,9:12:clinical_variable,14:20:upper_bound,17:20:clinical_variable,26:31:upper_bound,50:66:cancer	AST and ALT ≤3× ULN or < 5 ULN for patients with liver metastases
NCT01670877	1:12:clinical_variable,14:20:upper_bound,26:33:upper_bound,52:68:cancer	AST and ALT ≤3× ULN or ≤ 5 x ULN for patients with liver metastases
NCT01670877	27:34:chronic_disease,38:53:chronic_disease,64:81:treatment	Acute or currently active hepatic or biliary disease requiring antiviral therapy
NCT01670877	37:54:treatment,55:62:chronic_disease,66:81:chronic_disease	Acute or currently active/requiring antiviral therapy hepatic or biliary disease
NCT01670877	49:56:upper_bound	Adequate organ function as defined below within 2 weeks of registration
NCT01670877	49:56:upper_bound	Adequate organ function as defined below within 8 weeks of pre-registration
NCT01670877	27:32:cancer	Agree to provide archival tumor material for research
NCT01670877	10:18:lower_bound,22:25:age	At least 18 years of age
NCT01670877	31:53:treatment,57:80:treatment	Currently receiving any other investigational agents or systemic cancer therapy
NCT01670877	91:114:treatment,118:128:treatment	Currently taking medications and herbal or dietary supplements that are strong cytochrome P450 (CYP) 3A4 inducers or inhibitors
NCT01670877	1:24:clinical_variable,27:28:upper_bound	ECOG performance status ≤ 2
NCT01670877	1:24:clinical_variable,26:27:upper_bound	ECOG performance status ≤2
NCT01670877	1:3:clinical_variable,11:13:clinical_variable,97:102:cancer,182:193:treatment	ER and/or PR positivity by institutional standard is required on pathology from the most recent tumor specimen unless the tissue source (for example, pleural effusion or ascites or bone biopsy) may yield false negative ER and/or PR result, in which case the pathology from an earlier time point could be used and a discussion with the study chair is required
NCT01670877	14:21:lower_bound,33:41:chronic_disease	Experiencing grade 2 or greater diarrhea
NCT01670877	1:15:cancer,28:39:treatment	HER2 mutations detected by Guardant360
NCT01670877	43:47:cancer,99:112:cancer	Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or non-amplified by FISH) breast cancer that is stage IV
NCT01670877	24:39:chronic_disease,41:61:chronic_disease,79:90:chronic_disease	History of significant cardiac disease, cardiac risk factors, or uncontrolled arrhythmias
NCT01670877	1:5:clinical_variable,13:31:clinical_variable,39:46:upper_bound	LVEF > or = institutional ILLN within 4 weeks of registration
NCT01670877	1:4:gender,10:67:contraception_consent,77:86:treatment,95:103:lower_bound	Men must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product
NCT01670877	21:37:cancer,75:84:treatment,96:104:treatment,181:189:upper_bound	Patients with known brain metastasis are eligible, but must have received radiation and be off steroids and stable (without evidence of disease progression by imaging or exam) for 3 months
NCT01670877	1:15:clinical_variable,17:29:lower_bound	Platelet count ≥100 x 10^9/L
NCT01670877	1:9:pregnancy	Pregnant
NCT01670877	1:31:treatment	Prior treatment with neratinib
NCT01670877	1:13:clinical_variable,15:23:upper_bound,28:31:gender,42:50:upper_bound,55:60:gender,68:75:upper_bound	QTc interval ≤450 msec for men or < or ≤ 470 msec for women within 2 weeks of registration
NCT01670877	1:17:clinical_variable,19:28:upper_bound	Serum creatinine ≤1.5 x ULN
NCT01670877	13:35:chronic_disease,49:79:cancer,93:100:chronic_disease	Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest
NCT01670877	13:17:clinical_variable,122:146:chronic_disease	Testing for LVEF is not required for pre-registration, but patient must not have a recent LVEF < LLN or have symptoms of congestive heart failure
NCT01670877	33:50:treatment,67:73:lower_bound,88:109:treatment,201:210:treatment	The patient must have completed radiation therapy and be at least 1 week from the last systemic chemotherapy administration, with adequate recovery of bone marrow and organ functions, before starting neratinib
NCT01670877	67:76:treatment	The washout period must have been completed prior to the start of neratinib if the patient was taking any of these agents
NCT01670877	56:72:treatment	There is no limitation on the number of prior lines of systemic therapy
NCT01670877	32:43:treatment,62:94:treatment	To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with fulvestrant is not allowed
NCT01670877	32:43:treatment	To be eligible for the Part II fulvestrant-treated ER+ cohort, prior disease progression on fulvestrant is required
NCT01670877	7:16:clinical_variable,18:27:upper_bound	Total bilirubin ≤1.5 x ULN
NCT01670877	1:16:clinical_variable,18:27:upper_bound	Total bilirubin ≤1.5 × ULN
NCT01670877	1:6:cancer,34:47:cancer	Tumor tissue tested positive for HER2 mutation
NCT01670877	77:93:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,158:176:chronic_disease,181:218:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT01670877	14:34:chronic_disease,77:93:chronic_disease,95:119:chronic_disease,121:139:chronic_disease,144:181:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT01670877	1:6:gender	Women of childbearing potential
NCT01670877	1:4:gender	men
NCT01670877	6:41:contraception_consent,43:86:contraception_consent,88:98:contraception_consent	must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation
NCT01668563	1:9:chronic_disease	Aneurysm located at basilar apex
NCT01668563	10:13:lower_bound,26:36:cancer,38:59:chronic_disease,61:69:chronic_disease,77:89:upper_bound	At least one documented, intradural, intracranial aneurysm, ruptured within last 30 days
NCT01668563	19:27:lower_bound,31:34:age	Patients at least 18 years of age
NCT01668563	15:39:chronic_disease	Patients with AVM-associated aneurysms
NCT01668563	17:25:chronic_disease,64:72:treatment,76:98:treatment	The patient and aneurysm are considered appropriate for either surgical or endovascular treatment by the treating team
NCT01659749	16:19:chronic_disease,29:44:chronic_disease	Diagnosed with PKU or other aminoacidopathy
NCT01659749	1:4:age,5:7:lower_bound	age 11 or older
NCT01659749	1:7:gender	female
NCT01653080	1:44:chronic_disease	Acute or chronic severe renal insufficiency
NCT01653080	1:24:chronic_disease,36:57:chronic_disease,68:103:treatment	Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period
NCT01653080	1:4:age,7:9:lower_bound	Age > 60
NCT01653080	1:155:chronic_disease,69:104:chronic_disease	Exposure to gadolinium-based contrast agents increases the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or severe renal dysfunction
NCT01653080	12:20:chronic_disease	History of diabetes
NCT01653080	12:24:chronic_disease	History of hypertension
NCT01653080	19:34:chronic_disease,35:51:treatment	History of severe hepatic disease/liver transplant/pending liver transplant
NCT01653080	163:195:clinical_variable,214:223:upper_bound	In order to identify subjects at risk for the development of NSF, the American College of Radiology (http://acr.org) recommends obtaining a medical history and a glomerular filtration rate (GFR) assessment within six weeks of MR
NCT01653080	10:28:pregnancy	Patients cannot be pregnant and prisoners will not be considered for the study
NCT01653080	17:23:clinical_variable,26:30:upper_bound	Patients with a lesion < 2 mm
NCT01653080	1:14:chronic_disease,26:41:chronic_disease,43:59:treatment,61:72:cancer	Renal disease (including solitary kidney, renal transplant, renal tumor)
NCT01653080	20:32:cancer,82:91:treatment	The patient has an orbital mass which needs further diagnostic evaluation before treatment or for monitoring
NCT01653080	117:126:treatment,128:150:treatment,286:289:treatment,392:398:allergy_name,400:415:allergy_name,417:427:allergy_name,445:459:chronic_disease	The patient should not participate in this study is any of the following applies to the patient: the patients has a pacemaker, metallic cardiac valve(s), magnetic material such as surgical clips, implanted electronic infusion pumps or any other condition that would interfere with the MRI, the patient has a stent somewhere in the body, the patient has a history of allergic reaction to any metals, contrast agents, x-ray dyes, the patient has claustrophobia
NCT01653080	1:27:clinical_variable,30:48:upper_bound	glomerular filtration rate < 30 mL/min/1.73 m^2
NCT01653080	18:22:clinical_variable,28:46:upper_bound	subjects with an eGFR of < 30 mL/min/1.73 m^2
NCT01653080	115:158:clinical_variable,166:175:upper_bound	the form will be reviewed to determine whether the subject is at risk as defined above and the availability of an estimated glomerular filtration rate (eGFR) within six weeks of anticipated MR imaging
NCT01643460	20:24:chronic_disease,58:71:treatment	Investigator deems cyst does not meet safety or need for cyst ablation
NCT01643460	18:26:lower_bound,30:33:age	Patient at least 18 years of age
NCT01643460	27:39:lower_bound,44:57:upper_bound,77:101:treatment	Patients referred between January 2009 and February 2016 to EUS at IUMC for pancreatic cyst ablation and with no contraindications for anticipated safe and successful performance of the procedure
NCT01623167	1:26:clinical_variable,37:47:upper_bound	Absolute neutrophil count less than 500/microL
NCT01623167	1:28:clinical_variable,39:52:upper_bound	Absolute reticulocyte count less than 60,000/microL
NCT01623167	1:4:age,30:37:lower_bound	Age greater than or equal to 2 years old
NCT01623167	15:30:chronic_disease,64:72:upper_bound	Evidence of a clonal disorder on cytogenetics performed within 12 weeks of study entry
NCT01623167	21:32:allergy_name	Hypersensitivity to eltrombopag or its components
NCT01623167	52:59:treatment	Infection not adequately responding to appropriate therapy
NCT01623167	20:34:chronic_disease	Known diagnosis of Fanconi anemia
NCT01623167	31:38:chronic_disease,40:45:chronic_disease,47:54:chronic_disease,56:66:chronic_disease,68:77:chronic_disease,79:89:chronic_disease,94:111:chronic_disease,186:202:treatment,225:226:lower_bound,227:234:upper_bound	Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 7-10 days is likely
NCT01623167	1:15:clinical_variable,26:39:upper_bound	Platelet count less than 20,000/microL
NCT01623167	25:31:cancer,43:76:treatment	Potential subjects with cancer who are on active chemotherapeutic treatment or who take drugs with hematological effects
NCT01623167	1:32:treatment,42:45:treatment,47:58:treatment,73:89:treatment	Prior immunosuppressive therapy with any ATG, alemtuzumab, or high dose cyclophosphamide
NCT01623167	1:5:clinical_variable,9:13:clinical_variable,15:48:lower_bound	SGOT or SGPT >5 times the upper limit of normal
NCT01623167	1:23:chronic_disease,41:64:clinical_variable,75:85:upper_bound	Severe aplastic anemia characterized by Bone marrow cellularity less than 30 percent
NCT01623167	27:36:chronic_disease,85:97:treatment,102:113:treatment,130:137:clinical_variable,140:145:upper_bound	Subjects with known liver cirrhosis in severity that would preclude tolerability of cyclosporine and eltrombopag as evidenced by albumin < 35g/L
NCT01623167	1:7:clinical_variable,21:26:lower_bound	Weight greater than 12 kg
NCT01582191	1:26:clinical_variable,44:50:lower_bound	Absolute neutrophil count more or equal to 750/mL
NCT01582191	1:28:chronic_disease	Congenital long QT syndrome
NCT01582191	1:11:clinical_variable,29:60:upper_bound	Creatinine less or equal to 3 x upper limit of normal (ULN)
NCT01582191	1:61:clinical_variable,89:90:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status should be less or equal to 3
NCT01582191	21:34:upper_bound,51:57:chronic_disease,58:82:chronic_disease	History (within the last 3 months) or presence of stroke/cerebrovascular accident
NCT01582191	32:64:allergy_name	History of hypersensitivity to any component of the formulation
NCT01582191	32:41:treatment,43:55:treatment,57:67:treatment	History of hypersensitivity to sirolimus, temsirolimus, everolimus
NCT01582191	32:42:allergy_name,44:51:allergy_name,53:68:allergy_name,77:105:allergy_name	History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation
NCT01582191	27:34:lower_bound,57:79:treatment,106:107:lower_bound,185:201:treatment,277:294:treatment,296:330:treatment,415:424:treatment	Patients must be at least 3 weeks beyond their previous cytotoxic chemotherapy; patient must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy; in addition, patients must be at least 3 weeks beyond the last session of radiation therapy; local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment
NCT01582191	27:44:cancer,67:83:treatment,195:207:lower_bound	Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves survival by at least three months
NCT01582191	1:10:clinical_variable,28:37:lower_bound	Platelets more or equal to 50,000/mL
NCT01582191	1:9:pregnancy	Pregnant
NCT01582191	13:28:chronic_disease,93:115:chronic_disease	Presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia
NCT01582191	1:16:clinical_variable,39:42:upper_bound	Total bilirubin less than or equal to 3.0
NCT01582191	14:34:chronic_disease,66:88:chronic_disease,90:109:chronic_disease,120:132:treatment,143:162:treatment	Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support
NCT01553071	1:11:clinical_variable,14:61:upper_bound,64:72:upper_bound,91:107:cancer	ALT (SGPT) ≤ 2.5 x institutional upper limit of normal (ULN) ≤ 5 x IULN for patients with liver metastases
NCT01553071	1:11:clinical_variable,14:55:upper_bound,57:61:clinical_variable,65:73:upper_bound,92:108:cancer	AST (SGOT) ≤ 2.5 x institutional upper limit of normal (IULN) ≤ 5 x IULN for patients with liver metastases
NCT01553071	1:8:clinical_variable,11:14:upper_bound	AST/ALT ≤ 2.5 x the IULN
NCT01553071	1:32:clinical_variable,35:39:lower_bound,41:50:clinical_variable,53:60:lower_bound,83:117:chronic_disease	Absolute neutrophil count (ANC) ≥ 1500, platelets ≥ 100,000, unless due to direct bone marrow involvement of disease
NCT01553071	1:4:age,5:13:lower_bound	Age 18 years or greater
NCT01553071	1:4:age,6:14:lower_bound	Age >18 years
NCT01553071	57:59:treatment,61:64:treatment,127:140:upper_bound	All patients must have measurable disease documented by CT, MRI, or non-measurable disease documented by Physical Exam within 28 days prior to registration
NCT01553071	1:29:treatment,80:96:chronic_disease	Baseline (pre-treatment) EKG with any of the following changes consistent with cardiac ischemia
NCT01553071	11:24:treatment,26:48:clinical_variable,51:61:lower_bound	Baseline (pre-treatment) serum troponin T (TnT) ≥ 0.03 ng/mL
NCT01553071	18:31:clinical_variable,34:80:lower_bound,84:104:chronic_disease,115:125:treatment	Baseline fasting triglycerides > 2.5 institutional upper limit of normal (IULN) or hypertriglyceridemia requiring medication
NCT01553071	84:96:treatment,98:145:treatment,147:166:treatment,179:199:treatment,228:240:treatment,242:255:treatment,257:271:treatment,285:294:treatment,296:305:treatment,319:331:treatment,333:347:treatment,349:354:treatment,356:368:treatment,373:387:treatment,389:401:treatment,403:417:treatment,419:433:treatment,435:444:treatment,446:458:treatment,460:467:treatment,469:480:treatment,486:496:treatment	Concomitant use of the following drugs (see Concomitant Medications, Section 3.3): antioxidants; herbal or other alternative therapy medications; vitamin supplements (especially vitamins A, C, and E) other than a standard dose multivitamin, acetaminophen, cyclosporine A or analogue; verapamil; tamoxifen or analogue, ketoconazole, chlorpromazine; RU486; indomethacin; or sulfinpyrazone, tetracycline, nalidixic acid, nitrofurantoin, phenytoin, sulfonamides, lithium, ceftriaxone, and amiodarone
NCT01553071	1:24:clinical_variable,28:29:lower_bound,32:33:upper_bound	ECOG performance status of 0 - 2
NCT01553071	1:24:clinical_variable,28:29:lower_bound,32:33:upper_bound,69:77:upper_bound	ECOG performance status of 0 - 2 and estimated survival of at least 3 months
NCT01553071	12:23:treatment,28:36:treatment	Effects of fenretinide and safingol on the developing human fetus are unknown
NCT01553071	5:10:gender,41:65:pregnancy,90:104:upper_bound,118:128:treatment	For women of child-bearing potential, a negative serum pregnancy test is required within 72 hours prior to receiving study drug each cycle
NCT01553071	5:10:gender,41:65:pregnancy,90:103:upper_bound	For women of child-bearing potential, a negative serum pregnancy test is required within 72hours prior to receiving study drug each cycle
NCT01553071	1:11:clinical_variable,14:23:lower_bound,25:36:treatment	Hemoglobin ≥ 8.0 gm/dL; transfusion permitted to achieve this level
NCT01553071	1:10:clinical_variable,13:16:lower_bound	Karnofsky > 60%
NCT01553071	18:30:allergy_name,34:46:allergy_name	Known allergy to egg products or soy bean oil
NCT01553071	51:119:allergy_name,129:149:allergy_name,151:158:allergy_name,163:186:allergy_name	Known history of allergic reactions attributed to compounds of similar chemical or biologic composition to fenretinide, such as 13-cis-retinoic acid, retinol, or all-trans-retinoic acid
NCT01553071	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 3 months
NCT01553071	1:14:treatment,22:38:upper_bound,65:76:treatment,81:89:treatment	Major surgery in the last three weeks due to unknown effects of fenretinide and safingol on wound healing
NCT01553071	22:25:chronic_disease,45:68:treatment	Patients known to be HIV-positive receiving anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions
NCT01553071	62:72:cancer,131:139:treatment,143:162:treatment	Patients must have histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
NCT01553071	62:84:cancer,95:113:treatment	Patients must have histologically or cytologically confirmed non-Hodgkin's lymphoma for which standard therapies do not exist or are no longer effective
NCT01553071	49:62:treatment	Patients must have recovered from toxicities of prior therapy
NCT01553071	20:30:treatment,41:54:chronic_disease,71:86:clinical_variable	Patients requiring medication for other dyslipidemias (i.e., elevated LDL cholesterol)
NCT01553071	28:43:treatment,49:80:treatment,69:80:treatment	Patients who have received prior treatment with oral or intravenous fenretinide as a single agent are eligible, provided they did not experience severe toxicity related to fenretinide
NCT01553071	29:61:chronic_disease	Patients with an identified familial hyperlipidemia disorder
NCT01553071	15:32:cancer,62:76:cancer,176:190:treatment,195:217:treatment	Patients with esophageal cancer with unresected or recurrent primary tumors in the esophagus are only permitted after discussion of patient with Study Chair due to concern of tumor necrosis and esophageal perforation
NCT01553071	36:52:cancer,64:75:chronic_disease,77:86:chronic_disease,90:113:chronic_disease	Patients with previously untreated brain metastases (including parenchymal, meningeal or dural-based CNS lesions)
NCT01553071	19:36:chronic_disease,52:87:clinical_variable,93:102:lower_bound,108:122:clinical_variable,128:132:lower_bound	Poorly-controlled diabetes mellitus, as defined as fasting serum glucose concentration over 200 mg/dl or a hemoglobin A1C over 7.5%
NCT01553071	1:9:pregnancy,10:15:gender,68:79:treatment,84:92:treatment	Pregnant women are excluded from this study because the effects of fenretinide and safingol on the developing human fetus are unknown
NCT01553071	1:18:treatment,20:32:treatment,74:80:upper_bound,82:89:upper_bound,94:105:treatment,109:120:treatment,140:151:treatment,154:162:treatment	Radiation therapy, chemotherapy, and other investigational agents within 3weeks (6 weeks for nitrosourea or mitomycin C) prior to starting fenretinide + safingol
NCT01553071	1:17:clinical_variable,20:73:upper_bound	Serum creatinine ≤ 1.5 x the upper limits of institutional normal (IULN)
NCT01553071	10:15:gender,23:31:pregnancy	Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
NCT01553071	10:15:gender,16:31:pregnancy,23:31:pregnancy	Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
NCT01553071	16:27:treatment,32:40:treatment	The effects of fenretinide and safingol on the developing human fetus are unknown
NCT01553071	1:16:clinical_variable,19:33:upper_bound	Total bilirubin ≤ 1.5 x the IULN
NCT01553071	86:104:chronic_disease,106:142:chronic_disease,144:168:chronic_disease,170:188:chronic_disease,190:211:chronic_disease	Uncontrolled intercurrent illnesses including, but not limited to, ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, coagulation disorders
NCT01553071	1:26:clinical_variable,29:37:lower_bound	absolute neutrophil count ≥ 1,500/μL
NCT01553071	1:21:clinical_variable,24:41:lower_bound	creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
NCT01553071	1:11:clinical_variable	creatinine within institutional normal limits (WNL)
NCT01553071	1:9:cancer,76:93:treatment,98:104:treatment,122:129:upper_bound	lymphoma patients must have no marrow involvement as documented by routine marrow aspiration and biopsy performed within 30 days of study entry
NCT01553071	7:30:chronic_disease,79:98:chronic_disease,99:116:chronic_disease	other major medical illnesses of the cardiovascular or respiratory systems or psychiatric illness/social situations that would limit compliance with study requirements
NCT01553071	35:42:treatment,44:53:treatment,84:100:cancer,124:146:treatment,154:165:upper_bound,178:194:treatment	patients with previously treated (surgery, radiation or both), clinically inactive brain metastases, who have not received corticosteroid therapy within three weeks of starting protocol therapy
NCT01553071	1:10:clinical_variable,13:23:lower_bound	platelets ≥ 100,000/μL
NCT01553071	13:26:clinical_variable,46:50:lower_bound	significant ST depression (ST depression of ≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec from the end of the QRS complex)
NCT01553071	13:25:clinical_variable,29:32:lower_bound,36:45:clinical_variable,49:53:lower_bound,57:72:clinical_variable	significant ST elevation (> 1mm in limb lead or 2 mm in precordial lead measured at a point 0.04 sec (1 mm) after the J-point [the end of the QRS complex] and compared to baseline [line drawn from P start to T end])
NCT01553071	7:16:clinical_variable,19:24:upper_bound,25:67:clinical_variable	total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN)
NCT01553071	1:6:gender,3:6:gender,47:82:contraception_consent,186:196:lower_bound	women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study, and for two months after study participation
NCT01553071	1:6:gender,3:6:gender,47:82:contraception_consent,84:127:contraception_consent,129:139:contraception_consent	women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
NCT01553071	3:11:upper_bound,30:46:cancer	≤ 5 x IULN for patients with liver metastases
NCT01526603	1:8:chronic_disease	Cardiac
NCT01526603	1:21:clinical_variable,25:57:clinical_variable,60:77:lower_bound	Creatinine clearance or glomerular filtration rate (GFR) > 60 mL/min/1.73m^2
NCT01526603	11:19:upper_bound,23:26:age,43:56:cancer	Less than 30 years of age at diagnosis of neuroblastoma
NCT01526603	16:51:clinical_variable	Minimum frozen peripheral blood stem cells (PBSCs) of 2 x 10^6 CD34 cells/kg for transplant are mandatory and 2 x 10^6 CD34 cells/kg for back-up are strongly recommended (thus, PBSC of 4 x 106 CD34 cells/kg is encouraged)
NCT01526603	75:78:lower_bound	No evidence of disease progression: defined as increase in tumor size of >25% or new lesions
NCT01526603	43:55:treatment,63:70:lower_bound	Patients who are delayed in consolidation chemotherapy beyond 8 weeks
NCT01526603	15:34:chronic_disease,90:111:treatment	Patients with progressive disease should consider participating in phase I studies since consolidation therapy using the regimen outlined in this document have not been determined to be useful
NCT01526603	40:52:treatment	Recovery from last induction course of chemotherapy
NCT01526603	1:26:clinical_variable,29:32:lower_bound,37:45:clinical_variable,48:54:lower_bound	absolute neutrophil count > 500 and platelet > 20,000
NCT01526603	1:33:clinical_variable,36:75:upper_bound	aspartate aminotransferase (AST) < 3 x upper limit of institutional normal
NCT01526603	1:20:clinical_variable,23:26:lower_bound,30:47:clinical_variable,50:53:lower_bound,67:91:chronic_disease	shortening fraction ≥ 27% or ejection fraction ≥ 50%, no clinical congestive heart failure
NCT01522768	28:43:treatment	Able to swallow and retain oral medication
NCT01522768	1:29:chronic_disease,31:59:chronic_disease	Active hepatitis B infection, active hepatitis C infection
NCT01522768	25:46:treatment,37:46:treatment,71:84:treatment,86:103:treatment,127:144:treatment,150:173:treatment,289:305:treatment,348:351:clinical_variable,363:371:treatment,390:394:clinical_variable,548:563:treatment	Additional experimental anti-cancer treatment and/or standard chemo-, immunotherapy, hormone treatment (with the exception of megestrol acetate), or concurrent radiotherapy is not allowed concomitantly with the administration of study treatment (with the exception listed in section 9.0) 89Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permitted. Afatinib is a substrate of P-gp and its plasma concentrations can be affected by the use of P-gp inhibitors (data on file) and it is also likely that P-gp inducers could also influence afatinib plasma concentrations
NCT01522768	51:57:treatment,123:131:treatment,139:155:cancer,180:189:treatment,209:218:treatment,225:227:treatment	All patients with disease technically amenable to biopsy will be asked to undergo a biopsy. Patient must agree to allow 2 biopsies of any malignant lesion that can be accessed by endoscopy or with the aid or radiology (i.e. CT guided)
NCT01522768	15:48:cancer	Asymptomatic, central nervous system metastases
NCT01522768	10:13:lower_bound,25:42:cancer,77:84:chronic_disease,86:103:chronic_disease,109:124:cancer,174:185:clinical_variable,188:193:lower_bound,197:207:treatment,213:218:lower_bound	At least one measurable metastatic lesion according to RECIST 1.1 criteria. Ascites, pleural effusions, and bone metastases are not considered measurable. Minimum indicator lesion size = 10 mm by helical CT or = 20 mm by conventional techniques. Pathological nodes must be = 15 mm by the short axis to be considered measurable
NCT01522768	13:27:upper_bound,28:37:treatment,39:72:clinical_variable,78:103:clinical_variable,117:120:upper_bound,133:147:treatment	Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by echocardiogram
NCT01522768	15:44:treatment,24:36:treatment,46:59:lower_bound,76:91:treatment,189:200:treatment,224:240:treatment,260:278:treatment,292:314:chronic_disease	Completion of previous chemotherapy regimen ≥2 weeks prior to the start of study treatment. Other chemotherapy regimens may have been administered between the time of progression on prior trastuzumab containing regimen and protocol therapy. No restriction on prior chemotherapy regimens for advanced stage disease
NCT01522768	12:30:chronic_disease,93:109:chronic_disease,134:151:chronic_disease,165:171:cancer,173:202:chronic_disease,184:202:chronic_disease,239:247:upper_bound,250:253:chronic_disease	Concurrent medical conditions which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), HIV-positive
NCT01522768	1:24:treatment,69:78:treatment,190:197:chronic_disease	Concurrent radiotherapy is not permitted for disease progression on treatment on protocol (except in the context specified in section 9.0), but might be allowed for pre-existing non-target lesions
NCT01522768	56:61:cancer	Consent to preservation of frozen and fixed samples of tumor cores for evaluation
NCT01522768	59:79:treatment,88:92:clinical_variable,95:98:lower_bound	HER2 overexpression and/or amplification as determined by immunohistochemistry (3+) or FISH (≥2.0)
NCT01522768	44:72:chronic_disease,81:106:chronic_disease,108:132:chronic_disease,133:137:clinical_variable,159:174:chronic_disease,196:206:chronic_disease,208:229:chronic_disease,237:251:upper_bound	History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to study entry
NCT01522768	1:29:clinical_variable,31:34:lower_bound	Karnofsky performance status ≥60%
NCT01522768	7:10:chronic_disease	Known HIV carrier
NCT01522768	61:70:treatment	Known or suspected active drug or alcohol abuse. Restricted Therapies
NCT01522768	20:45:chronic_disease	Known pre-existing interstitial lung disease
NCT01522768	1:16:clinical_variable,29:45:lower_bound	Life expectancy of at least three (3) months
NCT01522768	30:39:treatment,177:184:upper_bound	May have previously received lapatinib as part of a regimen in the perioperative or metastatic setting with evidence of progression of disease. Washout period for lapatinib of 14 days
NCT01522768	1:29:pregnancy,53:58:gender,108:117:upper_bound	Negative serum HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after menopause
NCT01522768	43:65:cancer	Pathologically or cytologically confirmed esophagogastric cancer
NCT01522768	10:13:age,10:14:age,107:115:treatment	Patients aged 18 years or older, as no dosing or adverse event data are currently available on the use of afatinib in patients <18 years of age
NCT01522768	35:53:treatment,57:79:treatment,111:133:cancer,135:151:treatment,195:198:treatment	Patients receiving any concurrent anticancer therapy or investigational agents with the intention of treating esophagogastric cancer. 89Zr-trastuzumab uses as imaging agent for 89Zr-trastuzumab PET permitted
NCT01522768	52:64:treatment,167:172:gender,177:189:pregnancy	Patients who are unwilling to consent to mandatory tumor biopsy. Patients with archival tissue permitted to enroll on study per MSK Principal Investigator discretion Women who are pregnant or breast feeding
NCT01522768	65:76:treatment,108:114:treatment,131:138:treatment	Patients who have previously provided samples at any time after trastuzumab resistance will be exempt from biopsy at the start of therapy
NCT01522768	21:32:treatment,78:88:cancer,126:141:treatment,167:183:treatment	Previously received trastuzumab as part of a regimen in the perioperative or metastatic setting with evidence of progression 9Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permitted
NCT01522768	30:39:treatment,43:53:treatment,57:75:treatment	Prior disease progression on docetaxel or paclitaxel in metastatic setting
NCT01522768	23:55:chronic_disease,61:69:chronic_disease,95:110:chronic_disease,112:125:chronic_disease,130:140:clinical_variable,142:143:lower_bound	Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, malabsorption, or CTCAEGrade >2 diarrhea of any etiology
NCT01522768	19:34:treatment,46:58:treatment,60:72:treatment,74:86:treatment,88:100:treatment,102:111:treatment,113:146:treatment,148:157:treatment,159:168:treatment,170:179:treatment,192:205:treatment,217:231:treatment,233:243:treatment,270:293:treatment	The use of potent P-gp inhibitors (including cyclosporine, erythromycin, ketoconazole, itraconazole, quinidine, Phenobarbital salt with quinidine, ritonavir, valspodar, verapamil) and potent P-gp inducers (including St John's wort, rifampicin) has to be avoided during treatment with afatinib
NCT01522768	1:33:contraception_consent	Willingness to use birth control while on study
NCT01422005	39:64:chronic_disease,66:74:chronic_disease,89:103:chronic_disease,105:117:chronic_disease,119:126:chronic_disease,130:147:chronic_disease	Complicating medical problems such as uncontrolled hypertension, diabetes with signs of polyneuropathy, severe renal, cardiac or pulmonary disease, or evidence of other concurrent neurologic or orthopedic conditions precluding the subject from complying with the study protocol
NCT01422005	51:77:chronic_disease,86:103:chronic_disease,107:124:chronic_disease	Evidence of alcohol, drug abuse or other relevant neuropsychiatric condition such as psychotic illness or severe depression
NCT01422005	12:19:treatment	History of surgery or other significant injury to either upper extremity causing mechanical limitations that preclude task performance
NCT01422005	10:30:chronic_disease,39:50:chronic_disease,58:64:chronic_disease,66:74:chronic_disease,79:100:chronic_disease	Previous neurological illness such as head trauma, prior stroke, epilepsy, or demyelinating disease
NCT01422005	8:34:chronic_disease,51:65:clinical_variable,70:71:lower_bound	Severe upper extremity spasticity suggested by an Ashworth score of >3 at any joint
NCT01422005	26:43:chronic_disease	Subjects must have had a unilateral stroke
NCT01422005	28:35:treatment,78:101:language_fluency	ability to comply with the therapy protocol as assessed by the investigator; must be English speakin
NCT01420887	100:109:treatment,111:119:chronic_disease,121:134:chronic_disease,140:160:chronic_disease	Altered anatomy that might limit elbow motion, independent of the condition being treated, such as dysplasia, malunion, osteonecrosis, and congenital deformity
NCT01420887	28:31:treatment,35:65:treatment,75:93:chronic_disease,102:116:treatment	Contraindication to use of CPM or regional brachial plexus block, such as bleeding diathesis, use of anticoagulants or severe restriction in shoulder range of movement
NCT01420887	18:34:chronic_disease	Current or prior septic arthritis
NCT01420887	1:46:chronic_disease	Intra-operative or postoperative complication that could affect outcome
NCT01420887	36:52:treatment	Not possible to have postoperative physical therapy appointment
NCT01420887	100:113:chronic_disease,117:139:chronic_disease	Pre-existing factors that might limit ability to completely participate in rehabilitations such as neuromuscular or psychosocial condition
NCT01420887	16:39:chronic_disease,43:51:chronic_disease,86:100:chronic_disease	Progressive or recalcitrant neuropathy or neuritis, except for isolated intermittent ulnar neuritis
NCT01420887	45:65:chronic_disease,74:94:chronic_disease,96:125:chronic_disease,129:141:chronic_disease	Progressive or recurrent contracture due to inflammatory disease such as rheumatoid arthritis, juvenile idiopathic arthritis or chondrolysis
NCT01420887	1:8:treatment,33:58:treatment,62:129:treatment	Surgery to be performed will be arthroscopic capsulectomy or osteocapsular arthroplasty with removal of heterotopic ossification as necessary
NCT01420887	53:63:lower_bound,89:111:treatment	The contracture must have been present for at least six months and failed to respond to non-surgical treatment
NCT01420887	1:6:gender,22:34:pregnancy	Women that know they are pregnant or breastfeeding
NCT01409161	16:19:cancer,49:90:treatment,92:123:treatment,128:136:treatment	A diagnosis of APL based on the presence of the PML-RAR-alpha fusion gene by cytogenetics, polymerase chain reaction (PCR), or POD test
NCT01409161	31:36:gender,41:48:gender,77:126:contraception_consent	All sexually active subjects (males and females of child-bearing potential) agree to use 2 effective methods of contraception for the duration of the study
NCT01409161	22:40:clinical_variable,48:71:treatment,85:101:lower_bound	Fridericia corrected QT (QTcF) interval on the electrocardiogram (EKG) greater than 480 milliseconds
NCT01409161	18:25:treatment,30:33:cancer	Patients in whom therapy for APL was initiated on an emergent basis
NCT01409161	15:45:clinical_variable,46:78:clinical_variable,81:110:lower_bound,152:160:cancer,203:220:chronic_disease	Patients with alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 3 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease
NCT01409161	15:25:clinical_variable,28:37:lower_bound,38:59:clinical_variable,101:109:cancer,139:148:chronic_disease,162:169:chronic_disease	Patients with creatinine > 2.5 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease
NCT01409161	15:30:clinical_variable,34:65:lower_bound,107:115:cancer,145:154:chronic_disease,158:175:chronic_disease	Patients with total bilirubin >= 2.0 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease
NCT01409161	1:6:gender,46:70:pregnancy	Women of child-bearing potential must have a negative serum pregnancy test at screening
NCT01409161	5:24:gender,63:81:pregnancy,104:118:upper_bound	all female participants of childbearing potential must have a negative pregnancy test confirmed within 48 hours prior to dosing with the study drug
NCT01409161	50:54:treatment,56:59:treatment,80:90:treatment,119:126:treatment	patients may have already started treatment with ATRA, ATO, and/or one dose of idarubicin due to the urgency to start therapy early
NCT01360606	14:31:chronic_disease	A history of variceal bleeding where the varices have not been eradicated or decompressed by shunt placement
NCT01360606	3:18:clinical_variable,31:39:lower_bound,47:75:clinical_variable,88:90:lower_bound	A life expectancy of at least 6 months with a Karnofsky performance status of at least 70
NCT01360606	1:44:clinical_variable	Cirrhotic status of Child-Pugh class A or B
NCT01360606	11:29:cancer,52:55:lower_bound	Extensive liver tumor burden, defined as more than 75% of the liver
NCT01360606	22:48:chronic_disease	History of an active connective tissue disorder
NCT01360606	1:5:gender	Male
NCT01360606	192:199:treatment	Must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks and discomforts
NCT01360606	1:22:chronic_disease,33:47:lower_bound	Myocardial infarction more than 6 months prior to study entry
NCT01360606	10:22:treatment	No prior radiotherapy to the upper abdomen
NCT01360606	61:70:clinical_variable,73:79:upper_bound,81:88:clinical_variable,90:98:lower_bound,104:117:clinical_variable,128:165:upper_bound,167:177:clinical_variable,193:201:upper_bound,207:227:clinical_variable,230:238:upper_bound	Other baseline labs must meet the following criteria: total bilirubin < 3mg/dl, albumin> 2.5mg/dl, and liver enzymes less than three times the upper limit of normal. Creatinine must also be < 1.8mg/dl or a creatinine clearance > 50ml/min
NCT01360606	36:59:chronic_disease	Patient's will have no evidence of gross vascular invasion
NCT01360606	19:40:chronic_disease,25:40:chronic_disease,165:172:treatment,174:200:treatment,256:293:treatment	Patients can have extra-hepatic disease, provided the hepatic disease is the highest burden, the extra-hepatic disease is low burden and potentially treatable with surgery, ablative radiation therapy, or US Food and Drug Administration-approved first- or second-line systemic therapy regimens
NCT01360606	77:85:treatment,89:96:treatment	Patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists
NCT01360606	33:34:upper_bound,44:50:clinical_variable,65:90:upper_bound,106:131:upper_bound	Patients will have no more than 3 distinct lesions, all being ≤ 3cm in greatest dimension, OR 1 lesion ≤ 6cm in greatest dimension
NCT01360606	15:39:cancer	Patients with hepatocellular carcinoma will be excluded from this study
NCT01360606	15:28:cancer,42:50:cancer,52:60:cancer,65:80:cancer	Patients with primary tumor histology of lymphoma, leukemia, or germ cell tumor
NCT01360606	1:15:clinical_variable,18:28:lower_bound,30:40:clinical_variable,43:51:lower_bound,53:56:clinical_variable,59:66:lower_bound,67:103:clinical_variable,114:117:upper_bound	Platelet count ≥ 60 x 109/L, Hemoglobin ≥ 8.5 g/dL, WBC ≥ 2000/μL International normalized ratio (INR) must be ≤ 2.3
NCT01360606	1:22:chronic_disease	Portal vein occlusion
NCT01360606	1:9:pregnancy	Pregnant
NCT01360606	1:31:treatment,35:62:treatment,72:79:treatment,81:105:treatment,107:124:treatment,126:149:treatment,151:181:treatment,185:197:treatment,287:300:treatment,328:341:lower_bound,390:399:treatment,461:465:treatment,521:537:treatment,582:589:lower_bound	Previous systemic chemotherapy or non-radiation local therapy (such as surgery, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) is allowed. The lesion must however have shown criteria of progression based on RECIST. Local therapy must be completed at least 4 weeks prior to the baseline scan. This is to create a safer treatment environment and to help determine the effect of treatment by SBRT alone. Patients will be allowed to go onto appropriate systemic therapy, as determined by their medical oncologist, 2 weeks following delivery of SBRT
NCT01360606	1:14:chronic_disease,25:53:treatment	Renal failure requiring hemo- or peritoneal dialysis
NCT01360606	18:25:chronic_disease,27:40:chronic_disease,44:61:chronic_disease	Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
NCT01360606	61:64:lower_bound,111:131:clinical_variable,137:144:upper_bound	The target lesion(s) can be accurately measured in at least one dimension according to RECIST and must have a maximum tumor volume of ≤ 100 cm3
NCT01360606	14:35:chronic_disease,77:93:chronic_disease,97:104:lower_bound,137:191:clinical_variable,206:230:chronic_disease,234:267:clinical_variable,268:275:lower_bound,285:314:chronic_disease,316:335:chronic_disease,346:369:treatment,381:394:treatment,398:405:treatment,408:433:chronic_disease	Uncontrolled inter-current illness including, but not limited to ongoing or active infection (> grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 4.0), congestive heart failure (> New York Heart Association (NYHA) class 2), active coronary artery disease (CAD), cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), uncontrolled hypertension and any condition which could jeopardize the safety of the patient and his/her compliance in the study
NCT01360606	1:7:gender	female
NCT01360606	12:20:lower_bound,24:27:age	patients ≥ 18 years of age
NCT01319474	6:14:lower_bound	Be > 18 years old
NCT01319474	75:84:chronic_disease	Be suspected by the referring medical provider to have a first episode of acute DVT of the lower extremities
NCT01319474	11:26:treatment,72:91:chronic_disease	Long term anticoagulation will be required for another diagnosis (e.g. atrial fibrillation)
NCT01319474	1:10:pregnancy	Pregnancy confirmed by an objective test
NCT01319474	63:72:pregnancy	Previous venous ultrasound has been performed during the same pregnancy
NCT01319474	36:39:chronic_disease	The patient has a prior history of DVT in the ipsilateral leg
NCT01319474	61:91:chronic_disease	The patient is suspected by the referring clinician to have symptomatic pulmonary embolism
NCT01319474	25:38:treatment,72:80:lower_bound	Therapeutic doses of an anticoagulant have been received for more than 24 hours before enrollment
NCT01270516	1:9:pregnancy,10:17:gender	pregnant females
NCT01270516	11:33:treatment,48:56:lower_bound	requiring mechanical ventilation for more than 24 hours in one of the University of Kentucky adult ICU's
NCT01239095	1:7:cancer,31:38:lower_bound,42:43:upper_bound	Cancer should be judged to be stage 1 to 3 based on preoperative staging
NCT01239095	19:25:treatment,33:38:cancer,42:55:cancer	Patient must have biopsy proven colon or rectal cancer
NCT01239095	18:21:age,22:24:lower_bound,28:36:upper_bound	Patients must be age 18 to 85 years
NCT01239095	21:38:treatment,43:49:cancer	Patients undergoing emergency surgery for cancer are not eligible
NCT01239095	45:74:treatment,76:84:treatment,88:111:treatment	Patients who are immunosuppressed or taking immunosuppressive medications (steroids or chemotherapeutic agents) are not eligible
NCT01239095	39:50:treatment,61:82:treatment	Patients who are taking part in other neoadjuvant and early adjuvant chemotherapy trials are not eligible
NCT01239095	15:30:chronic_disease,34:52:chronic_disease	Patients with Crohn's disease or ulcerative colitis are not eligible
NCT01239095	15:21:cancer	Patients with cancer judged to be stage 4 are not eligible
NCT01239095	21:33:cancer	Patients with other malignancies are not eligible
NCT01228448	28:32:cancer,37:41:cancer,47:64:cancer,96:108:treatment	Adult subjects with brain, head and neck, and skull base tumors receiving external beam proton radiotherapy at the Francis H. Burr Proton Therapy Center at MGH
NCT01228448	1:4:age,5:7:lower_bound	Age 18 or over
NCT01228448	1:24:clinical_variable,25:26:lower_bound,33:34:upper_bound	ECOG Performance status 0, 1 or 2
NCT01228448	14:34:chronic_disease	Uncontrolled intercurrent illness that, in the opinion of the investigator, would limit the participant's compliance with study requirements
NCT01187368	8:28:chronic_disease	Active psychiatric disorder
NCT01187368	1:31:chronic_disease	Active, uncontrolled infection
NCT01187368	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT01187368	1:4:clinical_variable,7:13:upper_bound	BSA < 1.4 m²
NCT01187368	1:13:chronic_disease	Coagulopathy
NCT01187368	15:38:treatment	Intolerant of anticoagulation therapy
NCT01187368	12:30:treatment	Listed for cardiac transplant as a status 1A or 1B
NCT01187368	1:5:clinical_variable,6:28:chronic_disease	NYHA Class IV heart failure
NCT01187368	19:36:treatment	Patients refusing blood transfusion
NCT01187368	51:68:treatment	Patients with an unacceptable risk for successful LVAD implantation and maintenance
NCT01187368	1:10:pregnancy	Pregnancy
NCT01187368	34:47:chronic_disease,87:94:upper_bound	Presence of condition other than heart failure that would limit survival to less than 3 years
NCT01187368	1:33:chronic_disease	Severe right ventricular failure
NCT01187368	1:35:chronic_disease	irreversible cognitive dysfunction
NCT01174108	27:30:clinical_variable,55:62:clinical_variable,63:70:clinical_variable,190:196:clinical_variable	9/10 donors where all the HLA sequences have the same antigen/peptide binding domains in key exons to the patient. This can result in identical protein sequences between patient and donor. Allele mismatches in p and g groups can be considered acceptable due to the exact matching which exists in the binding domains
NCT01174108	1:4:age,30:31:lower_bound,58:70:upper_bound	Age greater than or equal to 4 and less than or equal to 80 years old
NCT01174108	1:5:age,6:7:lower_bound,11:13:upper_bound,36:42:clinical_variable,44:48:lower_bound	Ages 4 to 80 (both inclusive), and weight >18kg
NCT01174108	115:128:clinical_variable	Availability of HLA identical or single HLA locus mismatched family donor or 10/10 matched unrelated donor at the allelic level (HLA alleles A, B, C, DR, and DQ)
NCT01174108	13:17:clinical_variable	Donors with HbAS are acceptable
NCT01174108	1:24:clinical_variable,28:29:lower_bound,110:114:treatment	ECOG performance status of 3 or more (See Bone & Marrow Transplant Consortium Supportive Care Guidelines for HSCT Recipients)
NCT01174108	1:17:chronic_disease	Fanconi s anemia
NCT01174108	67:111:clinical_variable,120:125:clinical_variable,130:135:clinical_variable	Germline/Inherited gene panel in patients where a suspicion for a familial bone marrow failure syndrome (BMFS) exists, hTERC and hTERT, GATA2 mutation testing will be performed on protocol 04-H-0012 or performed elsewhere prior to enrolling on 04-H-0012
NCT01174108	1:4:chronic_disease,43:46:chronic_disease,48:51:chronic_disease,55:64:chronic_disease,66:82:chronic_disease	HIV positive (donors who are positive for HBV, HCV or HTLV-I/II, T.cruzi [Chagas] may be used at the discretion of the investigator following counseling and approval from the recipient)
NCT01174108	1:35:clinical_variable,37:40:upper_bound,55:59:treatment,65:68:upper_bound,83:87:treatment	Left ventricular ejection fraction <40% (evaluated by ECHO) or <30% (evaluated by MUGA)
NCT01174108	1:26:chronic_disease,30:43:chronic_disease,76:91:treatment	Major anticipated illness or organ failure incompatible with survival from PBSC transplant
NCT01174108	7:25:cancer,63:70:upper_bound	Other malignant diseases liable to relapse or progress within 5 years
NCT01174108	1:42:chronic_disease,76:86:chronic_disease,95:104:chronic_disease	Paroxysmal nocturnal hemoglobinuria (PNH) associated with life-threatening thrombosis, and/or cytopenia, and/or transfusion dependence and/or recurrent and debilitating hemolytic crisis
NCT01174108	46:66:chronic_disease,138:152:treatment,208:224:treatment	Patients diagnosed with one of the following hematologic diseases which are associated with reasonable longevity, shown to be curable by allogeneic BMT but where concern for a high procedural mortality with conventional BMT may delay or prevent such treatment
NCT01174108	1:9:pregnancy	Pregnant
NCT01174108	16:32:chronic_disease,74:81:treatment	Presence of an active infection not adequately responding to appropriate therapy
NCT01174108	1:23:chronic_disease,27:35:chronic_disease,65:76:treatment,95:106:chronic_disease	Refractory anemia (RA) or RARS MDS patients who have associated transfusion dependence and/or neutropenia
NCT01174108	29:43:chronic_disease,45:62:chronic_disease,64:72:chronic_disease,73:88:chronic_disease	Screening test positive for Chagas disease (Trypanosoma cruzi /T. cruzi/trypanosomiasis) confirmed by the Center for Disease Control (CDC)
NCT01174108	1:16:clinical_variable,30:37:lower_bound,39:52:clinical_variable,66:73:lower_bound,78:99:clinical_variable	Serum bilirubin greater than 4 mg/dl, transaminases greater than 5 times the upper limit of normal
NCT01174108	1:17:clinical_variable,31:39:lower_bound,43:63:clinical_variable,74:83:upper_bound	Serum creatinine greater than 2.5mg/dl or creatinine clearance less than 50 ml/min by 24 hr urine collection
NCT01174108	1:29:chronic_disease,33:60:chronic_disease,133:144:treatment,204:229:treatment	Severe aplastic anemia (SAA) or pure red cell aplasia (PRCA [acquired or congenital]) associated with transfusion dependence and/or neutropenia in patients who are not candidates for, or who have failed immunosuppressive therapy
NCT01174108	10:28:chronic_disease,39:43:chronic_disease,47:51:chronic_disease	Sickling hemoglobinopathies including HbSS or HbSC
NCT01174108	1:24:treatment	Telomere Length Testing
NCT01174108	45:48:age,49:50:lower_bound,52:60:upper_bound	The procedure will be explained to subjects age 8 -17 years with formal consent being obtained from parents or legal guardian
NCT01174108	18:36:treatment,48:57:treatment,70:76:chronic_disease,78:80:chronic_disease,82:97:chronic_disease,99:124:chronic_disease,133:146:chronic_disease,150:165:chronic_disease	Unfit to receive filgrastim (G-CSF) or undergo apheresis (history of stroke, MI, unstable angina, uncontrolled hypertension, severe heart disease or palpable spleen)
NCT01174108	1:7:clinical_variable,10:15:lower_bound	Weight > 18 kg
NCT01174108	10:32:cancer,39:70:treatment	separate hematologic malignancy where allogeneic stem cell transplant has been shown to be potentially curative
NCT01054196	1:4:clinical_variable,9:17:lower_bound	ANC > = 1,000/uL
NCT01054196	1:10:clinical_variable,11:20:clinical_variable,25:52:upper_bound	AST(SGOT)/ALT(SGPT) < = 2.5 X upper limit of normal
NCT01054196	1:4:age,9:17:lower_bound	Age > = 18 years
NCT01054196	81:150:treatment,177:195:treatment	All patients who participate in this study must be willing and able to tolerate prophylactic anticoagulation with low-molecular weight heparin (LMWH) for the required dates in treatment protocol
NCT01054196	1:26:clinical_variable,31:35:lower_bound	Cardiac Ejection Fraction > = 45 %
NCT01054196	1:21:clinical_variable,24:33:lower_bound	Creatinine clearance > 60 cc/min
NCT01054196	1:24:clinical_variable,29:30:lower_bound	ECOG performance status > = 2
NCT01054196	33:42:pregnancy	FCBP must also agree to ongoing pregnancy testing
NCT01054196	1:8:gender,54:87:pregnancy,124:133:lower_bound,141:143:lower_bound,146:153:upper_bound,171:185:upper_bound,201:213:treatment,251:257:upper_bound	Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide (prescriptions must be filled within 7 days)
NCT01054196	102:114:allergy_name,126:137:allergy_name,142:151:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (including thalidomide) or melphalan
NCT01054196	12:22:chronic_disease,26:46:chronic_disease,54:72:upper_bound	History of thrombosis or thromboembolic event within last 60 days prior to study entry
NCT01054196	20:23:chronic_disease,38:60:chronic_disease	Known positive for HIV or infectious hepatitis, type B or C
NCT01054196	1:13:treatment,48:69:chronic_disease,119:134:treatment,138:172:treatment	Lenalidomide has been shown to carry a risk of thromboembolic events, especially when used in combination with either corticosteroids or alkylating chemotherapeutic agents
NCT01054196	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 12 weeks
NCT01054196	1:4:gender,10:37:contraception_consent,67:71:clinical_variable,107:116:treatment	Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy
NCT01054196	49:56:treatment,107:116:treatment	Patients also must be able to tolerate low-dose aspirin, 81 mg daily, during the maintenance phase of the treatment protocol
NCT01054196	28:50:treatment,70:77:cancer	Patients may have received bisphosphonate therapy as part of routine myeloma care at any time prior to study entry
NCT01054196	41:63:treatment	Patients may not be receiving any other investigational agents
NCT01054196	82:97:treatment	Patients must have an adequate number of CD34+ stem cells collected to allow for transplantation
NCT01054196	62:70:cancer,72:90:cancer,95:135:cancer	Patients must have histologically or cytologically confirmed relapsed, primary refractory, or relapsed and refractory multiple myeloma
NCT01054196	23:38:treatment,46:59:upper_bound,171:178:lower_bound	Patients who have had myeloma therapy within 14 days prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier
NCT01054196	1:9:pregnancy,24:29:gender	Pregnant and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown
NCT01054196	10:15:gender,16:31:pregnancy,23:31:pregnancy	Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
NCT01054196	16:28:treatment,141:152:treatment	The effects of lenalidomide on the developing human fetus at the recommended therapeutic dose are unknown; however, it has been shown to be teratogenic other primates
NCT01054196	109:120:pregnancy	The treating physician will follow the adverse reporting guidelines as outlined in further detail below for pregnancies
NCT01054196	29:53:lower_bound,54:65:clinical_variable	This number is defined as ≥ 2 x 106 CD34+ cells / kg body weight
NCT01054196	1:21:chronic_disease,64:80:chronic_disease,94:118:chronic_disease,120:144:chronic_disease,146:164:chronic_disease,169:206:chronic_disease	Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT01054196	10:17:lower_bound,43:55:treatment	at least 28 days before she starts taking lenalidomide
NCT01054196	10:26:clinical_variable,31:38:lower_bound,48:70:clinical_variable	involved free light chain > = 10mg/dL provided serum free light chain ratio is abnormal
NCT01054196	13:73:contraception_consent,77:122:contraception_consent	must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME
NCT01054196	1:10:clinical_variable,15:24:lower_bound	platelets > = 50,000/uL
NCT01054196	1:16:clinical_variable,24:32:lower_bound	serum M-protein of > = 500mg/dL
NCT01054196	1:16:clinical_variable,21:48:upper_bound	total bilirubin < = 1.5 X upper limit of normal
NCT01054196	1:16:clinical_variable,24:39:lower_bound	urine M-protein of > = 200mg/ 24 hours
NCT01037790	1:32:clinical_variable,34:42:lower_bound	Absolute neutrophil count (ANC) >1500/mm3
NCT01037790	13:34:cancer,42:56:cancer,58:60:lower_bound,61:80:upper_bound	Advanced or metastatic esophageal and/or gastric cancer (15-30 enrollment slots)
NCT01037790	5:11:cancer	All tumors must test positive for Rb expression
NCT01037790	5:10:cancer	Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification OR any other functional alteration at the G1/S checkpoint
NCT01037790	5:10:cancer	Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification OR any other functional alteration at the G1/S checkpoint. (15-30 enrollment slots)
NCT01037790	1:10:clinical_variable,13:50:upper_bound	Bilirubin ≤ 1.5 x the upper limit of normal (ULN)
NCT01037790	1:21:cancer,36:52:cancer,54:56:lower_bound,57:59:upper_bound	Cisplatin-refractory, unresectable germ cell tumors (15-30 enrollment slots)
NCT01037790	1:37:cancer	ER positive metastatic breast tumors (data now shows all to be Rb positive.)
NCT01037790	1:16:gender,55:73:pregnancy	Female subjects of childbearing potential must have a negative pregnancy test at screening
NCT01037790	1:8:gender,66:71:gender,80:98:treatment,145:159:upper_bound	Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months
NCT01037790	19:35:cancer,37:67:clinical_variable,72:98:clinical_variable,101:108:upper_bound	For subjects with liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase ≤ 5 x ULN
NCT01037790	22:38:cancer,40:70:clinical_variable,75:107:clinical_variable,110:119:upper_bound	For subjects without liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN
NCT01037790	1:11:clinical_variable,14:20:lower_bound	Hemoglobin > 9 g/dL
NCT01037790	1:25:cancer,49:52:clinical_variable,105:110:clinical_variable,133:138:clinical_variable,155:166:treatment,171:188:treatment,196:198:upper_bound	Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B
NCT01037790	1:29:cancer,47:51:cancer,55:68:cancer	Metastatic colorectal cancer that harbors the Kras or BRAF mutation (15-30 enrollment slots)
NCT01037790	15:19:cancer,35:41:cancer,54:65:treatment,93:100:treatment,158:167:treatment	Patients with HER2-overexpressing tumors may receive trastuzumab up to the date of starting therapy, and may continue to receive trastuzumab while receiving PD0332991
NCT01037790	1:10:clinical_variable,12:23:lower_bound	Platelets >100,000/mm3
NCT01037790	1:17:clinical_variable,20:25:upper_bound,26:29:clinical_variable,44:64:clinical_variable,67:76:lower_bound	Serum creatinine ≤ 1.5 x UNL or calculated creatinine clearance ≥ 60 mL/min
NCT01037790	27:42:gender,49:86:contraception_consent,126:134:upper_bound,158:174:treatment	Sexually active subjects (male and female) must use accepted methods of contraception during the course of the study and for 3 months after the last dose of protocol drug(s)
NCT01037790	20:28:lower_bound	Subjects will be > 18 years old
NCT01037790	19:55:clinical_variable,58:64:lower_bound	The subject has a baseline corrected QT interval (QTc) > 470 ms
NCT01037790	20:80:clinical_variable,84:85:lower_bound,89:90:upper_bound	The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
NCT01037790	47:59:cancer	The subject has disease that is assessable by tumor marker, physical, or radiologic means
NCT01037790	74:87:treatment,123:124:upper_bound	The subject has not recovered from clinically-meaningful toxicity due to prior therapy (i.e., back to baseline or Grade ≤ 1)
NCT01037790	44:65:treatment,73:80:upper_bound,112:121:treatment	The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
NCT01037790	26:48:treatment,60:98:treatment,107:114:upper_bound,119:131:treatment,135:146:treatment,154:161:upper_bound,188:198:treatment	The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within 3 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first dose of PD 0332991
NCT01037790	45:79:chronic_disease	The subject is known to be positive for the human immunodeficiency virus (HIV)
NCT01037790	16:24:pregnancy	The subject is pregnant
NCT01037790	1:18:chronic_disease	diabetes mellitus
NCT01037790	1:13:chronic_disease	hypertension
NCT01037790	12:28:chronic_disease	ongoing or active infection
NCT01037790	13:37:chronic_disease,39:63:chronic_disease,65:71:chronic_disease,75:96:chronic_disease,104:112:upper_bound	symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months
NCT00967785	27:32:chronic_disease	Absence of a diagnosis of WHIMS
NCT00967785	43:52:chronic_disease	Absence of a documented history of severe infection
NCT00967785	23:28:chronic_disease,51:60:chronic_disease	Clinical diagnosis of WHIMS and documented severe infection
NCT00967785	1:8:contraception_consent,10:24:gender	Condoms, male or female, with or without a spermicide
NCT00967785	1:29:contraception_consent,31:39:contraception_consent,41:53:contraception_consent,63:96:contraception_consent	Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive method
NCT00967785	20:38:chronic_disease,42:57:chronic_disease	History of serious cardiac arrhythmia or cardiac defects that make such more likely
NCT00967785	1:5:gender,41:50:treatment	Male partner has previously undergone a vasectomy for which there is documentation of aspermatogenic sterility
NCT00967785	13:21:pregnancy	Must not be pregnant or breastfeeding
NCT00967785	1:12:chronic_disease,46:61:chronic_disease	Neutropenia due to maturation defects in the myeloid lineage or that the PI feels is unlikely to benefit from this medication
NCT00967785	22:30:upper_bound	Patient is less than 18 years old
NCT00967785	1:9:pregnancy,10:15:gender	Pregnant women or breastfeeding
NCT00967785	1:14:chronic_disease,27:54:clinical_variable,56:65:upper_bound	Renal failure (calculated creatinine clearance [CrCl] <15 mL/min or requiring dialysis)
NCT00967785	29:48:chronic_disease	Signs or symptoms of active microbial infection
NCT00967785	21:43:pregnancy,63:69:gender	Subjects must agree not to become pregnant or to impregnate a female
NCT00967785	51:68:clinical_variable,77:82:clinical_variable,86:92:clinical_variable,106:112:lower_bound,137:147:treatment	Willingness to interrupt medications to raise the white count (WBC) such as G-CSF or GM-CSF for at least 1 week before and while on the study drug
NCT00967785	26:28:lower_bound,55:63:upper_bound,67:70:age	greater than or equal to 18 and less than or equal to 75 years of age
NCT00871260	1:41:chronic_disease	Acute ST-elevation myocardial infarction
NCT00871260	1:4:age,6:14:upper_bound	Age <18 years
NCT00871260	1:19:treatment,33:36:treatment,38:47:treatment,49:62:treatment	Contra-indications to MRI (i.e. ICD, pacemaker, aneurysm clip, etc)
NCT00871260	1:24:chronic_disease	Hemodynamic instability
NCT00871260	1:10:pregnancy	Pregnancy
NCT00871260	1:32:chronic_disease	Second or third degree AV block
NCT00871260	1:21:chronic_disease,23:26:clinical_variable,28:36:upper_bound,40:52:treatment	Severe Renal Disease (GFR <30cc/min or hemodialysis)
NCT00871260	8:22:chronic_disease	Severe claustrophobia
NCT00871260	11:34:chronic_disease	Suspected coronary artery disease
NCT00871260	22:45:chronic_disease	Symptoms of possible coronary artery disease
NCT00737399	14:32:cancer	Diagnosis of cholangiocarcinoma
NCT00715611	3:6:lower_bound,7:18:cancer,22:44:cancer	> 10% Sarcomatoid or desmoplastic histology
NCT00715611	1:4:clinical_variable,6:10:clinical_variable,15:18:clinical_variable,20:24:clinical_variable,28:37:upper_bound	AST (SGOT) or ALT (SGPT) ≤ 3.0 X ULN
NCT00715611	1:26:clinical_variable,28:37:lower_bound	Absolute neutrophil count ≥1.5 K/mcL
NCT00715611	1:14:chronic_disease,54:66:treatment	Bulky disease in the fissure preventing lung-sparing pleural IMRT
NCT00715611	1:5:clinical_variable,8:11:lower_bound,37:40:clinical_variable	DLCO > 40% predicted (corrected for Hgb)
NCT00715611	1:42:cancer	Epithelioid or biphasic histology subtype
NCT00715611	1:5:clinical_variable,10:13:lower_bound,29:32:clinical_variable	FEV1 >/= 35% (corrected for Hgb)
NCT00715611	66:83:chronic_disease,115:133:treatment	For patients who develop or have baseline clinically significant pleural effusions before or during initiation of pemetrexed therapy
NCT00715611	1:29:clinical_variable,32:35:lower_bound	Karnofsky performance status ≥ 80%
NCT00715611	1:13:gender,14:47:contraception_consent	Men or women not using effective contraception
NCT00715611	10:34:chronic_disease	No acute congestive heart failure
NCT00715611	16:34:cancer	No evidence of metastatic disease
NCT00715611	21:47:treatment	Patients undergoing extrapleural pneumonectomy
NCT00715611	28:45:cancer,54:62:cancer,66:98:cancer	Patients with a concurrent active malignancy (except squamous or basal cell carcinoma of the skin)
NCT00715611	18:34:chronic_disease,48:68:treatment,70:79:treatment,84:105:treatment	Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments
NCT00715611	32:47:chronic_disease	Patients with serious unstable medical illness
NCT00715611	1:10:clinical_variable,12:21:lower_bound	Platelets ≥100 K/mcL
NCT00715611	1:9:pregnancy	Pregnant
NCT00715611	60:68:treatment	Presence of third space fluid that cannot be controlled by drainage
NCT00715611	1:27:treatment,7:27:treatment,36:47:treatment,99:124:treatment,126:146:treatment,148:169:treatment	Prior intrapleural therapy (except pleurodesis) or intrapleural therapy at the time of P/D (i.e.: intrapleural chemotherapy, photodynamic therapy, intrapleural betadine)
NCT00715611	1:18:treatment	Prior nephrectomy on the contralateral side of MPM
NCT00715611	1:33:treatment,45:70:treatment	Prior thoracic radiation therapy preventing hemithoracic pleural IMRT
NCT00715611	1:22:clinical_variable,25:34:upper_bound	Serum total bilirubin ≤ 1.5 X ULN
NCT00715611	1:6:gender,23:26:age	Women of childbearing age will be counseled to use birth control while on this study
NCT00715611	1:6:gender	Women should not breast-feed a baby while on this study
NCT00715611	1:4:age,7:15:lower_bound,22:30:upper_bound	age ≥ 18 years but ≤ 80 years at the time of consent
NCT00715611	30:37:lower_bound,38:41:upper_bound,42:72:cancer	at the participating site of stage I-III malignant pleural mesothelioma
NCT00715611	53:74:treatment	consideration should be given to drain the effusion prior to chemotherapy administration
NCT00715611	11:16:gender	lactating women
NCT00715611	15:23:cancer,45:48:upper_bound,49:60:cancer	patients with biphasic histology can have < 10% sarcomatoid
NCT00715611	8:27:pregnancy	should not become pregnant or father a baby while on this study because the drugs in this study
NCT00670358	1:4:clinical_variable,7:16:lower_bound	ANC ≥ 1,500/mm³
NCT00670358	1:4:clinical_variable,7:14:upper_bound,15:18:clinical_variable,20:27:upper_bound,63:71:cancer	AST ≤ 3 times ULN (5 times ULN if direct liver involvement by lymphoma)
NCT00670358	28:64:treatment,81:88:treatment,121:132:treatment,140:148:treatment,152:180:treatment	Able to receive concurrent prophylactic anticoagulation therapy (e.g., low-dose aspirin [81 mg] daily or an alternative prophylaxis [e.g., warfarin or low molecular weight heparin])
NCT00670358	1:21:clinical_variable,24:31:upper_bound,32:35:clinical_variable,37:44:upper_bound,80:88:cancer	Alkaline phosphatase ≤ 3 times ULN (5 times ULN if direct liver involvement by lymphoma)
NCT00670358	1:22:cancer	CD20-positive disease
NCT00670358	1:19:chronic_disease	Cardiac arrhythmia
NCT00670358	1:11:clinical_variable,14:25:upper_bound	Creatinine ≤ 2 times ULN
NCT00670358	1:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	ECOG performance status 0-2
NCT00670358	1:18:clinical_variable,21:24:lower_bound,28:32:treatment,36:40:treatment	Ejection fraction ≥ 45% by MUGA or ECHO
NCT00670358	9:24:gender,25:71:contraception_consent,78:85:lower_bound,146:153:treatment	Fertile female patients must use effective double-method contraception for ≥ 28 days before, during, and for ≥ 28 days after completion of study therapy
NCT00670358	9:22:gender,28:55:contraception_consent,73:80:lower_bound,107:114:treatment,151:160:treatment	Fertile male patients must use effective contraception during and for ≥ 28 days after completion of study therapy, even if they have had a successful vasectomy
NCT00670358	26:44:cancer,48:78:cancer	Histologically confirmed diffuse large cell or grade 3A/B follicular lymphoma
NCT00670358	1:19:clinical_variable,34:42:lower_bound,45:51:lower_bound,84:91:treatment,95:106:treatment,108:121:treatment	Measurable disease, defined as ≥ 1 lesion ≥ 1.5 cm in one diameter, as detected by CT scan or PET-CT scan (PET/CT fusion)
NCT00670358	1:19:pregnancy	Negative pregnancy test
NCT00670358	4:16:cancer,20:39:chronic_disease,57:81:cancer	No CNS lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells
NCT00670358	53:60:lower_bound,87:94:treatment	No blood, sperm, or semen donation during and for ≥ 28 days after completion of study therapy
NCT00670358	13:29:chronic_disease	No comorbid systemic illness or other severe concurrent disease that, in the judgment of the investigator, would preclude study entry or significantly interfere with the proper assessment of safety and toxicity of the prescribed study regimen
NCT00670358	15:43:treatment,51:58:treatment,60:67:treatment	No concurrent erythroid-stimulating agents (e.g., Procrit, Aranesp)
NCT00670358	15:27:treatment,29:41:treatment,46:59:treatment,79:89:cancer	No concurrent radiotherapy, chemotherapy, or immunotherapy for another active malignancy
NCT00670358	4:28:chronic_disease,59:66:treatment,88:111:chronic_disease	No congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias
NCT00670358	45:55:chronic_disease,56:64:chronic_disease,76:99:treatment,113:122:treatment	No history of life threatening or recurrent thrombosis/embolism (unless on anticoagulation therapy during study treatment)
NCT00670358	10:13:chronic_disease	No known HIV positivity
NCT00670358	4:25:chronic_disease,37:50:upper_bound	No myocardial infarction within the past 6 months
NCT00670358	10:27:cancer,46:70:cancer,64:70:cancer	No other active malignancy, except localized nonmelanotic skin cancer or any cancer that, in the judgment of the investigator, has been treated with curative intent and will not interfere with the study treatment plan and response assessment
NCT00670358	21:30:treatment,35:43:cancer	No other concurrent treatment for lymphoma
NCT00670358	4:55:chronic_disease	No post-transplant lymphoproliferative disorder (PTLD)
NCT00670358	10:22:treatment,28:31:lower_bound,39:50:clinical_variable	No prior radiotherapy to ≥ 25% of the bone marrow
NCT00670358	5:22:chronic_disease	Not immunocompromised
NCT00670358	1:13:pregnancy	Not pregnant or nursing
NCT00670358	19:28:chronic_disease	Ongoing or active infection
NCT00670358	1:15:clinical_variable,18:29:lower_bound	Platelet count ≥ 100,000/mm³
NCT00670358	1:37:chronic_disease	Psychiatric illness/social situation that would preclude compliance with study requirements
NCT00670358	1:9:lower_bound,19:21:upper_bound	Stage II, III, or IV disease
NCT00670358	1:37:chronic_disease	Symptomatic congestive heart failure
NCT00670358	1:16:clinical_variable,19:28:upper_bound,29:56:clinical_variable,60:83:clinical_variable	Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin normal
NCT00670358	10:25:chronic_disease	Unstable angina pectoris
NCT00573027	1:24:chronic_disease	Acute coronary syndrome (defined by the ACC/AHA criteria, Braunwald 2000)
NCT00573027	1:4:age,7:15:lower_bound	Age > 18 years old
NCT00573027	1:11:chronic_disease,19:40:chronic_disease,47:59:chronic_disease,61:70:chronic_disease,72:88:chronic_disease	Chest pain with a non-ischemic etiology (e.g.,pericarditis, pneumonia, esophageal spasm)
NCT00573027	22:31:allergy_name,35:57:allergy_name	Contraindications to adenosine or Regadenoson (Lexiscan)
NCT00573027	12:38:chronic_disease	Documented obstructive myocardiopathy
NCT00573027	1:14:chronic_disease,16:26:clinical_variable,27:30:lower_bound,34:36:upper_bound,40:49:treatment	Heart failure (NYHA Class III or IV on treatment)
NCT00573027	1:15:chronic_disease	LV dysfunction
NCT00573027	16:39:chronic_disease,61:79:upper_bound,83:85:upper_bound,86:105:chronic_disease,109:112:lower_bound,142:153:treatment	No obstructive coronary artery disease performed within the previous 24 months (<50% luminal obstruction in one or more coronary arteries on angiography)
NCT00573027	1:16:clinical_variable,19:39:lower_bound,54:82:lower_bound	Obstructive CAD ≥ 50% luminal diameter stenosis in ≥ 1 epicardial coronary artery
NCT00573027	26:43:chronic_disease,70:98:treatment	Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support
NCT00573027	9:31:chronic_disease,64:76:treatment,80:91:treatment	Primary valvular heart disease clearly indicating the need for valve repair or replacement
NCT00573027	7:26:chronic_disease,45:60:clinical_variable,62:69:upper_bound	Prior non-cardiac illness with an estimated life expectancy <4 years
NCT00573027	18:52:clinical_variable,56:60:treatment,64:78:chronic_disease,88:95:upper_bound	Prior or planned percutaneous coronary intervention or CABG or prior acute MI in prior 30 days
NCT00573027	1:6:gender,3:6:gender,20:50:chronic_disease,53:56:lower_bound,62:65:upper_bound,66:91:clinical_variable	Women and men with intermediate coronary stenoses (>20% but <50% luminal diameter stenosis assessed visually at the time of angiography) will undergo clinically indicated IVUS testing based on the judgment of the operator; those determined to have flow FFR or obstructing stenosis will be excluded from the overall study
NCT00573027	1:14:gender,42:61:chronic_disease,66:72:chronic_disease,95:105:chronic_disease,116:130:treatment,141:160:treatment,165:191:chronic_disease,232:235:treatment	Women and men with signs and symptoms of myocardial ischemia and angina or angina equivalent (chest pain, abnormal stress testing, abnormal noninvasive testing) or microvascular angina (MVA) which is defined as angina and ischemic ECG changes without organic obstructive stenosis or epicardial spasm of the coronary arteries
NCT00573027	1:18:clinical_variable,20:23:upper_bound	ejection fraction <40%
NCT00383656	1:4:bmi,7:15:lower_bound,27:39:clinical_variable,44:60:clinical_variable	BMI > 18 kg/m2 and normal testosterone and prolactin levels
NCT00383656	1:22:chronic_disease,119:133:treatment	Mitral valve prolapse with ballooning of the mitral valve will be cause for exclusion of the patient from intravenous GnRH treatment
NCT00383656	36:41:gender,46:52:gender	Subjects will be otherwise healthy women and female minors
NCT00383656	27:47:clinical_variable,49:59:clinical_variable,85:94:lower_bound,129:147:pregnancy	Subjects will have normal complete blood count (hemoglobin greater than or equal to 11.5gm/dl) and thyroid function tests and a negative pregnancy test
NCT00383656	1:6:gender,23:38:chronic_disease,42:88:chronic_disease,112:130:chronic_disease	Women and minors with GnRH deficiency or idiopathic hypogonadotropic hypogonadism (IHH) will have a history of primary amenorrhea
NCT00383656	1:6:gender,32:61:chronic_disease,85:97:cancer,101:116:cancer,130:137:treatment,167:179:treatment,196:220:treatment,224:242:treatment,247:255:cancer,259:281:cancer	Women and minors with acquired hypogonadotropic hypogonadism will have a history of hypothalamic or pituitary tumor treated with surgery alone or in combination with radiotherapy or a history of hypothalamic irradiation as adjunctive therapy for leukemia or craniofacial neoplasms
NCT00383656	1:6:gender,23:46:chronic_disease,70:90:chronic_disease,103:113:lower_bound,142:155:treatment,172:190:chronic_disease	Women and minors with hypothalamic amenorrhea will have a history of secondary amenorrhea of at least six months duration with low or normal gonadotropins or a history of primary amenorrhea in the presence of pulsatile patterns of LH or FAS on baseline frequent sampling studies
NCT00383656	24:48:clinical_variable,56:80:clinical_variable,125:135:treatment,139:142:treatment	a deficient pattern of luteinizing hormone (LH) and/or free alpha subunit (FAS) secretion on baseline sampling and a normal cranial CT or MRI
NCT00383656	14:21:lower_bound,28:39:treatment,47:64:treatment	a minimum of 2 years since irradiation and no gonadal radiation
NCT00383656	13:17:age,21:23:lower_bound,28:36:upper_bound	between the ages of 16 and 45 years
NCT00383656	23:40:treatment	normoprolactinemic on dopamine agonists if needed
NCT00383656	18:27:chronic_disease,31:50:treatment	patients will be euthyroid on thyroid replacement if needed
NCT00383656	11:49:treatment	receiving physiologic glucocorticoid replacement if needed
NCT00383656	22:37:treatment,64:71:lower_bound	who have not been on gonadal steroid preparations for at least 1 month
NCT00338377	3:22:treatment,24:39:treatment,41:52:treatment,54:79:treatment,120:136:chronic_disease,145:153:upper_bound,157:172:treatment,190:216:treatment	A stress cardiac test (stress thallium, stress MUGA, dobutamine echocardiogram or other stress test that will rule out cardiac ischemia) within 6 months of lymphodepletion. (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria)
NCT00338377	1:26:clinical_variable,52:59:lower_bound,62:103:treatment	Absolute neutrophil count greater than or equal to 750/mm3. (Turnstile II - Chemotherapy/Cell Infusion- Inclusion Criteria)
NCT00338377	34:49:treatment	Achieves PR or CR in response to B-RAF treatment (Cohort C)
NCT00338377	1:4:gender,30:38:lower_bound	Age greater than or equal to 12 years. (Turnstile I)
NCT00338377	5:31:chronic_disease,42:65:treatment,67:88:chronic_disease,104:121:chronic_disease,129:143:chronic_disease,145:156:chronic_disease,160:173:chronic_disease,183:203:clinical_variable,220:223:clinical_variable,335:347:treatment,348:361:treatment	Any active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, such as abnormal stress test and/or abnormal PFT. PI or his designee shall make the final determination regarding appropriateness of enrollment.(Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
NCT00338377	34:50:chronic_disease,96:108:treatment,112:129:treatment,146:163:clinical_variable,167:174:lower_bound,177:180:clinical_variable,184:193:lower_bound,209:233:chronic_disease,251:263:treatment,264:277:treatment	Any form of primary or secondary immunodeficiency. Must have recovered immune competence after chemotherapy or radiation therapy as evidenced by lymphocyte counts (> 500/mm3), WBC (> 3,000/mm3) or absence of opportunistic infections. (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
NCT00338377	32:36:clinical_variable,37:38:lower_bound,41:42:upper_bound,58:79:treatment,82:123:treatment	Clinical performance status of ECOG 0 - 2 at the time of chemotherapy infusion. (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria)
NCT00338377	1:28:clinical_variable,32:36:clinical_variable,37:38:lower_bound,39:40:upper_bound	Clinical performance status of ECOG 0-2. (Turnstile I)
NCT00338377	9:20:treatment,24:44:treatment,52:64:upper_bound,85:108:treatment	Has had prior B-RAF or MEK targeted therapy within 7 days prior to the start of the lymphodepletion regimen (Cohort A and Cohort B)
NCT00338377	9:53:treatment,65:80:upper_bound,113:128:treatment	Has had prior systemic cancer cytotoxic chemotherapy within the past four weeks at the time of the start of the lymphodepletion regimen
NCT00338377	1:11:clinical_variable,37:45:lower_bound,63:75:treatment,76:89:treatment	Hemoglobin greater than or equal to 8.0 g/dl. (Turnstile II - Chemotherapy/Cell Infusion)
NCT00338377	18:33:treatment,61:73:treatment,74:87:treatment	Is not receiving B-RAF treatment (Cohort C) (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
NCT00338377	1:20:treatment,28:35:upper_bound,39:54:chronic_disease,56:87:treatment,91:97:treatment,105:112:upper_bound	MRI/CT of the brain within 42 days of lymphodepletion. CT scan of chest/abdomen/pelvis or PET/CT within 30 days of lymphodepletion
NCT00338377	40:56:chronic_disease	Many patients present with concomitant systemic disease outside of the central nervous system
NCT00338377	19:32:chronic_disease,51:54:upper_bound,79:83:lower_bound,112:115:treatment,235:247:treatment,248:261:treatment	Patients may have brain lesions which measure </= 1cm each. Lesions that are >1 cm that have been treated with SRS and in the opinion of the PI or his designee no longer represents active disease will also be allowed. (Turnstile II - Chemotherapy/Cell Infusion- Inclusion Criteria)
NCT00338377	40:65:treatment,66:79:treatment	Patients must be HLA-A2 for cohort A. (Turnstile II-Chemotherapy/Cell Infusion-Inclusion Criteria)
NCT00338377	34:55:treatment	Patients must be able to undergo contrast-enhanced MRI. (Cohort D)
NCT00338377	30:45:treatment,120:135:treatment	Patients must be receiving a B-RAF inhibitor and failed to achieve PR or CR or have progressive disease in response to B-RAF treatment (Cohort C)
NCT00338377	20:43:clinical_variable,44:45:lower_bound,52:53:upper_bound,61:64:clinical_variable,67:69:lower_bound	Patients must have ECOG performance status 0, 1 or 2 and/or KPS > 50
NCT00338377	33:51:pregnancy,78:83:gender,113:127:upper_bound,140:161:treatment	Patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery
NCT00338377	31:50:cancer,68:80:treatment,81:94:treatment	Patients must have measurable metastatic melanoma. (Turnstile II - Chemotherapy/Cell Infusion -Inclusion Criteria)
NCT00338377	20:39:cancer,41:55:cancer,59:79:cancer,83:105:chronic_disease	Patients must have metastatic melanoma, uveal melanoma or stage III in-transit or regional nodal disease. (Turnstile I)
NCT00338377	26:45:treatment,49:55:treatment,63:71:upper_bound	Patients must receive an MRI/CT of the brain or PET/CT within 6 months of consenting. If new lesions are present, PI or his designee should make final determination regarding enrollment. (Turnstile I)
NCT00338377	31:53:contraception_consent,58:75:upper_bound,127:139:treatment,140:153:treatment	Patients of both genders must practice birth control for four months after receiving the preparative regimen. (Turnstile II - Chemotherapy/Cell Infusion- Inclusion Criteria)
NCT00338377	34:47:treatment,40:47:treatment,49:65:treatment,118:134:treatment	Patients previously treated with immunotherapy, targeted therapy, or no therapy will be eligible. Patients receiving cytotoxic agents will be evaluated by the PI or his designee as to suitable eligibility. (Turnstile I)
NCT00338377	60:63:treatment,84:91:upper_bound,95:110:treatment,126:138:treatment,139:152:treatment	Patients randomized to receive dendritic cells may have an MRI of the brain within 30 days of lymphodepletion. (Turnstile II-Chemotherapy/Cell Infusion-Inclusion Criteria)
NCT00338377	47:54:treatment,59:62:cancer	Patients who are currently being treated with IT IL-2 for LMD are eligible. No wash out period is required
NCT00338377	57:66:treatment,112:118:lower_bound	Patients who have been previously treated with other IT therapies are eligible, as long as there is at least a 2 week wash out period
NCT00338377	39:46:treatment,52:72:treatment	Patients who have previously received therapy with systemic TIL therapy are eligible
NCT00338377	15:18:treatment,31:34:cancer,64:86:cancer	Patients with MRI evidence of LMD, with or without evidence of malignant cells in CSF (positive cytology)
NCT00338377	15:24:treatment,97:111:treatment,130:137:upper_bound,165:180:treatment,192:213:treatment,217:242:treatment,279:286:lower_bound,292:307:treatment,364:371:clinical_variable,376:379:cancer	Patients with VP shunts must have VP shunts with on/off valves and must be expected to tolerate VP shunt valve off for more than 6 hours Patients who have received CNS irradiation, including whole brain radiation or stereotactic radiosurgery, are eligible, if they are at least 1 weeks post CNS-irradiation (Cohort D)Patients who are currently being treated with IT IL-2 for LMD are eligible. No wash out period is required. (Cohort D)
NCT00338377	27:43:chronic_disease,74:98:treatment	Patients with concomitant systemic disease under control with current or prior systemic treatment, as per primary treating physician
NCT00338377	27:42:cancer,91:94:treatment	Patients with evidence of malignant cells in the CSF (positive cytology), with or without MRI evidence of LMD
NCT00338377	45:61:cancer	Patients with rapidly advancing parenchymal brain metastases (Cohort D)
NCT00338377	33:49:chronic_disease,92:110:treatment	Patients with rapidly advancing systemic disease, especially those without good options of systemic treatment for their disease outside the CNS. (Cohort D)
NCT00338377	33:36:cancer,90:93:treatment	Patients with surgically-proven LMD (leptomeningeal involvement on pathology review) +/- MRI or CSF evidence by MRI or CSF cytology (Cohort D)
NCT00338377	34:50:chronic_disease,69:87:treatment	Patients without any evidence of systemic disease, either receiving systemic treatment or on active observation (Cohort D)
NCT00338377	1:15:clinical_variable,41:51:lower_bound,69:81:treatment,82:95:treatment	Platelet count greater than or equal to 75,000/mm3. (Turnstile II - Chemotherapy/Cell Infusion- Inclusion Criteria)
NCT00338377	1:10:pregnancy,44:56:upper_bound,60:69:treatment	Pregnancy testing will be performed within 7 days prior to treatment. (Turnstile II)
NCT00338377	1:9:pregnancy	Pregnant patients (Cohort D)
NCT00338377	27:46:chronic_disease,166:179:treatment,223:235:treatment,236:249:treatment	Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe or contraindicated. (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
NCT00338377	1:25:clinical_variable,27:31:clinical_variable,32:35:lower_bound,39:42:clinical_variable,67:75:upper_bound,79:94:treatment,112:124:treatment,125:138:treatment	Pulmonary function tests (FEV1>65% or FVC>65%of predicted) within 6 months of lymphodepletion. (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria)
NCT00338377	9:16:treatment,9:56:treatment,71:88:treatment,96:108:upper_bound,123:155:treatment,163:175:upper_bound,176:200:treatment,269:281:treatment,282:295:treatment	Require steroid therapy or steroid-containing compounds, or have used systemic steroids in the past 30 days, or have used topical or inhalational steroids in the past 2 weeks prior to lymphodepletion. Exception: Patients on physiologic dose of steroid (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
NCT00338377	1:10:clinical_variable,21:58:upper_bound,76:88:treatment,89:102:treatment	Serum ALT less than three times the upper limit of normal. (Turnstile II - Chemotherapy/Cell Infusion- Inclusion Criteria)
NCT00338377	1:17:clinical_variable,40:49:upper_bound,67:79:treatment,80:93:treatment	Serum creatinine less than or equal to 1.6 mg/dl. (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria)
NCT00338377	1:16:clinical_variable,39:48:upper_bound,74:92:chronic_disease,109:124:clinical_variable,135:144:upper_bound,162:174:treatment,175:188:treatment	Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl. (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria)
NCT00338377	95:154:contraception_consent,185:191:contraception_consent,193:202:contraception_consent,204:212:contraception_consent,214:217:contraception_consent,222:244:contraception_consent	Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), the patient agrees to continue to use a barrier method of contraception throughout the study such as: condom, diaphragm, hormonal, IUD, or sponge plus spermicide. Abstinence is an acceptable form of birth control. (Turnstile II)
NCT00338377	1:6:gender	Women
NCT00338377	1:9:pregnancy	pregnant
NCT00338377	82:94:treatment,125:137:treatment,138:151:treatment	will be excluded because of the potentially dangerous effects of the preparative chemotherapy on the fetus. (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
NCT00092222	88:96:upper_bound,100:103:age	A parent or guardian must be available for giving consent for pediatric subjects under 18 years of age
NCT00092222	1:4:age,30:38:lower_bound	Age greater than or equal to 12 years
NCT00092222	88:91:chronic_disease,114:117:chronic_disease	Any abnormality that would be scored as NCI CTC Grade IV toxicity that is unrelated to HIV, its treatment, or to MCD that would preclude protocol treatment and/or observation only
NCT00092222	15:19:chronic_disease,31:34:chronic_disease	Biopsy proven KSHV-associated MCD
NCT00092222	1:9:pregnancy,10:15:gender	Pregnant women are excluded from this study as certain of the study agents have the potential for teratogenic effects
NCT00092222	21:31:cancer,50:59:treatment,108:118:treatment,168:171:chronic_disease	Presence of another malignancy requiring current treatment that would preclude the use of all of the study treatments or the ability to monitor the natural history of MCD untreated
